

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspal202txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40
minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source
(CS) field
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for
U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and
Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human
translated claims for Chinese Applications and
Utility Models
NEWS 10 NOV 23 Addition of SCAN format to selected STN databases
NEWS 11 NOV 23 Annual Reload of IFI Databases
NEWS 12 DEC 01 FRFULL Content and Search Enhancements
NEWS 13 DEC 01 DGENE, USGENE, and PCTGEN: new percent identity
feature for sorting BLAST answer sets
NEWS 14 DEC 02 Derwent World Patent Index: Japanese FI-TERM
thesaurus added
NEWS 15 DEC 02 PCTGEN enhanced with patent family and legal status
display data from INPADOCDB
NEWS 16 DEC 02 USGENE: Enhanced coverage of bibliographic and
sequence information
NEWS 17 DEC 21 New Indicator Identifies Multiple Basic Patent
Records Containing Equivalent Chemical Indexing
in CA/CAPLUS

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial

10/ 582,823

gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:00:25 ON 11 JAN 2010

```
=> file reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          0.22        0.22
```

FILE 'REGISTRY' ENTERED AT 14:00:50 ON 11 JAN 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JAN 2010 HIGHEST RN 1201787-64-5
DICTIONARY FILE UPDATES: 10 JAN 2010 HIGHEST RN 1201787-64-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10582823.str



10/ 582,823

```

chain nodes :
11 18 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 43
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17
ring/chain nodes :
19
chain bonds :
7-11 9-12 18-19 20-21 20-22 23-24 25-27 25-26 28-32 28-29 28-31 30-34
30-33
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
exact/norm bonds :
2-7 3-10 7-8 7-11 8-9 9-10 18-19 20-21 20-22 23-24 25-27 25-26 28-32
28-29 28-31 30-34 30-33
exact bonds :
9-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 12 :

```

G1:X,Ak,OH,COOH,CN,N,Cy,Hy,[*1],[*2],[*3],[*4],[*5],[*6]

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 43:CLASS
44:Atom


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 X,Ak,OH,COOH,CN,N,Cy,Hy,[@1],[@2],[@3],[@4],[@5],[@6]

10/ 582,823

Structure attributes must be viewed using STN Express query preparation.

=> s 11 full

FULL SEARCH INITIATED 14:01:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 122532 TO ITERATE

100.0% PROCESSED 122532 ITERATIONS 10463 ANSWERS
SEARCH TIME: 00.00.03

L2 10463 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	191.54	191.76

FILE 'CAPLUS' ENTERED AT 14:01:37 ON 11 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jan 2010 VOL 152 ISS 3
FILE LAST UPDATED: 10 Jan 2010 (20100110/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12

L3 733 L2

=> s 13 not py>2003

8286581 PY>2003

L4 462 L3 NOT PY>2003

=> s 14/thu

QUALIFICATION NOT VALID FOR NUMERIC DATA 'PY/THU'
Numeric data cannot be field qualified.

10/ 582,823

=> s 12/thu
733 L2
1202514 THU/RL
L5 102 L2/THU
(L2 (L) THU/RL)



=> d 15 1- ibib abs fhistr
YOU HAVE REQUESTED DATA FROM 102 ANSWERS - CONTINUE? Y/(N):n

=> d 15 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 102 ANSWERS - CONTINUE? Y/(N):y

L5 ANSWER 1 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1141557 CAPLUS
DOCUMENT NUMBER: 151:381390
TITLE: Preparation of heterocycles as modulators of estrogen related receptors
INVENTOR(S): Ding, Ke; Wong, Chiwai; Kang, Zhanfang; Zhou, Xi
PATENT ASSIGNEE(S): Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Peop. Rep. China
SOURCE: PCT Int. Appl., 49pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2009111943	A1	20090917	WO 2009-CN234	20090305
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CN 101531638	A	20090916	CN 2008-10026782	20080313
PRIORITY APPLN. INFO.: OTHER SOURCE(S):	MARPAT 151:381390		CN 2008-10026782	A 20080313


GI




AB Title compds. [I; wherein A, B, D, and E independently = CH or N; n = 0, 1, or 2; R1 = H, OH, NO2, halo, or alkyl, etc.; R2 = H, (un)substituted alkyl, or aryl, etc.; R3 = (un)substituted alkyl, cycloalkyl, or aryl, etc.], and their pharmaceutically acceptable salts thereof, were prepared as modulators of estrogen related receptors, useful in the treatment of, e.g., metabolic disorders. Thus, the invention compound II was prepared by heterocyclization of 2-amino-4-methoxybenzoic acid with benzoyl chloride followed by condensation with methylamine.

IT 1187568-17-7P, 2-(4-Chlorophenyl)-7-methoxy-3-methylquinazolin-4(3H)-one 1187568-18-8P,
2-(4-Fluorophenyl)-7-methoxy-3-methylquinazolin-4(3H)-one
1187568-19-9P, 2-(4-Bromophenyl)-7-methoxy-3-methylquinazolin-4(3H)-one 1187568-20-2P,
2-(3-Fluorophenyl)-7-methoxy-3-methylquinazolin-4(3H)-one
1187568-21-3P 1187568-28-0P,
2-(3-Chlorophenyl)-7-methoxy-3-methylquinazolin-4(3H)-one
1187568-31-5P, 2-(4-Fluorophenyl)-7-methoxy-3-(2-morpholinoethyl)quinazolin-4(3H)-one 1187568-32-6P,
2-(4-Chlorophenyl)-7-methoxy-3-(2-morpholinoethyl)quinazolin-4(3H)-one
1187568-35-9P, 7-Chloro-2-(4-chlorophenyl)-3-methylquinazolin-4(3H)-one 1187568-36-0P,
7-Chloro-2-(4-fluorophenyl)-3-methylquinazolin-4(3H)-one
1187568-37-1P, 2-(4-Chlorophenyl)-6-methoxy-3-methylquinazolin-4(3H)-one 1187568-38-2P,
2-(4-Fluorophenyl)-6-methoxy-3-methylquinazolin-4(3H)-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocycles as modulators of estrogen related receptors)
RN 1187568-17-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-chlorophenyl)-7-methoxy-3-methyl- (CA INDEX NAME)




RN 1187568-18-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-7-methoxy-3-methyl- (CA INDEX NAME)




RN 1187568-19-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-bromophenyl)-7-methoxy-3-methyl- (CA INDEX NAME)




RN 1187568-20-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-7-methoxy-3-methyl- (CA INDEX NAME)




RN 1187568-21-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-bromophenyl)-7-hydroxy-3-methyl- (CA INDEX NAME)




RN 1187568-28-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-chlorophenyl)-7-methoxy-3-methyl- (CA INDEX NAME)




RN 1187568-31-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-7-methoxy-3-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 1187568-32-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-chlorophenyl)-7-methoxy-3-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 1187568-35-9 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-2-(4-chlorophenyl)-3-methyl- (CA INDEX NAME)




RN 1187568-36-0 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-(4-fluorophenyl)-3-methyl- (CA INDEX
 NAME)



RN 1187568-37-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-chlorophenyl)-6-methoxy-3-methyl- (CA INDEX
 NAME)



RN 1187568-38-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-6-methoxy-3-methyl- (CA INDEX
 NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2009:975498 CAPLUS
 DOCUMENT NUMBER: 151:267307
 TITLE: Macrocyclic compounds as serine protease inhibitors and their preparation and use in the treatment of HCV infection
 INVENTOR(S): Parsy, Christophe Claude; Alexandre, Francois-Rene; Surleraux, Dominique; Derock, Michel; Leroy, Frederic
 PATENT ASSIGNEE(S): Idenix Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 262 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009099596	A2	20090813	WO 2009-US688	20090203
WO 2009099596	A3	20091203		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20090202480	A1	20090813	US 2009-365127	20090203
PRIORITY APPLN. INFO.:			US 2008-26086P	P 20080204
			US 2008-83867P	P 20080725

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 151:267307

GI



AB Provided herein are macrocyclic serine protease inhibitor compds., for example, of formula I, pharmaceutical compns. comprising the compds., and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. Compds. of formula I wherein R5 is OH, NH2 and derivs., NHSO2H and derivs., NHSO2NH2 and derivs.; R6 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; L is a bond, C1-6 alkylene, C3-7 cycloalkylene, C2-6 alkenylene, etc.; Q1 is O, NH and derivs., (un)substituted methylene, etc.; Q2 is C3-9 alkylene, C3-9 alkenylene, C3-9 alkynylene, etc.; and single enantiomers, racemic mixts., mixts. of diastereoisomers, pharmaceutically acceptable salts, solvates and prodrugs thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their serine protease inhibitory activity. From the assay, it was determined that compound II exhibited IC50 and EC50 values of less than

1 μM and a CC50 value greater than 75 μM .

IT 1180495-05-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of macrocyclic compds. as serine protease inhibitors useful in treatment and prevention of HCV infection)

RN 1180495-05-9 CAPLUS

CN 12aH-Cyclopropa[m]pyrrolo[1,2-c][1,3,6]triazacyclotetradecine-12a-carboxamide, 2-[[8-chloro-2-(4-fluorophenyl)-7-methoxy-4-quinazolinyl]oxy]-1,2,3,3a,4,5,6,7,8,9,11a,12,13,14-tetradecahydro-5-methyl-N-[(1-methylcyclopropyl)sulfonyl]-4,14-dioxo-, (2S,3aS,10Z,11aS,12aR)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L5 ANSWER 3 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:852556 CAPLUS

DOCUMENT NUMBER: 151:171196

TITLE: Toll-like receptor or coreceptor antagonists and treatment or control of ocular allergies

INVENTOR(S): Zhang, Jinzhong; Ward, Keith Wayne; Vo, Toan P.

PATENT ASSIGNEE(S): Bausch & Lomb Incorporated, USA

SOURCE: PCT Int. Appl., 70pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009089401	A2	20090716	WO 2009-US30515	20090109
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2008-20156P P 20080110

AB The authors disclose the use of antagonists of Toll-like receptors, their coreceptors, or a combination thereof for the treatment and control of ocular allergies. Addnl., the therapy can include an anti-allergic medicament comprised of an antihistamine, a mast-cell stabilizer, a leukotriene inhibitor, an immunomodulator, or an anti-IgE agent. In one example, the Toll-like receptor antagonist is an inhibitory oligonucleotide.


IT 1095026-20-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antagonists of Toll-like receptors and TLR coreceptors for treatment of ocular allergies)

RN 1095026-20-2 CAPLUS

CN Ethanamine, N,N-diethyl-2-[[2-[4-(4-methyl-1-piperazinyl)phenyl]-4-quinazolinyl]oxy]- (CA INDEX NAME)



L5 ANSWER 4 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:592954 CAPLUS

DOCUMENT NUMBER: 151:8521

TITLE: preparation of quinolinone derivatives as phosphodiesterase inhibitors

INVENTOR(S): Shen, Jingshan; Zheng, Jin; Lai, Qinglin; Wang, Zhen; Zhang, Jinfeng; Tian, Guanghui

PATENT ASSIGNEE(S): Topharman Shanghai Co., Ltd., Peop. Rep. China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 43pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101429166	A	20090513	CN 2007-10047915	20071107
WO 2009062402	A1	20090522	WO 2008-CN1859	20081107
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: CN 2007-10047915 A 20071107

OTHER SOURCE(S): CASREACT 151:8521; MARPAT 151:8521

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; wherein R1 = H, halo, (un)substituted alkyl, OH, or NH2,


etc.; R2 to R4 independently = H, (un)substituted alkyl, or cycloalkyl; R5 = H, OH, NO2, halo, CN, or NH2, etc.), and their pharmaceutically acceptable salts thereof, were prepared. The compounds I have stronger inhibition activity to PDE5 than sildenafil, and have high selectivity to PDE6 in retina. For instance, the invention compound II was prepared by amidation of 2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)benzoic acid with compound III followed by heterocyclization.

IT 1159282-78-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinolinone derivs. as phosphodiesterase inhibitors)

RN 1159282-78-6 CAPLUS

CN 4(3H)-Quinazolinone, 8-bromo-2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5,7-dimethoxy- (CA INDEX NAME)




IT	1159282-79-7P	1159282-80-0P	1159282-81-1P
	1159282-82-2P	1159282-83-3P	1159282-84-4P
	1159282-85-5P	1159282-86-6P	1159282-87-7P
	1159282-88-8P	1159282-89-9P	1159282-90-2P
	1159282-91-3P	1159282-92-4P	1159282-93-5P
	1159282-94-6P	1159282-95-7P	1159282-96-8P
	1159282-97-9P	1159282-98-0P	1159282-99-1P
	1159283-00-7P	1159283-01-8P	1159283-02-9P
	1159283-03-0P	1159283-04-1P	1159283-05-2P
	1159283-06-3P	1159283-07-4P	1159283-08-5P
	1159283-09-6P	1159283-10-9P	1159283-11-0P
	1159283-12-1P	1159283-13-2P	1159283-14-3P
	1159283-15-4P	1159283-16-5P	1159283-17-6P
	1159283-18-7P	1159283-19-8P	1159283-20-1P
	1159283-21-2P	1159283-22-3P	1159283-23-4P
	1159283-24-5P	1159283-25-6P	1159283-26-7P
	1159283-29-0P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolinone derivs. as phosphodiesterase inhibitors)


RN 1159282-79-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5,7-dimethoxy-8-methyl- (CA INDEX NAME)




RN 1159282-80-0 CAPLUS

CN 4(3H)-Quinazolinone, 8-bromo-2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5-hydroxy-7-methoxy- (CA INDEX NAME)




RN 1159282-81-1 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[2-(4-morpholinyl)ethyl]-4-propoxy- (CA INDEX NAME)




RN 1159282-82-2 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[3-(4-morpholinyl)propyl]-4-propoxy- (CA INDEX NAME)




RN 1159282-83-3 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[2-(diethylamino)ethyl]-4-propoxy- (CA INDEX NAME)




RN 1159282-84-4 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[2-(dimethylamino)ethyl]-4-propoxy- (CA INDEX NAME)




RN 1159282-85-5 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-(2-hydroxyethyl)-N-[2-(4-morpholinyl)ethyl]-4-propoxy- (CA INDEX NAME)




RN 1159282-86-6 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-methyl-4-propoxy-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 1159282-87-7 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]-4-propoxy- (CA INDEX NAME)




RN 1159282-88-8 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-(2-ethoxyethyl)-N-[2-(4-morpholinyl)ethyl]-4-propoxy- (CA INDEX NAME)




RN 1159282-89-9 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-ethyl-N-[3-(1-piperidinyl)propyl]-4-propoxy- (CA INDEX NAME)




RN 1159282-90-2 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-ethyl-N-[2-(4-morpholinyl)ethyl]-4-propoxy- (CA INDEX NAME)




RN 1159282-91-3 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[2-(2-hydroxyethoxy)ethyl]-N-[2-(4-morpholinyl)ethyl]-4-propoxy- (CA INDEX NAME)




RN 1159282-92-4 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[2-(2-methoxyethoxy)ethyl]-N-[2-(4-morpholinyl)ethyl]-4-propoxy- (CA INDEX NAME)




RN 1159282-93-5 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[2-(dimethylamino)ethyl]-N-methyl-4-propoxy- (CA INDEX NAME)




RN 1159282-94-6 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[2-(4-morpholinyl)ethyl]-4-propoxy-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 1159282-95-7 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[2-(4-morpholinyl)ethyl]-4-propoxy-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 1159282-96-8 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[2-(4-morpholinyl)ethyl]-N-(phenylmethyl)-4-propoxy- (CA INDEX NAME)




RN 1159282-97-9 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[3-(4-morpholinyl)propyl]-N-(phenylmethyl)-4-propoxy- (CA INDEX NAME)




RN 1159282-98-0 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-N-methyl-4-propoxy- (CA INDEX NAME)




RN 1159282-99-1 CAPLUS

CN Benzenesulfonamide, 3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-propoxy- (CA INDEX NAME)




RN 1159283-00-7 CAPLUS

CN 4(3H)-Quinazolinone, 8-bromo-5,7-dimethoxy-2-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-propoxyphenyl]- (CA INDEX NAME)




RN 1159283-01-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-chloro-2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1159283-02-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-8-fluoro-5,7-dimethoxy- (CA INDEX NAME)




RN 1159283-03-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-8-iodo-5,7-dimethoxy- (CA INDEX NAME)




RN 1159283-04-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1159283-05-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-8-ethyl-5,7-dimethoxy- (CA INDEX NAME)




RN 1159283-06-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5,7-dimethoxy-8-propyl- (CA INDEX NAME)




RN 1159283-07-4 CAPLUS

CN 4(3H)-Quinazolinone, 8-butyl-2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1159283-08-5 CAPLUS

CN 4(3H)-Quinazolinone, 8-ethenyl-2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1159283-09-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5,7-dimethoxy-8-(2-propen-1-yl)- (CA INDEX NAME)




RN 1159283-10-9 CAPLUS

CN 4(3H)-Quinazolinone, 8-chloro-2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5-hydroxy-7-methoxy- (CA INDEX NAME)




RN 1159283-11-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-8-fluoro-5-hydroxy-7-methoxy- (CA INDEX NAME)




RN 1159283-12-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5-hydroxy-8-iodo-7-methoxy- (CA INDEX NAME)




RN 1159283-13-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5-hydroxy-7-methoxy- (CA INDEX NAME)



RN 1159283-14-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-8-ethyl-5-hydroxy-7-methoxy- (CA INDEX NAME)




RN 1159283-15-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5-hydroxy-7-methoxy-8-propyl- (CA INDEX NAME)




RN 1159283-16-5 CAPLUS

CN 4(3H)-Quinazolinone, 8-butyl-2-[[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5-hydroxy-7-methoxy- (CA INDEX NAME)




RN 1159283-17-6 CAPLUS

CN 4(3H)-Quinazolinone, 8-ethenyl-2-[[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5-hydroxy-7-methoxy- (CA INDEX NAME)




RN 1159283-18-7 CAPLUS

CN 4(3H)-Quinazolinone, 8-bromo-5-hydroxy-7-methoxy-2-[[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-propoxyphenyl]- (CA INDEX NAME)




RN 1159283-19-8 CAPLUS

CN 4(3H)-Quinazolinone, 5-hydroxy-8-iodo-7-methoxy-2-[[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-propoxyphenyl]- (CA INDEX NAME)




RN 1159283-20-1 CAPLUS

CN 4(3H)-Quinazolinone, 8-iodo-5,7-dimethoxy-2-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-propoxyphenyl]- (CA INDEX NAME)




RN 1159283-21-2 CAPLUS

CN Benzenesulfonamide, N-[2-[(aminoiminomethyl)amino]ethyl]-3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-(2-hydroxyethyl)-4-propoxy- (CA INDEX NAME)




RN 1159283-22-3 CAPLUS

CN Benzenesulfonamide, N-[2-[(aminoiminomethyl)amino]ethyl]-3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-phenyl-4-propoxy- (CA INDEX NAME)




RN 1159283-23-4 CAPLUS

CN Benzenesulfonamide, N-[3-[(aminoiminomethyl)amino]propyl]-3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-4-propoxy-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 1159283-24-5 CAPLUS

CN Benzenesulfonamide, N-[2-[(aminoiminomethyl)amino]ethyl]-3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-(phenylmethyl)-4-propoxy- (CA INDEX NAME)




RN 1159283-25-6 CAPLUS

CN Benzenesulfonamide, N-[3-[(aminoiminomethyl)amino]propyl]-3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-4-propoxy-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 1159283-26-7 CAPLUS

CN Benzenesulfonamide, N-[2-[(aminoiminomethyl)amino]ethyl]-3-(8-bromo-3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-N-ethyl-4-propoxy- (CA INDEX NAME)



RN 1159283-29-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5-hydroxy-7-methoxy-8-methyl- (CA INDEX NAME)



L5 ANSWER 5 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:578214 CAPLUS

DOCUMENT NUMBER: 151:282488

TITLE: Design and synthesis of a new 125I labeled prodrug
Hu, Ziwen; Wang, Ketai; Wan, Tao; Liao, Huajing; Wu, XiaorongCORPORATE SOURCE: College of Materials and Chemistry and Chemical
Engineering, Chengdu University of Technology,
Chengdu, 610059, Peop. Rep. China

SOURCE: Sichuan Daxue Xuebao, Ziran Kexueban (2009), 46(1),

195-200

CODEN: SCTHAO; ISSN: 0490-6756

PUBLISHER: Sichuan Daxue Xuebao Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

AB A new water-soluble radiolabeled prodrug 2-(2-phosphoryloxyphenyl)-6-125I-4(3H)-quinazolinone was designed and synthesized, which can be converted to a water-insol. radiolabeled drug by the action of alkaline phosphatase for antibody-directed enzyme prodrug therapy (ADEPT). When the pro-drug react with special enzyme on the surface of tumor, the prodrug changes to therapeutic drug and then pervades into tumor tissue and the radioactive 125I will use it radiance to kill the tumor cell. This compound, known as the ELF (enzyme-labeled-fluorescence) phosphatase substrate, produces a precipitate that fluoresces at about 500- 600 nm (bright yellow-green). The radiolabeled precipitate will be trapped within the tumor mass and should produce protracted irradiation of tumor cells. The compound

can


be hydrolyzed to water-insol. 2-(2-hydroxyphenyl)-6-iodo-4(3H)-quinazolinone when incubated with alkaline phosphatase. Bis(tributyl)stannane used to activate organic compound during labeling was good.

IT 752977-04-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (design and synthesis of a new prodrug 2-(2-phosphoryloxyphenyl)-6-iodo-125I-4(3H)-quinazolinone)

RN 752977-04-1 CAPLUS

CN 4(1H)-Quinazolinone, 6-(iodo-125I)-2-[2-(phosphonoxy)phenyl]- (CA INDEX NAME)



L5 ANSWER 6 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:478065 CAPLUS

DOCUMENT NUMBER: 151:48478

TITLE: Fragment and knowledge-based design of selective GSK-3 β inhibitors using virtual screening models
 AUTHOR(S): Vadivelan, S.; Sinha, Barij Nayan; Tajne, Sunita; Jagarlapudi, Sarma A. R. P.

CORPORATE SOURCE: GVK Biosciences Private Limited, Nungambakkam, Chennai, Tamil Nadu, 600 034, India

SOURCE: European Journal of Medicinal Chemistry (2009), 44(6), 2361-2371

CODEN: EJMCAS; ISSN: 0223-5234

PUBLISHER: Elsevier Masson SAS


DOCUMENT TYPE: Journal

LANGUAGE: English


AB Glycogen synthase kinase 3 β (GSK-3 β) is one of the important targets in the treatment of type II diabetes and Alzheimer's disease. Currently this target is in pursuit for type II diabetes and a few GSK-3 β inhibitors have been now advanced to Phases I and II of clin.

trials. The best validated HypoGen model consists of four pharmacophore features; (1) two hydrogen bond acceptors, (2) one hydrogen bond donor and (3) one hydrophobic. This pharmacophore model correlates well with the docking model, one hydrogen bond acceptor is necessary for the H-bond interaction with Val135, and second hydrogen bond acceptor is important for the H-bond interactions with Arg141 and the hydrophobic feature may be required for the weak H-bond interactions with Asp133. The comparative model was developed from analog and structure-based models like Catalyst, Glide SP & XP, Gold Fitness & ChemScore and Ligand Fit using multiple linear regression anal. A virtual library of 10,000 mols. was generated employing the fragment and knowledge-based approach and the comparative model was used to predict the activities of these mols. The H-bond with Arg141 appears to be unique to GSK-3 β and explains the high GSK-3 β selectivity observed for 1H-quinazolin-4-ones and benzo[e][1,3]oxazin-4-ones. This understanding of protein-ligand interactions and mol. recognition increases the rapid development of potent and selective inhibitors, and also helps to eliminate the increase in number of false positives and negatives.

IT 1160818-94-9 1160818-95-0
 RL: PAC (Pharmacological activity); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fragment and knowledge-based design of selective glycogen synthase
 kinase-3 β inhibitors using virtual screening models)
 RN 1160818-94-9 CAPLUS
 CN 7-Quinazolinecarbonitrile, 2-[4-(4-chlorobenzoyl)phenyl]-3,4-dihydro-4-oxo-
 (CA INDEX NAME)



RN 1160818-95-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-(4-pyridinylcarbonyl)phenyl]-7-(trifluoromethyl)-
 (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)
 REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:426350 CAPLUS
 DOCUMENT NUMBER: 150:464187
 TITLE: Hsp90 inhibitor 3h-quinazolin-4-one derivatives and their use as anticancer agents
 INVENTOR(S): Han, Ji Suk; Park, Hwang Seo; Kim, Yun Jeong
 PATENT ASSIGNEE(S): Seoul National University, Industry-Academy Cooperation Foundation, S. Korea
 SOURCE: Repub. Korean Kongkae Taeho Kongbo, 13pp.
 CODEN: KRXXA7
 DOCUMENT TYPE: Patent
 LANGUAGE: Korean
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2009033634	A	20090406	KR 2007-98765	20071001
KR 933559	B1	20091223		

PRIORITY APPLN. INFO.: KR 2007-98765 20071001


AB This invention relates to screening Hsp90 inhibitors, 3h-quinazolin-4-one derivs. The inhibitors were able to bind to Hsp90 ATP binding site and the ATPase activity of the Hsp90 was used for screening the effect of the inhibitors. Treatment of MCF-7 cells with the inhibitors resulted in the repressing the expression of Her2 protein and stimulating the expression of Hsp70. The inhibitors can be used for preparation anticancer agent composition

IT such as tablets, capsules and injections.

IT 1147097-24-2
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (hsp90 inhibitor 3h-quinazolin-4-one derivs. and their use anticancer agents)

RN 1147097-24-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-[(4-methoxy-2,5-cyclohexadien-1-yl)oxy]ethyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)



L5 ANSWER 8 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:24983 CAPLUS
 DOCUMENT NUMBER: 150:114279
 TITLE: Human Toll-like receptor antagonists and anti-infective compositions, including a fluoroquinolone, for treating or controlling eye infections
 INVENTOR(S): Zhang, Jinzhong; Ward, Keith Wayne
 PATENT ASSIGNEE(S): Bausch & Lomb Incorporated, USA
 SOURCE: PCT Int. Appl., 69pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009006141	A2	20090108	WO 2008-US68126	20080625
WO 2009006141	A3	20090219		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: US 2007-948060P P 20070705

AB Compsns. for treating or controlling an eye infection and sequelae thereof comprise an antagonist to a Toll-like receptor (TLR), a CD14 or MD-2 coreceptor thereof, or a combination thereof, and an anti-infective agent. The compsns. can also include another anti-inflammatory medicament. The claimed Toll-like receptor antagonists include sequences of anti-human TLR antibodies comprising a heavy-chain complementarity determining region (CDR)

and


a light-chain CDR and sequences of oligonucleotide antagonists. The invention also claims TLR antagonists that comprise ligands of vitamin D receptor. The invention further claims compds. that inhibit activation of a human TLR signaling pathway such as a soluble form of an extracellular domain of a human TLR that recognizes a microbe-expressed mol. structure, or a soluble form of the TLR coreceptors CD14 or MD-2. The oligonucleotide ODN 2088 provided dose-dependent inhibition of production of pro-inflammatory chemokines MIP-2, KC, TNF- α , IL-6 by murine neutrophils that were activated by bacterial DNA, whole killed bacteria, or a stimulatory oligonucleotide.

IT 1095026-20-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (TLR3, TLR7, TLR8 and TLR9 antagonists; human Toll-like receptor antagonists and anti-infective comps., including a fluoroquinolone, for treating or controlling eye infections)

RN 1095026-20-2 CAPLUS

CN Ethanamine, N,N-diethyl-2-[[2-[4-(4-methyl-1-piperazinyl)phenyl]-4-quinazolinyl]oxy]- (CA INDEX NAME)




DOCUMENT NUMBER: 150:96363
 TITLE: Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
 INVENTOR(S): Zhang, Jinzhong; Ward, Keith Wayne
 PATENT ASSIGNEE(S): Bausch & Lomb Incorporated, USA
 SOURCE: PCT Int. Appl., 61pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009002790	A2	20081231	WO 2008-US67419	20080619
WO 2009002790	A3	20090319		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AI, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-946261P P 20070626
 AB The authors disclose compns. and methods for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition. The compns. comprise an antagonist(s) to a Toll-like receptor. In one example, the antiinflammatory antagonist comprises ODN 2088.
 IT 1095026-20-2
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antagonists of human Toll-like receptors for treatment of dry eye)
 RN 1095026-20-2 CAPLUS
 CN Ethanamine, N,N-diethyl-2-[[2-[4-(4-methyl-1-piperazinyl)phenyl]-4-quinazolinyl]oxy]- (CA INDEX NAME)



L5 ANSWER 10 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:1372374 CAPLUS
 DOCUMENT NUMBER: 150:266
 TITLE: Development of novel
 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone
 derivatives as potent and selective histamine H3
 receptor inverse agonists
 AUTHOR(S): Mizutani, Takashi; Nagase, Tsuyoshi; Ito, Sayaka;
 Miyamoto, Yasuhisa; Tanaka, Takeshi; Takenaga,

CORPORATE SOURCE: Norihiro; Tokita, Shigeru; Sato, Nagaaki
Tsukuba Research Institute, Merck Research
Laboratories, Banyu Pharmaceutical Co., Ltd., 3 Okubo,
Tsukuba, Ibaraki, 300-2611, Japan

SOURCE: Bioorganic & Medicinal Chemistry Letters (2008),
18(23), 6041-6045
CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 150:266

GI



I

AB Novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivs. were identified as potent human H3 receptor inverse agonists. After systematic modification of lead 5a, the potent and selective analog 5r (I) was identified. Elimination of hERG K⁺ channel and human α 1A-adrenoceptor activities is the main focus of the present study.


IT 870996-38-6P 870996-40-0P 870996-46-6P
870996-48-8P 870996-52-4P 870996-54-6P
870996-63-7P 870996-83-1P 870996-84-2P
870996-85-3P 870996-88-6P 870997-06-1P
870997-40-3P 870997-42-5P 870997-43-6P
870997-44-7P 1026860-15-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(aminoalkoxy)phenyl quinazolinone derivs. as histamine H3 receptor inverse agonists)

RN 870996-38-6 CAPLUS


CN 4(3H)-Quinazolinone, 3-methyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)



10/ 582,823


RN 870996-40-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-ethyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-46-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-(1-piperidinyl)propoxy]phenyl]-3-propyl- (CA INDEX NAME)




RN 870996-48-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-52-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(1-methylethyl)-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-54-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-phenyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-63-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-
(CA INDEX NAME)




RN 870996-83-1 CAPLUS

CN 4(3H)-Quinazolinone, 8-chloro-2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-3-methyl-
(CA INDEX NAME)




RN 870996-84-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-3-methyl-8-(trifluoromethyl)-
(CA INDEX NAME)




RN 870996-85-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-3,8-dimethyl-
(CA INDEX NAME)




RN 870996-88-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-8-fluoro-3-methyl- (CA INDEX NAME)




RN 870997-06-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-7-methoxy-3-methyl- (CA INDEX NAME)



RN 870997-40-3 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-3-methyl- (CA INDEX NAME)



10/ 582,823


RN 870997-42-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyloxy)phenyl]-8-methoxy-3-methyl- (CA INDEX NAME)




RN 870997-43-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyloxy)phenyl]-6-methoxy-3-methyl- (CA INDEX NAME)




RN 870997-44-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyloxy)phenyl]-5-methoxy-3-methyl- (CA INDEX NAME)



RN 1026860-15-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1007107 CAPLUS

DOCUMENT NUMBER: 149:315569

TITLE: Therapeutic release agents, esters of alkylcarbamic
acids, as inhibitors of fatty acid amide hydrolase
activity

INVENTOR(S): Dasse, Olivier; Parrott, Jeff A.; Putman, David; Adam,
Julia

PATENT ASSIGNEE(S): N.V. Organon, Neth.

SOURCE: PCT Int. Appl., 250pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008100977	A2	20080821	WO 2008-US53785	20080213
WO 2008100977	A3	20081218		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2007-88909P P 20070214
US 2007-948082P P 20070705

OTHER SOURCE(S): MARPAT 149:315569


AB Pharmacol. inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compds. disclosed herein inhibit FAAH activity. Described herein are processes for the preparation of esters of alkylcarbamic acid compds., compns. that include them, and methods of use thereof. Thus, to prepare a parenteral pharmaceutical composition for injection, 100 mg of a water-soluble salt of a compound of the invention was dissolved in DMSO and mixed with 10 mL of 0.9% sterile

saline; the mixture was incorporated into dosage form unit suitable for administration by injection.

IT 242478-03-1D, derivs.
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic release agents, esters of alkylcarbamic acids, as inhibitors of fatty acid amide hydrolase activity)

RN 242478-03-1 CAPLUS

CN 4(3H)-Quinazolinone, 7-hydroxy-2-(4-hydroxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



L5 ANSWER 12 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:946244 CAPLUS

DOCUMENT NUMBER: 149:246409

TITLE: Preparation of phenyldimethoxyisoquinolinone derivatives and analogs as cardiovascular agents
 INVENTOR(S): Wong, Norman C.W.; Tucker, Joseph E.L.; Hansen, Henrik C.; Chiacchia, Fabrizio S.; McCaffrey, David
 PATENT ASSIGNEE(S): Resverlogix Corp., Can.
 SOURCE: U.S. Pat. Appl. Publ., 85 pp.
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080188467	A1	20080807	US 2007-670238	20070201
PRIORITY APPLN. INFO.:			US 2007-670238	20070201
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 149:246409				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [each W independently = C or N, wherein if W is N, then p = 0 or 1 and if W is C, then p = 1; X = CR11, N, NR11, etc.; Y = CR11, CO, CS, S, etc.; R1 and R3 independently = H, OH, halo, alkyl, etc.; R2 = H, halo, alkoxy, etc.; R4 = H; each R5 and R9 independently = H, halo, alkyl,


alkenyl, or alkynyl; R6 and R8 independently = H, halo, heterocyclyl, etc.; R7 = H, OH, alkoxy, etc.; R10 = H or Me; R11 = H, unsubstituted alkyl, alkenyl, or alkynyl; or two adjacent substituents selected from R1, R2, R3, R5, R6, R7, R8, R9, R10, and R11 are connected to form aryl, heteroaryl, cycloalkyl, or heterocyclyl; or each R5 or R9 may independently be taken together with R10 or R11 to form aryl, heteroaryl, cycloalkyl, or heterocyclyl; with provisions], and their pharmaceutically acceptable salts, are prepared and disclosed as cardiovascular agents. Thus, e.g., II was prepared by chlorination of 2-methyl-4,6-dimethoxybenzoic acid followed by amidation with methylamine, cyclocondensation with 4-(2-tert-butylidimethylsiloxy)-3,5-dimethylbenzonitrile, and deprotection. Select I were evaluated in ApoA-I mRNA quantification assays, e.g., II demonstrated activity by causing a >15% increase in ApoA-I mRNA at a concentration less than or equal to 100 μ M.

IT 1044870-39-4P 1044870-55-4P 1044870-65-6P
 1044870-72-5P 1044870-89-4P 1044870-95-2P
 1044870-96-3P 1044871-31-9P 1044871-46-6P
 1044871-78-4P 1044871-87-5P 1044871-88-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of phenyldimethoxyisoquinolinone derivs. and analogs as cardiovascular agents)


RN 1044870-39-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044870-55-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3,5-dimethyl-4-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 1044870-65-6 CAPLUS


CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-[4-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 1044870-72-5 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 1044870-89-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-hydroxy-3,5-dimethylphenyl)-6-(4-morpholinylmethyl)- (CA INDEX NAME)



RN 1044870-95-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044870-96-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-5,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 1044871-31-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-amino-3,5-dimethylphenyl)-5,7-dimethoxy- (CA INDEX NAME)



RN 1044871-46-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[4-(2-aminoethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-78-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[3,5-dimethyl-4-[2-(4-morpholinyl)ethoxy]phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-87-5 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (CA INDEX NAME)



RN 1044871-88-6 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-[4-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)



IT	1044870-30-5P	1044870-40-7P	1044870-43-0P
	1044870-44-1P	1044870-48-5P	1044870-49-6P
	1044870-50-9P	1044870-51-0P	1044870-52-1P
	1044870-56-5P	1044870-57-6P	1044870-60-1P
	1044870-61-2P	1044870-63-4P	1044870-66-7P
	1044870-68-9P	1044870-69-0P	1044870-70-3P
	1044870-73-6P	1044870-76-9P	1044870-77-0P
	1044870-78-1P	1044870-79-2P	1044870-80-5P
	1044870-82-7P	1044870-83-8P	1044870-84-9P
	1044870-86-1P	1044870-90-7P	1044870-92-9P
	1044870-93-0P	1044870-94-1P	1044870-98-5P
	1044871-04-6P	1044871-06-8P	1044871-09-1P
	1044871-11-5P	1044871-14-8P	1044871-15-9P
	1044871-17-1P	1044871-18-2P	1044871-19-3P
	1044871-20-6P	1044871-21-7P	1044871-29-5P
	1044871-33-1P	1044871-35-3P	1044871-36-4P
	1044871-38-6P	1044871-40-0P	1044871-41-1P
	1044871-43-3P	1044871-44-4P	1044871-45-5P
	1044871-48-8P	1044871-50-2P	1044871-52-4P
	1044871-54-6P	1044871-56-8P	1044871-58-0P


1044871-60-4P	1044871-62-6P	1044871-64-8P
1044871-66-0P	1044871-67-1P	1044871-68-2P
1044871-70-6P	1044871-71-7P	1044871-73-9P
1044871-74-0P	1044871-75-1P	1044871-76-2P
1044871-77-3P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenyldimethoxyisoquinolinone derivs. and analogs as cardiovascular agents)


RN 1044870-30-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy- (CA INDEX NAME)



RN 1044870-40-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-[3,5-dimethyl-4-[2-(4-morpholinyl)ethoxy]phenyl]-5,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1044870-43-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-hydroxyphenyl)-5,7-dimethoxy- (CA INDEX NAME)




RN 1044870-44-1 CAPLUS

CN Acetic acid, 2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)phenoxy]-
(CA INDEX NAME)




RN 1044870-48-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044870-49-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-5,7-dimethoxy- (CA INDEX NAME)



RN 1044870-50-9 CAPLUS


CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 1044870-51-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-(4-hydroxy-3-methoxyphenyl)-5,7-dimethoxy- (CA INDEX NAME)

INDEX NAME)




RN 1044870-52-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-chloro-4-hydroxyphenyl)-5,7-dimethoxy- (CA INDEX NAME)



RN 1044870-56-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-[3,5-dimethyl-4-[2-(4-morpholinyl)ethoxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1044870-57-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 1044870-60-1 CAPLUS

CN Acetamide, 2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)phenoxy]-
(CA INDEX NAME)




RN 1044870-61-2 CAPLUS

CN Acetic acid, 2-[4-(3,4-dihydro-4-oxo-2-quinazolinyl)phenoxy]- (CA INDEX
NAME)



RN 1044870-63-4 CAPLUS


CN Acetamide, 2-[4-(3,4-dihydro-4-oxo-2-quinazolinyl)phenoxy]- (CA INDEX
NAME)



RN 1044870-66-7 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-[4-(4-methyl-1-piperazinyl)phenyl]-,


hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1044870-68-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[bis(2-hydroxyethyl)amino]phenyl]- (CA INDEX NAME)




RN 1044870-69-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[bis(2-hydroxyethyl)amino]phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044870-70-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[bis(2-hydroxyethyl)amino]phenyl]-6,7-dimethoxy- (CA INDEX NAME)



RN 1044870-73-6 CAPLUS


CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-[4-(4-morpholinyl)phenyl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1044870-76-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-hydroxy-3,5-dimethylphenyl)-6,7-dimethoxy- (CA
INDEX NAME)




RN 1044870-77-0 CAPLUS

CN Benzenepropanoic acid, 4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-
(CA INDEX NAME)




RN 1044870-78-1 CAPLUS

CN Acetamide, N-[3,4-dihydro-2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-6-quinazolinyl]- (CA INDEX NAME)




RN 1044870-79-2 CAPLUS

CN Acetamide, 2-[4-(3,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]- (CA INDEX NAME)




RN 1044870-80-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-chloro-4-(2-hydroxyethoxy)phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044870-82-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(2-hydroxyethoxy)-3-methoxyphenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044870-83-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(2-hydroxyethoxy)-3,5-dimethoxyphenyl]-6,7-dimethoxy- (CA INDEX NAME)



RN 1044870-84-9 CAPLUS


CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1044870-86-1 CAPLUS

CN Acetamide, N-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenyl]-2-hydroxy- (CA INDEX NAME)



RN 1044870-90-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-(4-hydroxy-3,5-dimethylphenyl)-6-(4-morpholinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1044870-92-9 CAPLUS

CN Acetic acid, 2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]- (CA INDEX NAME)




RN 1044870-93-0 CAPLUS

CN Acetamide, N-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)phenyl]-2-hydroxy- (CA INDEX NAME)



RN 1044870-94-1 CAPLUS


CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-[4-(4-morpholinylmethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1044870-98-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-methoxy-3-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)




RN 1044871-04-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3,5-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, 5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-06-8 CAPLUS

CN Acetamide, N-[3,4-dihydro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-4-oxo-6-quinazolinyl]- (CA INDEX NAME)




RN 1044871-09-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-11-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethyl- (CA INDEX NAME)




RN 1044871-14-8 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-[4-(2-methoxyethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 1044871-15-9 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dichloro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 1044871-17-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy-6-(4-morpholinylmethyl)- (CA INDEX NAME)



RN 1044871-18-2 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6-methoxy- (CA INDEX NAME)



10/ 582,823


RN 1044871-19-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-chlorophenyl)-5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-20-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5-methoxy- (CA INDEX NAME)




RN 1044871-21-7 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-(2-methylphenyl)- (CA INDEX NAME)




RN 1044871-29-5 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-(4-methoxy-3,5-dimethylphenyl)- (CA INDEX NAME)




RN 1044871-33-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethylphenyl)-5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-35-3 CAPLUS

CN Methanimidamide, N'-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 1044871-36-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(4-hydroxy-3,5-dimethylphenyl)- (CA INDEX NAME)




RN 1044871-38-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 1044871-40-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[4-[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethoxy]-3,5-dimethylphenyl]- (CA INDEX NAME)



RN 1044871-41-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3,5-dimethyl-4-(phenylmethoxy)phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-43-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-(2-hydroxyethoxy)-3-methylphenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-44-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-hydroxy-3-methylphenyl)-5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-45-5 CAPLUS

CN 1,2-Benzenedicarboxamide, N1-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-N2-methyl- (CA INDEX NAME)




RN 1044871-48-8 CAPLUS

CN Benzenesulfonamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-4-methoxy- (CA INDEX NAME)




RN 1044871-50-2 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]- (CA INDEX NAME)




RN 1044871-52-4 CAPLUS

CN Methanesulfonamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]- (CA INDEX NAME)




RN 1044871-54-6 CAPLUS

CN Acetic acid, 2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2-methoxyphenoxy]- (CA INDEX NAME)




RN 1044871-56-8 CAPLUS

CN 4(3H)-Quinazolinone, 5-hydroxy-2-(4-hydroxy-3,5-dimethylphenyl)-7-methoxy- (CA INDEX NAME)




RN 1044871-58-0 CAPLUS

CN Carbamic acid, N-propyl-, 2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl ester (CA INDEX NAME)




RN 1044871-60-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3,5-dimethyl-4-[2-[[(methylamino) carbonyl]oxy]ethoxy]phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-62-6 CAPLUS

CN Benzamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-4-methyl- (CA INDEX NAME)




RN 1044871-64-8 CAPLUS

CN Carbamic acid, N-cyclohexyl-, 2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl ester (CA INDEX NAME)




RN 1044871-66-0 CAPLUS

CN Benzenesulfonamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]- (CA INDEX NAME)




RN 1044871-67-1 CAPLUS

CN Benzenesulfonamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-4-methyl- (CA INDEX NAME)




RN 1044871-68-2 CAPLUS

CN Benzenesulfonamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-4-methoxy- (CA INDEX NAME)




RN 1044871-70-6 CAPLUS

CN Acetamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]- (CA INDEX NAME)




RN 1044871-71-7 CAPLUS

CN Benzanide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]- (CA INDEX NAME)




RN 1044871-73-9 CAPLUS

CN Propanamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-2-methyl- (CA INDEX NAME)




RN 1044871-74-0 CAPLUS

CN Urea, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-N'-methyl- (CA INDEX NAME)




RN 1044871-75-1 CAPLUS

CN Urea, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)




RN 1044871-76-2 CAPLUS

CN Urea, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-N'-phenyl- (CA INDEX NAME)



RN 1044871-77-3 CAPLUS

CN Urea, N'-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-N,N-dimethyl- (CA INDEX NAME)




IT 1044871-91-1 1044871-92-2 1044871-93-3

1044871-95-5


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)(preparation of phenyldimethoxyisoquinolinone derivs. and analogs as
cardiovascular agents)

RN 1044871-91-1 CAPLUS


CN 1H-Isoidole-1,3(2H)-dione, 2-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-
quinazolinyl)-2,6-dimethylphenoxy]ethyl]- (CA INDEX NAME)

RN 1044871-92-2 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-(3-nitrophenyl)- (CA INDEX NAME)




RN 1044871-93-3 CAPLUS

CN Phenol, 4-(4-ethoxy-5,7-dimethoxy-2-quinazolinyl)-2,6-dimethyl- (CA INDEX
NAME)

RN 1044871-95-5 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-(4-methylphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L5 ANSWER 13 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:942513 CAPLUS

DOCUMENT NUMBER: 149:246407

TITLE: Preparation of phenyldimethoxyisoquinolinone derivatives and analogs as cardiovascular agents

INVENTOR(S): Hansen, Henrik

PATENT ASSIGNEE(S): Resverlogix Corp., Can.

SOURCE: PCT Int. Appl., 123pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008092231	A1	20080807	WO 2007-CA146	20070201
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2007345526	A1	20080807	AU 2007-345526	20070201
AU 2007345526	A2	20091008		
CA 2676984	A1	20080807	CA 2007-2676984	20070201
EP 2118074	A1	20091118	EP 2007-710597	20070201
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			WO 2007-CA146	A 20070201
OTHER SOURCE(S):	MARPAT 149:246407			

GI



I




II

AB Title compds. I [each W independently = C or N; X = N or CH; each R1 and R3 independently = H or alkoxy; R2 = H, alkyl, or alkoxy; R4, R5, and R10 = H; each R6 and R8 independently = H, Cl, alkyl, or alkoxy; R7 = NH2, OH, alkoxy, or alkyl substituted with a heterocyclyl; or two adjacent substituents selected from R6, R7, or R8 are connected to form a heterocyclyl; p = 0 or 1; with provisions], and their pharmaceutically acceptable salts, are prepared and disclosed as cardiovascular agents. Thus, e.g., II was prepared by chlorination of 2-methyl-4,6-dimethoxybenzoic acid followed by amidation with methylamine, cyclocondensation with 4-(2-tert-butyl-4,6-dimethoxyphenyl)-3,5-dimethyl benzonitrile, and deprotection. Select I were evaluated in ApoA-I mRNA quantification assays, e.g., II demonstrated activity by causing a >15% increase in ApoA-I mRNA at a concentration less than or equal to 100 μ M.

IT 1044870-39-4P 1044870-95-2P 1044871-46-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of phenyldimethoxyisoquinolinone derivs. and analogs as cardiovascular agents)


RN 1044870-39-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044870-95-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-5,7-dimethoxy- (CA INDEX NAME)



RN 1044871-46-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(2-aminoethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy- (CA INDEX NAME)



IT 1044870-30-5P 1044870-51-0P 1044870-69-0P

1044870-70-3P 1044870-96-3P 1044871-29-5P

1044871-31-9P 1044871-45-5P 1044871-48-8P

1044871-50-2P 1044871-52-4P 1044871-58-0P

1044871-60-4P 1044871-62-6P 1044871-64-8P

1044871-66-0P 1044871-67-1P 1044871-68-2P

1044871-70-6P 1044871-71-7P 1044871-73-9P

1044871-74-0P 1044871-75-1P 1044871-76-2P


1044871-77-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenyldimethoxyisoquinolinone derivs. and analogs as cardiovascular agents)


RN 1044870-30-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy- (CA INDEX NAME)




RN 1044870-51-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-hydroxy-3-methoxyphenyl)-5,7-dimethoxy- (CA INDEX NAME)




RN 1044870-69-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[bis(2-hydroxyethyl)amino]phenyl]-5,7-dimethoxy- (CA INDEX NAME)



RN 1044870-70-3 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[bis(2-hydroxyethyl)amino]phenyl]-6,7-dimethoxy- (CA INDEX NAME)



10/ 582,823

RN 1044870-96-3 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-5,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1044871-29-5 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dimethoxy-2-(4-methoxy-3,5-dimethylphenyl)- (CA INDEX NAME)




RN 1044871-31-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-amino-3,5-dimethylphenyl)-5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-45-5 CAPLUS

CN 1,2-Benzenedicarboxamide, N1-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-N2-methyl- (CA INDEX NAME)




RN 1044871-48-8 CAPLUS

CN Benzenesulfonamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-4-methoxy- (CA INDEX NAME)




RN 1044871-50-2 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]- (CA INDEX NAME)




RN 1044871-52-4 CAPLUS

CN Methanesulfonamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]- (CA INDEX NAME)




RN 1044871-58-0 CAPLUS

CN Carbamic acid, N-propyl-, 2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl ester (CA INDEX NAME)




RN 1044871-60-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3,5-dimethyl-4-[2-[[(methylamino) carbonyl]oxy]ethoxy]phenyl]-5,7-dimethoxy- (CA INDEX NAME)




RN 1044871-62-6 CAPLUS

CN Benzamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-4-methyl- (CA INDEX NAME)




RN 1044871-64-8 CAPLUS

CN Carbamic acid, N-cyclohexyl-, 2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl ester (CA INDEX NAME)




RN 1044871-66-0 CAPLUS

CN Benzenesulfonamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]- (CA INDEX NAME)




RN 1044871-67-1 CAPLUS

CN Benzenesulfonamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-4-methyl- (CA INDEX NAME)




RN 1044871-68-2 CAPLUS

CN Benzenesulfonamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-4-methoxy- (CA INDEX NAME)




RN 1044871-70-6 CAPLUS

CN Acetamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]- (CA INDEX NAME)




RN 1044871-71-7 CAPLUS

CN Benzanide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]- (CA INDEX NAME)




RN 1044871-73-9 CAPLUS

CN Propanamide, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-2-methyl- (CA INDEX NAME)




RN 1044871-74-0 CAPLUS

CN Urea, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-N'-methyl- (CA INDEX NAME)




RN 1044871-75-1 CAPLUS

CN Urea, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)




RN 1044871-76-2 CAPLUS

CN Urea, N-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-N'-phenyl- (CA INDEX NAME)



RN 1044871-77-3 CAPLUS


CN Urea, N'-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)-2,6-dimethylphenoxy]ethyl]-N,N-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:941505 CAPLUS
 DOCUMENT NUMBER: 149:246552
 TITLE: Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions and their preparation
 INVENTOR(S): Liu, Shifeng; Sun, Jianyu; Fraser, Robert; Fu, Jianmin; Kamboj, Rajender; Hou, Duanjie; Sviridov, Sergei
 PATENT ASSIGNEE(S): Xenon Pharmaceuticals Inc., Can.
 SOURCE: PCT Int. Appl., 255pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008094909	A2	20080807	WO 2008-US52315	20080129
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2007-887120P	P 20070129
			US 2007-891188P	P 20070222
OTHER SOURCE(S):		MARPAT 149:246552		
GI				




AB This invention is directed to compds. of formula I as a stereoisomer, enantiomer, tautomer thereof or mixts. thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Compds. of formula I wherein ring A is fused (hetero)aryl; each R₁

is independently H, (halo)alkyl, (halo)alkenyl, (halo)alkynyl, halo, cycloalkyl(alkyl), cycloalkylalkenyl, cycloalkylalkynyl, (hetero)aryl, aralkyl, etc.; R2 is H, (halo)alkyl, (halo)alkenyl, (halo)alkynyl, cycloalkyl(alkyl), cycloalkenyl, (hetero)aryl, etc.; R3 is H, (halo)alkyl, (halo)alkenyl, (halo)alkynyl, halo, cycloalkyl(alkyl), cycloalkylalkenyl, cycloalkylalkynyl, (hetero)aryl, aralkyl, aralkenyl, etc.; and their stereoisomers, enantiomers, tautomers, mixts. of stereoisomers, mixts. of enantiomers, mixts. of tautomers, pharmaceutically acceptable salts, solvates and prodrugs thereof, are claimed. Example compound II was prepared by hydrolysis of 2-butyl-3-[4-[(diphenylmethylidene)amino]phenyl]quinazolin-4(3H)-one. All the invention compds. were evaluated for their sodium channel inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value in the range of 10 - 100 nM.


IT 1043961-92-7P 1043961-93-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of quinazolinone and fused pyrimidinone compds. useful in treatment and prevention of sodium channel-mediated diseases)
 RN 1043961-92-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-bromophenyl)-3-butyl- (CA INDEX NAME)



RN 1043961-93-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[4-(3-butyl-3,4-dihydro-4-oxo-2-quinazolinyl)phenyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 1043961-94-9P 1043962-04-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of quinazolinone and fused pyrimidinone compds. useful in treatment and prevention of sodium channel-mediated diseases)
 RN 1043961-94-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-butyl-2-[4-(3-pyrrolidinylamino)phenyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 1043962-04-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[4-(4-morpholinyl)phenyl]-2-[3-[3-(trifluoromethyl)phenoxy]phenyl]- (CA INDEX NAME)



L5 ANSWER 15 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:829682 CAPLUS

DOCUMENT NUMBER: 149:143903

TITLE: Agents for reversing epigenetic silencing of genes

INVENTOR(S): Nelson, William G.; Yegnasubramanian, Srinivasan; Lin, Xiaohui; Speed, Traci J.; Reichert, Zachery

PATENT ASSIGNEE(S): The Johns Hopkins University, USA

SOURCE: PCT Int. Appl., 70pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008083098	A1	20080710	WO 2007-US88634	20071221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-877310P P 20061227


AB The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Addnl., compds. identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.

IT 18818-41-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(agents for reversing epigenetic silencing of genes)

RN 18818-41-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-methylphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:734086 CAPLUS

DOCUMENT NUMBER: 149:62748

TITLE: Vasopressin type 3 antagonists for the treatment or prevention of chronic pain

INVENTOR(S): Neumann, Inga

PATENT ASSIGNEE(S): N.V. Organon, Neth.

SOURCE: PCT Int. Appl., 25pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008071779	A1	20080619	WO 2007-EP63913	20071213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,				

TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

CA 2671891 A1 20080619 CA 2007-2671891 20071213
 EP 2101746 A1 20090923 EP 2007-857560 20071213

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR

MX 2009006313 A 20090623 MX 2009-6313 20090612

PRIORITY APPLN. INFO.: EP 2006-126003 A 20061213
 WO 2007-EP63913 W 20071213

OTHER SOURCE(S): MARPAT 149:62748

AB The present invention relates to a V3 antagonist for use in the treatment of chronic pain, in particular neuropathic pain. Thus, the vasopressin type 3 antagonist 2-[2-(3-Chlorophenyl)-4-oxo-6-(3-piperidin-1-ylpropoxy)-4H-quinazolin-3-yl]-N-isopropylacetamide (Compound 2) was tested on mech. hyperalgesia in a rat model of inflammatory pain. Rats were dosed orally with either vehicle or Compound 2 (3-30 mg/kg); readings were then made at 30 min and 2 h post drug administration. It was found that oral administration of Compound 2 (5.7, 18.9 or 56.6 µmol/kg) reversed mech. hyperalgesia induced by complete Freund's adjuvant in a dose-dependent fashion; the peak antialgesic effect was observed at 30 min post drug administration; the calculated ED50 value at peak effect was 19.2 µmol/kg p.o. These data demonstrate that the V3 receptor antagonist Compound 2 possesses potent oral antialgesic activity in a rat model of chronic inflammatory pain.


IT 909392-11-6, 2-[2-(3-Chlorophenyl)-4-oxo-6-(3-piperidin-1-ylpropoxy)-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-98-9, 2-[6-(3-Dimethylaminomethylphenyl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(V3 antagonists for treatment or prevention of chronic pain)


RN 909392-11-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909392-98-9 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-[3-[(dimethylamino)methyl]phenyl]-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



- IT 909391-81-7, 2-[2-(3-Chloro-4-fluorophenyl)-4-oxo-6-(3-piperidin-1-ylpropoxy)-4H-quinazolin-3-yl]-N-isopropylacetamide
 909391-83-9, N-tert-Butyl-2-[2-(3-chlorophenyl)-4-oxo-6-(3-pyrrolidin-1-ylpropoxy)-4H-quinazolin-3-yl]acetamide 909391-88-4
 , N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-(3-piperidin-1-ylpropoxy)-4H-quinazolin-3-yl]acetamide 909391-89-5,
 2-[2-(4-Fluoro-3-methoxyphenyl)-4-oxo-6-(3-piperidin-1-ylpropoxy)-4H-quinazolin-3-yl]-N-isopropylacetamide 909391-94-2,
 2-[2-(3-Chlorophenyl)-6-[3-(4-hydroxypiperidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-39-8
 909392-64-9, 2-[6-(5-Dimethylaminomethyl-2-fluorophenyl)-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide
 909392-82-1, 2-[6-(3-Dimethylaminomethylphenyl)-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (V3 antagonists for treatment or prevention of chronic pain)
 RN 909391-81-7 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




- RN 909391-83-9 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1,1-dimethylethyl)-4-oxo-6-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)




- RN 909391-88-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyloxy)propoxy]- (CA INDEX NAME)




RN 909391-89-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyloxy)propoxy]- (CA INDEX NAME)



RN 909391-94-2 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[3-(4-hydroxy-1-piperidinyloxy)propoxy]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 909392-39-8 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1-methylethyl)-6-[(2S)-2-methyl-3-(1-pyrrolidinyloxy)propoxy]-4-oxo- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 909392-64-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[5-[(dimethylamino)methyl]-2-fluorophenyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 909392-82-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-[(dimethylamino)methyl]phenyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:705768 CAPLUS

DOCUMENT NUMBER: 149:47695

TITLE: Compounds and methods for enzyme-mediated tumor imaging and therapy

INVENTOR(S): Kassiss, Amin I.

PATENT ASSIGNEE(S): Harvard College, USA

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008069976	A2	20080612	WO 2007-US24659	20071130
WO 2008069976	A3	20081016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007328336	A1	20080612	AU 2007-328336	20071130
EP 2099458	A2	20090916	EP 2007-853203	20071130
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
US 20090324495	A1	20091231	US 2009-476102	20090601
PRIORITY APPLN. INFO.:				
			US 2006-872073P	P 20061201
			US 2007-912688P	P 20070419
			US 2007-949240P	P 20070711
			WO 2007-US24659	W 20071130


OTHER SOURCE(S): MARPAT 149:47695
 AB The invention provides methods and compns., e.g., for tumor imaging and therapy.
 IT 1032084-21-1P 1032084-24-4P 1032084-27-7P
 RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (enzyme-mediated tumor imaging and therapy)
 RN 1032084-21-1 CAPLUS
 CN L-Glutamamide, N-(4-morpholinylcarbonyl)-L-histidyl-L-seryl-L-seryl-L-lysyl-L-leucyl-N-[2-[[[2-[3,4-dihydro-6-(iodo-123I)-4-oxo-2-quinazolinyl]phenoxy]hydroxyphosphinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 1032084-24-4 CAPLUS


CN L-Glutamamide, N-(4-morpholinylcarbonyl)-L-histidyl-L-seryl-L-seryl-L-lysyl-L-leucyl-N1-[2-[[[2-[3,4-dihydro-6-(iodo-125I)-4-oxo-2-quinazolinyl]phenoxy]hydroxyphosphinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 1032084-27-7 CAPLUS
 CN L-Glutamamide, N-(4-morpholinylcarbonyl)-L-histidyl-L-seryl-L-seryl-L-lysyl-L-leucyl-N1-[2-[[[2-[3,4-dihydro-6-(iodo-131I)-4-oxo-2-quinazolinyl]phenoxy]hydroxyphosphinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




IT 1032082-81-7D, peptide conjugate 1032082-86-2D,
 peptide conjugate 1032082-91-9 1032083-65-0
 RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (enzyme-mediated tumor imaging and therapy)
 RN 1032082-81-7 CAPLUS
 CN Yttrate(2-)-90Y, [10-[[[3,4-dihydro-4-oxo-2-[2-(phosphonoxy)phenyl]-6-quinazolinyl]methyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(5-)-, κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]-, hydrogen (1:2) (CA INDEX NAME)



● 2 H⁺


RN 1032082-86-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[5-(iodo-123I)-2-(phosphonoxy)phenyl]-6-methyl-
(CA INDEX NAME)




RN 1032082-91-9 CAPLUS

CN Benzoic acid, 4-[(aminoiminomethyl)amino]-, anhydride with
2-[3,4-dihydro-6-(iodo-131I)-4-oxo-2-quinazolinyl]phenyl dihydrogen
phosphate (1:1) (CA INDEX NAME)



RN 1032083-65-0 CAPLUS
 CN Benzoic acid, 4-[(aminoiminomethyl)amino]-, anhydride with
 4-[3,4-dihydro-6-(iodo-131I)-4-oxo-2-quinazolinyl]-3-hydroxyphenyl
 dihydrogen phosphate (1:1) (CA INDEX NAME)




L5 ANSWER 18 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN
 ACCESSION NUMBER: 2008:674922 CAPLUS
 DOCUMENT NUMBER: 149:10043
 TITLE: Preparation of quinazolinone modulators of TGR5 for
 treatment of metabolic, cardiovascular and
 inflammatory diseases
 INVENTOR(S): Pinkerton, Anthony B.; Kabakibi, Ayman; Hoffman,
 Timothy Z.; Siegel, Dana L.; Noble, Stewart A.
 PATENT ASSIGNEE(S): Kalypsys, Inc., USA
 SOURCE: PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008067219	A2	20080605	WO 2007-US85225	20071120
WO 2008067219	A3	20080717		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 20090035306 A1 20090205 US 2007-943097 20071120 PRIORITY APPLN. INFO.: US 2006-867783P P 20061129 US 2007-975561P P 20070927				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 149:10043


GI



- AB The present invention relates to quinazolinone compds. of general structure I (wherein X is (un)substituted C1-2alkyl; R6 and R7 are independently alkyl, alkenyl, alkynyl, etc.; R8, R10 are aryl, heteroaryl, cycloalkyl, etc.; R9 is H, alkyl, acyl, etc.) useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases. Synthetic procedures for preparing I are exemplified. Example compound II was prepared by reacting 2-(4-Fluorophenyl)-4H-benzo[d][1,3]oxazin-4-one with hydrazine to provide 3-amino-2-(4-fluorophenyl)quinazolin-4(3H)-one which was subsequently reacted with 4-bromobenzyl bromide. In an assay that measured cAMP production by HEK-293 cells transfected with TGR5, II had an EC50 of ≤ 10 μ M.
- IT 389576-52-7P, 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)quinazolin-4(3H)-one 1029981-17-6P, 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-7-methoxyquinazolin-4(3H)-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of quinazolinone modulators of TGR5 for treatment of metabolic, cardiovascular and inflammatory diseases)
- RN 389576-52-7 CAPLUS
- CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(4-fluorophenyl)]-
 (CA INDEX NAME)



- RN 1029981-17-6 CAPLUS
- CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(4-fluorophenyl)]-7-methoxy- (CA INDEX NAME)



IT 309925-98-2P, 4-Bromo-N-[2-(4-fluorophenyl)-4-oxo-4H-quinazolin-3-yl]benzamide 361180-56-5P,
 2-(4-Fluorophenyl)-3-[(4-isopropylbenzyl)amino]quinazolin-4(3H)-one 389577-36-0P, 3-[(3-Bromobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 389577-38-2P,
 3-[(2,4-Dichlorobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 389577-40-6P, 3-[(4-Bromobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 1029980-88-8P,
 3-[(2,4-Difluorobenzyl)amino]-2-(3-fluorophenyl)quinazolin-4(3H)-one 1029980-89-9P, 3-[(4-Bromobenzyl)amino]-2-[2-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 1029980-90-2P,
 3-[(4-Bromobenzyl)amino]-2-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 1029980-91-3P, 3-[(4-Bromobenzyl)amino]-2-(2-chlorophenyl)quinazolin-4(3H)-one 1029980-92-4P,
 3-[(4-tert-Butylbenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 1029980-93-5P, 3-[(2,4-Difluorobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 1029980-94-6P,
 3-[(3,5-Difluorobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 1029980-95-7P, 3-[(3,4-Difluorobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 1029980-96-8P,
 3-[(4-Bromobenzyl)amino]-2-(o-tolyl)quinazolin-4(3H)-one 1029980-98-0P, 2-(2-Fluorophenyl)-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one 1029980-99-1P,
 3-[(3-Chlorobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 1029981-00-7P, 3-[(4-Bromobenzyl)amino]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 1029981-01-8P,
 2-(2-Fluorophenyl)-3-[[3-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one 1029981-02-9P, 3-[[3-Fluoro-4-(trifluoromethyl)benzyl]amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 1029981-03-0P, 2-(2-Fluorophenyl)-3-[[4-(methylbenzyl)amino]quinazolin-4(3H)-one 1029981-04-1P,
 2-(2-Fluorophenyl)-3-[[4-(trifluoromethoxy)benzyl]amino]quinazolin-4(3H)-one 1029981-05-2P, 3-[[4-Bromobenzyl]amino]-2-(2-fluorophenyl)-7-methylquinazolin-4(3H)-one 1029981-06-3P,
 3-[(2,4-Difluorobenzyl)amino]-2-(2-fluorophenyl)-7-methylquinazolin-4(3H)-one 1029981-07-4P, 3-[[4-Bromobenzyl]amino]-2-(2-fluorophenyl)-6-methoxyquinazolin-4(3H)-one 1029981-08-5P,
 3-[(2,4-Difluorobenzyl)amino]-2-(2-fluorophenyl)-6-methoxyquinazolin-4(3H)-one 1029981-09-6P, 3-[[4-Bromobenzyl]amino]-2-(2-fluorophenyl)-7-(trifluoromethyl)quinazolin-4(3H)-one 1029981-10-9P,
 3-[(2,4-Difluorobenzyl)amino]-2-(2-fluorophenyl)-7-(trifluoromethyl)quinazolin-4(3H)-one 1029981-12-1P,
 3-[(4-Chlorobenzyl)amino]-2-(2-fluorophenyl)-7-(trifluoromethyl)quinazolin-4(3H)-one 1029981-19-8P,
 3-[(2,4-Difluorobenzyl)amino]-2-(4-fluorophenyl)-7-methoxyquinazolin-4(3H)-one 1029981-21-2P, 3-[[4-Chlorobenzyl]amino]-2-(4-fluorophenyl)-7-methoxyquinazolin-4(3H)-one 1029981-23-4P,
 2-(4-Fluorophenyl)-7-methoxy-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one 1029981-25-6P

, 2-(4-Fluorophenyl)-3-[[pyridin-3-yl)methyl]amino]quinazolin-4(3H)-one
 1029981-27-8P, 2-(4-Fluorophenyl)-3-[[naphthalen-2-yl)methyl]amino]quinazolin-4(3H)-one 1029981-30-3P,
 2-(4-Fluorophenyl)-3-(4-morpholinobutylamino)quinazolin-4(3H)-one
 1029981-36-9P, 3-[(4-Bromobenzyl)amino]-2-[4-(dimethylamino)phenyl]quinazolin-4(3H)-one 1029981-38-1P,
 3-[(4-Chlorobenzyl)amino]-2-[4-(dimethylamino)phenyl]quinazolin-4(3H)-one
 1029981-45-0P, 3-[(4-Bromobenzyl)amino]-2-(3-chlorophenyl)quinazolin-4(3H)-one 1029981-47-2P,
 3-[(4-Bromobenzyl)amino]-2-(4-chlorophenyl)quinazolin-4(3H)-one
 1029981-49-4P, 3-[(4-Chlorobenzyl)amino]-2-(3-chlorophenyl)quinazolin-4(3H)-one 1029981-51-8P,
 2-(3-Chlorophenyl)-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one
 1029981-53-0P, 2-(3-Chlorophenyl)-3-[(3,4-difluorobenzyl)amino]quinazolin-4(3H)-one 1029981-55-2P,
 3-[(4-Chlorobenzyl)amino]-2-(4-chlorophenyl)quinazolin-4(3H)-one
 1029981-57-4P, 2-(4-Chlorophenyl)-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one 1029981-59-6P
 , 2-(4-Chlorophenyl)-3-[(3,4-difluorobenzyl)amino]quinazolin-4(3H)-one
 1029981-61-0P, 3-[(4-Bromobenzyl)amino]-2-(4-fluoro-3-methylphenyl)quinazolin-4(3H)-one 1029981-63-2P,
 3-[(4-Bromobenzyl)amino]-2-(3-methoxyphenyl)quinazolin-4(3H)-one
 1029981-65-4P, 3-[(4-Chlorobenzyl)amino]-2-(3-methoxyphenyl)quinazolin-4(3H)-one 1029981-67-6P,
 3-[(4-Chlorobenzyl)amino]-2-(4-fluoro-3-methylphenyl)quinazolin-4(3H)-one
 1029981-69-8P, 3-[(4-Bromobenzyl)amino]-2-(3,5-dimethoxyphenyl)quinazolin-4(3H)-one 1029981-71-2P,
 3-[(4-Chlorobenzyl)amino]-2-(3,5-dimethoxyphenyl)quinazolin-4(3H)-one
 1029981-73-4P, 3-[(4-Bromobenzyl)amino]-2-[3-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one
 1029981-75-6P, 3-[(4-Chlorobenzyl)amino]-2-[3-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one
 1029981-77-8P, 3-[(4-Chlorobenzyl)amino]-2-(3,4-dimethoxyphenyl)quinazolin-4(3H)-one 1029981-84-7P,
 3-[(4-Bromobenzyl)amino]-2-(3-methoxy-4-methylphenyl)quinazolin-4(3H)-one
 1029981-86-9P, 3-[(4-Chlorobenzyl)amino]-2-(3-methoxy-4-methylphenyl)quinazolin-4(3H)-one 1029981-88-1P,
 3-[(4-Fluorobenzyl)amino]-2-(3-methoxy-4-methylphenyl)quinazolin-4(3H)-one
 1029981-90-5P, 2-(3-Methoxy-4-methylphenyl)-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one 1029981-92-7P
 , 3-[(3,4-Difluorobenzyl)amino]-2-(3-methoxy-4-methylphenyl)quinazolin-4(3H)-one 1029981-94-9P,
 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-8-methylquinazolin-4(3H)-one
 1029981-96-1P, 3-[(4-Chlorobenzyl)amino]-2-(4-fluorophenyl)-8-methylquinazolin-4(3H)-one 1029981-98-3P,
 3-[(4-Bromobenzyl)amino]-2-(4-fluoro-3-methoxyphenyl)quinazolin-4(3H)-one
 1029982-00-0P, 3-[(4-Chlorobenzyl)amino]-2-(4-fluoro-3-methoxyphenyl)quinazolin-4(3H)-one 1029982-02-2P,
 3-[(4-Bromobenzyl)amino]-2-(4-chloro-3-methoxyphenyl)-3H-quinazolin-4-one
 1029982-04-4P, 3-[(4-Chlorobenzyl)amino]-2-(4-chloro-3-methoxyphenyl)-3H-quinazolin-4-one 1029982-06-6P,
 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-8-methoxy-3H-quinazolin-4-one
 1029982-08-8P, 3-[(4-Chlorobenzyl)amino]-2-(4-fluorophenyl)-8-methoxy-3H-quinazolin-4-one 1029982-10-2P,
 2-(4-Fluorophenyl)-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one
 1029982-12-4P, 3-[(4-Chlorobenzyl)amino]-2-(4-fluorophenyl)quinazolin-4(3H)-one 1029982-14-6P,
 3-[(2,4-Difluorobenzyl)amino]-2-(4-fluorophenyl)quinazolin-4(3H)-one
 1029982-16-8P, 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-7-methylquinazolin-4(3H)-one 1029982-18-0P,
 2-(4-Fluorophenyl)-7-methyl-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-


4(3H)-one 1029982-20-4P,
 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-6,7-dimethoxyquinazolin-4(3H)-one 1029982-22-6P, 3-(3-Bromophenethylamino)-2-(4-fluorophenyl)quinazolin-4(3H)-one 1029982-24-8P,
 3-(4-Bromophenethylamino)-2-(4-fluorophenyl)quinazolin-4(3H)-one 1029982-34-0P, 3-[(4-Bromobenzyl)(methyl)amino]-2-(4-fluorophenyl)quinazolin-4(3H)-one 1029982-36-2P,
 3-[[3,5-Bis(trifluoromethyl)benzyl]amino]-2-(4-fluorophenyl)quinazolin-4(3H)-one 1029982-38-4P,
 3-[(4-Bromobenzyl)amino]-2-(3,4-difluorophenyl)quinazolin-4(3H)-one 1029982-40-8P, 3-[(4-Bromobenzyl)(ethyl)amino]-2-(4-fluorophenyl)quinazolin-4(3H)-one 1029982-42-0P,
 3-[(4-Bromobenzyl)(propyl)amino]-2-(4-fluorophenyl)quinazolin-4(3H)-one 1029982-44-2P, 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-7-hydroxyquinazolin-4(3H)-one 1029982-46-4P,
 3-[(4-Bromobenzyl)amino]-2-(3-hydroxyphenyl)quinazolin-4(3H)-one 1029982-48-6P, 3-[(4-Bromobenzyl)amino]-2-(4-hydroxyphenyl)quinazolin-4(3H)-one 1029982-50-0P,
 3-[(4-Chlorobenzyl)amino]-2-(4-fluorophenyl)-6-hydroxyquinazolin-4(3H)-one 1029982-52-2P, 3-[(4-Bromobenzyl)amino]-2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-one 1029982-54-4P,
 3-[(4-Chlorobenzyl)amino]-2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-one 1029982-56-6P, 1029982-64-6P,
 3-(Benzylamino)-6-fluoro-2-(3-fluorophenyl)quinazolin-4(3H)-one 1029982-70-4P, 3-[(4-Bromobenzyl)amino]-2-(3-fluorophenyl)quinazolin-4(3H)-one 1029982-72-6P,
 3-[(4-Bromobenzyl)amino]-6-fluoro-2-(3-fluorophenyl)quinazolin-4(3H)-one 1029982-74-8P, 3-[[4-Fluoro-3-(trifluoromethyl)benzyl]amino]-2-(3-fluorophenyl)quinazolin-4(3H)-one 1029982-76-0P,
 3-[(4-Chlorobenzyl)amino]-7-fluoro-2-(4-fluorophenyl)quinazolin-4(3H)-one 1029982-78-2P, 3-[(4-Bromobenzyl)amino]-2-(3-chloro-4-methylphenyl)quinazolin-4(3H)-one 1029982-80-6P,
 2-(3-Chloro-4-methylphenyl)-3-[(4-chlorobenzyl)amino]quinazolin-4(3H)-one 1029982-82-8P, 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-5-methylquinazolin-4(3H)-one 1029982-84-0P,
 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-8-hydroxyquinazolin-4(3H)-one 1029982-86-2P, 3-[(4-Chlorobenzyl)amino]-2-(4-fluorophenyl)-8-hydroxyquinazolin-4(3H)-one 1029982-88-4P,
 3-[(4-Bromobenzyl)amino]-5-fluoro-2-(4-fluorophenyl)quinazolin-4(3H)-one 1029982-94-2P, 3-[(4-Bromobenzyl)amino]-2-(3-hydroxy-4-methoxyphenyl)quinazolin-4(3H)-one 1029982-96-4P,
 3-[(4-Chlorobenzyl)amino]-2-(3-hydroxy-4-methoxyphenyl)quinazolin-4(3H)-one 1029998-52-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinazolinone modulators of TGR5 for treatment of metabolic, cardiovascular and inflammatory diseases)


RN 309925-98-2 CAPLUS

CN Benzamide, 4-bromo-N-[2-(4-fluorophenyl)-4-oxo-3(4H)-quinazolinyl]- (CA INDEX NAME)




RN 361180-56-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[[4-(1-methylethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 389577-36-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3-(3-bromophenyl)methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)



RN 389577-38-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[2-(2,4-dichlorophenyl)methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 389577-40-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[4-(3-bromophenyl)methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)


10/ 582,823

(CA INDEX NAME)




RN 1029980-88-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(2,4-difluorophenyl)methyl]amino]-2-(3-fluorophenyl)- (CA INDEX NAME)




RN 1029980-89-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methyl]amino]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1029980-90-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methyl]amino]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1029980-91-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(2-chlorophenyl)-
(CA INDEX NAME)




RN 1029980-92-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 1029980-93-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[2-(2,4-difluorophenyl)methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 1029980-94-6 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[3-(3,5-difluorophenyl)methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 1029980-95-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[(3,4-difluorophenyl)methylamino]-2-(2-fluorophenyl)- (CA INDEX NAME)



RN 1029980-96-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[(4-bromophenyl)methylamino]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 1029980-98-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[[4-(trifluoromethyl)phenyl]methylamino]- (CA INDEX NAME)



10/ 582,823


RN 1029980-99-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-chlorophenyl)methyl]amino]-2-(2-fluorophenyl)-
(CA INDEX NAME)




RN 1029981-00-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methyl]amino]-2-(2-methoxyphenyl)-
(CA INDEX NAME)




RN 1029981-01-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 1029981-02-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 1029981-03-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[4-(trifluoromethyl)phenyl]methyl]amino- (CA INDEX NAME)




RN 1029981-04-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[4-(trifluoromethoxy)phenyl]methyl]amino- (CA INDEX NAME)




RN 1029981-05-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[4-(bromophenyl)methyl]amino]-7-methyl- (CA INDEX NAME)




RN 1029981-06-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(2,4-difluorophenyl)methyl]amino]-2-(2-fluorophenyl)-7-methyl- (CA INDEX NAME)




RN 1029981-07-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methyl]amino]-2-(2-fluorophenyl)-6-methoxy- (CA INDEX NAME)




RN 1029981-08-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(2,4-difluorophenyl)methyl]amino]-2-(2-fluorophenyl)-6-methoxy- (CA INDEX NAME)




RN 1029981-09-6 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methyl]amino]-2-(2-fluorophenyl)-7-(trifluoromethyl)- (CA INDEX NAME)




RN 1029981-10-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(2,4-difluorophenyl)methyl]amino]-2-(2-fluorophenyl)-7-(trifluoromethyl)- (CA INDEX NAME)



RN 1029981-12-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(4-chlorophenyl)methyl]amino]-2-(2-fluorophenyl)-7-(trifluoromethyl)- (CA INDEX NAME)




RN 1029981-19-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(2,4-difluorophenyl)methyl]amino]-2-(4-fluorophenyl)-7-methoxy- (CA INDEX NAME)




RN 1029981-21-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-chlorophenyl)methyl]amino]-2-(4-fluorophenyl)-7-methoxy- (CA INDEX NAME)




RN 1029981-23-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-7-methoxy-3-[[(4-(trifluoromethyl)phenyl)methyl]amino]- (CA INDEX NAME)




RN 1029981-25-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)




RN 1029981-27-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[(2-naphthalenylmethyl)amino]- (CA INDEX NAME)




RN 1029981-30-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[4-(4-morpholinyl)butyl]amino]-
(CA INDEX NAME)




RN 1029981-36-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 1029981-38-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methyl]amino]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 1029981-45-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(3-chlorophenyl)-
(CA INDEX NAME)




RN 1029981-47-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methyl]amino]-2-(4-chlorophenyl)-
(CA INDEX NAME)



RN 1029981-49-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-(3-chlorophenyl)-3-[[4-chlorophenyl)methyl]amino]-
(CA INDEX NAME)



RN 1029981-51-8 CAPLUS


CN 4(3H)-Quinazolinone, 2-(3-chlorophenyl)-3-[[[4-(trifluoromethyl)phenyl)methyl]amino]- (CA INDEX NAME)

10/ 582,823




RN 1029981-53-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-chlorophenyl)-3-[[3,4-difluorophenyl)methylamino]- (CA INDEX NAME)




RN 1029981-55-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-chlorophenyl)-3-[[4-chlorophenyl)methylamino]- (CA INDEX NAME)




RN 1029981-57-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-(4-chlorophenyl)-3-[[4-(trifluoromethyl)phenyl)methylamino]- (CA INDEX NAME)





RN 1029981-59-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-chlorophenyl)-3-[[3,4-difluorophenyl)methylamino]- (CA INDEX NAME)



RN 1029981-61-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methylamino]-2-(4-fluoro-3-methylphenyl)- (CA INDEX NAME)





RN 1029981-63-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methylamino]-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 1029981-65-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(4-chlorophenyl)methyl]amino]-2-(3-methoxyphenyl)-
(CA INDEX NAME)




RN 1029981-67-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(4-chlorophenyl)methyl]amino]-2-(4-fluoro-3-methylphenyl)- (CA INDEX NAME)




RN 1029981-69-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(4-bromophenyl)methyl]amino]-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 1029981-71-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(3,5-dimethoxyphenyl)methyl]amino]-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)





RN 1029981-73-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(3,5-dimethoxyphenyl)methyl]amino]-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 1029981-75-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(3,5-dimethoxyphenyl)methyl]amino]-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 1029981-77-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(4-chlorophenyl)methyl]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 1029981-84-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(4-bromophenyl)methyl]amino]-2-(3-methoxy-4-methylphenyl)- (CA INDEX NAME)




RN 1029981-86-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(4-chlorophenyl)methyl]amino]-2-(3-methoxy-4-methylphenyl)- (CA INDEX NAME)




RN 1029981-88-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methyl]amino]-2-(3-methoxy-4-methylphenyl)- (CA INDEX NAME)





RN 1029981-90-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-methoxy-4-methylphenyl)-3-[[4-(4-fluorophenyl)methyl]amino]- (CA INDEX NAME)




RN 1029981-92-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-[(3,4-difluorophenyl)methyl]amino]-2-(3-methoxy-4-methylphenyl)- (CA INDEX NAME)




RN 1029981-94-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(4-(2-bromophenyl)methyl)amino]-2-(4-fluorophenyl)-8-methyl- (CA INDEX NAME)




RN 1029981-96-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(4-(2-chlorophenyl)methyl)amino]-2-(4-fluorophenyl)-8-methyl- (CA INDEX NAME)




RN 1029981-98-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(4-(2-bromophenyl)methyl)amino]-2-(4-fluoro-3-methoxyphenyl)- (CA INDEX NAME)




RN 1029982-00-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-chlorophenyl)methyl]amino]-2-(4-fluoro-3-methoxyphenyl)- (CA INDEX NAME)




RN 1029982-02-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(4-chloro-3-methoxyphenyl)- (CA INDEX NAME)



RN 1029982-04-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-[(4-chloro-3-methoxyphenyl)methyl]amino]-3-[[[(4-chlorophenyl)methyl]amino]- (CA INDEX NAME)



10/ 582,823


RN 1029982-06-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(4-fluorophenyl)-8-methoxy- (CA INDEX NAME)




RN 1029982-08-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-chlorophenyl)methyl]amino]-2-(4-fluorophenyl)-8-methoxy- (CA INDEX NAME)




RN 1029982-10-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 1029982-12-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-chlorophenyl)methyl]amino]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 1029982-14-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(2,4-difluorophenyl)methyl]amino]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 1029982-16-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(4-fluorophenyl)-7-methyl- (CA INDEX NAME)




RN 1029982-18-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-7-methyl-3-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 1029982-20-4 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(4-fluorophenyl)-6,7-dimethoxy- (CA INDEX NAME)




RN 1029982-22-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[2-(3-bromophenyl)ethyl]amino]-2-(4-fluorophenyl)-
(CA INDEX NAME)

RN 1029982-24-8 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[2-(4-bromophenyl)ethyl]amino]-2-(4-fluorophenyl)-
(CA INDEX NAME)

RN 1029982-34-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]methylamino]-2-(4-fluorophenyl)-
(CA INDEX NAME)


RN 1029982-36-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-(4-fluorophenyl)-
(CA INDEX NAME)




RN 1029982-38-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methyl]amino]-2-(3,4-difluorophenyl)- (CA INDEX NAME)




RN 1029982-40-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methyl]ethylamino]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 1029982-42-0 CAPLUS



CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methyl]propylamino]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 1029982-44-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methyl]amino]-2-(4-fluorophenyl)-7-hydroxy- (CA INDEX NAME)



RN 1029982-46-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methyl]amino]-2-(3-hydroxyphenyl)- (CA INDEX NAME)




RN 1029982-48-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methyl]amino]-2-(4-hydroxyphenyl)- (CA INDEX NAME)



10/ 582,823


RN 1029982-50-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-chlorophenyl)methyl]amino]-2-(4-fluorophenyl)-6-hydroxy- (CA INDEX NAME)




RN 1029982-52-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(4-hydroxy-3-methoxyphenyl)- (CA INDEX NAME)




RN 1029982-54-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-chlorophenyl)methyl]amino]-2-(4-hydroxy-3-methoxyphenyl)- (CA INDEX NAME)




RN 1029982-56-6 CAPLUS


CN Benzoic acid, 4-[[[2-(3-fluorophenyl)-4-oxo-3(4H)-quinazolinyl]amino]methyl]- (CA INDEX NAME)




RN 1029982-64-6 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-2-(3-fluorophenyl)-3-[(phenylmethyl)amino]-
 (CA INDEX NAME)



RN 1029982-70-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methyl]amino]-2-(3-fluorophenyl)-
 (CA INDEX NAME)




RN 1029982-72-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methyl]amino]-6-fluoro-2-(3-fluorophenyl)- (CA INDEX NAME)




RN 1029982-74-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(4-bromophenyl)methyl]amino]-3-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 1029982-76-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-chlorophenyl)methyl]amino]-7-fluoro-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 1029982-78-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methyl]amino]-2-(3-chloro-4-methylphenyl)- (CA INDEX NAME)




RN 1029982-80-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-chloro-4-methylphenyl)-3-[[4-chlorophenyl)methyl]amino]- (CA INDEX NAME)




RN 1029982-82-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methyl]amino]-2-(4-fluorophenyl)-5-methyl- (CA INDEX NAME)



RN 1029982-84-0 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methyl]amino]-2-(4-fluorophenyl)-8-hydroxy- (CA INDEX NAME)



RN 1029982-86-2 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[4-chlorophenyl)methyl]amino]-2-(4-fluorophenyl)-

8-hydroxy- (CA INDEX NAME)




RN 1029982-88-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-5-fluoro-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 1029982-94-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(3-hydroxy-4-methoxyphenyl)- (CA INDEX NAME)




RN 1029982-96-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methyl]amino]-2-(3-hydroxy-4-methoxyphenyl)- (CA INDEX NAME)



RN 1029998-52-4 CAPLUS
 CN Benzonitrile, 4-[[[2-(4-fluorophenyl)-4-oxo-3(4H)-quinazolinyl]amino]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)

L5 ANSWER 19 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:609207 CAPLUS

DOCUMENT NUMBER: 148:585911

TITLE: Preparation of 2-(2-hydroxyphenyl)quinazolin-4-ones
 for treating obesity and diabetes

INVENTOR(S): Olesen, Preben Houlberg; Petersen, Anders Klarskov;
 Nielsen, Flemming Elmelund; Christiansen, Lise Brown;
 Hansen, Holger Claus

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 59pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008059024	A1	20080522	WO 2007-EP62407	20071115
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2669867	A1	20080522	CA 2007-2669867	20071115
EP 2097391	A1	20090909	EP 2007-822642	20071115
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			DK 2006-1487	A 20061115
			WO 2007-EP62407	W 20071115
OTHER SOURCE(S):		CASREACT 148:585911; MARPAT 148:585911		
GI				



I



II

AB The title compds. I [$m = 0$, such that R3 is linked directly to the benzene ring by a bond; or $m = 1-2$; X, when present, represents CR8:CR9 or C.tplbond.C; R1 = alkyl, cycloalkyl, Ph, etc.; R2 = H, halo, alkyl, etc.; R3 = H, NH2, NO2, etc.; R4 = halo, OH, alkyl, etc.; R5-R7 = H, NO2, CN, etc.; R8, R9 = H, alkyl, cycloalkyl, etc.] that act as chemical uncouplers and are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith, were prepared and formulated. E.g., a 2-step synthesis of II, starting from 3-bromo-5-tert-butyl-6-hydroxy-2-methylbenzoic acid and phenol, was given.


IT	1027348-75-9P	1027348-77-1P	1027348-79-3P
	1027348-81-7P	1027348-83-9P	1027348-87-3P
	1027348-89-5P	1027349-09-2P	1027349-11-6P
	1027349-13-8P	1027349-15-0P	1027349-17-2P
	1027349-19-4P	1027349-21-8P	1027349-23-0P
	1027349-25-2P	1027349-27-4P	1027349-29-6P
	1027349-31-0P	1027349-34-3P	1027349-36-5P
	1027349-38-7P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(2-hydroxyphenyl)quinazolin-4-ones for treating and preventing obesity and diabetes)


RN 1027348-75-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-bromo-5-(1,1-dimethylethyl)-6-hydroxy-2-methylphenyl]- (CA INDEX NAME)




RN 1027348-77-1 CAPLUS


CN 4(3H)-Quinazolinone, 2-[3-chloro-5-(1,1-dimethylethyl)-6-hydroxy-2-methylphenyl]-6-fluoro- (CA INDEX NAME)




RN 1027348-79-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-5-fluoro-2-hydroxy-6-methylphenyl]-6-fluoro- (CA INDEX NAME)



RN 1027348-81-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-chloro-5-(1,1-dimethylethyl)-6-hydroxy-2-methylphenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 1027348-83-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-5-fluoro-2-hydroxy-6-methylphenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 1027348-87-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-chloro-5-(1,1-dimethylethyl)-2-ethyl-6-hydroxyphenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 1027348-89-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-bromo-5-(1,1-dimethylethyl)-6-hydroxy-2-(1-methylethyl)phenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 1027349-09-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-bromo-5-(1,1-dimethylethyl)-6-hydroxy-2-methylphenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 1027349-11-6 CAPLUS

CN Benzonitrile, 3-[3,4-dihydro-4-oxo-6-[(trifluoromethyl)sulfonyl]-2-quinazolinyl]-5-(1,1-dimethylethyl)-4-hydroxy-2-methyl- (CA INDEX NAME)




RN 1027349-13-8 CAPLUS

CN Methanesulfonamide, N-[3-[3,4-dihydro-4-oxo-6-[(trifluoromethyl)sulfonyl]-2-quinazolinyl]-5-(1,1-dimethylethyl)-4-hydroxy-2-methylphenyl]- (CA INDEX NAME)




RN 1027349-15-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-2-hydroxy-6-methyl-5-[(trifluoromethyl)thio]phenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 1027349-17-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-2-hydroxy-6-methyl-5-(methylthio)phenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 1027349-19-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-2-hydroxy-6-methyl-5-(methylsulfinyl)phenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 1027349-21-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-2-hydroxy-6-methyl-5-[(R)-methylsulfinyl]phenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1027349-23-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-2-hydroxy-6-methyl-5-[(S)-methylsulfinyl]phenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1027349-25-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-2-hydroxy-6-methyl-5-(methylsulfonyl)phenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)



RN 1027349-27-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-6-ethyl-2-hydroxy-5-(methylsulfonyl)phenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 1027349-29-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-5-fluoro-2-hydroxy-6-(methylsulfonyl)phenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 1027349-31-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-chloro-5-(1,1-dimethylethyl)-6-hydroxy-2-methylphenyl]-6-(methylsulfonyl)- (CA INDEX NAME)




RN 1027349-34-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-2-hydroxy-6-(1-methylethyl)phenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)




RN 1027349-36-5 CAPLUS

CN 4(3H)-Quinazolinone, 8-chloro-2-[3-(1,1-dimethylethyl)-5-fluoro-2-hydroxy-6-methylphenyl]-6-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)



RN 1027349-38-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-(1,1-dimethylethyl)-2-hydroxy-6-methylphenyl]-6-
[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:451468 CAPLUS

DOCUMENT NUMBER: 150:182700

TITLE: 3D-QSAR and docking studies of 3-arylquinazolinethione derivatives as selective estrogen receptor modulators
Xiao, Aijing; Zhang, Zhuoyong; An, Liying; Xiang, Yuhong

CORPORATE SOURCE: Department of Chemistry, Capital Normal University, Beijing, 100037, Peop. Rep. China

SOURCE: Journal of Molecular Modeling (2008), 14(2), 149-159

CODEN: JMMOFK; ISSN: 0948-5023

URL: <http://www.springerlink.com/content/fm75310v9rg7t883/fulltext.pdf>

PUBLISHER: Springer GmbH

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

AB 3D-QSAR and mol. docking anal. were performed to explore the interaction of estrogen receptors (ER α and ER β) with a series of 3-arylquinazolinethione derivs. Using the conformations of these compds. revealed by mol. docking, CoMFA anal. resulted in the first quant. structure-activity relation (QSAR) and first quant. structure-selectivity relation (QSSR) models predicting the inhibitory activity against ER β and the selectivity against ER α . The q $_2$ and R $_2$ values, along with further testing, indicate that the obtained 3D-QSAR and 3D-QSSR models will be valuable in predicting both the inhibitory activity and selectivity of 3-arylquinazolinethione derivs. for these protein targets. A set of 3D contour plots drawn based on the 3D-QSAR and 3D-QSSR models reveal modifications of substituents at C2 and C5 of the quinazolinone which may be useful to improve both the activity and selectivity of ER β /ER α . Results showed that both the steric and electrostatic factors should appropriately be taken into account in future rational design and development of more active and more selective ER β inhibitors for the therapeutic treatment of osteoporosis.

IT 887469-02-5


RL: PAC (Pharmacological activity); PRP (Properties); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(QSAR and docking studies of arylquinazolinethione derivs. as SERMs)

RN 887469-02-5 CAPLUS

CN 4(3H)-Quinazolinone, 7-hydroxy-2,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:441939 CAPLUS

DOCUMENT NUMBER: 148:449652

TITLE: Preparation of pyrido[4,3-d]pyrimidin-4(3H)-one
derivatives as calcium receptor antagonists for
treating disease characterized by abnormal bone or
mineral homeostasis

INVENTOR(S): Bi, Feng; Didiuk, Mary Theresa; Griffith, David
Andrew; Guzman-Perez, Angel; Liu, Kevin Kun-Chin;
Walker, Daniel Patrick

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008041118	A2	20080410	WO 2007-IB2976	20070926
WO 2008041118	A3	20081023		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007303846	A1	20080410	AU 2007-303846	20070926
CA 2663436	A1	20080410	CA 2007-2663436	20070926
KR 2009074066	A	20090703	KR 2009-708869	20070926
EP 2079739	A2	20090722	EP 2007-825294	20070926
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR			
US 20080085887	A1	20080410	US 2007-867255	20071004
NO 2009001328	A	20090504	NO 2009-1328	20090401
MX 2009003673	A	20090422	MX 2009-3673	20090403
CN 101547922	A	20090930	CN 2007-80037475	20090407

IN 2009DN02839
PRIORITY APPLN. INFO.:



A 20090619

IN 2009-DN2839
US 2006-828162P
US 2007-969083P
WO 2007-1B2976

20090429
P 20061004
P 20070830
W 20070926

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 148:449652

GI



AB The title compds. I [R1 = Q or alkyl-Q; R2 = (un)substituted alkyl, cycloalkyl, (hetero)aryl; R3 = H, alkyl, cycloalkyl, etc.; R4, R5 = H, halo, cyano, etc.; Q = (un)substituted (hetero)aryl], useful as calcium receptor antagonists, were prepared E.g., a multi-step synthesis of II, starting from 4-amino-2-chloronicotinic acid and phenethylamine, was described. Exemplified compds. I were tested in FLIPR assay for evaluating the potency and selectivity of test compds. (data given). Also provided are pharmaceutical compns. comprising the compds. I as well as methods of treatment employing compds. I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.


IT 1018678-24-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrido[4,3-d]pyrimidin-4(3H)-ones as calcium receptor antagonists for treating disease characterized by abnormal bone or mineral homeostasis)

RN 1018678-24-4 CAPLUS

CN Benzonitrile, 2-[3-(2-(2-fluorophenyl)ethyl)-3,4-dihydro-4-oxo-5-(trifluoromethyl)-2-quinazolinyl]- (CA INDEX NAME)



TITLE: Quinazolinone and isoquinolinone acetamide derivatives as V3 modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Letourneau, Jeffrey; Jokiel, Patrick; Napier, Elizabeth; Ho, Koc-Kan; Ohlmeyer, Michael; Mcarthur, Duncan Robert; Fiona, Jeremiah; Ratcliffe, Paul David; Jurgen, Schulz

PATENT ASSIGNEE(S): N.V. Organon, Neth.

SOURCE: PCT Int. Appl., 151pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008033764	A2	20080320	WO 2007-US78022	20070910
WO 2008033764	A3	20081218		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, CA			
AU 2007296634	A1	20080320	AU 2007-296634	20070910
CA 2663161	A1	20080320	CA 2007-2663161	20070910
US 20080090802	A1	20080417	US 2007-852762	20070910
EP 2069315	A2	20090617	EP 2007-842157	20070910
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
KR 2009107994	A	20091014	KR 2009-707035	20070910
NO 2009001012	A	20090326	NO 2009-1012	20090306
CN 101600698	A	20091209	CN 2007-80041625	20090508
PRIORITY APPLN. INFO.:			US 2006-843718P	P 20060911
			WO 2007-US78022	W 20070910
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 148:355816		
GI				




AB The invention relates to compds. of formula I, pharmaceutically acceptable salts, prodrugs or solvates thereof. Compds. of formula I wherein R1 is (un)substituted C1-6 alkyl, (un)substituted C3-6 cycloalkyl, (un)substituted cycloalkyl-C1-3 alkyl, C2-6 alkenyl and C2-6 alkynyl; R2 is (un)substituted C6-10 aryl, (un)substituted 5- to 10-membered heteroaryl, and C4-7 cycloalkyl; R3 is (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy and halo; R4 is (un)substituted aminoethylamino and (un)substituted aminopropylamino; X is CH and N; and their pharmaceutically acceptable salts, and solvates thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their V3 binding affinity (some data given).

IT 1012782-05-6P 1012782-06-7P 1012782-07-8P
 1012782-08-9P 1012782-09-0P 1012782-10-3P
 1012782-11-4P 1012782-12-5P 1012782-14-7P
 1012782-15-8P 1012782-16-9P 1012782-41-0P
 1012783-13-9P 1012783-18-4P 1012783-54-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate and intermediate; preparation of quinazolinone and isoquinolinone acetamide derivs. as V3 modulators useful in the treatment of diseases)


RN 1012782-05-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-(hexahydro-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-06-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1,1-dimethylethyl)-6-(hexahydro-1H-1,4-diazepin-1-yl)-4-oxo- (CA INDEX NAME)




RN 1012782-07-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-2-(4-fluoro-3-methoxyphenyl)-6-(hexahydro-1H-1,4-diazepin-1-yl)-4-oxo- (CA INDEX NAME)



RN 1012782-08-9 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(hexahydro-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-09-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1-methylethyl)-6-[(3S)-3-(1-methylethyl)-1-piperazinyl]-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.




RN 1012782-10-3 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1-methylethyl)-4-oxo-6-(1-piperazinyl)- (CA INDEX NAME)



RN 1012782-11-4 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(hexahydro-3-methyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-12-5 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-(hexahydro-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-14-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(hexahydro-6,6-dimethyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-15-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-(hexahydro-6,6-dimethyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012782-16-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(hexahydro-1H-1,4-diazepin-1-yl)-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-, hydrochloride (1:?) (CA INDEX NAME)




●_x HCl

RN 1012782-41-0 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1-methylethyl)-6-[(3R)-3-methyl-1-piperazinyl]-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 1012783-13-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(3-ethylhexahydro-1H-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-18-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012783-54-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(hexahydro-3-propyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



IT	1012782-03-4P	1012782-04-5P	1012782-13-6P
	1012782-17-0P	1012782-18-1P	1012782-19-2P
	1012782-20-5P	1012782-21-6P	1012782-22-7P
	1012782-23-8P	1012782-24-9P	1012782-25-0P
	1012782-26-1P	1012782-27-2P	1012782-28-3P
	1012782-29-4P	1012782-30-7P	1012782-31-8P
	1012782-32-9P	1012782-33-0P	1012782-34-1P
	1012782-35-2P	1012782-36-3P	1012782-37-4P
	1012782-38-5P	1012782-39-6P	1012782-40-9P
	1012782-42-1P	1012782-43-2P	1012782-44-3P
	1012782-45-4P	1012782-46-5P	1012782-47-6P
	1012782-48-7P	1012782-49-8P	1012782-50-1P
	1012782-51-2P	1012782-52-3P	1012782-53-4P
	1012782-54-5P	1012782-55-6P	1012782-56-7P
	1012782-57-8P	1012782-58-9P	1012782-59-0P
	1012782-60-3P	1012782-61-4P	1012782-62-5P
	1012782-63-6P	1012782-64-7P	1012782-65-8P
	1012782-66-9P	1012782-67-0P	1012782-68-1P
	1012782-69-2P	1012782-70-5P	1012782-71-6P
	1012782-72-7P	1012782-73-8P	1012782-74-9P
	1012782-75-0P	1012782-76-1P	1012782-77-2P
	1012782-78-3P	1012782-79-4P	1012782-80-7P
	1012782-81-8P	1012782-82-9P	1012782-83-0P
	1012782-84-1P	1012782-85-2P	1012782-86-3P
	1012782-87-4P	1012782-88-5P	1012782-89-6P
	1012782-90-9P	1012782-91-0P	1012782-92-1P
	1012782-93-2P	1012782-94-3P	1012782-95-4P
	1012782-96-5P	1012782-97-6P	1012782-98-7P
	1012782-99-8P	1012783-00-4P	1012783-01-5P
	1012783-02-6P	1012783-03-7P	1012783-04-8P
	1012783-05-9P	1012783-06-0P	1012783-07-1P


1012783-08-2P	1012783-09-3P	1012783-10-6P
1012783-11-7P	1012783-12-8P	1012783-14-0P
1012783-15-1P	1012783-16-2P	1012783-17-3P
1012783-19-5P	1012783-20-8P	1012783-21-9P
1012783-22-0P	1012783-23-1P	1012783-24-2P
1012783-25-3P	1012783-26-4P	1012783-27-5P
1012783-28-6P	1012783-29-7P	1012783-30-0P
1012783-31-1P	1012783-32-2P	1012783-33-3P
1012783-34-4P	1012783-35-5P	1012783-36-6P
1012783-37-7P	1012783-38-8P	1012783-39-9P
1012783-40-2P	1012783-41-3P	1012783-42-4P
1012783-43-5P	1012783-44-6P	1012783-45-7P
1012783-46-8P	1012783-47-9P	1012783-48-0P
1012783-49-1P	1012783-51-5P	1012783-52-6P
1012783-53-7P	1012783-55-9P	1012783-58-2P
1012783-59-3P	1012783-60-6P	1012783-62-8P
1012783-63-9P	1012783-64-0P	1012783-66-2P
1012783-67-3P	1012783-68-4P	1012783-69-5P
1012783-72-0P	1012783-73-1P	1012783-74-2P
1012783-75-3P	1012783-77-5P	1012783-78-6P
1012783-79-7P	1012783-81-1P	1012783-82-2P
1012783-83-3P	1012783-85-5P	1012783-86-6P
1012783-87-7P	1012783-88-8P	1012783-89-9P
1012783-90-2P	1012783-91-3P	1012783-92-4P
1012783-93-5P	1012783-94-6P	1012783-95-7P
1012783-96-8P	1012783-97-9P	1012783-98-0P
1012783-99-1P	1012784-00-7P	1012784-01-8P
1012784-02-9P	1012784-03-0P	1012784-04-1P
1012784-05-2P	1012784-06-3P	1012784-07-4P
1012784-08-5P	1012784-09-6P	1012784-10-9P
1012784-11-0P	1012784-12-1P	1012784-13-2P
1012784-14-3P	1012784-15-4P	1012784-16-5P
1012784-17-6P	1012784-18-7P	1012784-19-8P
1012784-20-1P	1012784-21-2P	1012784-46-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinazolinone and isoquinolinone acetamide derivs. as V3 modulators useful in the treatment of diseases)

RN 1012782-03-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1,1-dimethylethyl)-6-(hexahydro-1H-1,4-diazepin-1-yl)-4-oxo- (CA INDEX NAME)




RN 1012782-04-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1,1-dimethylethyl)-6-(hexahydro-1H-1,4-diazepin-1-yl)-4-oxo-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

10/ 582,823

CRN 1012782-03-4
CMF C25 H30 Cl N5 O2




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 1012782-13-6 CAPLUS
CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(6-fluorohexahydro-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-17-0 CAPLUS
CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-(1-piperazinyl)- (CA INDEX NAME)




RN 1012782-18-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-19-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-(dimethylamino)-1-pyrrolidinyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-20-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-[(dimethylamino)methyl]-1-piperidinyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012782-21-6 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-(4-methyl-1-piperazinyl)-4-oxo- (CA INDEX NAME)



RN 1012782-22-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-
[(3S)-3-(1-piperidinylmethyl)-1-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1012782-23-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-
[(3R)-3-(1-piperidinylmethyl)-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1012782-24-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-
[3-(1-piperidinylmethyl)-1-piperidinyl]- (CA INDEX NAME)


RN 1012782-25-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(hexahydro-4-phenyl-1H-1,4-diazepin-1-yl)-2-
(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-26-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1,1-dimethylethyl)-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-4-oxo- (CA INDEX NAME)




RN 1012782-27-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-28-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[1,4'-bipiperidin]-1'-yl-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-29-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[3-[2-(1-piperidinyl)ethyl]-1-azetidiny]- (CA INDEX NAME)




RN 1012782-30-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-[(3-(4-morpholinylmethyl)-1-piperidinyl)-4-oxo-]-(CA INDEX NAME)




RN 1012782-31-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[(3-(1-piperidinylmethyl)-1-pyrrolidinyl)]-(CA INDEX NAME)




RN 1012782-32-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[(3-(1-piperidinylmethyl)-1-azetidinyl)]-(CA INDEX NAME)



RN 1012782-33-0 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-[4-(dimethylamino)-1-piperidinyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012782-34-1 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-6-[(3S)-3-methyl-1-piperazinyl]-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 1012782-35-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(3,3-dimethyl-1-piperazinyl)-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-36-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(2,5-dimethyl-1-piperazinyl)-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-37-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-6-(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)-4-oxo- (CA INDEX NAME)




RN 1012782-38-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(3,5-dimethyl-1-piperazinyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-39-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(1,4-diazabicyclo[3.2.2]non-4-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-40-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-4-(2-hydroxyethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-42-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1-methylethyl)-6-[4-(1-methylethyl)-1-piperazinyl]-4-oxo- (CA INDEX NAME)




RN 1012782-43-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-6-[4-(1-methylethyl)-1-piperazinyl]-4-oxo- (CA INDEX NAME)



RN 1012782-44-3 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 1012782-45-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-46-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[hexahydro-4-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-1-yl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-47-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[hexahydro-4-(2-methoxyethyl)-1H-1,4-diazepin-1-yl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-48-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[hexahydro-4-(phenylmethyl)-1H-1,4-diazepin-1-yl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012782-49-8 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-[4-(cyanomethyl)hexahydro-1H-1,4-diazepin-1-yl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012782-50-1 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[4-(cyclopropylmethyl)hexahydro-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo-

(CA INDEX NAME)




RN 1012782-51-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[4-(cyclopropylmethyl)hexahydro-1H-1,4-diazepin-1-yl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-52-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1,1-dimethylethyl)-6-[hexahydro-4-(2-hydroxyethyl)-1H-1,4-diazepin-1-yl]-4-oxo- (CA INDEX NAME)




RN 1012782-53-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-(2-hydroxyethyl)-1H-1,4-diazepin-1-yl]-4-oxo- (CA INDEX NAME)




RN 1012782-54-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-[(3-methyl-3-oxetanyl)methyl]-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-55-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[4-[(2,2-difluorocyclopropyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-56-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-[(3-methyl-3-oxetanyl)methyl]-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-57-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[4-[(2,2-difluorocyclopropyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-58-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-4-[(3-methyl-3-oxetan-1-yl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-59-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[4-[(2,2-difluorocyclopropyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-60-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-(2-hydroxyethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-61-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1,1-dimethylethyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-4-oxo- (CA INDEX NAME)




RN 1012782-62-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-4-oxo- (CA INDEX NAME)




RN 1012782-63-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-4-(2-methoxyethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-64-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-(2-methoxyethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-65-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-(2-methoxyethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-66-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-(2-hydroxyethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-67-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-68-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1,1-dimethylethyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-4-oxo- (CA INDEX NAME)




RN 1012782-69-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-70-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1,1-dimethylethyl)-6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-4-oxo- (CA INDEX NAME)




RN 1012782-71-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[4-(cyclopropylmethyl)-1-piperazinyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-72-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(4-ethyl-1-piperazinyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-73-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-(hexahydro-4-propyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-74-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-ethylhexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012782-75-0 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-4-(1-methylethyl)-3-propyl-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012782-76-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[(3S)-4-(cyclopropylmethyl)-3-(1-methylethyl)-1-piperazinyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012782-77-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1-methylethyl)-6-[(3R)-3-methyl-4-(1-methylethyl)-1-piperazinyl]-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012782-78-3 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[(3R)-4-(cyclopropylmethyl)-3-methyl-1-piperazinyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.



RN 1012782-79-4 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1,1-dimethylethyl)-6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-4-oxo- (CA INDEX NAME)



RN 1012782-80-7 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1,1-dimethylethyl)-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-4-oxo- (CA INDEX NAME)

INDEX NAME)




RN 1012782-81-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo- (CA INDEX NAME)




RN 1012782-82-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(4-cyclopentylhexahydro-1H-1,4-diazepin-1-yl)-N-(1,1-dimethylethyl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo- (CA INDEX NAME)




RN 1012782-83-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-2-(4-fluoro-3-methoxyphenyl)-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-4-oxo- (CA INDEX NAME)




RN 1012782-84-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-4-(2-methylpropyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-85-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(hexahydro-4,6,6-trimethyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-86-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-(hexahydro-4,6,6-trimethyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-87-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[4-(1,2-dimethylpropyl)hexahydro-1H-1,4-diazepin-1-yl]-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-88-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[4-ethylhexahydro-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-89-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-(1-methylpropyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-90-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[4-(cyclopentylmethyl)hexahydro-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-91-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[4-[2-(dimethylamino)-1-methylethyl]hexahydro-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-92-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-(3-methylbutyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-93-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-(2-methoxy-1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-94-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[4-(1-cyclopropylethyl)hexahydro-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-95-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[4-(2,2-dimethylpropyl)cyclopropylethyl]hexahydro-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-96-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[4-(4-cyclopentyl)hexahydro-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-97-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[4-(1-ethylpropyl)hexahydro-1H-1,4-diazepin-1-yl]-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-98-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[4-(cyclopentylmethyl)hexahydro-1H-1,4-diazepin-1-yl]-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012782-99-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[4-(cyclobutyl)hexahydro-1H-1,4-diazepin-1-yl]-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-00-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-01-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-(hexahydro-4-propyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-02-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(4-butylhexahydro-1H-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-03-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-(1-methylbutyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-04-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-05-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-06-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(hexahydro-4-propyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-07-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[(hexahydro-3-methyl-4-(1-methylethyl)-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)]




RN 1012783-08-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[(3-ethylhexahydro-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)]




RN 1012783-09-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)]




RN 1012783-10-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(hexahydropyrido[1,2-a]pyrazin-2(1H)-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-11-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[3-(fluoromethyl)-1-piperazinyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012783-12-8 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(3,3-dimethyl-1-piperazinyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



10/ 582,823


RN 1012783-14-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-(3-ethylhexahydro-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012783-15-1 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-(1,4-diazabicyclo[3.2.2]non-4-yl)-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012783-16-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1-methylethyl)-4-oxo-6-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1012783-17-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-6-[(3R)-3-methyl-1-piperazinyl]-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.




RN 1012783-19-5 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(hexahydro-5-methyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012783-20-8 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-(3,5-dimethoxyphenyl)-6-(hexahydro-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-21-9 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-[3-chloro-5-(trifluoromethyl)phenyl]-6-(hexahydro-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-22-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3,5-difluorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-23-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3,5-dichlorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-24-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-5-fluorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-25-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-[3-fluoro-5-(trifluoromethyl)phenyl]-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-26-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-2-[3-methoxy-5-(trifluoromethyl)phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-27-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3,5-dimethylphenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-28-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3,5-dimethoxyphenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-29-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-[3-chloro-5-(trifluoromethyl)phenyl]-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-30-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-[3-chloro-5-(trifluoromethoxy)phenyl]-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-31-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(2-fluoro-3-methoxyphenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-32-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-[2-fluoro-3-(trifluoromethyl)phenyl]-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-33-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(2,3-dichlorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-34-4 CAPLUS

CN 3-(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-3-[2-(methylsulfonyl)ethyl]-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-35-5 CAPLUS

CN 3-(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-3-[2-(methylsulfonyl)ethyl]-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012783-36-6 CAPLUS


CN 3-(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-3-[2-(methylsulfonyl)ethyl]-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012783-37-7 CAPLUS

CN 3-(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[(3S)-hexahydro-3-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012783-38-8 CAPLUS

CN 3-(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[(3S)-hexahydro-3-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.




10/ 582,823

RN 1012783-39-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[(3S)-hexahydro-3-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012783-40-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[(3R)-hexahydro-3-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012783-41-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[(3R)-hexahydro-3-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012783-42-4 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[(3R)-hexahydro-3-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 1012783-43-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-chloro-3-fluorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-44-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-[4-fluoro-3-(trifluoromethyl)phenyl]-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-45-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-2-(3-methoxy-4-methylphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-46-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-fluoro-4-methylphenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-47-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3,4-dichlorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-48-0 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-(3,4-dimethylphenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-49-1 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1-methylethyl)-6-[(3R)-3-(1-methylethyl)-1-piperaziny]-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 1012783-51-5 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-[2-fluoro-4-(trifluoromethyl)phenyl]-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-52-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-(hexahydro-6,6-dimethyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-53-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-(hexahydro-3-propyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-55-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-(hexahydro-3-propyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-58-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-2-(3-fluorophenyl)-6-(hexahydro-1H-1,4-diazepin-1-yl)-4-oxo- (CA INDEX NAME)




RN 1012783-59-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-2-(3-fluorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-4-oxo- (CA INDEX NAME)




RN 1012783-60-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-fluorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-62-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(2-fluorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-63-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3,4-difluorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-64-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-66-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-(hexahydro-3,6,6-trimethyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012783-67-3 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-(3-ethylhexahydro-6,6-dimethyl-1H-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012783-68-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[(3S)-hexahydro-6,6-dimethyl-3-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012783-69-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(hexahydro-6,6-dimethyl-1H-1,4-diazepin-1-yl)-4-oxo-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012783-72-0 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(hexahydro-6,6-dimethyl-1H-1,4-diazepin-1-yl)-4-oxo-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1012783-73-1 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1,1-dimethylethyl)-6-(hexahydro-6,6-dimethyl-1H-1,4-diazepin-1-yl)-4-oxo- (CA INDEX NAME)



RN 1012783-74-2 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-(hexahydro-6,6-dimethyl-3-propyl-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)

INDEX NAME)



RN 1012783-75-3 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-(1,4-diazabicyclo[3.2.2]non-4-yl)-N-(1,1-dimethylethyl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo- (CA INDEX NAME)



RN 1012783-77-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[(3R)-3-methyl-1-piperazinyl]-4-oxo-N-(2,2,2-trifluoro-1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012783-78-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-4-oxo-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012783-79-7 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-
(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-4-oxo-N-[(1S)-2,2,2-trifluoro-1-
methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1012783-81-1 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-4-(1-
methylethyl)-1H-1,4-diazepin-1-yl]-4-oxo-N-(2,2,2-trifluoro-1,1-
dimethylethyl)- (CA INDEX NAME)



RN 1012783-82-2 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-4-(1-

methylethyl)-1H-1,4-diazepin-1-yl]-4-oxo-N-(2,2,2-trifluoro-1-methylethyl)-
(CA INDEX NAME)




RN 1012783-83-3 CAPLUS

CN 3-(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)



RN 1012783-85-5 CAPLUS


CN 3-(4H)-Quinazolineacetamide, 6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo-N-(2,2,2-trifluoro-1,1-dimethylethyl)- (CA INDEX NAME)



RN 1012783-86-6 CAPLUS

CN 3-(4H)-Quinazolineacetamide, 6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012783-87-7 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1012783-88-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-cyclobutyl-6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo- (CA INDEX NAME)



RN 1012783-89-9 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)



RN 1012783-90-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-4-oxo-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1012783-91-3 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-4-oxo-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1012783-92-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-cyclobutyl-6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-4-oxo- (CA INDEX NAME)



RN 1012783-93-5 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)



RN 1012783-94-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-(2-hydroxyethyl)-1H-1,4-diazepin-1-yl]-4-oxo-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




10/ 582,823

RN 1012783-95-7 CAPLUS


CN 3-(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-(2-hydroxyethyl)-1H-1,4-diazepin-1-yl]-4-oxo-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1012783-96-8 CAPLUS

CN 3-(4H)-Quinazolineacetamide, N-cyclobutyl-2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-(2-hydroxyethyl)-1H-1,4-diazepin-1-yl]-4-oxo- (CA INDEX NAME)



RN 1012783-97-9 CAPLUS


CN 3-(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-(2-hydroxyethyl)-1H-1,4-diazepin-1-yl]-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)



10/ 582,823


RN 1012783-98-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-methyl-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012783-99-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-ethyl-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-4-oxo- (CA INDEX NAME)




RN 1012784-00-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-cyclobutyl-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-4-oxo- (CA INDEX NAME)




RN 1012784-01-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-4-oxo-N-(2,2,2-trifluoro-1-methylethyl)- (CA INDEX NAME)




RN 1012784-02-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)




RN 1012784-03-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-4-oxo-N-(2,2,2-trifluoro-1,1-dimethylethyl)- (CA INDEX NAME)




RN 1012784-04-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(1,4-diazabicyclo[3.2.2]non-4-yl)-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012784-05-2 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-(1,4-diazabicyclo[3.2.2]non-4-yl)-2-(4-fluoro-3-methoxyphenyl)-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)



RN 1012784-06-3 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-(1,4-diazabicyclo[3.2.2]non-4-yl)-2-(4-fluoro-3-methoxyphenyl)-N-[(1R)-1-methylpropyl]-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.



RN 1012784-07-4 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-(1,4-diazabicyclo[3.2.2]non-4-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo-N-[1-(trifluoromethyl)propyl]- (CA INDEX NAME)



RN 1012784-08-5 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-(1,4-diazabicyclo[3.2.2]non-4-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo-N-(2,2,2-trifluoro-1,1-dimethylethyl)- (CA INDEX NAME)

INDEX NAME)




RN 1012784-09-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(1,4-diazabicyclo[3.2.2]non-4-yl)-2-(4-fluoro-3-methoxyphenyl)-N-(2-methoxy-1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012784-10-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1-cyano-1-methylethyl)-6-(1,4-diazabicyclo[3.2.2]non-4-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo- (CA INDEX NAME)




RN 1012784-11-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(cyclopropylmethyl)-6-(1,4-diazabicyclo[3.2.2]non-4-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo- (CA INDEX NAME)




RN 1012784-12-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(1,4-diazabicyclo[3.2.2]non-4-yl)-2-(3,5-dimethoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012784-13-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(4-cyclopropylhexahydro-1H-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012784-14-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-(4-cyclopropylhexahydro-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012784-15-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-(4-cyclopropylhexahydro-1H-1,4-diazepin-1-yl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012784-16-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012784-17-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012784-18-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[hexahydro-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)methyl]-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012784-19-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)methyl]-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012784-20-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[hexahydro-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)methyl]-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 1012784-21-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[hexahydro-4-(1-methylethyl)-4-oxido-1H-1,4-diazepin-1-yl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 1012784-46-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L5 ANSWER 23 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN

ACCESSION NUMBER: 2008:124483 CAPLUS

DOCUMENT NUMBER: 148:183391

TITLE: Heme oxygenase inhibitors and methods of therapeutic use as antimicrobial agents

INVENTOR(S): Wilks, Angela; Mackerell, Alexander D., Jr.; Lopes, Pedro; Furci, Lena M.

PATENT ASSIGNEE(S): University of Maryland, USA

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008014266	A2	20080131	WO 2007-US74233	20070724
WO 2008014266	A3	20081127		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,

BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 AU 2007276763 A1 20080131 AU 2007-276763 20070724
 CA 2658877 A1 20080131 CA 2007-2658877 20070724
 EP 2046122 A2 20090415 EP 2007-840495 20070724
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
 AL, BA, HR, MK, RS
 PRIORITY APPLN. INFO.: US 2006-832892P P 20060724
 US 2007-945710P P 20070622
 WO 2007-US74233 W 20070724
 GI



AB The present invention relates to inhibitors of microbial heme oxygenase, especially heme oxygenase of *Pseudomonas aeruginosa* (pa-HO) and *Neisseria meningitidis* (nm-HO) and their use for treatment of microbial infections and bioremediation. The inhibitors of microbial heme oxygenase are useful as a new class of antimicrobial agents to target infections that are persistently difficult to combat with the current spectrum of antimicrobial agents. Screening methods for selecting inhibitors of microbial heme oxygenase are also described. Thus, the compound I was tested in vitro for inhibiting microbial heme oxygenase by testing its ability to bind to the microbial heme oxygenase and to inhibit the production of α -biliverdin in *Escherichia coli* cells expressing said microbial heme oxygenase; the binding affinity (KD) against nm-HO and pa-HO activity was $12.2 \pm 1.0 \mu\text{M}$ and $15.9 \pm 1.1 \mu\text{M}$, resp., and no biliverdin was observed
 IT 35729-61-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (screening and therapeutic uses of heme oxygenase inhibitors as antimicrobial agents)
 RN 35729-61-4 CAPLUS
 CN Benzoic acid, 2-(3,4-dihydro-4-oxo-2-quinazolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L5 ANSWER 24 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1059556 CAPLUS

DOCUMENT NUMBER: 147:397858

TITLE: Quinazolinone Derivatives as Orally Available Ghrelin Receptor Antagonists for the Treatment of Diabetes and Obesity

AUTHOR(S): Rudolph, Joachim; Esler, William P.; O'Connor, Stephen; Coish, Philip D. G.; Wickens, Philip L.; Brands, Michael; Bierer, Donald E.; Bloomquist, Brian T.; Bondar, Georgiy; Chen, Libing; Chuang, Chih-Yuan; Claus, Thomas H.; Fathi, Zahra; Fu, Wenlang; Khire, Uday R.; Kristie, James A.; Liu, Xiao-Gao; Lowe, Derek B.; McClure, Andrea C.; Michels, Martin; Ortiz, Astrid A.; Ramsden, Philip D.; Schoenleber, Robert W.; Shelekhn, Tatiana E.; Vakalopoulos, Alexandros; Tang, Weifeng; Wang, Lei; Yi, Lin; Gardell, Stephen J.; Livingston, James N.; Sweet, Laurel J.; Bullock, William H.

CORPORATE SOURCE: Departments of Chemistry Research, Metabolic Disorders Research, and Research Technologies, Bayer Pharmaceuticals Corporation, West Haven, CT, 06516, USA

SOURCE: Journal of Medicinal Chemistry (2007), 50(21), 5202-5216

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:397858

AB The peptide hormone ghrelin is the endogenous ligand for the type 1a growth hormone secretagogue receptor (GHS-R1a) and the only currently known circulating appetite stimulant. GHS-R1a antagonism has therefore been proposed as a potential approach for obesity treatment. More recently, ghrelin has been recognized to also play a role in controlling glucose-induced insulin secretion, which suggests another possible benefit for a GHS-R1a antagonist, namely, the role as an insulin secretagogue with potential value for diabetes treatment. In our labs., piperidine-substituted quinazolinone derivs. were identified as a new class of small-mol. GHS-R1a antagonists. Starting from an agonist with poor oral bioavailability, optimization led to potent, selective, and orally bioavailable antagonists. In vivo efficacy evaluation of selected compds. revealed suppression of food intake and body weight reduction as well

as glucose-lowering effects mediated by glucose-dependent insulin secretion.

IT 875258-64-3P 875260-65-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic


preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(piperidine-substituted quinazolinone derivs. as GHS-R1a antagonists)


RN 875258-64-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)



RN 875260-65-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-2-(2-methylphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)



IT 875258-66-5P 875258-80-3P 875258-81-4P

875259-09-9P 875259-44-2P 875259-73-7P

875259-76-0P 875260-49-4P 875260-72-3P

875261-04-4P 875261-05-5P 875261-06-6P

875261-11-3P 875262-55-8P 875262-60-5P

875263-31-3P 875269-27-5P 950908-77-7P


950908-79-9P 950908-92-6P 950908-94-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(piperidine-substituted quinazolinone derivs. as GHS-R1a antagonists)


RN 875258-66-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875258-80-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)- (CA INDEX NAME)



RN 875258-81-4 CAPLUS


CN 4(3H)-Quinazolinone, 3-[(1-ethyl-3-piperidinyl)methyl]-6-methoxy-2-(2-methoxyphenyl)- (CA INDEX NAME)



RN 875259-09-9 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(3R)-1-ethyl-3-piperidinylmethyl]-2-(2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 875259-44-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methylphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875259-73-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[4-(1-methylethyl)-2-morpholinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875259-76-0 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-1,2,5,6-tetrahydro-3-pyridinyl)methyl]-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875260-49-4 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-3-[(3S)-1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 875260-72-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875261-04-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875261-05-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875261-06-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclobutyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875261-11-3 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-methylphenyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 875262-55-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-fluoroethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875262-60-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methylphenyl)-3-[[1-(3,3,3-trifluoropropyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875263-31-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
2-(2-methylphenyl)- (CA INDEX NAME)


RN 875269-27-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-[[1-(1-methylethyl)-3-piperidinyl)methyl]- (CA INDEX NAME)




RN 950908-77-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methylphenyl)-3-[[1-(2,2,2-trifluoroethyl)-3-piperidinyl)methyl]- (CA INDEX NAME)




RN 950908-79-9 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[2-(1-ethyl-3-piperidinyl)ethyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)



RN 950908-92-6 CAPLUS
 CN 4(3H)-Quinazolinone, 7-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
 2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 950908-94-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-
 methylphenyl)- (CA INDEX NAME)



IT 875260-48-3 875260-97-2 875260-99-4
 950913-52-7 950913-53-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (piperidine-substituted quinazolinone derivs. as GHS-R1a antagonists)
 RN 875260-48-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-3-[[1-(1-methylethyl)-3-
 piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-97-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[4-(trifluoromethyl)phenyl]-1-ethyl-3-piperidinylmethyl]-2-[[4-(trifluoromethyl)phenyl]-1-ethyl-3-piperidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-99-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[4-(trifluoromethyl)phenyl]-1-ethyl-3-piperidinylmethyl]-2-[[4-(trifluoromethyl)phenyl]-1-ethyl-3-piperidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 950913-52-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(trifluoromethyl)phenyl]-1-ethyl-3-piperidinylmethyl]-2-[[4-(trifluoromethyl)phenyl]-1-ethyl-3-piperidinylmethyl]-6-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 950913-53-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3R)-1-ethyl-3-piperidiny]methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
 REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:754498 CAPLUS

DOCUMENT NUMBER: 147:143463

TITLE: Heterocycle-substituted amide derivatives, their preparation, and pharmaceuticals and ACAT inhibitors containing them

INVENTOR(S): Natsukari, Hideaki; Uede, Tomonori

PATENT ASSIGNEE(S): Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 34pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007176809	A	20070712	JP 2005-374007	20051227
PRIORITY APPLN. INFO.:			JP 2005-374007	20051227
OTHER SOURCE(S):		MARPAT 147:143463		


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title derivs. I [ring A = (un)substituted benzene ring, heteroarom. ring; rings B and C = (un)substituted benzene ring; X = N, CR1 [R1 = H, (un)substituted lower alkyl, halo]; m = 1, 2; n = 0-2; except the cases where rings A, B, and C = benzene ring, C₆H₄Cl-2, and C₆H₃F₂-2,4, resp., X = N, m = 1, and n = 0] or their salts, are prepared by reaction of carboxylic acids II (rings A and B, X, n = same as above) or their salts with amines III (ring C, n = same as above) or their salts or by cyclization of IV (rings A, B, and C, X, m, n = same as above) or their salts. Title pharmaceuticals and inhibitors, useful for treatment of hypercholesterolemia, arteriosclerosis, etc., are also claimed. Thus, a DMF solution of [2-(2-chlorophenyl)-4-oxo-4H-quinazolin-3-yl]-acetic acid (preparation given) was treated with 2,6-dimethoxyaniline and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride at room temperature for 16 h to give 60% 2-[2-(2-chlorophenyl)-4-oxo-4H-quinazolin-3-yl]-N-(2,6-dimethoxyphenyl)acetamide. IC₅₀ of this compound against ACAT of rat liver microsome was 0.0213 μ M.
- IT 362494-38-0P 943754-81-2P 943754-82-3P
 943754-83-4P 943754-84-5P 943754-85-6P
 943754-87-8P
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocycle-substituted amide derivs. as ACAT inhibitors for pharmaceuticals)
- RN 362494-38-0 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-(2-chlorophenyl)-N-(2,4-difluorophenyl)-4-oxo- (CA INDEX NAME)




- RN 943754-81-2 CAPLUS
 CN 3(4H)-Quinazolineacetamide, 2-(2-chlorophenyl)-N-(2,6-dimethoxyphenyl)-4-oxo- (CA INDEX NAME)




- RN 943754-82-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(2,6-dimethoxyphenyl)-2-(2-methylphenyl)-4-oxo- (CA INDEX NAME)




RN 943754-83-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-chloro-N-(2,6-dimethoxyphenyl)-2-(2-methylphenyl)-4-oxo- (CA INDEX NAME)




RN 943754-84-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(2-chlorophenyl)-N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-4-oxo- (CA INDEX NAME)




RN 943754-85-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(2-chlorophenyl)-N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-4-oxo- (CA INDEX NAME)



RN 943754-87-8 CAPLUS
 CN 3(4H)-Quinazolineacetamide, N-[4-fluoro-2-(trifluoromethyl)phenyl]-2-(2-methylphenyl)-4-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)

L5 ANSWER 26 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:703686 CAPLUS

DOCUMENT NUMBER: 147:118255

TITLE: Quinoline and quinazoline compositions and methods for modulating gated ion channels and their preparation
 INVENTOR(S): Vohra, Rahul; Babinski, Kazimierz; Brochu, Jean-Louis; Ntirampebura, Deogratias; Wei, Chang-Qing; Zamboni, Robert Joseph

PATENT ASSIGNEE(S): Painceptor Pharma Corporation, Can.

SOURCE: PCT Int. Appl., 155pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007071055	A1	20070628	WO 2006-CA2105	20061221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006329202	A1	20070628	AU 2006-329202	20061221
CA 2634491	A1	20070628	CA 2006-2634491	20061221
US 20070197509	A1	20070823	US 2006-643640	20061221
EP 1968968	A1	20080917	EP 2006-840532	20061221
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009520700	T	20090528	JP 2008-546060	20061221
MX 2008007889	A	20080731	MX 2008-7889	20080618

CN 101360738	A	20090204	CN 2006-80051167	20080716
KR 2008089416	A	20081006	KR 2008-717629	20080718
IN 2008DN06306	A	20081024	IN 2008-DN6306	20080718
PRIORITY APPLN. INFO.:			US 2005-753201P	P 20051221
			WO 2006-CA2105	W 20061221

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 147:118255
 GI



AB Disclosed are quinoline and quinazoline compds. of formula I, which modulate the activity of the gated ion channels compds. that modulate these gated ion channels are useful in the treatment of diseases and disorders related to pam, inflammation, the neurol. system, the gastrointestinal system and genitourinary system. The preferred compds. include quinoline or quinazoline derivs. substituted at the 4- position via N(H), C(O) or O moieties. Compds. of formula I wherein dashed line is single or double bond, wherein when the dashed lines is single bond, N of the ring may be bond to H and R1; R1, R3 and R4 are independently H, (un)substituted amine, CN, NO2, CO2H, and, halo, etc.; R2 is H, (un)substituted amino, amide, halo, NO2, (un)substituted aryl, etc.; R5 is N, C and CH; and their pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereoisomers, and racemates thereof, are claimed. Example compound II was prepared by substitution of 4-chloro-2-methylquinoline with 1-benzylpiperidin-4-ol. All the invention compds. were evaluated for their gated ion channel modulatory activity.


IT 942906-31-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinoline and quinazoline compds. as gated ion channels modulators useful in treatment of diseases)

RN 942906-31-2 CAPLUS

CN Quinazoline, 4-(4-chlorobutoxy)-2-(4-methylphenyl)-6-nitro- (CA INDEX NAME)



(7 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:584604 CAPLUS

DOCUMENT NUMBER: 147:9944

TITLE: Preparation of condensed pyrimidines, their use as serum phosphorus level-lowering agents and phosphoric acid-transport inhibitors, and their pharmaceutical compositions

INVENTOR(S): Eto, Nobuaki; Nagao, Rika; Sakai, Teruyuki; Kato, Shinichiro

PATENT ASSIGNEE(S): Kirin Brewery Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 108pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007131532	A	20070531	JP 2001-303288	20010928
PRIORITY APPLN. INFO.:			JP 2001-303288	20010928
OTHER SOURCE(S):	MARPAT	147:9944		

GI



AB Title compds. I [A = (un)substituted 5- to 9-membered (hetero)cyclic ring; R5 = (un)substituted C1-6 alkyl(oxy), aryl(oxy), C1-6 alkylamino, arylthio, heterocyclyl, etc.; R6, R7 = H, (un)substituted C1-6 alkyl, aryl C2-6 alkenyl, C2-6 alkynyl, aryl, heterocyclyl], their pharmacol. acceptable salts, or solvates are prepared. Thus, Me 2-aminobenzoate was amidated with 3,4-dimethoxybenzoyl chloride, cyclized with NH₂NH₂.H₂O, and reacted with trans-cinnamaldehyde to give I (A = benzene residue, R5 = 3,4-dimethoxyphenyl, R6 = H, R7 = trans-PhCH:CH), which inhibited Na-dependent phosphate transport with IC₅₀ value of 9.11 μM.

IT	328033-29-0P	937706-65-5P	937706-66-6P
	937706-67-7P	937706-68-8P	937706-69-9P
	937706-70-2P	937706-71-3P	937706-72-4P
	937706-73-5P	937706-74-6P	937706-75-7P
	937706-76-8P	937706-77-9P	937706-78-0P
	937706-79-1P	937706-80-4P	937706-81-5P
	937706-82-6P	937706-83-7P	937706-84-8P
	937706-85-9P	937706-86-0P	937706-87-1P
	937706-88-2P	937706-89-3P	937706-90-6P
	937706-91-7P	937706-92-8P	937706-93-9P
	937706-94-0P	937706-95-1P	937706-96-2P
	937706-97-3P	937706-98-4P	937706-99-5P


937707-00-1P	937707-01-2P	937707-02-3P
937707-03-4P	937707-04-5P	937707-05-6P
937707-06-7P	937707-07-8P	937707-08-9P
937707-09-0P	937707-10-3P	937707-11-4P
937707-12-5P	937707-13-6P	937707-14-7P
937707-15-8P	937707-16-9P	937707-17-0P
937707-18-1P	937707-19-2P	937707-20-5P
937707-21-6P	937707-22-7P	937707-23-8P
937707-24-9P	937707-25-0P	937707-26-1P
937707-27-2P	937707-28-3P	937707-29-4P
937707-30-7P	937707-31-8P	937707-32-9P
937707-33-0P	937707-34-1P	937707-35-2P
937707-36-3P	937707-37-4P	937707-38-5P
937707-39-6P	937707-40-9P	937707-41-0P
937707-42-1P	937707-43-2P	937707-44-3P
937707-45-4P	937707-46-5P	937707-47-6P
937707-48-7P	937707-49-8P	937707-50-1P
937707-51-2P	937707-52-3P	937707-53-4P
937707-54-5P	937707-55-6P	937707-56-7P
937707-57-8P	937707-58-9P	937707-59-0P
937707-60-3P	937707-61-4P	937707-62-5P
937707-63-6P	937707-64-7P	937707-65-8P
937707-66-9P	937707-67-0P	937707-68-1P
937707-69-2P	937707-70-5P	937707-71-6P
937707-72-7P	937707-73-8P	937707-74-9P
937707-75-0P	937707-76-1P	937707-77-2P
937707-78-3P	937707-79-4P	937707-80-7P
937707-81-8P	937707-82-9P	937707-83-0P
937707-84-1P	937707-85-2P	937707-86-3P
937707-87-4P	937707-88-5P	937707-89-6P
937707-90-9P	937707-91-0P	937708-02-6P
937708-03-7P	937708-04-8P	937708-05-9P
937708-06-0P	937708-07-1P	937708-08-2P
937708-09-3P	937708-10-6P	937708-11-7P
937708-12-8P	937708-13-9P	937708-41-3P
937708-42-4P	937708-43-5P	937708-44-6P
937708-45-7P	937708-46-8P	937708-58-2P
937708-59-3P	937708-60-6P	937708-61-7P
937708-62-8P	937708-63-9P	937708-64-0P
937708-65-1P	937708-67-3P	937708-68-4P
937708-69-5P	937708-70-8P	937708-71-9P
937708-72-0P	937708-76-4P	937708-77-5P
937708-87-7P	937708-90-2P	937708-91-3P
937708-92-4P	937708-93-5P	937708-94-6P
937708-95-7P	937708-96-8P	937708-97-9P
937708-98-0P	937708-99-1P	937709-00-7P
937709-01-8P	937709-02-9P	937709-03-0P
937709-04-1P	937709-05-2P	937709-11-0P
937709-12-1P	937709-13-2P	937709-14-3P
937709-15-4P	937709-16-5P	937709-17-6P
937709-18-7P	937709-19-8P	937709-20-1P
937709-21-2P	937709-22-3P	937709-35-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)

RN 328033-29-0 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[[(2-bromophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



RN 937706-65-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(2E)-3-phenyl-2-propen-1-ylidene]amino]- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 937706-66-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(2-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-67-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(2-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-68-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[2-methoxyphenyl)methylene]amino]- (CA INDEX NAME)



RN 937706-69-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3-methoxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-70-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



RN 937706-71-3 CAPLUS



CN 4(3H)-Quinazolinone, 2-((3,4-dimethoxyphenyl)-3-[[2E)-2-methyl-3-phenyl-2-propen-1-ylidene]amino]- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 937706-72-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3,5-bis(trifluoromethyl)phenyl]methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)





RN 937706-73-5 CAPLUS

CN Benzonitrile, 3-[[[2-(3,4-dimethoxyphenyl)-4-oxo-3(4H)-quinazolin-2-ylidene]imino]methyl]- (CA INDEX NAME)





RN 937706-74-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(4-hydroxy-3-methoxyphenyl)methylene]amino]- (CA INDEX NAME)



RN 937706-75-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(3,4,5-trimethoxyphenyl)methylene]amino]- (CA INDEX NAME)



RN 937706-76-8 CAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[(2E)-3-phenyl-2-propen-1-ylidene]amino]- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 937706-77-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(2-bromophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937706-78-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-79-1 CAPLUS


CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-80-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(phenylmethylene)amino]-
(CA INDEX NAME)



RN 937706-81-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3-
hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-82-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-
hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-83-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-84-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(2-furanylmethylene)amino]- (CA INDEX NAME)




RN 937706-85-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(5-methyl-2-furanyl)methylene]amino]- (CA INDEX NAME)




RN 937706-86-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(2-thienylmethylene)amino]- (CA INDEX NAME)




RN 937706-87-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(3-thienylmethylene)amino]-
(CA INDEX NAME)





RN 937706-88-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(2,4-dihydroxyphenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937706-89-3 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[[(3,4-dihydroxyphenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937706-90-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[(phenylmethylene)amino]- (CA INDEX NAME)




RN 937706-91-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[2-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-92-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[3-fluorophenyl)methylene]amino]- (CA INDEX NAME)





RN 937706-93-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[[(2-methylphenyl)methylene]amino]- (CA INDEX NAME)



RN 937706-94-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-95-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[(3-chloro-4-fluorophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)





RN 937706-96-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-((3,4-dimethoxyphenyl)methylene)amino-1,3-dihydro- (trifluoromethoxy)phenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-97-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(((3-bromo-4-methoxyphenyl)methylene)amino)-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)





RN 937706-98-4 CAPLUS



CN 4(3H)-Quinazolinone, 3-(((3-chlorophenyl)methylene)amino)-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



RN 937706-99-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-hydroxy-3,5-dimethylphenyl]methylene]amino]- (CA INDEX NAME)




RN 937707-00-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3-ethoxy-4-hydroxyphenyl]methylene]amino]- (CA INDEX NAME)




RN 937707-01-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-02-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-03-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[4-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-04-5 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



RN 937707-05-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-(4-hydroxy-3-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-06-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[2,5-dimethylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-07-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methylene]amino]- (CA INDEX NAME)




RN 937707-08-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[[4-hydroxy-3-methylphenyl]methylene]amino]- (CA INDEX NAME)



RN 937707-09-0 CAPLUS



CN 4(3H)-Quinazolinone, 3-[[[(2,5-dimethylphenyl)methylene]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)



RN 937707-10-3 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[[(3-fluorophenyl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)

10/ 582,823





RN 937707-11-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-fluorophenyl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 937707-12-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(4-methoxyphenyl)-3-[[3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-13-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(3-hydroxyphenyl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 937707-14-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-3-[[4-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-15-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-(2-propen-1-yloxy)phenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-16-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3,5-dimethoxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-17-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3-(3-(trifluoromethyl)phenoxy]phenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-18-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[[3-(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-19-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[[4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-20-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[[4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-21-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[[3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-22-7 CAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-chlorophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-23-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-chlorophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-24-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[4-(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-25-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[4-(4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-26-1 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[[(3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)



RN 937707-27-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[[(4-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-28-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[[[(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-29-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-30-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-31-8 CAPLUS


CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-32-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)



RN 937707-33-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(4-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-34-1 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-(3,4-dimethoxyphenyl)-3-[(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-35-2 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-(3,4-dimethoxyphenyl)-3-[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-36-3 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-(3,4-dimethoxyphenyl)-3-[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-37-4 CAPLUS


CN 4(3H)-Quinazolinone, 7-chloro-2-(3,4-dimethoxyphenyl)-3-[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-38-5 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-(3,4-dimethoxyphenyl)-3-[[3-(4-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)



RN 937707-39-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[3-(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-40-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[3-(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-41-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[3-(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-42-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[4-(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-43-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[4-(3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-44-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-((3-fluorophenyl)-3-[[[(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-45-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-((3-fluorophenyl)-3-[[[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-46-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-((3-fluorophenyl)-3-[[[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-47-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-[(4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-48-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-[(3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-49-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-[(3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-50-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)





RN 937707-51-2 CAPLUS



CN 4(3H)-Quinazolinone, 6-chloro-3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



RN 937707-52-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)





RN 937707-53-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)





RN 937707-54-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[(3,4-dimethylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-55-6 CAPLUS



CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[[(3,4-dimethylphenyl)methylene]amino]- (CA INDEX NAME)



RN 937707-56-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[[(3,4-dimethylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-57-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[(3,4-dimethylphenyl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 937707-58-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3,4-dimethylphenyl)methylene]amino]-2-(3-fluorophenyl)- (CA INDEX NAME)





RN 937707-59-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3,4-dimethylphenyl)methylene]amino]-2-(4-fluorophenyl)- (CA INDEX NAME)





RN 937707-60-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(3-bromo-4-methoxyphenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)





RN 937707-61-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-bromo-4-methoxyphenyl)methylene]amino]-6-chloro-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-62-5 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[(3-bromo-4-methoxyphenyl)methylene]amino]-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-63-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-bromo-4-methoxyphenyl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 937707-64-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-bromo-4-methoxyphenyl)methylene]amino]-2-(3-fluorophenyl)- (CA INDEX NAME)




RN 937707-65-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-bromo-4-methoxyphenyl)methylene]amino]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 937707-66-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3-nitrophenyl)methylene]amino]- (CA INDEX NAME)



RN 937707-67-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-(dimethylamino)phenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-68-1 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-2-(4-fluorophenyl)-3-[[3-fluorophenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-69-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-((4-fluorophenyl)methyleneamino)-3-((4-fluorophenyl)methyleneamino)- (CA INDEX NAME)




RN 937707-70-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-(((3-chlorophenyl)methyleneamino)-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 937707-71-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-3-(((4-chlorophenyl)methyleneamino)-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 937707-72-7 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(4-fluorophenyl)-3-[[3-(4-chlorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-73-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[3-(3-pyridinylmethylene)amino]- (CA INDEX NAME)




RN 937707-74-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[[3-(3-pyridinylmethylene)amino]- (CA INDEX NAME)




RN 937707-75-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-3-[(3-pyridinylmethylene)amino]-
 (CA INDEX NAME)



RN 937707-76-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[(3-pyridinylmethylene)amino]-
 (CA INDEX NAME)




RN 937707-77-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(3,5-dimethoxyphenyl)-3-[[3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-78-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-((3,5-dimethoxyphenyl)methyleneamino)-3-((4-fluorophenyl)methyleneamino)- (CA INDEX NAME)




RN 937707-79-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-(((3-chlorophenyl)methyleneamino)-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-80-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-(((4-chlorophenyl)methyleneamino)-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-81-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,5-dimethoxyphenyl)-3-[[3-(4-chlorophenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-82-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,5-dimethoxyphenyl)-3-[[4-(4-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-83-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-(3-fluorophenyl)methylene]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)





RN 937707-84-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-fluorophenyl)methylene]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)





RN 937707-85-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-chlorophenyl)methylene]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)





RN 937707-86-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-chlorophenyl)methylene]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 937707-87-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-methylphenyl)methylene]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)





RN 937707-88-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-[3-(dimethylamino)propoxy]-3-[[4-(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-89-6 CAPLUS



CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[[3-(4-dimethoxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-90-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[3,4-dimethoxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-91-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(3,5-dimethoxyphenyl)-3-[[3,4-dimethoxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-02-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-[2-(dimethylamino)ethoxy]-3-
 [[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-03-7 CAPLUS
 CN 4(3H)-Quinazolinone, 6-[2-(diethylamino)ethoxy]-2-(3,4-dimethoxyphenyl)-3-
 [[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-04-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3-fluorophenyl)methylene]amino]-6-methoxy- (CA INDEX NAME)




RN 937708-05-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-fluorophenyl)methylene]amino]-6-methoxy- (CA INDEX NAME)



RN 937708-06-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-methoxy-3-[[3-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937708-07-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-methoxy-3-[[4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-08-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(3,4-dimethylphenyl)methylene]amino]-6-methoxy- (CA INDEX NAME)




RN 937708-09-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(3-fluorophenyl)methylene]amino]-6-methyl- (CA INDEX NAME)




RN 937708-10-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(4-fluorophenyl)methylene]amino]-6-methyl- (CA INDEX NAME)





RN 937708-11-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-methyl-3-[(4-methylphenyl)methylene]amino]- (CA INDEX NAME)



RN 937708-12-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-methyl-3-[(4-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937708-13-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(3,4-dimethylphenyl)methylene]amino]-6-methyl- (CA INDEX NAME)




RN 937708-41-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(4-ethylphenyl)-3-[[3-fluorophenyl)methyleneamino]- (CA INDEX NAME)





RN 937708-42-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(4-ethylphenyl)-3-[[3-fluorophenyl)methyleneamino]- (CA INDEX NAME)




RN 937708-43-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(4-ethylphenyl)-3-[[3-methylphenyl)methyleneamino]- (CA INDEX NAME)





RN 937708-44-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(4-ethylphenyl)-3-[[4-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937708-45-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-methylphenyl)methylene]amino]-2-(4-ethylphenyl)- (CA INDEX NAME)




RN 937708-46-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-(4-ethylphenyl)- (CA INDEX NAME)




RN 937708-58-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3-fluorophenyl)methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-59-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(4-fluorophenyl)methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-60-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3-methylphenyl)methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-61-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(4-methylphenyl)methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-62-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3,4-dimethylphenyl)methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-63-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-64-0 CAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[[(1-methyl-1H-pyrrol-2-yl)methylene]amino]- (CA INDEX NAME)




RN 937708-65-1 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[4,5-dimethyl-2-furanyl)methylene]amino]- (CA INDEX NAME)




RN 937708-67-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3-fluorophenyl)methylene]amino]-6-iodo- (CA INDEX NAME)




RN 937708-68-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-fluorophenyl)methylene]amino]-6-iodo- (CA INDEX NAME)



RN 937708-69-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-iodo-3-[[3-(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-70-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-iodo-3-[[4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-71-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3,4-dimethylphenyl)methylene]amino]-6-iodo- (CA INDEX NAME)

fluorophenyl)ethylidene]amino]- (CA INDEX NAME)




RN 937708-87-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6,7-dimethoxy-3-[(phenylmethylene)amino]- (CA INDEX NAME)




RN 937708-90-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6,7-dimethoxy-3-[(2-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-91-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[2-(2-chlorophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937708-92-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[6-methoxy-2-naphthalenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-93-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1,1'-biphenyl]-4-ylmethylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937708-94-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937708-95-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-96-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[3-(1,1-dimethylethyl)-2-hydroxyphenyl]methylene]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)



RN 937708-97-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[[4-nitrophenyl]methylene]amino]- (CA INDEX NAME)




RN 937708-98-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[4-(diethylamino)phenyl]methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937708-99-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[(3-fluorophenyl)methylene]amino]-6-hydroxy- (CA INDEX NAME)




RN 937709-00-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[(2-pyridinylmethylene)amino]- (CA INDEX NAME)




RN 937709-01-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(2-pyridinylmethylene)amino]- (CA INDEX NAME)




RN 937709-02-9 CAPLUS


CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(2-pyridinylmethylene)amino]- (CA INDEX NAME)





RN 937709-03-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[[6-methyl-2-pyridinyl)methylene]amino]- (CA INDEX NAME)



RN 937709-04-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[6-methyl-2-pyridinyl)methylene]amino]- (CA INDEX NAME)




RN 937709-05-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[4-(1,1-dimethylethyl)phenyl]-3-[[3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937709-11-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3-fluorophenyl)methylene]amino]-2-[4-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937709-12-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(4-fluorophenyl)methylene]amino]-2-[4-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937709-13-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3-methylphenyl)methylene]amino]-2-[4-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937709-14-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-((4-methylphenyl)methylene)amino]-2-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937709-15-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3,4-dimethylphenyl)methylene]amino]-2-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)





RN 937709-16-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)





RN 937709-17-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3-fluorophenyl)methylene]amino]-2-[4-[[[(2-hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)





RN 937709-18-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(4-fluorophenyl)methylene]amino]-2-[4-[[[(2-hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)





RN 937709-19-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-[4-[[[(2-hydroxyethyl)thio]methyl]phenyl]-3-[[[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937709-20-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-[4-[(2-hydroxyethylthio)methyl]phenyl]-3-[[4-(4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937709-21-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3,4-dimethylphenyl)methylene]amino]-2-[4-[(2-hydroxyethylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937709-22-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-[4-[(2-hydroxyethylthio)methyl]phenyl]- (CA INDEX NAME)



RN 937709-35-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[[(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)



L5 ANSWER 28 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:380558 CAPLUS

DOCUMENT NUMBER: 148:308279

TITLE: Synthesis and characterization of new quinazolines as potential antimicrobial agents

AUTHOR(S): Desai, N. C.; Shihora, P. N.; Moradia, D. L.
CORPORATE SOURCE: University Department of Chemistry, Bhavnagar University, Bhavnagar, 364 002, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2007), 46B(3), 550-553

CODEN: IJSBDB; ISSN: 0376-4699

PUBLISHER: National Institute of Science Communication and Information Resources


DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 148:308279

AB Et 4-[2-(2-chlorophenyl)-4-oxo-3-hydroquinazolin-3-yl]benzoate which reacts with hydrazine hydrate in presence of methanol resulted into N-amino{4-[2-(2-chlorophenyl)-4-oxo-(3-hydroquinazolin-3-yl)]phenyl}carboxamide (I). Compound I on treatment with aryl isothiocyanates in presence of acetone is converted into aryl-N-[[{4-[2-(2-chlorophenyl)-4-oxo-(3-hydroquinazolin-3-yl)]phenyl}carbonylamino]amino]thioxomethyl}amides. The last amide compds., in presence of sulfuric acid yielded aryl-N-(5-{4-[2-(2-chlorophenyl)-4-oxo(3-hydroquinazolin-3-yl)]-phenyl}(1,3,4,thiadiazol-2-yl))amides. Newly synthesized compds. were screened for their antibacterial and antifungal activities on *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Staphylococcus*


pyogenes, *C. albicans*, *A. niger* and *A. clavatus*.
 IT 1009361-19-6P 1009361-20-9P 1009361-21-0P
 1009361-22-1P 1009361-23-2P 1009361-24-3P
 1009361-25-4P 1009361-26-5P 1009361-27-6P
 1009361-28-7P 1009361-29-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation and antibacterial and antifungal of
 arylamidothiadiazolyl-phenyl-hydroquinazolinones starting from Et
 hydroquinazolinonyl-benzoate and hydrazine hydrate)
 RN 1009361-19-6 CAPLUS
 CN Benzamide, N-[5-[4-[2-(2-chlorophenyl)-4-oxo-3(4H)-quinazolinyl]phenyl]-
 1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 1009361-20-9 CAPLUS
 CN Benzamide, N-[5-[4-[2-(2-chlorophenyl)-4-oxo-3(4H)-
 quinazolinyl]phenyl]-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 1009361-21-0 CAPLUS
 CN Benzamide, N-[5-[4-[2-(2-chlorophenyl)-4-oxo-3(4H)-quinazolinyl]phenyl]-
 1,3,4-thiadiazol-2-yl]-3-nitro- (CA INDEX NAME)




RN 1009361-22-1 CAPLUS

CN Benzamide, 2-chloro-N-[5-[4-[2-(2-chlorophenyl)-4-oxo-3(4H)-quinazolinyl]phenyl]-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 1009361-23-2 CAPLUS

CN Benzamide, 3-chloro-N-[5-[4-[2-(2-chlorophenyl)-4-oxo-3(4H)-quinazolinyl]phenyl]-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 1009361-24-3 CAPLUS

CN Benzamide, 4-chloro-N-[5-[4-[2-(2-chlorophenyl)-4-oxo-3(4H)-quinazolinyl]phenyl]-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 1009361-25-4 CAPLUS

CN Benzamide, 2,3-dichloro-N-[5-[4-[2-(2-chlorophenyl)-4-oxo-3(4H)-quinazolinyl]phenyl]-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 1009361-26-5 CAPLUS

CN Benzamide, N-[5-[4-[2-(2-chlorophenyl)-4-oxo-3(4H)-quinazolinyl]phenyl]-1,3,4-thiadiazol-2-yl]-4-methyl- (CA INDEX NAME)




RN 1009361-27-6 CAPLUS

CN Benzamide, N-[5-[4-[2-(2-chlorophenyl)-4-oxo-3(4H)-quinazolinyl]phenyl]-1,3,4-thiadiazol-2-yl]-4-methoxy- (CA INDEX NAME)




RN 1009361-28-7 CAPLUS

CN Benzeneacetamide, N-[5-[4-[2-(2-chlorophenyl)-4-oxo-3(4H)-quinazolinyl]phenyl]-1,3,4-thiadiazol-2-yl]-4-nitro- (CA INDEX NAME)



RN 1009361-29-8 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[5-[4-[2-(2-chlorophenyl)-4-oxo-3(4H)-quinazolinyl]phenyl]-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:342095 CAPLUS

DOCUMENT NUMBER: 146:517116

TITLE: Evaluation of chemical, physical, and biologic properties of tumor-targeting radioiodinated quinazolinone derivative

AUTHOR(S): Wang, Ketai; Kirichian, Agop M.; Al Aowad, Ayman F.; Adelstein, S. James; Kassiss, Amin I.

CORPORATE SOURCE: Department of Radiology, Harvard Medical School, Boston, MA, 02115, USA

SOURCE: Bioconjugate Chemistry (2007), 18(3), 754-764
 CODEN: BCCHE; ISSN: 1043-1802

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 146:517116

AB Our group is developing a novel technol., enzyme-mediated cancer imaging and therapy (EMCIT), that aims to entrap radioiodinated compds. within solid tumors for noninvasive tumor detection and therapy. In this approach, a water-soluble, radioiodinated prodrug is hydrolyzed in vivo to a highly water-insol. compound by an enzyme overexpressed extracellularly by tumor cells. We have synthesized and characterized the water-soluble prodrug, 2-(2'-phosphoryloxyphenyl)-6-[125I]iodo-4-(3H)-quinazolinone [125I]5, which is readily hydrolyzed by alkaline phosphatase, an enzyme expressed by many tumor cell lines, to a water-insol. drug, 2-(2'-hydroxyphenyl)-6-[125I]iodo-4-(3H)-quinazolinone [125I]1. In the course of our study, we discovered that ammonium 2-(2'-phosphoryloxyphenyl)-6-tributylstannyl-4-(3H)-quinazolinone, an intermediate in the radioiodination of the prodrug, exists as two isomers (3 and 4) whose radioiodination leads, resp., to [125I]6 and [125I]5. These prodrugs have different in vitro and in vivo biol. activities. Compound 6 is not hydrolyzed by alkaline phosphatase (ALP), whereas 5 is highly soluble (mg/mL) in aqueous solution and is rapidly dephosphorylated in the presence of ALP to 1, a water-insol. mol. (ng/mL). Mouse biodistribution studies

indicate that [125I]6 has high uptake in kidney and liver and [125I]5 has very low uptake in all normal organs. Comps. 3 and 6 are converted, resp., to 4 and 5 after incubation in DMSO. The stability of 5 in human serum is high. The min. ALP concentration needed to hydrolyze 5 is much greater than the ALP level in the blood of patients with cancer, and the latter should not affect the pharmacokinetics of the compound. Incubation of 5 with viable human and mouse tumor-cell lines-but not with normal human cells and mouse tissues-leads to its hydrolysis and the formation of large crystals of 1. We expect that 5 will also be hydrolyzed in vivo by tumor cells that express phosphatase activity extracellularly and anticipate the specific precipitation of radioiodinated 1 within tumor cell clusters. This should lead to high tumor-to-normal-tissue ratios and enable imaging (SPECT/PET) and radionuclide therapy of solid tumors.


IT 414902-12-8P 414902-13-9P
 RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (tumor-targeting radioiodinated quinazolinone derivative for tumor imaging and radiotherapy)

RN 414902-12-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(iodo-125I)-2-[2-(phosphonooxy)phenyl]-, ammonium salt (1:2) (CA INDEX NAME)



● 2 NH₃

RN 414902-13-9 CAPLUS
 CN 4(1H)-Quinazolinone, 2-(2-hydroxyphenyl)-6-(iodo-125I)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 30 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:230013 CAPLUS
 DOCUMENT NUMBER: 146:477920

TITLE: Computational Modeling and Experimental Evaluation of a Novel Prodrug for Targeting the Extracellular Space of Prostate Tumors

AUTHOR(S): Pospisil, Pavel; Wang, Ketai; Al Aowad, Ayman F.; Iyer, Lakshmanan K.; Adelstein, S. James; Kassis, Amin I.

CORPORATE SOURCE: Department of Radiology, Harvard Medical School, Harvard University, Boston, MA, USA

SOURCE: Cancer Research (2007), 67(5), 2197-2205
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal


LANGUAGE: English

AB We are developing a noninvasive approach for targeting imaging and therapeutic radionuclides to prostate cancer. Our method, Enzyme-Mediated Cancer Imaging and Therapy (EMCIT), aims to use enzyme-dependent, site-specific, in vivo precipitation of a radioactive mol. within the extracellular space of solid tumors. Advanced methods for data mining of the literature, protein databases, and knowledge bases (IT.Omics LSGraph and Ingenuity Systems) identified prostatic acid phosphatase (PAP) as an enzyme overexpressed in prostate cancer and secreted in the extracellular space. Using AutoDock 3.0 software, the prodrug ammonium 2-(2'-phosphoryloxyphenyl)-6-iodo-4-(3H)-quinazolinone (IQ2-P) was docked in silico into the X-ray structure of PAP. The data indicate that IQ2-P docked into the PAP active site with a calculated inhibition constant (Ki) more favorable than that of the PAP inhibitor α -benzylaminobenzylphosphonic acid. When ¹²⁵IQ2-P, the radiolodinated form of the water-soluble prodrug, was incubated with PAP, rapid hydrolysis of the compound was observed as exemplified by formation of the water-insol. 2-(2'-hydroxyphenyl)-6-[¹²⁵I]iodo-4-(3H)-quinazolinone (¹²⁵IQ2-OH). Similarly, the incubation of IQ2-P with human LNCaP, PC-3, and 22Rv1 prostate tumor cells resulted in the formation of large fluorescent IQ2-OH crystals. No hydrolysis was seen in the presence of normal human cells. Autoradiog. of tumor cells incubated with ¹²⁵IQ2-P showed accumulation of radioactive grains (¹²⁵IQ2-OH) around the cells. We anticipate that the EMCIT approach will enable the active in vivo entrapment of radioimaging and radiotherapeutic compds. within the extracellular spaces of primary prostate tumors and their metastases.

IT 752977-04-1
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel prodrug evaluation for targeting prostatic acid phosphatase-expressing prostate tumors)

RN 752977-04-1 CAPLUS

CN 4(1H)-Quinazolinone, 6-(iodo-¹²⁵I)-2-[2-(phosphonoxy)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 31 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:150951 CAPLUS

DOCUMENT NUMBER: 146:206650

TITLE: Preparation of macrocyclic inhibitors of hepatitis C virus

INVENTOR(S): Raboissan, Pierre Jean-Marie Bernard; De Kock, Herman Augustinus; Hu, Lili; Simmen, Kenneth Alan; Lindquist, Karin Charlotta; Lindstroem, Mats Stefan; Belfrage, Anna Karin Gertrud Linnea; Waehling, Horst Juergen; Nilsson, Karl Magnus; Samuelsson, Bengt Bertil; Rosenquist, Aasa Annica Kristina; Sahberg, Sven Crister; Wallberg, Hans Kristian; Kahnberg, Pia Cecilia; Classon, Bjoern Olof

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.; Medivir AB

SOURCE: PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014927	A2	20070208	WO 2006-EP64822	20060728
WO 2007014927	A3	20071129		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006274866	A1	20070208	AU 2006-274866	20060728
CA 2617103	A1	20070208	CA 2006-2617103	20060728
EP 1912981	A2	20080423	EP 2006-764268	20060728
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2009502890	T	20090129	JP 2008-523383	20060728
US 20090118312	A1	20090507	US 2008-995900	20080116
IN 2008DN06631	A	20080711	IN 2008-DN631	20080123
MX 2008001393	A	20080701	MX 2008-1393	20080128
ZA 2008000859	A	20090624	ZA 2008-859	20080128
CN 101233131	A	20080730	CN 2006-80027883	20080129
KR 2008033475	A	20080416	KR 2008-704894	20080228
NO 2008001075	A	20080425	NO 2008-1075	20080229
PRIORITY APPLN. INFO.:			EP 2005-107057	A 20050729
			EP 2006-113097	A 20060425
			WO 2006-EP64822	W 20060728

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 146:206650

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to macrocyclic compds. I [the dashed line represents an optional double bond; X is (CH₂)₃₋₆; L is N, CH, or C; A is OH, OR₄, or NHSO₁-2R₅, where R₄ and R₅ are alkyl, alkylenecarbocyclyl, or alkyleneheterocyclyl; R₁ is (un)substituted quinazolinyl; R₂ is H, alkyl; R₃ is H, alkyl, alkoxyalkyl, or cycloalkyl], including N-oxides, salts, and stereoisomers, which have utility in the treatment or prophylaxis of flaviviral infections such as HCV. Thus, macrocycle II was prepared by a multistep procedure which includes ring-forming metathesis reaction and assayed for inhibition of HCV NS3/4A protease (EC₅₀ = 0.5-199 nM, K_i = 0.1-4.9 nM).

IT	923274-67-3P	923274-84-4P	923274-90-2P
	923275-08-5P	923275-09-6P	923275-15-4P
	923275-29-0P	923275-35-8P	923275-36-9P
	923275-37-0P	923275-40-5P	923275-45-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of macrocyclic inhibitors of hepatitis C virus)

RN 923274-67-3 CAPLUS

CN Cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide, 2-[[2-(4-cyanophenyl)-4-quinazolinyl]oxy]-N-(cyclopropylsulfonyl)-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-5-methyl-4,14-dioxo-, (2R,3aR,10Z,11aS,12aR,14aR)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 923274-84-4 CAPLUS

CN 13aH-Cyclopropa[g]pyrrolo[1,2-c][1,3,6]triazacyclotetradecine-13a-carboxamide, N-(cyclopropylsulfonyl)-2-[[2-(4-fluorophenyl)-7-methoxy-8-methyl-4-quinazolinyl]oxy]-1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-6-methyl-5,15-dioxo-, (2R,11Z,12aS,13aR,15aS)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



RN 923274-90-2 CAPLUS

CN Cyclopropa[g]pyrrolo[1,2-c][1,3,6]triazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-2-[[2-(4-fluorophenyl)-7-methoxy-8-methyl-4-quinazolinyl]oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-, (2R,12Z,13aS,14aR,16aS)- (CA INDEX NAME)




RN 923275-08-5 CAPLUS

CN 13aH-Cyclopropa[g]pyrrolo[1,2-c][1,3,6]triazacyclopentadecine-13a-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-2-[[7-methoxy-2-(4-methoxyphenyl)-8-methyl-4-quinazolinyl]oxy]-6-methyl-5,15-dioxo-, (2R,11Z,12aS,13aR,15aS)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 923275-09-6 CAPLUS

CN 13aH-Cyclopropa[g]pyrrolo[1,2-c][1,3,6]triazacyclotetradecine-13a-carboxamide, 1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-2-[[7-methoxy-2-(4-methoxyphenyl)-8-methyl-4-quinazolinyl]oxy]-6-methyl-N-[(1-methylcyclopropyl)sulfonyl]-5,15-dioxo-, (2R,11Z,12aS,13aR,15aS)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 923275-15-4 CAPLUS


CN Cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide, N-(cyclopropylsulfonyl)-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-[[7-methoxy-2-(4-methoxyphenyl)-8-methyl-4-quinazolinyl]oxy]-5-methyl-4,14-dioxo-, (2R,3aR,10Z,11aS,12aR,14aR)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 923275-29-0 CAPLUS
 CN Cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide,
 N-(cyclopropylsulfonyl)-2-[[2-(4-fluorophenyl)-7-methoxy-8-methyl-4-
 quinazolinyl]oxy]-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-5-
 methyl-4,14-dioxo-, (2R,3aR,10Z,11aS,12aR,14aR)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 923275-35-8 CAPLUS
 CN Cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide,
 N-(cyclopropylsulfonyl)-2-[[2-(3-fluorophenyl)-7-methoxy-8-methyl-4-
 quinazolinyl]oxy]-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-5-
 methyl-4,14-dioxo-, (2R,3aR,10Z,11aS,12aR,14aR)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 923275-36-9 CAPLUS


CN Cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide,
 2-[[2-(3-fluorophenyl)-7-methoxy-8-methyl-4-quinazolinyl]oxy]-
 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-5-methyl-N-[(1-
 methylcyclopropyl)sulfonyl]-4,14-dioxo-, (2R,3aR,10Z,11aS,12aR,14aR)- (CA
 INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 923275-37-0 CAPLUS

CN Cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide,
 2-[[2-(3-fluorophenyl)-7-methoxy-8-methyl-4-quinazolinyl]oxy]-
 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-5-methyl-N-[(1-
 methylcyclopropyl)sulfonyl]-4,14-dioxo-, (2R,3aR,10Z,11aS,12aR,14aR)- (CA INDEX
 NAME)




RN 923275-40-5 CAPLUS

CN 13aH-Cyclopropa[g]pyrrolo[1,2-c][1,3,6]triazacyclotetradecine-13a-carboxamide, N-(cyclopropylsulfonyl)-2-[[2-(3-fluorophenyl)-7-methoxy-8-methyl-4-quinazolinyl]oxy]-1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-6-methyl-5,15-dioxo-, (2R,11Z,12aS,13aR,15aS)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 923275-45-0 CAPLUS

CN Cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide, N-(cyclopropylsulfonyl)-2-[[2-(3,5-difluorophenyl)-7-methoxy-8-methyl-4-quinazolinyl]oxy]-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-5-methyl-4,14-dioxo-, (2R,3aR,10Z,11aS,12aR,14aR)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L5 ANSWER 32 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:143902 CAPLUS

DOCUMENT NUMBER: 146:229081

TITLE: Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices

INVENTOR(S): Johansson, Jan O.; Hansen, Henrik C.; Chiacchia, Fabrizio S.; Wong, Norman C.W.

PATENT ASSIGNEE(S): Resverlogix Corp., Can.

SOURCE: PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016525	A2	20070208	WO 2006-US29827	20060728
WO 2007016525	A3	20070531		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006275514	A1	20070208	AU 2006-275514	20060728
CA 2617213	A1	20070208	CA 2006-2617213	20060728
EP 1909788	A2	20080416	EP 2006-800576	20060728

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR


JP 2009502970	T	20090129	JP 2008-524272	20060728
MX 2008001257	A	20080512	MX 2008-1257	20080128
IN 2008KN00498	A	20080808	IN 2008-KN498	20080204
US 20090029987	Al	20090129	US 2008-990162	20080207
KR 2008034180	A	20080418	KR 2008-705148	20080229
CN 101365446	A	20090211	CN 2006-80034234	20080318
PRIORITY APPLN. INFO.:			US 2005-704035P	P 20050729
			WO 2006-US29827	W 20060728
OTHER SOURCE(S):		CASREACT 146:229081;	MARPAT 146:229081	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to polyphenol-like compds. I [X = CR11, CR11R13, C:O, C:S, O, S, SO, SO2,N, NR11; Y = CR12, CR12R14, C:O, C:S, O, S, SO, SO2,N, NR12 (wherein, if Y = O, then X ≠ C:O); W = C, N, (wherein, if W = N, then p = 0 and if W = C, then p = 1); R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R17 = alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, CN, cycloalkyl, ester, ether, CHO, halogen, haloalkyl, heteroaryl, heterocyclyl, H, OH, ketone, NO2, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, thio ketone; two adjacent selected from R1 - R14 are connected in a 5- to 6-membered ring to form a bicyclic aryl, heteroaryl or heterocycle; z1, z2, z3 = single or double bond (wherein, if at least one W ≠ N, then (a) X = Y = C:O, (b) X = NR11 and Z2 = double bond), or (c) two adjacent substituents R5, R6, R7, R8, R9 are connected in a 5- to 6-membered ring to form a bicyclic aryl, heteroaryl or heterocycle] and pharmaceutically acceptable salts and hydrates thereof, that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. Thus, 2-(4-Hydroxyphenyl)pyrano[2,3-b]pyridin-4-one (II) was prepared from Et 2-chloronicotinate, via methanolysis with NaOMe in MeOH, condensation with the sodium salt of 4-methoxyacetophenone in DMF, and thermal O-demethylation/intramol. cyclocondensation with pyridine hydrochloride. The disclosed compds. are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states. The inhibitory activity of II was determined [≥40% inhibition of VCAM-1 expression; <40% inhibition of MCP-1 expression; <40% inhibition of SMC proliferation].

IT 924299-91-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pharmaceutical compds. for the prevention and treatment of inflammatory and cardiovascular diseases)

RN 924299-91-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-6-(4-morpholinylmethyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L5 ANSWER 33 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:61837 CAPLUS
DOCUMENT NUMBER: 146:156236
TITLE: Cellular cholesterol absorption modifiers, and their therapeutic use
INVENTOR(S): Gardiner, Elisabeth M.; Duron, Sergio G.; Massari, Mark E.; Severance, Daniel L.; Semple, Joseph E.
PATENT ASSIGNEE(S): Kalypsys, Inc., USA
SOURCE: PCT Int. Appl., 300pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007008541	A2	20070118	WO 2006-US26242	20060705
WO 2007008541	A3	20070726		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRIORITY APPLN. INFO.:				
			US 2005-697659P	P 20050708
			US 2005-697686P	P 20050708
			US 2005-697814P	P 20050708
			US 2005-727646P	P 20051017
			US 2006-782303P	P 20060313

OTHER SOURCE(S): MARPAT 146:156236
AB The invention discloses compds. and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of vascular disease and atherosclerosis.
IT 338412-56-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cholesterol absorption modifiers and therapeutic use)
RN 338412-56-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dichlorophenyl)-3-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L5 ANSWER 34 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:1323336 CAPLUS

DOCUMENT NUMBER: 146:290529

TITLE: In silico design, synthesis, and biological evaluation of radiolabeled quinazolinone derivatives for alkaline phosphatase-mediated cancer diagnosis and therapy

AUTHOR(S): Chen, Kai; Wang, Ketai; Kirichian, Agop M.; Al Aowad, Ayman F.; Iyer, Lakshmanan K.; Adelstein, S. James; Kassis, Amin I.

CORPORATE SOURCE: Department of Radiology, Harvard Medical School, Harvard University, Cambridge, MA, USA

SOURCE: Molecular Cancer Therapeutics (2006), 5(12), 3001-3013
CODEN: MCTOCF; ISSN: 1535-7163

PUBLISHER: American Association for Cancer Research


DOCUMENT TYPE: Journal

LANGUAGE: English

AB As part of the development of enzyme-mediated cancer imaging and therapy, a novel technol. to entrap water-insol. radioactive mols. within solid tumors, we show that a water-soluble, radioactive quinazolinone prodrug, ammonium 2-(2'-phosphoryloxyphenyl)-6-[125I]iodo-4-(3H)-quinazolinone (125IQ2-P), is hydrolyzed by alkaline phosphatase to a water-insol., radiolabeled drug, 2-(2'-hydroxyphenyl)-6-[125I]iodo-4-(3H)-quinazolinone (125IQ2-OH). Biodistribution data suggest the existence of two isoforms of the prodrug (IQ2-P(I) and IQ2-P), and this has been confirmed by their synthesis and characterization. Structural differences of the two isoforms have been examined using in silico mol. modeling techniques and docking methods to describe the interaction/binding between the isoforms and human placental alkaline phosphatase (PLAP), a tumor cell, membrane-associated, hydrolytic enzyme whose structure is known by X-ray crystallog. determination. Docking data show that IQ2-P, but not IQ2-P(I), fits the active binding site of PLAP favorably and interacts with the catalytic amino acid Ser92, which plays an important role in the hydrolytic process. The binding free energies (AGbinding) of the isoforms to PLAP predict that IQ2-P will be the better substrate for PLAP. The in vitro incubation of the isoforms with PLAP leads to the rapid hydrolysis of IQ2-P only and confirms the in silico expectations. Fluorescence microscopy shows that in vitro incubation of IQ2-P with mouse and human tumor cells causes the extracellular, alkaline phosphatase-mediated hydrolysis of the mol. and precipitation of fluorescent crystals of IQ2-OH. No hydrolysis is seen in the presence of normal mouse and human cells. Furthermore, the intratumoral injection of 125IQ2-P into alkaline phosphatase-expressing solid human tumors grown s.c. in nude rats results in efficient hydrolysis of


the compound and retention of .apprx.70% of the injected radioactivity, whereas similar injection into normal tissues (e.g., muscle) does not produce any measurable hydrolysis (.apprx.1%) or retention of radioactivity at the injected site. These studies support the enzyme-mediated cancer imaging and therapy technol. and show the potential of such quinazolinone derivs. in the in vivo radio-detection (123I/124I) and therapy (131I) of solid tumors.

IT 414902-12-8 414902-16-2
 RL: DGN (Diagnostic use); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (radioiodinated quinazolinone derivs. for alkaline phosphatase-mediated cancer imaging and therapy)
 RN 414902-12-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(iodo-125I)-2-[2-(phosphonooxy)phenyl]-, ammonium salt (1:2) (CA INDEX NAME)



● 2 NH₃

RN 414902-16-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(iodo-125I)-2-[2-(phosphonooxy)phenyl]-, ammonium salt (1:2) (CA INDEX NAME)



● 2 NH₃

OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
 REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 35 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:1113398 CAPLUS
 DOCUMENT NUMBER: 147:301096
 TITLE: Synthesis of 1,3,5-tri-p-[(2-aryl-3h-quinazolin-4-one-3-yl)-phenyl]-2,4,6-hexahydro-1,3,5-s-triazines as

potential antiTMV and antibacterial agents
 AUTHOR(S): Pandey, V. K.; Kumar, Jitendra
 CORPORATE SOURCE: Chemistry Department, University of Lucknow, Lucknow,
 226 007, India
 SOURCE: Indian Journal of Heterocyclic Chemistry (2006),
 16(1), 65-66
 CODEN: IJCHEI; ISSN: 0971-1627
 PUBLISHER: Prof. R. S. Varma
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 147:301096

AB 2-Aryl-3-(4-aminophenyl)-3H-quinazolin-4-ones were treated with formalin
 in excess in abs ethanol to furnish
 1,3,5-tri-p-[(2-aryl-3H-quinazolin-4-one-3-yl)phenyl]-2,4,6-hexahydro-
 1,3,5-s-triazines. The s-triazines were screened for their antiviral
 activity against Tobacco mosaic virus (TMV) from the host Nicotiana
 tabacum CV samsun NN and antibacterial activity against five strains of
 bacteria.

IT 946853-41-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation, antiviral and antibacterial activities of
 tri[(arylquinazolinonyl)phenyl]hexahydrotriazines by trimerization
 (arylquinazolinonyl)aniline with formalin)

RN 946853-41-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3,3',3''-(1,3,5-triazine-1,3,5(2H,4H,6H)-triytri-4,1-
 phenylene)tris[2-(4-chlorophenyl)- (CA INDEX NAME)]




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 36 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:1012671 CAPLUS
 DOCUMENT NUMBER: 145:377381
 TITLE: Preparation of quinazolines as modulators of ion
 channels
 INVENTOR(S): Gonzalez, Jesus E.; Wilson, Dean M.; Termin, Andreas
 P.; Grootenhuys, Peter D. J.; Zhang, Yulian; Petzoldt,
 Benjamin J.; Fanning, Lev Tyler Dewey; Neubert,
 Timothy D.; Tung, Roger D.; Martinborough, Esther;
 Zimmerman, Nicole

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: U.S. Pat. Appl. Publ., 351 pp., Cont.-in-part of U.S. Ser. No. 792,688.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060217377	A1	20060928	US 2004-935008	20040902
US 20040248890	A1	20041209	US 2004-792688	20040303
ZA 2005007979	A	20070328	ZA 2005-7979	20040303
PRIORITY APPLN. INFO.:			US 2003-451458P	P 20030303
			US 2003-463797P	P 20030418
			US 2004-792688	A2 20040303

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 145:377381
 GI



AB The title compds. [I; NR¹R² = (un)substituted 3-12 membered monocyclic or bicyclic (un)saturated ring having 0-3 heteroatoms selected from N, S or O; ring A = (un)substituted 5-7 membered aryl, 8-10 membered bicyclic aryl having 0-3 heteroatoms selected from N, S or O, etc.; x = 0-4; R³ = QR (wherein Q = a bond, alkylidene wherein up to two non-adjacent methylene units are optionally replaced by S, O, CS, etc.; R = halo, NO₂, CN, etc.); with provisos], useful as inhibitors of voltage-gated sodium channels and calcium channels, were prepared. Thus, reacting 2-(4-chloro-7-methylquinazolin-2-yl)phenol with 4-aminopiperidine in the presence of Et₃N in CH₂Cl₂ afforded 89% II. Representative compds. I were found to possess desired N-type calcium channel modulation activity and selectivity (no specific data given). Also, representative compds. I were found to possess desired voltage gated sodium channel activity and selectivity (no specific data given). The invention also provides pharmaceutically acceptable compns. comprising the compds. I and methods of using the compns. in the treatment of various disorders.

IT 378766-55-3P 421581-48-8P 757985-37-8P
 757985-42-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of quinazolines as modulators of ion channels for treating pain associated with various diseases)


RN 378766-55-3 CAPLUS

CN Phenol, 2-[4-(1-methylethoxy)-2-quinazolinyl]- (CA INDEX NAME)




RN 421581-48-8 CAPLUS

CN Phenol, 2-(4-ethoxy-2-quinazolinyl)- (CA INDEX NAME)




RN 757985-37-8 CAPLUS

CN Quinazoline, 7-chloro-2-(2-fluorophenyl)-4-(phenylmethoxy)- (CA INDEX NAME)



RN 757985-42-5 CAPLUS

CN Phenol, 2-(4-propoxy-2-quinazolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L5 ANSWER 37 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:945689 CAPLUS

DOCUMENT NUMBER: 145:315012

TITLE: Preparation of 2-(4-oxo-4H-quinazolin-3-yl)acetamides
as vasopressin V3 receptor antagonists

INVENTOR(S): Letourneau, Jeffrey; Riviello, Christopher; Ho,
Koc-Kan; Chan, Jui-Hsiang; Ohlmeyer, Michael; Jokiel,
Patrick; Neagu, Irina; Morphy, John Richard; Napier,
Susan Elizabeth

PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.; Pharmacopeia Drug Discovery,
Inc.

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006095014	A1	20060914	WO 2006-EP60612	20060310
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006221962	A1	20060914	AU 2006-221962	20060310
CA 2599511	A1	20060914	CA 2006-2599511	20060310
EP 1861380	A1	20071205	EP 2006-725007	20060310
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, YU			
JP 2008532981	T	20080821	JP 2008-500206	20060310
NZ 560958	A	20090925	NZ 2006-560958	20060310
NO 2007004275	A	20070927	NO 2007-4275	20070822
ZA 2007007090	A	20081029	ZA 2007-7090	20070822
MX 2007011023	A	20080312	MX 2007-11023	20070907
US 20080214553	A1	20080904	US 2007-908221	20070910
IN 2007CN03959	A	20071123	IN 2007-CN3959	20070911
CN 101258134	A	20080903	CN 2006-80007957	20070911
KR 2008009076	A	20080124	KR 2007-723214	20071010
PRIORITY APPLN. INFO.:			US 2005-660926P	P 20050311
			US 2005-715875P	P 20050909
			WO 2006-EP60612	W 20060310


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:315012; MARPAT 145:315012

GI




I




II

- AB Title compds. represented by the formula I [wherein R1 = (cyclo)alkyl, alkenyl, Ph, etc.; R2 = (hetero)aryl or cycloalkyl; R3 = H, alkyl(oxy) or halo; R4 = pyridinylmethoxy, (alkyl)aminoalkyleneoxy, (alkyl)aminophenyl, etc.; and pharmaceutically acceptable salts or solvates thereof] were prepared as vasopressin V3 receptor antagonists. For example, II was provided in a multi-step synthesis starting from the reaction of 2-amino-N-[(isopropylcarbamoyl)methyl]-5-[3-(piperidin-1-yl)propoxy]benzamide (preparation given) with 5-quinolinecarboxaldehyde. Selected I showed biol. activity with human V3 receptor. Thus, I and their pharmaceutical compns. are useful as vasopressin V3 antagonists, particularly for the treatment of depression.
- IT 909391-81-7P, 2-[2-(3-Chloro-4-fluorophenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide
 909392-11-6P, 2-[2-(3-Chlorophenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide
 909392-28-5P, N-Isopropyl-2-[6-[(4-methoxybenzyl)[3-(piperidin-1-yl)propyl]amino]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]acetamide
 909393-06-2P, N-tert-Butyl-2-[2-(3-chlorophenyl)-4-oxo-6-[4-(pyrrolidin-1-yl)but-1-enyl]-4H-quinazolin-3-yl]acetamide
 909393-10-8P, N-Isopropyl-2-[2-(3-methoxyphenyl)-6-[4-(morpholin-4-yl)but-1-enyl]-4-oxo-4H-quinazolin-3-yl]acetamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 2-(4-oxo-4H-quinazolin-3-yl)acetamides as vasopressin V3 receptor antagonists)
- RN 909391-81-7 CAPLUS
- CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909392-11-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909392-28-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-6-[[4-methoxyphenyl)methyl][3-(1-piperidinyl)propyl]amino]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909393-06-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1,1-dimethylethyl)-4-oxo-6-[4-(1-pyrrolidinyl)-1-buten-1-yl]- (CA INDEX NAME)



RN 909393-10-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-[4-(4-morpholinyl)-1-buten-1-yl]-4-oxo- (CA INDEX NAME)



IT 909391-63-5P, 2-[2-(3-Isopropoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide
 909391-64-6P, N-Isopropyl-2-[4-oxo-6-[3-(piperidin-1-yl)propoxy]-2-(3-(3-propoxyphenyl)-4H-quinazolin-3-yl)]acetamide 909391-65-7P,
 2-[2-(2-Fluoro-5-methoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide 909391-66-8P,
 N-Isopropyl-2-[4-oxo-6-[3-(piperidin-1-yl)propoxy]-2-(3-trifluoromethylphenyl)-4H-quinazolin-3-yl]acetamide 909391-67-9P
 , N-Isopropyl-2-[4-oxo-6-[3-(piperidin-1-yl)propoxy]-2-(3,4,5-trifluorophenyl)-4H-quinazolin-3-yl]acetamide 909391-68-0P,
 2-[2-(3-Iodophenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide 909391-70-4P,
 2-[2-[3-(Cyclopentyloxy)phenyl]-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide 909391-72-6P,
 N-Isopropyl-2-[4-oxo-6-[3-(piperidin-1-yl)propoxy]-2-[3-(pyrrol-1-yl)phenyl]-4H-quinazolin-3-yl]acetamide 909391-73-7P,
 3-[3-[(Isopropylcarbamoyl)methyl]-4-oxo-6-[3-(piperidin-1-yl)propoxy]-3,4-dihydroquinazolin-2-yl]benzoic acid methyl ester 909391-74-8P,
 2-[2-(3-Dimethylaminophenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide 909391-75-9P,
 2-[2-(3-Cyanophenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide 909391-76-0P,
 2-[2-[3-(Cyclobutyloxy)phenyl]-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide 909391-77-1P,
 N-Isopropyl-2-[4-oxo-6-[3-(piperidin-1-yl)propoxy]-2-(3-trifluoromethoxyphenyl)-4H-quinazolin-3-yl]acetamide
 909391-79-3P, 2-[2-(3-Chloro-4-fluorophenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide hydrochloride
 909391-82-8P, N-tert-Butyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[3-(pyrrolidin-1-yl)propoxy]-4H-quinazolin-3-yl]acetamide
 909391-83-9P, N-tert-Butyl-2-[2-(3-chlorophenyl)-4-oxo-6-[3-(pyrrolidin-1-yl)propoxy]-4H-quinazolin-3-yl]acetamide
 909391-84-0P, N-tert-Butyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]acetamide

909391-85-1P, 2-[2-(3,4-Difluorophenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide
 909391-86-2P, N-tert-Butyl-2-[2-(3-chlorophenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]acetamide
 909391-87-3P, 2-[2-(3-Ethoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide
 909391-88-4P, N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]acetamide
 909391-89-5P, 2-[2-(4-Fluoro-3-methoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide
 909391-90-8P, N-tert-Butyl-2-[2-(3-chlorophenyl)-6-(3-dimethylaminopropoxy)-4-oxo-4H-quinazolin-3-yl]acetamide
 909391-91-9P, N-tert-Butyl-2-[6-(3-dimethylaminopropoxy)-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]acetamide 909391-92-0P
 , N-tert-Butyl-2-[6-(3-diethylaminopropoxy)-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]acetamide 909391-93-1P,
 N-tert-Butyl-2-[2-(3-chlorophenyl)-6-(3-diethylaminopropoxy)-4-oxo-4H-quinazolin-3-yl]acetamide 909391-94-2P,
 2-[2-(3-Chlorophenyl)-6-[3-(4-hydroxypiperidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909391-95-3P,
 2-[2-(3-Chlorophenyl)-6-[3-(3-hydroxypiperidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909391-96-4P,
 2-[2-(4-Fluoro-3-methoxyphenyl)-6-[3-(4-hydroxypiperidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909391-97-5P,
 2-[2-(3-Chloro-4-fluorophenyl)-6-[3-(4-hydroxypiperidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909391-98-6P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[4-(piperidin-1-yl)butoxy]-4H-quinazolin-3-yl]acetamide 909391-99-7P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[2-(piperidin-1-yl)ethoxy]-4H-quinazolin-3-yl]acetamide 909392-00-3P,
 2-[2-(3-Methoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-phenylacetamide 909392-01-4P,
 N-Benzyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]acetamide 909392-02-5P,
 N-Isopropyl-2-[7-methoxy-2-(3-methoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]acetamide 909392-03-6P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-7-methyl-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]acetamide 909392-04-7P,
 2-[7-Chloro-2-(3-methoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-05-8P,
 N-tert-Butyl-2-[2-(3-chlorophenyl)-6-[3-(4-hydroxy-4-methylpiperidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]acetamide 909392-06-9P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-6-[3-(4-methylpiperidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]acetamide 909392-07-0P,
 2-[6-[3-(4,4-Dimethylpiperidin-1-yl)propoxy]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-08-1P,
 2-[6-[3-(4-Hydroxy-4-methylpiperidin-1-yl)propoxy]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-09-2P,
 2-[2-(3-Methoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-(2,2,2-trifluoroethyl)acetamide 909392-10-5P,
 2-[2-(3-Chlorophenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide hydrochloride 909392-12-7P,
 N-(Cyclopropylmethyl)-2-[2-(3-methoxyphenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]acetamide 909392-13-8P,
 N-Cyclopropyl-2-[2-(3-methoxyphenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]acetamide hydrochloride 909392-14-9P,
 2-[2-(3-Chlorophenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-cyclopropylmethylacetamide 909392-15-0P,
 N-(Cyclopropylmethyl)-2-[6-[3-(morpholin-4-yl)propoxy]-4-oxo-2-(o-tolyl)-4H-quinazolin-3-yl]acetamide 909392-16-1P,

N-(Cyclopropylmethyl)-2-[2-(4-fluorophenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]acetamide 909392-17-2P,
 N-Cyclopropyl-2-[6-[3-(morpholin-4-yl)propoxy]-4-oxo-2-(m-tolyl)-4H-quinazolin-3-yl]acetamide 909392-19-4P,
 2-[2-(3-Chlorophenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-20-7P,
 2-[2-(3-Chlorophenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-cyclopropylacetamide 909392-21-8P,
 N-(Cyclopropylmethyl)-2-[2-(3,5-dimethoxyphenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]acetamide 909392-22-9P,
 2-[2-(3-Ethylphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-23-0P,
 N-Cyclopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]acetamide 909392-24-1P,
 2-[2-(2,3-Dichlorophenyl)-4-oxo-6-[3-(piperidin-1-yl)propoxy]-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-25-2P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-6-[3-(4-methylpiperazin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]acetamide 909392-29-6P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-6-[methyl[3-(piperidin-1-yl)propyl]amino]-4-oxo-4H-quinazolin-3-yl]acetamide 909392-30-9P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[3-(piperidin-1-yl)propyl]sulfanyl]-4H-quinazolin-3-yl]acetamide 909392-31-0P,
 N-(Cyclopropylmethyl)-2-[2-(3-hydroxyphenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]acetamide 909392-33-2P,
 (S)-(+)-2-[6-[3-Diethylamino-2-methylpropoxy]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylethanamide 909392-37-6P,
 2-[6-[3-(Diethylamino-2-methylpropoxy)-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-39-8P,
 (S)-(+)-2-[2-(3-Chlorophenyl)-6-[2-methyl-3-(pyrrolidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-isopropylethanamide 909392-40-1P
 909392-41-2P 909392-42-3P,
 (S)-(+)-2-[6-[3-Dimethylamino-2-methylpropoxy]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylethanamide 909392-43-4P,
 (S)-(+)-2-[2-(3-Fluorophenyl)-6-[2-methyl-3-(morpholin-4-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-isopropylethanamide 909392-44-5P,
 (S)-(+)-2-[6-[3-(Dimethylamino-2-methylpropoxy)-2-(3-fluorophenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylethanamide 909392-45-6P,
 (S)-(+)-2-[6-[3-(Azetidin-1-yl)-2-methylpropoxy]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylethanamide 909392-46-7P,
 (S)-(+)-2-[2-(3-Fluorophenyl)-6-[2-methyl-3-(pyrrolidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-isopropylethanamide 909392-48-9P,
 (S)-(+)-N-Isopropyl-2-[2-(3-methoxyphenyl)-6-[2-methyl-3-(pyrrolidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]ethanamide 909392-50-3P,
 (S)-(+)-N-Ethyl-2-[2-(3-methoxyphenyl)-6-[2-methyl-3-(piperidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]ethanamide 909392-52-5P,
 (S)-(+)-2-[2-(3-Chlorophenyl)-6-[2-methyl-3-(piperidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-propylethanamide 909392-53-6P,
 (S)-(+)-2-[2-(3-Methoxyphenyl)-6-[2-methyl-3-(piperidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-propylethanamide 909392-54-7P,
 (S)-(+)-2-[2-(3-Fluorophenyl)-6-[2-methyl-3-(piperidin-1-yl)propoxy]-4-oxo-4H-quinazolin-3-yl]-N-isopropylethanamide 909392-58-1P,
 (S)-(+)-2-[6-[3-(Diethylamino-2-methylpropoxy)-2-(3-fluorophenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylethanamide 909392-64-9P,
 2-[6-[5-[(Dimethylamino)methyl]-2-fluorophenyl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-68-3P,
 2-[6-[6-[(Dimethylamino)methyl]pyridin-2-yl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-69-4P,
 2-[6-[4-[(Dimethylamino)methyl]pyridin-2-yl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-73-0P,
 N-(Cyclopropylmethyl)-2-[2-(3-Methoxyphenyl)-6-[3-(piperidin-1-

yl)methyl)phenyl]-4-oxo-4H-quinazolin-3-yl]acetamide
 909392-74-1P, 2-[2-(3-Chlorophenyl)-4-oxo-6-[3-((piperidin-1-yl)methyl)phenyl]-4H-quinazolin-3-yl]-N-isopropylacetamide
 909392-75-2P, N-Isobutyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[3-((piperidin-1-yl)methyl)phenyl]-4H-quinazolin-3-yl]acetamide
 909392-76-3P, N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[3-((piperidin-1-yl)methyl)phenyl]-4H-quinazolin-3-yl]acetamide
 909392-77-4P, N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[3-((pyrrolidin-1-yl)methyl)phenyl]-4H-quinazolin-3-yl]acetamide
 909392-78-5P, 2-[2-(3-Chlorophenyl)-4-oxo-6-[3-((pyrrolidin-1-yl)methyl)phenyl]-4H-quinazolin-3-yl]-N-isopropylacetamide
 909392-80-9P, 2-[2-(3-Chlorophenyl)-6-[3-((diethylamino)methyl)phenyl]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-81-0P,
 2-[6-[3-((Diethylamino)methyl)phenyl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-82-1P,
 2-[6-[3-((Dimethylamino)methyl)phenyl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-83-2P,
 2-[2-(3-Chlorophenyl)-6-[3-((dimethylamino)methyl)phenyl]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-85-4P,
 2-[6-[3-((Dimethylamino)methyl)phenyl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isobutylacetamide 909392-86-5P,
 2-[2-(3-Chlorophenyl)-6-[3-((isopropylmethylamino)methyl)phenyl]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-87-6P,
 2-[6-[3-((Isobutylmethylamino)methyl)phenyl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-88-7P,
 N-Isopropyl-2-[6-[3-((isopropylmethylamino)methyl)phenyl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]acetamide 909392-89-8P,
 2-[6-[3-((Ethylmethylamino)methyl)phenyl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-90-1P,
 2-[2-(3-Chlorophenyl)-6-[3-((ethylmethylamino)methyl)phenyl]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-91-2P,
 2-[2-(3-Chlorophenyl)-6-[3-((morpholin-4-yl)methyl)phenyl]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-92-3P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-6-[3-((morpholin-4-yl)methyl)phenyl]-4-oxo-4H-quinazolin-3-yl]acetamide 909392-93-4P,
 2-[2-(3-Chlorophenyl)-6-[3-((4-hydroxypiperidin-1-yl)methyl)phenyl]-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-94-5P,
 2-[6-[3-((4-Hydroxypiperidin-1-yl)methyl)phenyl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-96-7P,
 N-tert-Butyl-2-[6-[3-((dimethylamino)methyl)phenyl]-2-(4-fluoro-3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]acetamide 909392-97-8P,
 N-tert-Butyl-2-[2-(4-fluoro-3-methoxyphenyl)-4-oxo-6-[3-((pyrrolidin-1-yl)methyl)phenyl]-4H-quinazolin-3-yl]acetamide 909392-98-9P,
 2-[6-[3-((Dimethylamino)methyl)phenyl]-2-(4-fluoro-3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909392-99-0P,
 2-[7-[3-((Dimethylamino)methyl)phenyl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909393-01-7P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-7-[3-((piperidin-1-yl)methyl)phenyl]-4H-quinazolin-3-yl]acetamide 909393-02-8P,
 2-[6-[5-((Azetidin-1-yl)methyl)furan-2-yl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909393-05-1P,
 2-[6-[5-((Dimethylamino)methyl)pyridin-3-yl]-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 909393-11-9P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[4-(piperidin-1-yl)but-1-enyl]-4H-quinazolin-3-yl]acetamide 909393-12-0P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[4-(pyrrolidin-1-yl)but-1-enyl]-4H-quinazolin-3-yl]acetamide 909393-13-1P,
 N-tert-Butyl-2-[2-(3-chlorophenyl)-4-oxo-6-[4-(pyrrolidin-1-yl)butyl]-4H-quinazolin-3-yl]acetamide 909393-14-2P,


N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[4-(pyrrolidin-1-yl)butyl]-4H-quinazolin-3-yl]acetamide 909393-15-3P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-6-[4-(morpholin-4-yl)butyl]-4-oxo-4H-quinazolin-3-yl]acetamide 909393-16-4P,
 N-tert-Butyl-2-[2-(4-fluoro-3-methoxyphenyl)-4-oxo-6-[4-(piperidin-1-yl)butyl]-4H-quinazolin-3-yl]acetamide 909393-17-5P,
 N-tert-Butyl-2-[2-(4-fluoro-3-methoxyphenyl)-4-oxo-6-[4-(pyrrolidin-1-yl)butyl]-4H-quinazolin-3-yl]acetamide 909393-18-6P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-6-[2-(1-methylpiperidin-2-yl)ethoxy]-4-oxo-4H-quinazolin-3-yl]acetamide 909393-21-1P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[[3-(piperidin-1-yl)propyl]amino]-4H-quinazolin-3-yl]acetamide 909393-22-2P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-6-[(1-methylpiperidin-3-yl)methoxy]-4-oxo-4H-quinazolin-3-yl]acetamide 909393-23-3P,
 N-Isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-[(pyridin-3-yl)methoxy]-4H-quinazolin-3-yl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(4-oxo-4H-quinazolin-3-yl)acetamides as vasopressin V3 receptor antagonists)


RN 909391-63-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-[3-(1-methylethoxy)phenyl]-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909391-64-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]-2-(3-propoxyphenyl)- (CA INDEX NAME)




RN 909391-65-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(2-fluoro-5-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909391-66-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 909391-67-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]-2-(3,4,5-trifluorophenyl)- (CA INDEX NAME)




RN 909391-68-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-iodophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909391-70-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-[3-(cyclopentyloxy)phenyl]-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidiny)propoxy]- (CA INDEX NAME)




RN 909391-72-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1-methylethyl)-4-oxo-6-[3-(1-piperidiny)propoxy]-2-[3-(1H-pyrrol-1-yl)phenyl]- (CA INDEX NAME)




RN 909391-73-7 CAPLUS

CN Benzoic acid, 3-[3,4-dihydro-3-[2-[(1-methylethyl)amino]-2-oxoethyl]-4-oxo-6-[3-(1-piperidiny)propoxy]-2-quinazolinyl]-, methyl ester (CA INDEX NAME)




RN 909391-74-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-[3-(dimethylamino)phenyl]-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidiny)propoxy]- (CA INDEX NAME)




RN 909391-75-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-cyanophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909391-76-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-[3-(cyclobutyloxy)phenyl]-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909391-77-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 909391-79-3 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 909391-82-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-2-(3-methoxyphenyl)-4-oxo-6-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)




RN 909391-83-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1,1-dimethylethyl)-4-oxo-6-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)




RN 909391-84-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-2-(3-methoxyphenyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909391-85-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3,4-difluorophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909391-86-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1,1-dimethylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909391-87-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-ethoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909391-88-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909391-89-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909391-90-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[3-(dimethylamino)propoxy]-N-(1,1-dimethylethyl)-4-oxo- (CA INDEX NAME)




RN 909391-91-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-(dimethylamino)propoxy]-N-(1,1-dimethylethyl)-2-(3-methoxyphenyl)-4-oxo- (CA INDEX NAME)




RN 909391-92-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-(diethylamino)propoxy]-N-(1,1-dimethylethyl)-2-(3-methoxyphenyl)-4-oxo- (CA INDEX NAME)




RN 909391-93-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[3-(diethylamino)propoxy]-N-(1,1-dimethylethyl)-4-oxo- (CA INDEX NAME)




RN 909391-94-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[3-(4-hydroxy-1-piperidinyl)propoxy]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909391-95-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[3-(3-hydroxy-1-piperidinyl)propoxy]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909391-96-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(4-fluoro-3-methoxyphenyl)-6-[3-(4-hydroxy-1-piperidinyl)propoxy]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909391-97-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chloro-4-fluorophenyl)-6-[3-(4-hydroxy-1-piperidinyl)propoxy]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909391-98-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[4-(1-piperidinyl)butoxy]- (CA INDEX NAME)



RN 909391-99-7 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 909392-00-3 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-4-oxo-N-phenyl-6-[3-(1-

piperidinyl)propoxy]- (CA INDEX NAME)




RN 909392-01-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-4-oxo-N-(phenylmethyl)-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909392-02-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 7-methoxy-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 909392-03-6 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-7-methyl-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 909392-04-7 CAPLUS


CN 3(4H)-Quinazolineacetamide, 7-chloro-2-(3-methoxyphenyl)-N-(1-methylethyl)-

4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909392-05-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1,1-dimethylethyl)-6-[3-(4-hydroxy-4-methyl-1-piperidinyl)propoxy]-4-oxo- (CA INDEX NAME)




RN 909392-06-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-[3-(4-methyl-1-piperidinyl)propoxy]-4-oxo- (CA INDEX NAME)




RN 909392-07-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-(4,4-dimethyl-1-piperidinyl)propoxy]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-08-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-(4-hydroxy-4-methyl-1-piperidinyl)propoxy]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-09-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 909392-10-5 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 909392-12-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(cyclopropylmethyl)-2-(3-methoxyphenyl)-6-[3-(4-morpholinyl)propoxy]-4-oxo- (CA INDEX NAME)



RN 909392-13-8 CAPLUS


CN 3(4H)-Quinazolineacetamide, N-cyclopropyl-2-(3-methoxyphenyl)-6-[3-(4-morpholinyl)propoxy]-4-oxo-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 909392-14-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(cyclopropylmethyl)-6-[3-(4-morpholinyl)propoxy]-4-oxo- (CA INDEX NAME)




RN 909392-15-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(cyclopropylmethyl)-2-(2-methylphenyl)-6-[3-(4-morpholinyl)propoxy]-4-oxo- (CA INDEX NAME)




RN 909392-16-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(cyclopropylmethyl)-2-(4-fluorophenyl)-6-[3-(4-morpholinyl)propoxy]-4-oxo- (CA INDEX NAME)




RN 909392-17-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-cyclopropyl-2-(3-methylphenyl)-6-[3-(4-morpholinyl)propoxy]-4-oxo- (CA INDEX NAME)




RN 909392-19-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1-methylethyl)-6-[3-(4-morpholinyl)propoxy]-4-oxo- (CA INDEX NAME)



RN 909392-20-7 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-cyclopropyl-6-[3-(4-morpholinyl)propoxy]-4-oxo- (CA INDEX NAME)



RN 909392-21-8 CAPLUS


CN 3(4H)-Quinazolineacetamide, N-(cyclopropylmethyl)-2-(3,5-dimethoxyphenyl)-6-[3-(4-morpholinyl)propoxy]-4-oxo- (CA INDEX NAME)

6-[3-(4-morpholinyl)propoxy]-4-oxo- (CA INDEX NAME)




RN 909392-22-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-ethylphenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909392-23-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-cyclopropyl-2-(3-methoxyphenyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909392-24-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(2,3-dichlorophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 909392-25-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-[3-(4-methyl-1-piperazinyl)propoxy]-4-oxo- (CA INDEX NAME)




RN 909392-29-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-[methyl[3-(1-piperidinyl)propyl]amino]-4-oxo- (CA INDEX NAME)




RN 909392-30-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[[3-(1-piperidinyl)propyl]thio]- (CA INDEX NAME)



RN 909392-31-0 CAPLUS


CN 3(4H)-Quinazolineacetamide, N-(cyclopropylmethyl)-2-(3-hydroxyphenyl)-6-[3-(4-morpholinyl)propoxy]-4-oxo- (CA INDEX NAME)



RN 909392-33-2 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-[(2S)-3-(diethylamino)-2-methylpropoxy]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 909392-37-6 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-[3-(diethylamino)-2-methylpropoxy]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)



RN 909392-39-8 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1-methylethyl)-6-[(2S)-2-methyl-3-(1-pyrrolidinyl)propoxy]-4-oxo- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 909392-40-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-7-
[2-(1-piperidinyloxy)]- (CA INDEX NAME)



RN 909392-41-2 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-7-
[3-(1-piperidinyloxy)]- (CA INDEX NAME)



RN 909392-42-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[(2S)-3-(dimethylamino)-2-methylpropoxy]-2-
(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 909392-43-4 CAPLUS

CN 3 (4H)-Quinazolineacetamide, 2-(3-fluorophenyl)-N-(1-methylethyl)-6-[(2S)-2-methyl-3-(4-morpholinyl)propoxy]-4-oxo- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 909392-44-5 CAPLUS

CN 3 (4H)-Quinazolineacetamide, 6-[(2S)-3-(dimethylamino)-2-methylpropoxy]-2-(3-fluorophenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 909392-45-6 CAPLUS

CN 3 (4H)-Quinazolineacetamide, 6-[(2S)-3-(1-azetidiny)-2-methylpropoxy]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 909392-46-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-fluorophenyl)-N-(1-methylethyl)-6-[(2S)-2-methyl-3-(1-pyrrolidinyl)propoxy]-4-oxo- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 909392-48-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-fluorophenyl)-N-(1-methylethyl)-6-[(2S)-2-methyl-3-(1-pyrrolidinyl)propoxy]-4-oxo- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 909392-50-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-ethyl-2-(3-methoxyphenyl)-6-[(2S)-2-methyl-3-(1-piperidiny)propoxy]-4-oxo- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 909392-52-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[(2S)-2-methyl-3-(1-piperidinyl)propoxy]-4-oxo-N-propyl- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 909392-53-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-6-[(2S)-2-methyl-3-(1-piperidinyl)propoxy]-4-oxo-N-propyl- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 909392-54-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-fluorophenyl)-N-(1-methylethyl)-6-[(2S)-2-methyl-3-(1-piperidinyl)propoxy]-4-oxo- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 909392-58-1 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-[(2S)-3-(diethylamino)-2-methylpropoxy]-2-(3-fluorophenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 909392-64-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[5-[(dimethylamino)methyl]-2-fluorophenyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-68-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[6-[(dimethylamino)methyl]-2-pyridinyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-69-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[4-[(dimethylamino)methyl]-2-pyridinyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-73-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(cyclopropylmethyl)-2-(3-methoxyphenyl)-4-oxo-6-[3-(1-piperidinylmethyl)phenyl]- (CA INDEX NAME)




RN 909392-74-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinylmethyl)phenyl]- (CA INDEX NAME)




RN 909392-75-2 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(2-methylpropyl)-4-oxo-6-[3-(1-piperidinylmethyl)phenyl]- (CA INDEX NAME)




RN 909392-76-3 CAPLUS
CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-piperidinylmethyl)phenyl]- (CA INDEX NAME)




RN 909392-77-4 CAPLUS
CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)



RN 909392-78-5 CAPLUS
CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1-methylethyl)-4-oxo-6-[3-(1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)




RN 909392-80-9 CAPLUS
CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[3-(diethylamino)methyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-81-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-[(diethylamino)methyl]phenyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-82-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-[(dimethylamino)methyl]phenyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-83-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[3-[(dimethylamino)methyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-85-4 CAPLUS


CN 3(4H)-Quinazolineacetamide, 6-[3-[(dimethylamino)methyl]phenyl]-2-(3-methoxyphenyl)-N-(2-methylpropyl)-4-oxo- (CA INDEX NAME)




RN 909392-86-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1-methylethyl)-6-[3-
[[methyl(1-methylethyl)amino]methyl]phenyl]-4-oxo- (CA INDEX NAME)

RN 909392-87-6 CAPLUS


CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-[3-
[[methyl(2-methylpropyl)amino]methyl]phenyl]-4-oxo- (CA INDEX NAME)

RN 909392-88-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-[3-
[[methyl(1-methylethyl)amino]methyl]phenyl]-4-oxo- (CA INDEX NAME)


RN 909392-89-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-[(ethylmethylamino)methyl]phenyl]-2-(3-
methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-90-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[3-[(ethylmethylamino)methyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-91-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1-methylethyl)-6-[3-(4-morpholinylmethyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 909392-92-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-[3-(4-morpholinylmethyl)phenyl]-4-oxo- (CA INDEX NAME)




RN 909392-93-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-6-[3-[(4-hydroxy-1-piperidinyl)methyl]phenyl]-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-94-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-[(4-hydroxy-1-piperidiny)methyl]phenyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-96-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-[(dimethylamino)methyl]phenyl]-N-(1,1-dimethylethyl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo- (CA INDEX NAME)




RN 909392-97-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-2-(4-fluoro-3-methoxyphenyl)-6-[3-(1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)




RN 909392-98-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[3-[(dimethylamino)methyl]phenyl]-2-(4-fluoro-3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909392-99-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 7-[3-[(dimethylamino)methyl]phenyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909393-01-7 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-7-[3-(1-piperidinylmethyl)phenyl]- (CA INDEX NAME)




RN 909393-02-8 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[5-(1-azetidinylmethyl)-2-furanyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909393-05-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 6-[5-[(dimethylamino)methyl]-3-pyridinyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo- (CA INDEX NAME)




RN 909393-11-9 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[4-(1-piperidinyl)-1-buten-1-yl]- (CA INDEX NAME)




RN 909393-12-0 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[4-(1-pyrrolidinyl)-1-buten-1-yl]- (CA INDEX NAME)




RN 909393-13-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-chlorophenyl)-N-(1,1-dimethylethyl)-4-oxo-6-[4-(1-pyrrolidinyl)butyl]- (CA INDEX NAME)




RN 909393-14-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[4-(1-pyrrolidinyl)butyl]- (CA INDEX NAME)




RN 909393-15-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-[4-(4-morpholinyl)butyl]-4-oxo- (CA INDEX NAME)




RN 909393-16-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo-6-[4-(1-piperidinyl)butyl]- (CA INDEX NAME)




RN 909393-17-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-(1,1-dimethylethyl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo-6-[4-(1-pyrrolidinyl)butyl]- (CA INDEX NAME)




RN 909393-18-6 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-[2-(1-methyl-2-piperidinyl)ethoxy]-4-oxo- (CA INDEX NAME)




RN 909393-21-1 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-[[3-(1-piperidinyl)propyl]amino]- (CA INDEX NAME)




RN 909393-22-2 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-6-[(1-methyl-3-piperidinyl)methoxy]-4-oxo- (CA INDEX NAME)



RN 909393-23-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-(3-methoxyphenyl)-N-(1-methylethyl)-4-oxo-6-(3-pyridinylmethoxy)- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS


RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 38 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:685844 CAPLUS
 DOCUMENT NUMBER: 146:358790
 TITLE: Synthesis and antiviral activity of quinazolinyl
 syndones
 AUTHOR(S): Pandey, V. K.; Mukesh; Tandon, Meenal
 CORPORATE SOURCE: Department of Chemistry, University of Lucknow, 226
 007, India
 SOURCE: Indian Journal of Heterocyclic Chemistry (2006),
 15(4), 399-400
 CODEN: IJCHEI; ISSN: 0971-1627
 PUBLISHER: Prof. R. S. Varma
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:358790


AB Anthranilic acid on reaction with an aromatic acid chloride in presence of
 pyridine cyclizes to 2-aryl-4-oxo-3,1-benzoxazines, which on treatment
 with hydrazine hydrate in dry pyridine affords
 2-aryl-3-amino-4-oxo-(3H)-quinazolines. Reaction of quinazolines with Et
 chloroacetate in presence of sodium acetate yields
 2-aryl-4-oxo-(3H)-quinazolin-3-aminoethyl acetates, which on hydrolysis
 furnishes 2-aryl-4-oxo-(3H)-quinazolin-3-amino-acetic acids. Reaction of
 2-aryl-4-oxo-(3H)-quinazolin-3-amino-acetic acids. with sodium nitrite and
 conc HCl results in 2-aryl-4-oxo-(3H)-quinazolin-nitrosoaminoacetic acids.
 Heating the later compds. with acetic anhydride gives N-(2-aryl-4-oxo (3H)
 quinazolinyl) syndones in yields varying from 30 to 50%. The syndnone
 compds. were screened for their antiviral activity in vitro.

IT 929878-77-3P 929878-78-4P 929878-79-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation and antiviral activity of quinazolinyl syndones)

RN 929878-77-3 CAPLUS
 CN 1,2,3-Oxadiazolium, 3-[2-(2,4-dichlorophenyl)-4-oxo-3(4H)-quinazolinyl]-
 4,5-dihydro-5-hydroxy-, inner salt (CA INDEX NAME)




RN 929878-78-4 CAPLUS
 CN 1,2,3-Oxadiazolium, 3-[2-(2-chlorophenyl)-4-oxo-3(4H)-quinazolinyl]-4,5-
 dihydro-5-hydroxy-, inner salt (CA INDEX NAME)



RN 929878-79-5 CAPLUS

CN 1,2,3-Oxadiazolium, 3-[2-(3,5-dinitrophenyl)-4-oxo-3(4H)-quinazolinyl]-4,5-dihydro-5-hydroxy-, inner salt (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 39 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:365240 CAPLUS

DOCUMENT NUMBER: 144:412505

TITLE: Benzimidazole or indole amides as inhibitors of pin1 and their preparation, pharmaceutical compositions, and use for treatment of diseases associated with abnormal cell growth

INVENTOR(S): Do, Quyen-Quyen Thuy; Guo, Chuangxing; Humphries, Paul Stuart; Marakovits, Joseph Timothy; Dong, Liming; Hou, Xinjun; Johnson, Mary Catherine

PATENT ASSIGNEE(S): Pfizer, Inc., USA

SOURCE: PCT Int. Appl., 396 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006040646	A1	20060420	WO 2005-IB3019	20051003
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
 NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
 SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
 YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM


PRIORITY APPLN. INFO.: US 2004-619211P P 20041014
 OTHER SOURCE(S): CASREACT 144:412505; MARPAT 144:412505
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. of the formula I and to pharmaceutically acceptable salts and solvates thereof, wherein the variables are defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compds. of formula I and to pharmaceutical compns. for treating such disorders that contain the compds. of formula I. The invention also relates to methods of preparing the compds. of formula I. Compds. of formula I wherein Q, Q1, Q2, and Q3 are independently N, CH2 or CH, where not more than two of the Qs are N; T is CH or N; T1 is O, NH or NMe; X is NH, O, CH=, or NR'; R' is (un)substituted alkyl; Y is CO, CH2, or CONH and derivs.; Z is H or (un)substituted alkyl; XY and X can form a heterocyclic ring or X and Y can form a heterocyclic ring; R and V are independently H, halo, alkyl, halogenated alkyl, alkoxy, OH, NH2, CN; R1 is (un)substituted (hetero)aryl, (un)substituted aryloxy, (un)substituted arylsulfanyl, (un)substituted arylvinyl or (un)substituted arylalkyl(amino), etc.; R3 is CO2H, tetrazole, CO2CHR4OCOR4 or CONH2 and derivs.; R4 is H or alkyl; and their pharmaceutically acceptable salts and solvates are claimed in this invention. Example compound II was prepared by substitution of compound II with benzoxazole-2-thiol followed by hydrolysis at the ester. Addnl. 1400 example compds. were prepared in this invention. All invention compds. were evaluated for their pin1 inhibitory activity. Example compound II showed 10% inhibition at 1 μ M and 73% inhibition at 10 μ M concentration. Most of the invention compds. showed good inhibitory activity at 10 μ M concentration.

IT 884038-29-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of benzimidazole or indole amides as inhibitors of pin1 useful for treatment of diseases associated with abnormal cell growth)

RN 884038-29-3 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[4-(3,4-dihydro-4-oxo-2-quinazolinyl)phenoxy]methyl]-4-[(6-fluoro-1H-indol-2-yl)methyl]-4,5-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 40 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:104528 CAPLUS

DOCUMENT NUMBER: 144:192275

TITLE: Preparation of quinazolinone derivatives useful for
the regulation of glucose homeostasis and food intake
INVENTOR(S): Rudolph, Joachim; O'Connor, Stephen; Coish, Philip;
Wickens, Philip; Bondar, Georgiy; Chuang, Chih-Yuan;
Ramsden, Philip; Lowe, Derek; Bierer, Donald; Chen,
Libing; Fu, Wenlang; Khire, Uday; Liu, Xiao-Gao;
McClure, Andrea; Wang, Lei; Yi, Lin; Esler, William
Bayer Pharmaceuticals Corporation, USA

PATENT ASSIGNEE(S):
SOURCE: PCT Int. Appl., 559 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012577	A2	20060202	WO 2005-US26192	20050722
WO 2006012577	A3	20060928		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-590804P P 20040722

OTHER SOURCE(S): CASREACT 144:192275; MARPAT 144:192275

GI



AB The invention is related to substituted quinazolinone derivs. I [R1 = (un)substituted pyrrolidin-3-yl, piperidin-3-yl, morpholin-4-yl, etc.; R2 = H, (un)substituted cyclo/alkyl, pyridinyl, Ph, etc.; R3 = H, halo, haloalkyl, (un)substituted Ph, alkyl, etc.; L = a bond, O, CO, S, SO2, NHSO2, NH and derivs., etc.; X = (CH2)m; m = 0-2; Y = (CH2)n; n = 1-2; p = 0-2; with provisos], and their pharmaceutically acceptable salts, and their compns., and methods for treating diabetes, obesity and related disorders, and regulation of glucose homeostasis and food intake (e.g., stimulation and suppression) (no data). The invention is also related to the preparation of quinazolinones I. Five biol. tests are given (no data). Thus, II•TFA was prepared by amination of 5-fluoro-2-nitrobenzoic acid with N-methylbutylamine, reduction of the nitro compound, cyclocondensation

with

o-anisoyl chloride, reaction with tert-Bu 3-(aminomethyl)piperidine-1-carboxylate (intermediate not isolated), and Boc-deprotection in the presence of TFA.

IT 875261-21-5P, 6-(3-Fluorophenyl)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; [preparation of quinazolinones useful for regulation of glucose homeostasis and food intake])


RN 875261-21-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-fluorophenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-20-4

CMF C27 H26 F N3 O2



CM 2

CRN 76-05-1

CMF C 2 H F3 O2




IT 875258-72-3P, 2-(2-Methylphenyl)-3-[(piperidin-3-yl)methyl]-6-[(tetrahydro-2H-pyran-4-yl)oxy]quinazolin-4(3H)-one 875258-74-5P, (S)-6-Isobutoxy-2-(2-methylphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875258-77-8P, (S)-6-[(3-Chloropyridin-2-yl)oxy]-2-(2-methylphenyl)-3-(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875258-83-6P, 6-(4-Fluorophenoxy)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875258-93-8P, 6-[(4-Fluorophenyl)amino]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-07-7P, (R)-6-(4-Chlorophenyl)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate 875259-44-2P, 6-(4-Chlorophenyl)-2-(2-methylphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-56-6P, 6-Bromo-2-[4-(difluoromethoxy)phenyl]-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-58-8P, 6-(Cyclopropylethynyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-67-9P, 6-[Butyl(methyl)amino]-2-(2-methoxyphenyl)-3-[(pyrrolidin-3-yl)methyl]quinazolin-4(3H)-one monohydrochloride 875259-70-4P, 6-(4-Fluorophenoxy)-2-(2-methylphenyl)-3-[(morpholin-2-yl)methyl]quinazolin-4(3H)-one 875259-72-6P, 3-[(4-Benzylmorpholin-2-yl)methyl]-6-(4-chlorophenyl)-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-78-2P, (S)-2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-81-7P, 6-Bromo-3-[[1-(cyclobutylmethyl)piperidin-3-yl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]quinazolin-4(3H)-one 875260-33-6P, 2-(2-Methylphenyl)-3-[(piperidin-3-yl)methyl]-6-(trifluoromethoxy)quinazolin-4(3H)-one 875260-66-5P 875260-73-4P 875269-27-5P, 2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of quinazolinones useful for regulation of
 glucose homeostasis and food intake)

RN 875258-72-3 CAPLUS


CN 4(3H)-Quinazolinone, 2-(2-methylphenyl)-3-(3-piperidinylmethyl)-6-
 [(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 875258-74-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methylphenyl)-6-(2-methylpropoxy)-3-[(3S)-3-
 piperidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875258-77-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-[(3-chloro-2-pyridinyl)oxy]-2-(2-methylphenyl)-3-
 [(3S)-3-piperidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875258-83-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-2-(2-methoxyphenyl)-3-(3-
 piperidinylmethyl)- (CA INDEX NAME)

10/ 582,823



RN 875258-93-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-[(4-fluorophenyl)amino]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875259-07-7 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-[(3R)-3-piperidinylmethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-06-6

CMF C27 H26 Cl N3 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 875259-44-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methylphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875259-56-6 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[4-(difluoromethoxy)phenyl]-3-(3-piperidinylmethyl)- (CA INDEX NAME)



RN 875259-58-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(2-cyclopropylethynyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875259-67-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-(3-pyrrolidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 875259-70-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-2-(2-methylphenyl)-3-(2-morpholinylmethyl)- (CA INDEX NAME)



RN 875259-72-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methylphenyl)-3-[[4-(phenylmethyl)-2-morpholinyl]methyl]- (CA INDEX NAME)



RN 875259-78-2 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-[(3S)-3-piperidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 875259-81-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)




RN 875260-33-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methylphenyl)-3-(3-piperidinylmethyl)-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 875260-66-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-2-[4-(phenylmethoxy)phenyl]-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875260-73-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 875269-27-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



IT 875258-65-4P, 6-[Butyl(methyl)amino]-2-(2-methoxyphenyl)-3-[[1-(piperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate
 875258-67-6P, 6-[Butyl(methyl)amino]-3-[[1-(ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875258-69-8P, 6-[Butyl(methyl)amino]-2-(2-methoxyphenyl)-3-[[1-(methylpiperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate
 875258-70-1P, 6-[Butyl(methyl)amino]-3-[[1-(cyclopropylmethyl)piperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875258-71-2P,
 6-[Butyl(methyl)amino]-2-(2-methoxyphenyl)-3-[[1-(4,4,4-trifluorobutyl)piperidin-3-yl)methyl]quinazolin-4(3H)-one
 875258-73-4P, 3-[[1-(Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[(tetrahydro-2H-pyran-4-yl)oxy]quinazolin-4(3H)-one
 875258-75-6P, (S)-6-Isobutoxy-3-[[1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875258-76-7P

, (5)-6-(Cyclobutylloxy)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875258-78-9P,
 (S)-6-[(3-Chloropyridin-2-yl)oxy]-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875258-79-0P,
 3-[[1-(2-Hydroxy-1-(hydroxymethyl)ethyl)piperidin-3-yl]methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)quinazolin-4(3H)-one 875258-80-3P, 3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)quinazolin-4(3H)-one 875258-82-5P
 875258-84-7P, 6-(4-Fluorophenoxy)-3-[(1-isobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875258-94-9P
 , 6-[Ethyl(4-fluorophenyl)amino]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875258-96-1P,
 N-[3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl]benzenesulfonamide 875259-01-1P,
 6-(3-Chlorophenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875259-08-8P,
 (R)-6-(4-Chlorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875259-09-9P,
 (R)-6-(4-Chlorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-10-2P,
 6-(4-Chlorophenyl)-3-[[1-(2-hydroxyethyl)piperidin-3-yl]methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-11-3P,
 6-(4-Chlorophenyl)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one monohydrochloride 875259-13-5P,
 6-(4-Chlorophenyl)-3-[(1-cyclopentylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875259-15-7P, (R)-6-(4'-Chlorobiphenyl-4-yl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875259-18-0P, 6-(1,3-Benzodioxol-5-yl)-2-[2-(difluoromethoxy)phenyl]-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-20-4P, 6-(3-Chlorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875259-22-6P, 6-(3-Chlorophenyl)-3-[[1-(cyclopropylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875259-24-8P,
 6-(4-Chlorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(4-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875259-26-0P, 6-(3-Fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3-trifluoropropyl)piperidin-3-yl]methyl]quinazolin-4(3H)-one monotrifluoroacetate 875259-28-2P,
 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(3-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875259-35-1P, 6-(4-Chlorophenyl)-2-[4-(difluoromethoxy)phenyl]-3-[(1-ethylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-48-6P
 , 3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875259-50-0P,
 6-Butyl-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875259-51-1P,
 6-Butyl-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-53-3P, 3-[(1-Ethylpiperidin-3-yl)methyl]-6-hexyl-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875259-55-5P, 6-[4-(3-Chloro-2-thienyl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875259-57-7P,
 6-Cyclopentyl-2-[4-(difluoromethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-59-9P,
 6-(2-Cyclopropylethyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-60-2P,
 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-pentylquinazolin-4(3H)-one 875259-64-6P,

6-Acetyl-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-69-1P,
 6-[Butyl(methyl)amino]-2-(2-methoxyphenyl)-3-[[1-(3-methylbutyl)pyrrolidin-3-yl]methyl]quinazolin-4(3H)-one monotrifluoroacetate
 875259-71-5P, 6-(4-Fluorophenoxy)-3-[(4-isopropylmorpholin-2-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-73-7P
 , 6-(4-Chlorophenyl)-3-[(4-isopropylmorpholin-2-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-74-8P,
 6-(4-Chlorophenyl)-3-[(4-ethylmorpholin-2-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-75-9P,
 3-[(1-Ethyl-1,2,5,6-tetrahydropyridin-3-yl)methyl]-6-(4-fluorophenoxy)-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-76-0P,
 6-(4-Chlorophenyl)-3-[(1-ethyl-1,2,5,6-tetrahydropyridin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875259-77-1P,
 3-[(1(3R)-1-Azabicyclo[2.2.2]oct-3-yl)methyl]-6-(4-chlorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875259-79-3P,
 (S)-2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-80-6P
 , (S)-2-[2-Fluoro-4-(2-methoxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-82-8P
 , 3-[[1-(Cyclobutylmethyl)piperidin-3-yl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-phenoxyquinazolin-4(3H)-one 875259-83-9P
 , 6-Anilino-3-[[1-(cyclobutylmethyl)piperidin-3-yl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]quinazolin-4(3H)-one 875259-84-0P,
 6-(3-Chlorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-85-1P,
 6-(3-Chlorophenyl)-3-[[1-(cyclobutylmethyl)piperidin-3-yl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]quinazolin-4(3H)-one 875259-86-2P, 6-Anilino-2-[2,4-bis(2-hydroxyethoxy)phenyl]-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-87-3P,
 2-[2,4-Bis(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-88-4P,
 2-[2,4-Bis(2-hydroxyethoxy)phenyl]-6-(3-chlorophenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-91-9P,
 6-(4-Fluorophenoxy)-2-(4-hydroxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-94-2P,
 2-[[6-[Butyl(methyl)amino]-2-(2-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl]methyl]piperidinium trifluoroacetate 875259-96-4P,
 2-[[6-[Butyl(methyl)amino]-2-(3-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl]methyl]piperidinium trifluoroacetate 875259-98-6P
 875260-00-7P, 3-[[6-[Butyl(methyl)amino]-2-(3-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl]methyl]-1-ethylpiperidinium trifluoroacetate
 875260-02-9P, 6-[Butyl(methyl)amino]-3-[[1-(2-methoxyethyl)pyrrolidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875260-03-0P,
 6-[Butyl(methyl)amino]-2-(2-methoxyphenyl)-3-[[1-(4,4,4-trifluorobutyl)pyrrolidin-3-yl]methyl]quinazolin-4(3H)-one 875260-05-2P, 6-[Butyl(methyl)amino]-3-[[1-(cyclopropylmethyl)pyrrolidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875260-07-4P,
 6-[Butyl(methyl)amino]-3-[(1-isobutylpyrrolidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875260-09-6P, 3-[[6-[Butyl(methyl)amino]-2-(3-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl]methyl]-1-methylpiperidinium trifluoroacetate 875260-10-9P, 3-[[6-[Butyl(methyl)amino]-2-(2-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl]methyl]-1-ethylpiperidinium chloride 875260-11-0P, 6-[Butyl(methyl)amino]-3-[[1-isobutylpiperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875260-13-2P
 , 3-[[6-[Butyl(methyl)amino]-2-(2-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl]methyl]-1-(2-methoxyethyl)piperidinium trifluoroacetate

875260-15-4P, 6-[Butyl(methyl)amino]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875260-16-5P, (S)-6-(2,2-Difluoroethoxy)-2-(2-methylphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875260-17-6P,
 (S)-3-[(1-Cyclobutylpiperidin-3-yl)methyl]-6-(cyclopropylmethoxy)-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-18-7P,
 (S)-3-[(1-Cyclobutylpiperidin-3-yl)methyl]-6-isobutoxy-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-19-8P,
 (S)-3-[(1-Cyclobutylpiperidin-3-yl)methyl]-6-(2,2-difluoroethoxy)-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-20-1P,
 (S)-3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(2,2,3,3-tetrafluoropropoxy)quinazolin-4(3H)-one 875260-21-2P,
 6-(Cyclopropylmethoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-22-3P,
 (S)-3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(2,2,2-trifluoroethoxy)quinazolin-4(3H)-one 875260-23-4P,
 (S)-6-(2,2-Difluoroethoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-24-5P,
 (S)-6-Isopropoxy-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-25-6P,
 (S)-2-(2-Methylphenyl)-3-[(piperidin-3-yl)methyl]-6-[[4-(trifluoromethyl)pyridin-2-yl]oxy]quinazolin-4(3H)-one
 875260-26-7P, (S)-6-(2,2-Difluoroethoxy)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-27-8P,
 (S)-3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(2,2,2-trifluoroethoxy)quinazolin-4(3H)-one 875260-28-9P,
 (S)-6-[(5-Chloropyridin-2-yl)oxy]-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-29-0P,
 (S)-3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[[4-(trifluoromethyl)pyridin-2-yl]oxy]quinazolin-4(3H)-one
 875260-30-3P, (S)-6-(Difluoromethoxy)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-31-4P,
 (S)-3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[(2,2,3,3-tetrafluoropropyl)oxy]quinazolin-4(3H)-one 875260-32-5P,
 (S)-3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[(pyridin-2-yl)oxy]quinazolin-4(3H)-one 875260-34-7P,
 3-[(1-(Cyclopropylmethyl)piperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)quinazolin-4(3H)-one 875260-35-8P,
 3-[(1-(Cyclobutylmethyl)piperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)quinazolin-4(3H)-one 875260-36-9P,
 3-[(1-Cyclopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)quinazolin-4(3H)-one 875260-37-0P,
 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)quinazolin-4(3H)-one 875260-38-1P,
 3-[(1-Cyclobutylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)quinazolin-4(3H)-one 875260-39-2P,
 3-[(1-(Cyclobutylmethyl)piperidin-3-yl)methyl]-6-(4-fluorophenoxy)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875260-47-2P,
 2-[2-(Difluoromethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]-6-(2-methoxyphenoxy)quinazolin-4(3H)-one 875260-48-3P,
 (R)-6-(4-Fluorophenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-49-4P,
 (S)-6-(4-Fluorophenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-55-2P,
 2-(3-Methoxyphenyl)-6-phenoxy-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875260-56-3P, 3-[(1-Isobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-phenoxyquinazolin-4(3H)-one 875260-59-6P,
 6-[(3-Chlorophenyl)amino]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875260-60-9P,
 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-[[4-

methoxyphenyl)amino]quinazolin-4(3H)-one 875260-61-0P,
 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-[(2-methoxyphenyl)amino]quinazolin-4(3H)-one 875260-62-1P,
 6-[(4-Fluorophenyl)(propyl)amino]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-63-2P,
 6-[(4-Fluorophenyl)(pentyl)amino]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-64-3P,
 2-[2-(Difluoromethoxy)phenyl]-6-(4-fluorophenoxy)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875260-65-4P,
 6-(4-Fluorophenoxy)-2-(2-methylphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875260-67-6P,
 6-(4-Fluoro-2-methylphenoxy)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875260-71-2P,
 2-[2-(Difluoromethoxy)phenyl]-6-(4-fluorophenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875260-72-3P,
 6-(4-Fluorophenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875260-74-5P,
 6-(4-Fluoro-2-methylphenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875260-78-9P,
 3-[(1-Isopropylpiperidin-3-yl)methyl]-6-(3-methoxyphenoxy)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875260-79-0P,
 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-[(2-methylphenyl)oxy]quinazolin-4(3H)-one 875260-80-3P,
 6-[(2-Ethylphenyl)oxy]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875260-81-4P,
 6-(5-Chloro-2-methylphenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875260-82-5P,
 6-(4-Chloro-2-methylphenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875260-83-6P,
 6-(2,5-Dimethylphenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875260-94-9P,
 (S)-6-(4-Chlorophenyl)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875260-95-0P,
 (R)-6-(4-Chlorophenyl)-3-[(piperidin-3-yl)methyl]-2-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one monohydrochloride 875260-96-1P, (S)-6-(4-Chlorophenyl)-3-[(piperidin-3-yl)methyl]-2-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one monohydrochloride 875260-97-2P, (S)-6-(4-Chlorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875260-98-3P, (S)-3-[(1-Ethylpiperidin-3-yl)methyl]-6-phenyl-2-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875260-99-4P, (R)-6-(4-Chlorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875261-00-0P, (R)-3-[(1-Ethylpiperidin-3-yl)methyl]-6-phenyl-2-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875261-01-1P, 6-(4-Chlorophenyl)-2-(2-methylphenyl)-3-[[1-[2-(1H-pyrrol-1-yl)ethyl]piperidin-3-yl)methyl]quinazolin-4(3H)-one 875261-03-3P, 6-(4-Chlorophenyl)-3-[(1-cyclopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875261-04-4P, 6-(4-Chlorophenyl)-3-[[1-(2-methoxyethyl)piperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875261-05-5P, 6-(4-Chlorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875261-06-6P, 6-(4-Chlorophenyl)-3-[(1-cyclobutylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875261-11-3P, (S)-6-(4-Chlorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875261-12-4P, 6-(4-Chlorophenyl)-3-[[1-(cyclopropylmethyl)piperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875261-13-5P, 6-(4-Chlorophenyl)-3-[(1-isobutylpiperidin-3-yl)methyl]-2-(2-

methylphenyl)quinazolin-4(3H)-one 875261-14-6P,
 6-(2,4-Difluorophenyl)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875261-15-7P,
 (S)-6-(2,4-Difluorophenyl)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875261-17-9P,
 6-(4-Fluorophenyl)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate 875261-19-1P,
 6-(3-Chlorophenyl)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate 875261-22-6P,
 6-(2,4-Difluorophenyl)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate 875261-23-7P,
 3-[[6-(4-Chlorophenyl)-2-(2-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl]methyl]pyrrolidinium chloride 875261-25-9P,
 6-(4-Chlorophenyl)-3-[(1-isopropylpyrrolidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-27-1P,
 6-(4-Chlorophenyl)-3-[[1-(cyclobutylmethyl)pyrrolidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-29-3P,
 6-(4-Chlorophenyl)-3-[[1-(1-cyclohexylmethyl)pyrrolidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-31-7P,
 6-(4-Chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylbutyl)pyrrolidin-3-yl]methyl]quinazolin-4(3H)-one monotrifluoroacetate 875261-33-9P,
 6-(4-Chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(4,4,4-trifluorobutyl)pyrrolidin-3-yl]methyl]quinazolin-4(3H)-one monotrifluoroacetate 875261-35-1P,
 6-(4-Chlorophenyl)-3-[[1-(1-cyclobutylpyrrolidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-37-3P,
 6-(4-Chlorophenyl)-3-[[1-(1-cyclopentylpyrrolidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-39-5P,
 6-(4-Chlorophenyl)-3-[[1-(1-ethylbutyl)pyrrolidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-41-9P,
 6-(4-Chlorophenyl)-3-[[1-(1-isobutylpyrrolidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-42-0P,
 (R)-2-(2-Methoxyphenyl)-6-phenyl-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875261-43-1P,
 (R)-6-(2,4-Difluorophenyl)-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875261-44-2P,
 3-[(Azetidin-3-yl)methyl]-6-(4-chlorophenyl)-2-(2-methylphenyl)quinazolin-4(3H)-one 875261-45-3P,
 6-(4-Chlorophenyl)-3-[[1-(1-isopropylazetidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875261-49-7P,
 (S)-6-(4-Chlorophenyl)-3-[[1-(1-cyclopropylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-51-1P,
 6-(4-Chlorophenyl)-3-[[1-(1-isobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-53-3P,
 6-(4-Chlorophenyl)-3-[[1-(1-cyclohexylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-55-5P,
 6-(4-Chlorophenyl)-3-[[1-(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-56-6P,
 (S)-6-(2,4-Difluorophenyl)-3-[[1-(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875261-58-8P,
 6-(3-Chlorophenyl)-3-[[1-(1-cyclohexylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-60-2P,
 6-(3-Chlorophenyl)-3-[[1-(1-cyclopentylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-62-4P,
 3-[(1-sec-Butylpiperidin-3-yl)methyl]-6-(3-chlorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875261-64-6P,
 3-[[1-(1-cyclohexylpiperidin-3-yl)methyl]-6-(4-

fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-66-8P, 3-[[1-(Cyclopentylpiperidin-3-yl)methyl]-6-(4-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-68-0P, 3-[[1-(sec-Butylpiperidin-3-yl)methyl]-6-(4-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-70-4P, 3-[[1-(2-Ethylbutyl)piperidin-3-yl)methyl]-6-(4-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-72-6P, 6-(3-Chlorophenyl)-3-[[1-(2-ethylbutyl)piperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-74-8P, 6-(4-Fluorophenyl)-3-[[1-(1-isopropylpiperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-76-0P, 6-(3-Chlorophenyl)-3-[[1-(1-isopropylpiperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-78-2P, 3-[[1-(1-Ethylpropyl)piperidin-3-yl)methyl]-6-(4-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-80-6P, 6-(3-Chlorophenyl)-3-[[1-(1-ethylpropyl)piperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-82-8P, 6-(4-Fluorophenyl)-3-[[1-(1-isobutylpiperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-84-0P, 6-(3-Chlorophenyl)-3-[[1-(1-isobutylpiperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-86-2P, 3-[[1-(Cyclobutylmethyl)piperidin-3-yl)methyl]-6-(4-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-88-4P, 6-(3-Chlorophenyl)-3-[[1-(cyclobutylmethyl)piperidin-
 3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-90-8P, 3-[[1-(Cyclohexylmethyl)piperidin-3-yl)methyl]-6-(4-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-92-0P, 6-(4-Fluorophenyl)-3-[[1-(2-methoxyethyl)piperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-94-2P, 6-(3-Chlorophenyl)-3-[[1-(2-methoxyethyl)piperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-96-4P, 6-(3-Fluorophenyl)-3-[[1-(1-isobutylpiperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875261-98-6P, 3-[[1-(2-Ethylbutyl)piperidin-3-yl)methyl]-6-(3-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-00-3P, 3-[[1-(Cyclobutylmethyl)piperidin-3-yl)methyl]-6-(3-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-02-5P, 6-(3-Fluorophenyl)-3-[[1-(1-isopropylpiperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-04-7P, 3-[[1-(1-Ethylpropyl)piperidin-3-yl)methyl]-6-(3-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-06-9P, 3-[[1-(Cyclopropylpiperidin-3-yl)methyl]-6-(3-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-08-1P, 3-[[1-(Cyclopentylpiperidin-3-yl)methyl]-6-(3-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-10-5P, 3-[[1-(Cyclohexylpiperidin-3-yl)methyl]-6-(3-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-12-7P, 6-(3-Fluorophenyl)-3-[[1-(2-methoxyethyl)piperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-14-9P, 3-[[1-(Cyclobutylpiperidin-3-yl)methyl]-6-(3-
 fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-16-1P, (R)-6-(4-Chlorophenyl)-3-[[1-(1-isobutylpiperidin-3-
 yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-18-3P, (R)-6-(4-Chlorophenyl)-3-[[1-(1-
 (cyclobutylmethyl)piperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-
 4(3H)-one monotrifluoroacetate 875262-20-7P,
 (R)-6-(4-Chlorophenyl)-3-[[1-(1-isopropylpiperidin-3-yl)methyl]-2-(2-
 methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-22-9P, 6-(2,4-Difluorophenyl)-3-[[1-(2-
 methoxyethyl)piperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-

one monotrifluoroacetate 875262-24-1P,
 6-(2,4-Difluorophenyl)-3-[(1-isobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-26-3P, 6-(2,4-Difluorophenyl)-3-[[1-(2-ethylbutyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-28-5P 875262-30-9P,
 3-[(1-Cyclobutylpiperidin-3-yl)methyl]-6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-32-1P, 3-[(1-Cyclopentylpiperidin-3-yl)methyl]-6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-34-3P,
 3-[(1-Cyclohexylpiperidin-3-yl)methyl]-6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-36-5P, 6-(2,4-Difluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-38-7P, 6-(2,4-Difluorophenyl)-3-[[1-(1-ethylpropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-39-8P,
 6-(4-Chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3-methylbutyl)piperidin-3-yl]methyl]quinazolin-4(3H)-one 875262-41-2P,
 6-(4-Chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(4,4,4-trifluorobutyl)piperidin-3-yl]methyl]quinazolin-4(3H)-one monotrifluoroacetate 875262-43-4P,
 6-(4-Chlorophenyl)-3-[[1-(2-ethylbutyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-45-6P, 6-(4-Chlorophenyl)-3-[[1-(cyclohexylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875262-46-7P, (R)-3-[(1-Isobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875262-47-8P,
 (R)-3-[[1-(2-Ethylbutyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875262-48-9P,
 (R)-3-[[1-(2-Methoxyethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875262-49-0P,
 (R)-3-[[1-(Cyclopropylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875262-50-3P,
 (R)-3-[[1-(Cyclobutylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875262-51-4P,
 (R)-3-[(1-Cyclobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875262-52-5P,
 (R)-3-[(1-Cyclopentylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinazolinones useful for regulation of glucose homeostasis and food intake)


RN 875258-65-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875258-64-3

CME C26 H34 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875258-67-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875258-66-5

CMF C28 H38 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875258-69-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-[(1-methyl-3-piperidinyl)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875258-68-7
CMF C27 H36 N4 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875258-70-1 CAPLUS
CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-3-[[1-(cyclopropylmethyl)-3-piperidinyl)methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875258-71-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-[[1-(4,4,4-trifluorobutyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875258-73-4 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 875258-75-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(2-methylpropoxy)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875258-76-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(cyclobutylloxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875258-78-9 CAPLUS


CN 4(3H)-Quinazolinone, 6-[(3-chloro-2-pyridinyl)oxy]-3-[[1-(3S)-1-ethyl-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 875258-79-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-[2-hydroxy-1-(hydroxymethyl)ethyl]3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)- (CA INDEX NAME)



RN 875258-80-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-ethyl-3-piperidinyl)methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 875258-82-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-ethyl-3-piperidinyl)methyl]-6-methoxy-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 875258-81-4

CMF C24 H29 N3 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 875258-84-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl)methyl]- (CA INDEX NAME)




RN 875258-94-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-[ethyl(4-fluorophenyl)amino]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875258-96-1 CAPLUS

CN Benzenesulfonamide, N-[3-[[1-ethyl-3-piperidinyl]methyl]-3,4-dihydro-2-(2-methoxyphenyl)-4-oxo-6-quinazolinyl]- (CA INDEX NAME)



RN 875259-01-1 CAPLUS


CN 4(3H)-Quinazolinone, 6-(3-chlorophenoxy)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875259-08-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[(3R)-1-ethyl-3-piperidinylmethyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875259-09-9 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[(3R)-1-ethyl-3-piperidinylmethyl]-2-(2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 875259-10-2 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-hydroxyethyl)-3-piperidinylmethyl]-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875259-11-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/ 582,823




● HCl

RN 875259-13-5 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-cyclopentyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-12-4
CMF C32 H34 Cl N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875259-15-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4'-chloro[1,1'-biphenyl]-4-yl)-3-[[3-(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-14-6
CMF C35 H34 Cl N3 O2

10/ 582,823

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 875259-18-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(1,3-benzodioxol-5-yl)-2-[2-(difluoromethoxy)phenyl]-3-(3-piperidinylmethyl)- (CA INDEX NAME)



RN 875259-20-4 CAPLUS


CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-19-1

CMF C29 H30 Cl N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875259-22-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-21-5

CMF C31 H32 Cl N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875259-24-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(4-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-23-7

CMF C29 H30 Cl N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875259-26-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)-3-piperidinyl)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-25-9

CMF C30 H29 F4 N3 O2



CM 2

CRN 76-05-1

10/ 582,823

CMF C2 H F3 O2




RN 875259-28-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl)methyl]-2-(2-methylphenyl)-6-(3-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-27-1

CMF C31 H35 N3 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 875259-35-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-[4-(difluoromethoxy)phenyl]-3-[(1-ethyl-3-piperidinyl)methyl]- (CA INDEX NAME)




RN 875259-48-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-47-5

CMF C23 H27 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875259-50-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-butyl-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-49-7

CMF C27 H35 N3 O2




CM 2

10/ 582,823

CRN 76-05-1
CMF C2 H F3 O2




RN 875259-51-1 CAPLUS
CN 4(3H)-Quinazolinone, 6-butyl-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)-
(CA INDEX NAME)



RN 875259-53-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(1-ethyl-3-piperidinyl)methyl]-6-hexyl-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-52-2
CMF C29 H39 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875259-55-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-[4-(3-chloro-2-thienyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-54-4

CMF C31 H31 Cl N4 O S2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 875259-57-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-cyclopentyl-2-[4-(difluoromethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875259-59-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2-cyclopropylethyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875259-60-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-pentyl- (CA INDEX NAME)



RN 875259-64-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-acetyl-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875259-69-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-[[1-(3-methylbutyl)-3-pyrrolidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-68-0

CMF C30 H42 N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 875259-71-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-3-[[4-(1-methylethyl)-2-morpholinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875259-73-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[4-(1-methylethyl)-2-morpholinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875259-74-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[4-ethyl-2-morpholinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875259-75-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-ethyl-1,2,5,6-tetrahydro-3-pyridinyl)methyl]-6-(4-fluorophenoxy)-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875259-76-0 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-1,2,5,6-tetrahydro-3-pyridinyl)methyl]-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875259-77-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-6-(4-chlorophenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875259-79-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875259-80-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-methoxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 875259-82-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-phenoxy- (CA INDEX NAME)




RN 875259-83-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(phenylamino)- (CA INDEX NAME)




RN 875259-84-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875259-85-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)




RN 875259-86-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2,4-bis(2-hydroxyethoxy)phenyl]-6-(phenylamino)-3-(3-piperidinylmethyl)- (CA INDEX NAME)



RN 875259-87-3 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2,4-bis(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-(3-piperidinylmethyl)- (CA INDEX NAME)



RN 875259-88-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2,4-bis(2-hydroxyethoxy)phenyl]-6-(3-chlorophenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)

10/ 582,823



RN 875259-91-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-2-(4-hydroxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875259-94-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-(2-piperidinylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-93-1

CMF C26 H34 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875259-96-4 CAPLUS
CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(3-methoxyphenyl)-3-(2-piperidinylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-95-3
CMF C26 H34 N4 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 875259-98-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-[(1-methyl-4-piperidinyl)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875259-97-5
CMF C27 H36 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2





RN 875260-00-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-3-[(1-ethyl-3-piperidiny)methyl]-2-(3-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875259-99-7

CMF C28 H38 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875260-02-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-3-[[1-(2-methoxyethyl)-3-pyrrolidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
 (CA INDEX NAME)

CM 1

CRN 875260-01-8
 CMF C28 H38 N4 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 875260-03-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-[[1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl)methyl]- (CA INDEX NAME)




RN 875260-05-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-3-[[1-(cyclopropylmethyl)-3-pyrrolidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)

(CA INDEX NAME)

CM 1

CRN 875260-04-1

CMF C29 H38 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875260-07-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-pyrrolidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875260-06-3

CMF C29 H40 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/ 582,823



RN 875260-09-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(3-methoxyphenyl)-3-[(1-methyl-3-piperidinyl)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875260-08-5
CMF C27 H36 N4 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875260-10-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 875260-11-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875260-13-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875260-12-1

CMF C29 H40 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875260-15-4 CAPLUS
CN 4(3H)-Quinazolinone, 6-(butylmethylamino)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875260-14-3
CMF C29 H40 N4 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 875260-16-5 CAPLUS
CN 4(3H)-Quinazolinone, 6-(2,2-difluoroethoxy)-2-(2-methylphenyl)-3-[(3S)-3-piperidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-17-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3S)-1-cyclobutyl-3-piperidinyl]methyl]-6-(cyclopropylmethoxy)-2-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-18-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3S)-1-cyclobutyl-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(2-methylpropoxy)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-19-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3S)-1-cyclobutyl-3-piperidinyl]methyl]-6-(2,2-difluoroethoxy)-2-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-20-1 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(2,2,3,3-tetrafluoropropoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 875260-21-2 CAPLUS


CN 4(3H)-Quinazolinone, 6-(cyclopropylmethoxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875260-22-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-23-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2,2-difluoroethoxy)-3-[(3S)-1-(1-methylethyl)-3-piperidinylmethyl]-2-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-24-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(1-methylethoxy)-3-[(3S)-1-(1-methylethyl)-3-piperidinylmethyl]-2-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-25-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methylphenyl)-3-[(3S)-3-piperidinylmethyl]-6-[[4-(trifluoromethyl)-2-pyridinyl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-26-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2,2-difluoroethoxy)-3-[(3S)-1-ethyl-3-piperidinylmethyl]-2-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-27-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(3S)-1-ethyl-3-piperidinylmethyl]-2-(2-methylphenyl)-6-(2,2-trifluoroethoxy)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-28-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-[(5-chloro-2-pyridinyl)oxy]-3-[(3S)-1-ethyl-3-piperidinylmethyl]-2-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-29-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3S)-1-ethyl-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[[4-(trifluoromethyl)-2-pyridinyl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-30-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(difluoromethoxy)-3-[[[(3S)-1-ethyl-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-31-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3S)-1-ethyl-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(2,2,3,3-tetrafluoropropoxy)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-32-5 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-ethyl-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(2-pyridinyloxy)- (CA INDEX NAME)

Absolute stereochemistry.




RN 875260-34-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 875260-35-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 875260-36-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclopropyl-3-piperidinyl)methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 875260-37-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 875260-38-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidinyl)methyl]-2-(2-methylphenyl)-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 875260-39-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-6-(4-fluorophenoxy)-2-(2-methoxyphenyl)- (CA INDEX NAME)



RN 875260-47-2 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2-(difluoromethoxy)phenyl]-6-(2-methoxyphenoxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875260-48-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-49-4 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 875260-55-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-methoxyphenyl)-6-phenoxy-3-(3-piperidinylmethyl)-
(CA INDEX NAME)




RN 875260-56-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]-6-phenoxy- (CA INDEX NAME)




RN 875260-59-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-[(3-chlorophenyl)amino]-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875260-60-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-[(4-methoxyphenyl)amino]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875260-61-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-[(2-methoxyphenyl)amino]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875260-62-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-[(4-fluorophenyl)propylamino]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875260-63-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-[(4-fluorophenyl)pentylamino]-3-[1-(1-methylethyl)-3-piperidinylmethyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875260-64-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-(difluoromethoxy)phenyl]-6-(4-fluorophenoxy)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875260-65-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-2-(2-methylphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875260-67-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-fluoro-2-methylphenoxy)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875260-71-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-(difluoromethoxy)phenyl]-6-(4-fluorophenoxy)-3-
 [[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875260-72-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-fluorophenoxy)-3-[[1-(1-methylethyl)-3-
 piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875260-74-5 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-fluoro-2-methylphenoxy)-2-(2-methoxyphenyl)-3-
 [[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875260-78-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-methoxyphenoxy)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875260-79-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-6-(2-methylphenoxy)- (CA INDEX NAME)




RN 875260-80-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2-ethylphenoxy)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875260-81-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(5-chloro-2-methylphenoxy)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875260-82-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chloro-2-methylphenoxy)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875260-83-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-(2,5-dimethylphenoxy)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875260-94-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-[(3S)-3-piperidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-95-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(3R)-3-piperidinylmethyl]-2-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 875260-96-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(3S)-3-piperidinylmethyl]-2-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

10/ 582,823

RN 875260-97-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[(3S)-1-ethyl-3-piperidinylmethyl]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-98-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3S)-1-ethyl-3-piperidinylmethyl]-6-phenyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875260-99-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[(3R)-1-ethyl-3-piperidinylmethyl]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 875261-00-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3R)-1-ethyl-3-piperidinylmethyl]-6-phenyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


10/ 582,823

Absolute stereochemistry.




RN 875261-01-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methylphenyl)-3-[[1-[2-(1H-pyrrol-1-yl)ethyl]-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875261-03-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclopentyl-3-piperidinyl)methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875261-04-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875261-05-5 CAPLUS

RN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875261-06-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclobutyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875261-11-3 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(3S)-1-ethyl-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 875261-12-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875261-13-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methylphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875261-14-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)



RN 875261-15-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-3-[(3S)-3-piperidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875261-17-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-fluorophenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-16-8
 CMF C27 H26 F N3 O2



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 875261-19-1 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-18-0
 CMF C27 H26 Cl N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-22-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-14-6

CMF C27 H25 F2 N3 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



10/ 582,823

RN 875261-23-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-(3-pyrrolidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 875261-25-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-pyrrolidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-24-8

CMF C29 H30 Cl N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-27-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclobutylmethyl)-3-pyrrolidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

10/ 582,823

CRN 875261-26-0
CMF C31 H32 Cl N3 O2




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 875261-29-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclohexylmethyl)-3-pyrrolidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1
CRN 875261-28-2
CMF C33 H36 Cl N3 O2



CM 2
CRN 76-05-1
CMF C2 H F3 O2


10/ 582,823



RN 875261-31-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylbutyl)-3-pyrrolidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-30-6
CMF C31 H34 Cl N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875261-33-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(4,4,4-trifluorobutyl)-3-pyrrolidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-32-8
CMF C30 H29 Cl F3 N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-35-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-cyclobutyl-3-pyrrolidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875261-34-0

CMF C30 H30 Cl N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/ 582,823


RN 875261-37-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclopentyl-3-pyrrolidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875261-36-2

CMF C31 H32 Cl N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-39-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-ethylbutyl)-3-pyrrolidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875261-38-4

CMF C32 H36 Cl N3 O2



CM 2

CRN 76-05-1

10/ 582,823


CMF C2 H F3 O2



RN 875261-41-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-pyrrolidiny]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-40-8
CMF C30 H32 Cl N3 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 875261-42-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-phenyl-3-[(3R)-3-piperidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875261-43-1 CAPLUS


CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-3-[(3R)-3-piperidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 875261-44-2 CAPLUS


CN 4(3H)-Quinazolinone, 3-(3-azetidinylmethyl)-6-(4-chlorophenyl)-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875261-45-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-methylethyl)-3-azetidiny]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-53-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875261-52-2

CMF C32 H34 Cl N3 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 875261-55-5 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-54-4
 CMF C30 H32 Cl N3 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 875261-56-6 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-3-[(1S)-1-(1-methylethyl)-3-piperidinyl]methyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 875261-58-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-3-[(1-cyclohexyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

10/ 582,823

CM 1

CRN 875261-57-7

CMF C33 H36 Cl N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-60-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-((3-chlorophenyl)-3-[(1-cyclopentyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-59-9

CMF C32 H34 Cl N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875261-62-4 CAPLUS
CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylpropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-61-3
CMF C31 H34 Cl N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875261-64-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(1-cyclohexyl-3-piperidinyl)methyl]-6-(4-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-63-5
CMF C33 H36 F N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-66-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclopentyl-3-piperidinyl)methyl]-6-(4-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-65-7

CMF C32 H34 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/ 582,823


RN 875261-68-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylpropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-67-9

CMF C31 H34 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-70-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(2-ethylbutyl)-3-piperidinyl]methyl]-6-(4-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-69-1

CMF C33 H38 F N3 O2



CM 2

CRN 76-05-1

10/ 582,823


CMF C2 H F3 O2



RN 875261-72-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-3-[[1-(2-ethylbutyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-71-5
CMF C33 H38 Cl N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875261-74-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-73-7
CMF C30 H32 F N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-76-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-75-9

CMF C30 H32 Cl N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875261-78-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-6-(4-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-77-1
CMF C32 H36 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875261-80-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-79-3
CMF C32 H36 Cl N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-82-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-81-7

CMF C31 H34 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875261-84-0 CAPLUS
CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-83-9
CMF C31 H34 Cl N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875261-86-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-6-(4-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-85-1
CMF C32 H34 F N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-88-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-87-3

CMF C32 H34 Cl N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/ 582,823


RN 875261-90-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclohexylmethyl)-3-piperidinyl]methyl]-6-(4-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-89-5

CMF C34 H38 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-92-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-91-9

CMF C30 H32 F N3 O3



CM 2

CRN 76-05-1

10/ 582,823


CMF C2 H F3 O2



RN 875261-94-2 CAPLUS
CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-93-1
CMF C30 H32 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875261-96-4 CAPLUS
CN 4(3H)-Quinazolinone, 6-(3-fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-95-3
CMF C31 H34 F N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875261-98-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(2-ethylbutyl)-3-piperidinyl]methyl]-6-(3-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-97-5

CMF C33 H38 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875262-00-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-6-(3-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875261-99-7

CMF C32 H34 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875262-02-5 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(3-fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-01-4

CMF C30 H32 F N3 O2



CM 2

10/ 582,823


CRN 76-05-1
CMF C2 H F3 O2



RN 875262-04-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(1-ethylpropyl)-3-piperidinyl)methyl]-6-(3-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-03-6
CMF C32 H36 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875262-06-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(1-cyclopropyl-3-piperidinyl)methyl]-6-(3-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-05-8
CMF C30 H30 F N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875262-08-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclopentyl-3-piperidinyl)methyl]-6-(3-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-07-0

CMF C32 H34 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/ 582,823


RN 875262-10-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclohexyl-3-piperidinyl)methyl]-6-(3-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-09-2

CMF C33 H36 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875262-12-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-fluorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-11-6

CMF C30 H32 F N3 O3



CM 2

CRN 76-05-1

10/ 582,823


CMF C2 H F3 O2



RN 875262-14-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidinyl)methyl]-6-(3-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-13-8
CMF C31 H32 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875262-16-1 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-[[(3R)-1-(2-methylpropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-15-0
CMF C31 H34 Cl N3 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875262-18-3 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[[(3R)-1-(cyclobutylmethyl)-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875262-17-2

CMF C32 H34 Cl N3 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875262-20-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-[[(3R)-1-(1-methylethyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-19-4
CMF C30 H32 Cl N3 O2

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 875262-22-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-21-8
CMF C30 H31 F2 N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875262-24-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-3-[(1-(2-methylpropyl)-3-piperidinyl)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-23-0

CMF C31 H33 F2 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875262-26-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-3-[[1-(2-ethylbutyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875262-25-2
CMF C33 H37 F2 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875262-28-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-27-4
CMF C32 H33 F2 N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875262-30-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidinyl)methyl]-6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-29-6

CMF C31 H31 F2 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875262-32-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(1-cyclopentyl-3-piperidinyl)methyl]-6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-31-0
CMF C32 H33 F2 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875262-34-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(1-cyclohexyl-3-piperidinyl)methyl]-6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-33-2
CMF C33 H35 F2 N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875262-36-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-35-4

CMF C30 H31 F2 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875262-38-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875262-37-6

CMF C32 H35 F2 N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 875262-39-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3-methylbutyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875262-41-2 CAPLUS


10/ 582,823

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(4,4,4-trifluorobutyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-40-1

CMF C31 H31 Cl F3 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875262-43-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-ethylbutyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-42-3

CMF C33 H38 Cl N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875262-45-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclohexylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875262-44-5

CMF C34 H38 Cl N3 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 875262-46-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]-6-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 875262-47-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3R)-1-(2-ethylbutyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 875262-48-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3R)-1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 875262-49-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3R)-1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 875262-50-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3R)-1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 875262-51-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3R)-1-cyclobutyl-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 875262-52-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3R)-1-cyclopentyl-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 875262-53-6P, (R)-3-[(1-Cyclohexylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875262-54-7P, (R)-6-(2,4-Difluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875262-55-8P, 6-(4-Chlorophenyl)-3-[(1-(2-fluoroethyl)piperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875262-60-5P, 6-(4-Chlorophenyl)-2-(2-methylphenyl)-3-[(1-(3,3,3-trifluoropropyl)piperidin-3-yl)methyl]quinazolin-4(3H)-one 875262-90-1P, 6-(1,3-Benzodioxol-5-yl)-2-[2-(difluoromethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875262-92-3P, 3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one monotrifluoroacetate 875262-94-5P, 6-(2-Chlorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875262-96-7P, 6-(4-Chlorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875262-98-9P, 3-[(1-Ethylpiperidin-3-yl)methyl]-6-(3-fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-00-6P, 3-[(1-Ethylpiperidin-3-yl)methyl]-6-(4-fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-02-8P, 3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-04-0P, 3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-06-2P, 6-(3,4-Difluorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-08-4P, 6-(2,4-Difluorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-10-8P, 6-(3-Chloro-4-fluorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-12-0P, 6-(3,4-Dichlorophenyl)-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-13-1P, 3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-[3-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875263-14-2P, 3-[(1-Ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875263-16-4P, 3-[[6-(3-Chlorophenyl)-4-oxo-2-[2-(trifluoromethyl)phenyl]quinazolin-3(4H)-yl]methyl]-1-ethylpiperidinium trifluoroacetate 875263-18-6P, 3-[[6-(3-Chlorophenyl)-4-oxo-2-[2-(trifluoromethoxy)phenyl]quinazolin-3(4H)-yl]methyl]-1-ethylpiperidinium trifluoroacetate 875263-20-0P, 875263-22-2P, 3-[[6-(4-Chlorophenyl)-4-oxo-2-[3-(trifluoromethyl)phenyl]quinazolin-3(4H)-yl]methyl]-1-ethylpiperidinium trifluoroacetate 875263-24-4P, 3-[[6-(4-Chlorophenyl)-4-oxo-2-[4-(trifluoromethyl)phenyl]quinazolin-3(4H)-

yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-26-6P
 875263-28-8P, 3-[[6-(4-Chlorophenyl)-4-oxo-2-[3-(trifluoromethoxy)phenyl]quinazolin-3(4H)-yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-30-2P,
 3-[[6-(4-Chlorophenyl)-4-oxo-2-[4-(trifluoromethoxy)phenyl]quinazolin-3(4H)-yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-32-4P, 3-[[6-(4-Chlorophenyl)-2-(2-methylphenyl)-4-oxoquinazolin-3(4H)-yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-34-6P, 3-[[6-(4-Chlorophenyl)-2-(3-methylphenyl)-4-oxoquinazolin-3(4H)-yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-36-8P, 3-[[6-(4-Chlorophenyl)-2-(2-fluorophenyl)-4-oxoquinazolin-3(4H)-yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-38-0P, 3-[[6-(4-Chlorophenyl)-2-(3-fluorophenyl)-4-oxoquinazolin-3(4H)-yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-40-4P, 3-[[6-(4-Chlorophenyl)-2-(4-fluorophenyl)-4-oxoquinazolin-3(4H)-yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-46-0P, 3-[[2-(2-Chlorophenyl)-6-(4-chlorophenyl)-4-oxoquinazolin-3(4H)-yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-48-2P, 3-[[6-(4-Chlorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-4-oxoquinazolin-3(4H)-yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-50-6P,
 3-[[6-(4-Chlorophenyl)-2-(2,5-difluorophenyl)-4-oxoquinazolin-3(4H)-yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-52-8P,
 3-[[6-(4-Chlorophenyl)-2-(4-fluoro-3-methylphenyl)-4-oxoquinazolin-3(4H)-yl)methyl]-1-ethylpiperidinium trifluoroacetate 875263-62-0P,
 6-Bromo-3-[[1-(1-ethylpropyl)piperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875263-63-1P,
 6-Bromo-3-[[1-(isopropyl)piperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875263-64-2P,
 3-[[1-(Isobutyl)piperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875263-65-3P,
 3-[[1-(Cyclobutyl)piperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875263-66-4P,
 3-[[1-(2-Methoxyethyl)piperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875263-67-5P,
 3-[[1-(Cyclopentyl)piperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875263-69-7P,
 6-(4-Fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)piperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate 875263-71-1P,
 6-(3-Chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)piperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate 875263-73-3P,
 6-(3-Chloro-4-fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)piperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate 875263-75-5P,
 2-(2-Methoxyphenyl)-6-(3-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)piperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate 875263-77-7P 875263-79-9P,
 6-(3,5-Difluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)piperidin-3-yl)methyl]quinazolin-4(3H)-one monotrifluoroacetate 875263-81-3P,
 3-[[1-(Cyclopropylmethyl)piperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one monotrifluoroacetate 875263-83-5P,
 3-[[1-(Cyclopropylmethyl)piperidin-3-yl)methyl]-6-(3-fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-85-7P, 3-[[1-(Cyclopropylmethyl)piperidin-3-yl)methyl]-6-(4-fluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-87-9P, 6-(4-Chlorophenyl)-3-[[1-(cyclopropylmethyl)piperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-

4(3H)-one monotrifluoroacetate 875263-89-1P,
 6-(3-Chloro-4-fluorophenyl)-3-[[1-(cyclopropylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-91-5P, 3-[[1-(Cyclopropylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-93-7P,
 3-[[1-(Cyclopropylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-95-9P, 3-[[1-(Cyclopropylmethyl)piperidin-3-yl]methyl]-6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-97-1P,
 3-[[1-(Cyclopropylmethyl)piperidin-3-yl]methyl]-6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875263-99-3P, 3-[[1-(Cyclopropylmethyl)piperidin-3-yl]methyl]-6-(3,5-difluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-00-9P,
 3-[[1-(Isobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)quinazolin-4(3H)-one 875264-01-0P,
 3-[[1-(Isobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)quinazolin-4(3H)-one 875264-02-1P,
 6-(3,4-Difluorophenyl)-3-[[1-isobutylpiperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-03-2P,
 6-(3,5-Difluorophenyl)-3-[[1-isobutylpiperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-04-3P,
 6-(3-Fluoro-4-methoxyphenyl)-3-[[1-isobutylpiperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-05-4P,
 6-(3-Fluoro-4-methylphenyl)-3-[[1-isobutylpiperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-06-5P,
 6-(3-Chloro-4-fluorophenyl)-3-[[1-isobutylpiperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-07-6P,
 3-[[1-(Isobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-(3-(trifluoromethyl)phenyl)quinazolin-4(3H)-one 875264-08-7P,
 6-(3,4-Dichlorophenyl)-3-[[1-isobutylpiperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-09-8P,
 6-(4-Ethoxyphenyl)-3-[[1-isobutylpiperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-10-1P,
 3-[[1-(Cyclobutylpiperidin-3-yl)methyl]-6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-11-2P,
 3-[[1-(Cyclobutylpiperidin-3-yl)methyl]-6-(3,5-difluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-12-3P,
 6-(3-Chloro-4-fluorophenyl)-3-[[1-cyclobutylpiperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-13-4P,
 3-[[1-(Cyclobutylpiperidin-3-yl)methyl]-6-(3-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-14-5P,
 3-[[1-(Cyclobutylpiperidin-3-yl)methyl]-6-(3-fluoro-4-methylphenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-15-6P,
 3-[[1-(Cyclobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-(3-(trifluoromethyl)phenyl)quinazolin-4(3H)-one 875264-16-7P,
 3-[[1-(Cyclobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one 875264-17-8P,
 3-[[1-(Cyclobutylpiperidin-3-yl)methyl]-6-(4-ethoxyphenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-18-9P,
 3-[[1-(2-Methoxyethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)quinazolin-4(3H)-one 875264-19-0P,
 3-[[1-(2-Methoxyethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)quinazolin-4(3H)-one 875264-20-3P,
 6-(3,4-Difluorophenyl)-3-[[1-(2-methoxyethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-21-4P,
 6-(3,5-Difluorophenyl)-3-[[1-(2-methoxyethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-22-5P,

6-(3-Fluoro-4-methoxyphenyl)-3-[[1-(2-methoxyethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-23-6P,
6-(3-Fluoro-4-methylphenyl)-3-[[1-(2-methoxyethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-24-7P,
6-(3-Chloro-4-fluorophenyl)-3-[[1-(2-methoxyethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-25-8P,
3-[[1-(2-Methoxyethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875264-26-9P,
3-[[1-(2-Methoxyethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-[3-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875264-27-0P,
3-[[1-(1-Ethylpropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-phenylquinazolin-4(3H)-one 875264-28-1P,
3-[[1-(1-Ethylpropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)quinazolin-4(3H)-one 875264-29-2P,
3-[[1-(1-Ethylpropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)quinazolin-4(3H)-one 875264-30-5P,
6-(3,4-Difluorophenyl)-3-[[1-(1-ethylpropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-31-6P,
6-(3,5-Difluorophenyl)-3-[[1-(1-ethylpropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-32-7P,
3-[[1-(1-Ethylpropyl)piperidin-3-yl]methyl]-6-(3-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-33-8P,
3-[[1-(1-Ethylpropyl)piperidin-3-yl]methyl]-6-(3-fluoro-4-methylphenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-34-9P,
6-(3-Chloro-4-fluorophenyl)-3-[[1-(1-ethylpropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-35-0P,
6-(4-Ethoxyphenyl)-3-[[1-(1-ethylpropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-36-1P,
3-[[1-(1-Cyclopentyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)quinazolin-4(3H)-one 875264-37-2P,
3-[[1-(1-Cyclopentyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)quinazolin-4(3H)-one 875264-38-3P,
3-[[1-(1-Cyclopentyl)piperidin-3-yl]methyl]-6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-39-4P,
3-[[1-(1-Isopropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)quinazolin-4(3H)-one 875264-40-7P,
3-[[1-(1-Isopropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)quinazolin-4(3H)-one 875264-41-8P,
6-(3-Fluoro-4-methoxyphenyl)-3-[[1-(1-isopropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-42-9P,
3-[[1-(1-Isopropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875264-43-0P,
6-(3-Chloro-4-fluorophenyl)-3-[[1-(1-isopropyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-44-1P,
3-[[1-(1-Cyclobutylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)quinazolin-4(3H)-one 875264-45-2P,
3-[[1-(1-Cyclobutylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)quinazolin-4(3H)-one 875264-46-3P,
3-[[1-(1-Cyclobutylmethyl)piperidin-3-yl]methyl]-6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-47-4P,
3-[[1-(1-Cyclobutylmethyl)piperidin-3-yl]methyl]-6-(3-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-48-5P,
3-[[1-(1-Cyclobutylmethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)-6-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875264-49-6P,
6-(3-Chloro-4-fluorophenyl)-3-[[1-(1-cyclopentyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-50-9P,
6-(3-Chloro-4-fluorophenyl)-3-[[1-(1-cyclopentyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-51-0P,
6-(3,4-Difluorophenyl)-3-[[1-(1-isopropyl)piperidin-3-yl]methyl]-2-(2-

methoxyphenyl)quinazolin-4(3H)-one 875264-52-1P,
 6-(3,5-Difluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-53-2P,
 3-[[1-(Cyclobutylmethyl)piperidin-3-yl)methyl]-6-(3,5-difluorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875264-54-3P,
 3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-(3-thienyl)quinazolin-4(3H)-one 875264-55-4P,
 3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-(4-methyl-2-thienyl)quinazolin-4(3H)-one 875264-56-5P,
 (S)-6-(2-Fluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875264-58-7P,
 6-[4-(Cyclopropylmethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-60-1P, 3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(thien-2-yl)quinazolin-4(3H)-one monotrifluoroacetate 875264-62-3P, 6-(3,4-Dimethoxyphenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-64-5P, 6-(3-Hydroxyphenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-66-7P, 6-(4-Hydroxyphenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-68-9P, 6-(1,3-Benzodioxol-5-yl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-70-3P, 3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(4-vinylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-72-5P, 6-(3-Amino-4-methoxyphenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-74-7P, 3-[(1-isopropylpiperidin-3-yl)methyl]-6-(6-methoxy-pyridin-3-yl)-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-76-9P, 6-(3-Fluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-78-1P 875264-80-5P, 6-(2-Fluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-82-7P, 6-(2-Aminophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-84-9P, 6-(3-Furyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-86-1P, 4-[3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl]benzonitrile monotrifluoroacetate 875264-88-3P, 6-(4-Aminophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-90-7P, 6-(4-Fluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875264-92-9P, 3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[3-(trifluoromethyl)phenyl]quinazolin-4(3H)-one monotrifluoroacetate 875264-94-1P, 3-[3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl]benzonitrile monotrifluoroacetate 875264-96-3P 875265-02-4P, 6-(4-Butylphenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875265-04-6P, 6-(2-Fluorobiphenyl-4-yl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875265-06-8P, 6-(4-Ethylphenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875265-08-0P, 6-(Biphenyl-3-yl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate

875265-10-4P, 6-(5-Isopropyl-2-methoxyphenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one
 monotrifluoroacetate 875265-12-6P,
 3-[(1-Isopropylpiperidin-3-yl)methyl]-6-(2-methoxyphenyl)-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875265-14-8P, 6-(4-tert-Butylphenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875265-16-0P, 6-(2,4-Difluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875265-18-2P, 6-[3-(Hydroxymethyl)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875265-20-6P, 6-(2-Furyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875265-22-8P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-6-(3-methoxyphenyl)-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875265-24-0P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(2-naphthyl)quinazolin-4(3H)-one monotrifluoroacetate
 875265-26-2P
 , 6-[4-(Ethylthio)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875265-28-4P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(methylsulfonyl)phenyl]quinazolin-4(3H)-one monotrifluoroacetate 875265-30-8P,
 6-(4-Isopropylphenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875265-32-0P, [4-[3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl]phenyl]acetonitrile monotrifluoroacetate 875265-34-2P,
 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(4-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875265-36-4P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(3-nitrophenyl)quinazolin-4(3H)-one monotrifluoroacetate
 875266-33-4P, (S)-3-[(1-Ethylpiperidin-3-yl)methyl]-6-(2-fluorophenyl)-2-(2-methylphenyl)quinazolin-4(3H)-one
 875266-82-3P, 2-[4-(Difluoromethoxy)phenyl]-3-[(1-ethylpiperidin-3-yl)methyl]-6-[4-(methylsulfonyl)phenyl]quinazolin-4(3H)-one
 875266-83-4P, 2-[4-(Difluoromethoxy)phenyl]-3-[(1-ethylpiperidin-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]quinazolin-4(3H)-one
 875266-84-5P, 2-[4-(Difluoromethoxy)phenyl]-3-[(1-ethylpiperidin-3-yl)methyl]-6-(3-methoxyphenyl)quinazolin-4(3H)-one 875266-85-6P
 , 2-[4-(Difluoromethoxy)phenyl]-3-[(1-ethylpiperidin-3-yl)methyl]-6-(4-fluorophenyl)quinazolin-4(3H)-one 875266-86-7P,
 2-[4-(Difluoromethoxy)phenyl]-3-[(1-ethylpiperidin-3-yl)methyl]-6-(3-fluorophenyl)quinazolin-4(3H)-one 875266-91-4P,
 3-[[6-(4-Chlorophenyl)-4-oxo-2-[3-(trifluoromethoxy)phenyl]quinazolin-3(4H)-yl]methyl]piperidinium trifluoroacetate 875266-93-6P,
 3-[[6-(4-Chlorophenyl)-4-oxo-2-[4-(trifluoromethoxy)phenyl]quinazolin-3(4H)-yl]methyl]piperidinium trifluoroacetate 875266-95-8P,
 3-[[6-(4-Chlorophenyl)-4-oxo-2-[2-(trifluoromethoxy)phenyl]quinazolin-3(4H)-yl]methyl]piperidinium trifluoroacetate 875266-96-9P,
 6-(4-Chlorophenyl)-3-[[1-(2-methoxyethyl)piperidin-3-yl]methyl]-2-[3-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875266-97-0P,
 6-(4-Chlorophenyl)-3-[[1-(isopropylpiperidin-3-yl)methyl]-2-[3-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875266-98-1P,
 6-(4-Chlorophenyl)-3-[[1-(isobutylpiperidin-3-yl)methyl]-2-[3-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875266-99-2P,
 6-(4-Chlorophenyl)-3-[[1-(cyclopropylmethyl)piperidin-3-yl]methyl]-2-[3-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-00-8P,
 6-(4-Chlorophenyl)-3-[(1-cyclopentylpiperidin-3-yl)methyl]-2-[3-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-01-9P,

6-(4-Chlorophenyl)-3-[[1-(2-methoxyethyl)piperidin-3-yl]methyl]-2-[4-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-02-0P,
 6-(4-Chlorophenyl)-3-[[1-(isopropylpiperidin-3-yl)methyl]-2-[4-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-03-1P,
 6-(4-Chlorophenyl)-3-[[1-(isobutylpiperidin-3-yl)methyl]-2-[4-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-04-2P,
 6-(4-Chlorophenyl)-3-[[1-(cyclopropylmethyl)piperidin-3-yl]methyl]-2-[4-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-05-3P,
 6-(4-Chlorophenyl)-3-[[1-(1-cyclopentylpiperidin-3-yl)methyl]-2-[4-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-06-4P,
 6-(4-Chlorophenyl)-3-[[1-(2-methylbutyl)piperidin-3-yl]methyl]-2-[4-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-07-5P,
 6-(4-Chlorophenyl)-3-[[1-(cyclobutylmethyl)piperidin-3-yl]methyl]-2-[4-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-08-6P,
 6-(4-Chlorophenyl)-3-[[1-(cyclohexylpiperidin-3-yl)methyl]-2-[4-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-09-7P,
 3-[[1-(sec-Butylpiperidin-3-yl)methyl]-6-(4-chlorophenyl)-2-[4-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-10-0P,
 6-(4-Chlorophenyl)-3-[[1-(2-methoxyethyl)piperidin-3-yl]methyl]-2-[2-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-11-1P,
 6-(4-Chlorophenyl)-3-[[1-(cyclobutylmethyl)piperidin-3-yl]methyl]-2-[2-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-12-2P,
 6-(4-Chlorophenyl)-3-[[1-(isobutylpiperidin-3-yl)methyl]-2-[2-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-13-3P,
 3-[[1-(sec-Butylpiperidin-3-yl)methyl]-6-(4-chlorophenyl)-2-[2-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-14-4P,
 6-(4-Chlorophenyl)-3-[[1-(2-methylbutyl)piperidin-3-yl]methyl]-2-[2-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-15-5P,
 6-(4-Chlorophenyl)-3-[[1-(1-ethylpropyl)piperidin-3-yl]methyl]-2-[2-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-16-6P,
 6-(4-Chlorophenyl)-3-[[1-(1-cyclopentylpiperidin-3-yl)methyl]-2-[2-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-17-7P,
 6-(4-Chlorophenyl)-3-[[1-(cyclobutylpiperidin-3-yl)methyl]-2-[2-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-18-8P,
 6-(4-Chlorophenyl)-3-[[1-(2-ethylbutyl)piperidin-3-yl]methyl]-2-[2-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-19-9P,
 6-(4-Chlorophenyl)-3-[[1-(isopropylpiperidin-3-yl)methyl]-2-[2-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 875267-92-8P,
 2-(2-Methoxyphenyl)-6-(4-methoxyphenyl)-3-[[piperidin-3-yl]methyl]quinazolin-4(3H)-one 875267-93-9P,
 6-(4-Chloro-3-methylphenyl)-2-(2-methoxyphenyl)-3-[[piperidin-3-yl]methyl]quinazolin-4(3H)-one 875267-94-0P,
 6-(3-Fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)-3-[[piperidin-3-yl]methyl]quinazolin-4(3H)-one 875267-95-1P,
 2-(2-Methoxyphenyl)-3-[[piperidin-3-yl]methyl]-6-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875267-96-2P,
 6-(3,5-Difluorophenyl)-2-(2-methoxyphenyl)-3-[[piperidin-3-yl]methyl]quinazolin-4(3H)-one 875267-97-3P,
 6-(3,4-Dichlorophenyl)-2-(2-methoxyphenyl)-3-[[piperidin-3-yl]methyl]quinazolin-4(3H)-one 875267-98-4P,
 6-(3-Fluoro-4-methylphenyl)-2-(2-methoxyphenyl)-3-[[piperidin-3-yl]methyl]quinazolin-4(3H)-one 875267-99-5P,
 6-(4-Ethoxyphenyl)-2-(2-methoxyphenyl)-3-[[piperidin-3-yl]methyl]quinazolin-4(3H)-one 875268-00-1P,
 6-(3,4-Difluorophenyl)-2-(2-methoxyphenyl)-3-[[piperidin-3-yl]methyl]quinazolin-4(3H)-one 875268-01-2P,
 2-(2-Methoxyphenyl)-6-(3-methoxyphenyl)-3-[[piperidin-3-yl]methyl]quinazolin-4(3H)-one 875268-02-3P,
 6-(3-Chloro-4-fluorophenyl)-2-(2-methoxyphenyl)-3-[[piperidin-3-yl]methyl]quinazolin-4(3H)-one 875268-19-2P,


6-Ethyl-3-[(1-ethylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-20-5P,
 6-Isobutyl-2-(2-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875268-21-6P, 6-Isobutyl-3-[(1-isobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875268-22-7P,
 3-[(1-Cyclobutylpiperidin-3-yl)methyl]-6-isobutyl-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875268-23-8P,
 6-Isobutyl-3-[[1-(2-methoxyethyl)piperidin-3-yl]methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875268-24-9P,
 3-[[1-(1-Ethylpropyl)piperidin-3-yl]methyl]-6-isobutyl-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875268-25-0P,
 3-[[1-(1-Cyclopentylpiperidin-3-yl)methyl]-6-isobutyl-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875268-26-1P,
 6-Isobutyl-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875268-27-2P,
 3-[[1-(1-Cyclobutylmethyl)piperidin-3-yl]methyl]-6-isobutyl-2-(2-methoxyphenyl)quinazolin-4(3H)-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinazolinones useful for regulation of glucose homeostasis and food intake)

RN 875262-53-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[{(3R)-1-cyclohexyl-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 875262-54-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-3-[[{(3R)-1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



10/ 582,823


RN 875262-55-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-fluoroethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875262-60-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2-methylphenyl)-3-[[1-(3,3,3-trifluoropropyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875262-90-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(1,3-benzodioxol-5-yl)-2-[2-(difluoromethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875262-92-3 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-ethyl-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-91-2

CMF C29 H31 N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875262-94-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-93-4

CMF C29 H30 Cl N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




10/ 582,823

RN 875262-96-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-95-6
CMF C29 H30 Cl N3 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 875262-98-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(1-ethyl-3-piperidinyl)methyl]-6-(3-fluorophenyl)-
2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-97-8
CMF C29 H30 F N3 O2



CM 2

10/ 582,823


CRN 76-05-1
CMF C2 H F3 O2



RN 875263-00-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(1-ethyl-3-piperidinyl)methyl]-6-(4-fluorophenyl)-
2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875262-99-0
CMF C29 H30 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875263-02-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-
6-(3-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-01-7
CMF C30 H33 N3 O3

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-04-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-03-9

CMF C30 H33 N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




10/ 582,823

RN 875263-06-2 CAPLUS
CN 4(3H)-Quinazolinone, 6-(3,4-difluorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875263-05-1
CMF C29 H29 F2 N3 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 875263-08-4 CAPLUS
CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875263-07-3
CMF C29 H29 F2 N3 O2



10/ 582,823

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-10-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875263-09-5

CMF C29 H29 Cl F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875263-12-0 CAPLUS


CN 4(3H)-Quinazolinone, 6-(3,4-dichlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875263-11-9

CMF C29 H29 Cl2 N3 O2

10/ 582,823



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 875263-13-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 875263-14-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 875263-16-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


10/ 582,823

NAME)

CM 1

CRN 875263-15-3

CMF C29 H27 Cl F3 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-18-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-[2-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-17-5

CMF C29 H27 Cl F3 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875263-20-0 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX
NAME)

CM 1

CRN 875263-19-7
CMF C29 H27 Cl F3 N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2





RN 875263-22-2 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
2-[3-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX
NAME)

CM 1

CRN 875263-21-1
CMF C29 H27 Cl F3 N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-24-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-[4-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-23-3

CMF C29 H27 Cl F3 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875263-26-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
2-[2-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX
NAME)

CM 1

CRN 875263-25-5
CMF C29 H27 Cl F3 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875263-28-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
2-[3-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX
NAME)

CM 1

CRN 875263-27-7
CMF C29 H27 Cl F3 N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-30-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-[4-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-29-9

CMF C29 H27 Cl F3 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875263-32-4 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-31-3
CMF C29 H30 Cl N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2





RN 875263-34-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
2-(3-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-33-5
CMF C29 H30 Cl N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-36-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-fluorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-35-7

CMF C28 H27 Cl F N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875263-38-0 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
2-(3-fluorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-37-9
CMF C28 H27 Cl F N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875263-40-4 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
2-(4-fluorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-39-1
CMF C28 H27 Cl F N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-46-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-chlorophenyl)-6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-45-9

CMF C28 H27 Cl2 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/ 582,823


RN 875263-48-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-
2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA
INDEX NAME)

CM 1

CRN 875263-47-1

CMF C30 H31 Cl F N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-50-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-(2,5-difluorophenyl)-3-[(1-ethyl-
3-piperidinyl)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-49-3

CMF C28 H26 Cl F2 N3 O



10/ 582,823

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-52-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[(1-ethyl-3-piperidinyl)methyl]-2-(4-fluoro-3-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-51-7

CMF C29 H29 Cl F N3 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 875263-62-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[1-(1-ethylpropyl)-3-piperidinyl)methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875263-63-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinylmethyl]- (CA INDEX NAME)




RN 875263-64-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinylmethyl]-6-phenyl- (CA INDEX NAME)



RN 875263-65-3 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-(1-cyclobutyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-phenyl- (CA INDEX NAME)



RN 875263-66-4 CAPLUS


10/ 582,823

CN 4(3H)-Quinazolinone, 3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-phenyl- (CA INDEX NAME)



RN 875263-67-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-cyclopentyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-phenyl- (CA INDEX NAME)




RN 875263-69-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-68-6

CMF C30 H29 F4 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875263-71-1 CAPLUS
CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-70-0

CMF C30 H29 Cl F3 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-73-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-72-2

CMF C30 H28 Cl F4 N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-75-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-(3-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-74-4

CMF C31 H32 F3 N3 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 875263-77-7 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-76-6
 CMF C30 H28 F5 N3 O2



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 875263-79-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(3,5-difluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-78-8
 CMF C30 H28 F5 N3 O2



10/ 582,823

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-81-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-80-2

CMF C31 H33 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875263-83-5 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-6-(3-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-82-4

CMF C31 H32 F N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-85-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-6-(4-fluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-84-6

CMF C31 H32 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/ 582,823


RN 875263-87-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875263-86-8

CMF C31 H32 Cl N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-89-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875263-88-0

CMF C31 H31 Cl F N3 O2



10/ 582,823

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-91-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-90-4

CMF C32 H35 N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875263-93-7 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-92-6

CMF C32 H35 N3 O3

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-95-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875263-94-8

CMF C31 H31 F2 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




10/ 582,823

RN 875263-97-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875263-96-0

CMF C31 H31 F2 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875263-99-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-6-(3,5-difluorophenyl)-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875263-98-2

CMF C31 H31 F2 N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 875264-00-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-(3-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875264-01-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-(4-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



10/ 582,823


RN 875264-02-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidiny]methyl]- (CA INDEX NAME)




RN 875264-03-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3,5-difluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidiny]methyl]- (CA INDEX NAME)




RN 875264-04-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidiny]methyl]- (CA INDEX NAME)




RN 875264-05-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-fluoro-4-methylphenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidiny]methyl]- (CA INDEX NAME)




RN 875264-06-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875264-07-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 875264-08-7 CAPLUS


CN 4(3H)-Quinazolinone, 6-(3,4-dichlorophenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



10/ 582,823


RN 875264-09-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-ethoxyphenyl)-2-(2-methoxyphenyl)-3-[[1-(2-methylpropyl)-3-piperidiny]methyl]- (CA INDEX NAME)




RN 875264-10-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidiny]methyl]-6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-11-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidiny]methyl]-6-(3,5-difluorophenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-12-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-3-[(1-cyclobutyl-3-piperidiny]methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-13-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidinyl)methyl]-6-(3-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-14-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidinyl)methyl]-6-(3-fluoro-4-methylphenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-15-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 875264-16-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidiny)methyl]-2-(2-methoxyphenyl)-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 875264-17-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidiny)methyl]-6-(4-ethoxyphenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-18-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(2-methoxyethyl)-3-piperidiny)methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)- (CA INDEX NAME)




RN 875264-19-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(2-methoxyethyl)-3-piperidiny)methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)- (CA INDEX NAME)




RN 875264-20-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3,4-difluorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-21-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3,5-difluorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-22-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-fluoro-4-methoxyphenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-23-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-fluoro-4-methylphenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-24-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-25-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 875264-26-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 875264-27-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-phenyl- (CA INDEX NAME)




RN 875264-28-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)- (CA INDEX NAME)




RN 875264-29-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)- (CA INDEX NAME)




RN 875264-30-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3,4-difluorophenyl)-3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-31-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3,5-difluorophenyl)-3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-32-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-6-(3-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)



RN 875264-33-8 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-6-(3-fluoro-4-methylphenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)



10/ 582,823


RN 875264-34-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-3-[[1-(1-ethylpropyl)-3-piperidinyl)methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-35-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-ethoxyphenyl)-3-[[1-(1-ethylpropyl)-3-piperidinyl)methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-36-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclopentyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)- (CA INDEX NAME)




RN 875264-37-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclopentyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)- (CA INDEX NAME)




RN 875264-38-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclopentyl-3-piperidinyl)methyl]-6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-39-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-(3-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875264-40-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-(4-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875264-41-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875264-42-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 875264-43-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875264-44-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)- (CA INDEX NAME)




RN 875264-45-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)- (CA INDEX NAME)




RN 875264-46-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-47-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-6-(3-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-48-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 875264-49-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-50-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-3-[[1-(cyclopentyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-51-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875264-52-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3,5-difluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875264-53-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-6-(3,5-difluorophenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 875264-54-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinylmethyl]-6-(3-thienyl)- (CA INDEX NAME)



RN 875264-55-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinylmethyl]-6-(4-methyl-2-thienyl)- (CA INDEX NAME)



RN 875264-56-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2-fluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinylmethyl]-2-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875264-58-7 CAPLUS
 CN 4(3H)-Quinazolinone, 6-[4-(cyclopropylmethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-57-6
 CMF C34 H39 N3 O2



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 875264-60-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(2-thienyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-59-8
 CMF C28 H31 N3 O S

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875264-62-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3,4-dimethoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-61-2

CMF C32 H37 N3 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 875264-64-5 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(3-hydroxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-63-4
 CMF C30 H33 N3 O2



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 875264-66-7 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-hydroxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-65-6
 CMF C30 H33 N3 O2



10/ 582,823

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 875264-68-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-(1,3-benzodioxol-5-yl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-67-8
CMF C31 H33 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875264-70-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-ethenylphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-69-0
CMF C32 H35 N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875264-72-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-amino-4-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-71-4

CMF C31 H36 N4 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 875264-74-7 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(6-methoxy-3-pyridinyl)-3-[[1-(1-methylethyl)-3-piperidinylmethyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-73-6
 CMF C30 H34 N4 O2



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 875264-76-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(3-fluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinylmethyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-75-8
 CMF C30 H32 F N3 O



10/ 582,823

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875264-78-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(1-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-77-0

CMF C34 H35 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875264-80-5 CAPLUS


CN 4(3H)-Quinazolinone, 6-(2-fluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-79-2

CMF C30 H32 F N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875264-82-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2-aminophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-81-6

CMF C30 H34 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875264-84-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-(3-furanyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-83-8
CMF C28 H31 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875264-86-1 CAPLUS
CN Benzonitrile, 4-[3,4-dihydro-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-4-oxo-6-quinazolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-85-0
CMF C31 H32 N4 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875264-88-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-aminophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-87-2

CMF C30 H34 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875264-90-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-fluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-89-4
CMF C30 H32 F N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875264-92-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[3-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-91-8
CMF C31 H32 F3 N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875264-94-1 CAPLUS

CN Benzonitrile, 3-[3,4-dihydro-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-4-oxo-6-quinazolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-93-0

CMF C31 H32 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875264-96-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-[4-(dimethylamino)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875264-95-2

CMF C32 H38 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875265-02-4 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-butylphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-01-3

CMF C34 H41 N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875265-04-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2-fluoro[1,1'-biphenyl]-4-yl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-03-5

CMF C36 H36 F N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875265-06-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-ethylphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-05-7
CMF C32 H37 N3 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 875265-08-0 CAPLUS
CN 4(3H)-Quinazolinone, 6-[1,1'-biphenyl]-3-yl-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-07-9
CMF C36 H37 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875265-10-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-[2-methoxy-5-(1-methylethyl)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl)methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-09-1

CMF C34 H41 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875265-12-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-11-5

CMF C31 H35 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875265-14-8 CAPLUS


CN 4(3H)-Quinazolinone, 6-[4-(1,1-dimethylethyl)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-13-7

CMF C34 H41 N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875265-16-0 CAPLUS

CN 4-(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-15-9

CMF C30 H31 F2 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875265-18-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-[3-(hydroxymethyl)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-17-1

CMF C31 H35 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875265-20-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2-furanyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-19-3

CMF C28 H31 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875265-22-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-21-7

CMF C31 H35 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875265-24-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(2-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-23-9
CMF C34 H35 N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875265-26-2 CAPLUS
CN 4(3H)-Quinazolinone, 6-[4-(ethylthio)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-25-1
CMF C32 H37 N3 O S

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875265-28-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[4-(methylsulfonyl)phenyl]-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 875265-27-3

CMF C31 H35 N3 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875265-30-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-[4-(1-methylethyl)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-29-5

CMF C33 H39 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875265-32-0 CAPLUS

CN Benzeneacetonitrile, 4-[3,4-dihydro-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-4-oxo-6-quinazolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-31-9

CMF C32 H34 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875265-34-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(4-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-33-1

CMF C31 H35 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875265-36-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(3-nitrophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875265-35-3

CMF C30 H32 N4 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 875266-33-4 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-(3S)-1-ethyl-3-piperidinyl]methyl]-6-(2-fluorophenyl)-2-(2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 875266-82-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-3-[(1-ethyl-3-piperidinyl)methyl]-6-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 875266-83-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-3-[(1-ethyl-3-piperidinyl)methyl]-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 875266-84-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-3-[(1-ethyl-3-piperidinyl)methyl]-6-(3-methoxyphenyl)- (CA INDEX NAME)



10/ 582,823


RN 875266-85-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-3-[(1-ethyl-3-piperidinyl)methyl]-6-(4-fluorophenyl)- (CA INDEX NAME)



RN 875266-86-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-3-[(1-ethyl-3-piperidinyl)methyl]-6-(3-fluorophenyl)- (CA INDEX NAME)




RN 875266-91-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-(3-piperidinylmethyl)-2-[3-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875266-90-3

CMF C27 H23 Cl F3 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875266-93-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-(3-piperidinylmethyl)-2-[4-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875266-92-5
CMF C27 H23 Cl F3 N3 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 875266-95-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-(3-piperidinylmethyl)-2-[2-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875266-94-7
CMF C27 H23 Cl F3 N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 875266-96-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875266-97-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875266-98-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875266-99-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-00-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclopentyl-3-piperidinyl)methyl]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-01-9 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-02-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-03-1 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-04-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-05-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclopentyl)-3-piperidinyl]methyl]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-06-4 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-methylbutyl)-3-piperidinyl]methyl]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-07-5 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-08-6 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclohexylmethyl)-3-piperidinyl]methyl]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-09-7 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-methylpropyl)-3-piperidinyl]methyl]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-10-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-11-1 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 875267-12-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-13-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-methylpropyl)-3-piperidinyl]methyl]-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-14-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-methylbutyl)-3-piperidinyl]methyl]-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-15-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-16-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-cyclopentyl)-3-piperidinyl]methyl]-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-17-7 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-cyclobutyl)-3-piperidinyl]methyl]-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-18-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(2-ethylbutyl)-3-piperidinyl]methyl]-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 875267-19-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 875267-92-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-(4-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875267-93-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chloro-3-methylphenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875267-94-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875267-95-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 875267-96-2 CAPLUS


CN 4(3H)-Quinazolinone, 6-(3,5-difluorophenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)



10/ 582,823


RN 875267-97-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3,4-dichlorophenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875267-98-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-fluoro-4-methylphenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875267-99-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-ethoxyphenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875268-00-1 CAPLUS


CN 4(3H)-Quinazolinone, 6-(3,4-difluorophenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)



RN 875268-01-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-(3-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875268-02-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-2-(2-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)



RN 875268-19-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-ethyl-3-[(1-ethyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-18-1
 CMF C25 H31 N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 875268-20-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-(2-methylpropyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875268-21-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-6-(2-methylpropyl)-3-[[1-(2-methylpropyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875268-22-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-(2-methylpropyl)- (CA INDEX NAME)




RN 875268-23-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(2-methoxyethyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-(2-methylpropyl)- (CA INDEX NAME)




RN 875268-24-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-ethylpropyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-(2-methylpropyl)- (CA INDEX NAME)



RN 875268-25-0 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-(1-cyclopentyl)-3-piperidinyl]methyl]-2-(2-methoxyphenyl)-6-(2-methylpropyl)- (CA INDEX NAME)



RN 875268-26-1 CAPLUS


CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-[[1-(1-methylethyl)-3-

piperidinyl)methyl]-6-(2-methylpropyl)- (CA INDEX NAME)



RN 875268-27-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-(2-methylpropyl)- (CA INDEX NAME)



IT 875268-29-4P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(pyridin-4-yl)-1,3-thiazol-2-yl]quinazolin-4(3H)-one monotrifluoroacetate 875268-31-8P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(pyridin-3-yl)-1,3-thiazol-2-yl]quinazolin-4(3H)-one monotrifluoroacetate 875268-33-0P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(pyridin-2-yl)-1,3-thiazol-2-yl]quinazolin-4(3H)-one monotrifluoroacetate 875268-35-2P, 6-[4-(1,3-Benzodioxol-5-yl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-37-4P, 6-[4-(3,4-Difluorophenyl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-39-6P, 6-[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-41-0P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-6-[4-(2-methoxyphenyl)-1,3-thiazol-2-yl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-43-2P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(4-(methylsulfonyl)phenyl)-1,3-thiazol-2-yl]quinazolin-4(3H)-one monotrifluoroacetate 875268-45-4P, 6-(4-tert-Butyl-1,3-thiazol-2-yl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-47-6P, 6-(4-Ethyl-1,3-thiazol-2-yl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-49-8P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(4-methylphenyl)-1,3-thiazol-2-yl]quinazolin-4(3H)-one monotrifluoroacetate 875268-51-2P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-6-[4-(3-methoxyphenyl)-1,3-thiazol-2-yl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-53-4P, Ethyl

2-[3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl]-1,3-thiazole-4-carboxylate monotrifluoroacetate 875268-55-6P, 6-[4-(4-Fluorophenyl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-57-8P, 6-[4-(2-Furyl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-59-0P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(2-(trifluoromethoxy)phenyl)-1,3-thiazol-2-yl]quinazolin-4(3H)-one monotrifluoroacetate 875268-61-4P, 6-[4-(2-Fluorophenyl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-63-6P, 6-[4-(3,5-Difluorophenyl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-65-8P, 6-[4-(3-Chloro-4-fluorophenyl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-67-0P 875268-69-2P, 6-(4,5-Dimethyl-1,3-thiazol-2-yl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-71-6P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(phenyl-1,3-thiazol-2-yl)quinazolin-4(3H)-one monotrifluoroacetate 875268-73-8P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(5-methyl-4-phenyl-1,3-thiazol-2-yl)quinazolin-4(3H)-one monotrifluoroacetate 875268-75-0P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(4-(pyrrolidin-1-yl)phenyl)-1,3-thiazol-2-yl]quinazolin-4(3H)-one monotrifluoroacetate 875268-77-2P 875268-79-4P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(4-nitrophenyl)-1,3-thiazol-2-yl]quinazolin-4(3H)-one monotrifluoroacetate 875268-81-8P, 4-[2-[3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl]-1,3-thiazol-4-yl]benzonitrile monotrifluoroacetate 875268-83-0P, 6-[4-(2,5-Dimethoxyphenyl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-85-2P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]quinazolin-4(3H)-one monotrifluoroacetate 875268-87-4P, 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-[4-(4-(trifluoromethoxy)phenyl)-1,3-thiazol-2-yl]quinazolin-4(3H)-one monotrifluoroacetate 875268-89-6P, 6-[4-[4-(Difluoromethoxy)phenyl]-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-91-0P, 6-[4-(2,4-Dimethylphenyl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-93-2P, 6-[5-Ethyl-4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875268-94-3P, 6-(4-Chlorophenyl)-2-[4-(difluoromethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875268-95-4P, 3-[4-(Difluoromethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]-6-[3-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875268-96-5P, 2-[4-(Difluoromethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]-6-(3-methoxyphenyl)quinazolin-4(3H)-one 875268-97-6P, 2-[4-(Difluoromethoxy)phenyl]-6-(4-fluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875268-98-7P, 2-[4-(Difluoromethoxy)phenyl]-6-(3-fluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875268-99-8P,

2-[4-(Difluoromethoxy)phenyl]-6-(2,4-difluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-00-4P
 , 6-(3-Acetylphenyl)-2-[4-(difluoromethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-01-5P
 , 2-[4-(Difluoromethoxy)phenyl]-6-(1H-indol-5-yl)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-02-6P,
 2-[4-(Difluoromethoxy)phenyl]-6-(3,4-difluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-03-7P
 , 6-(3-Chloro-4-fluorophenyl)-2-[4-(difluoromethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-04-8P
 , 2-[4-(Difluoromethoxy)phenyl]-6-(3-furyl)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-05-9P,
 2-[4-(Difluoromethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]-6-(3-thienyl)quinazolin-4(3H)-one 875269-06-0P,
 6-Cyclopropyl-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875269-08-2P,
 3-[(1-Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-((E)-2-phenylvinyl)quinazolin-4(3H)-one monotrifluoroacetate 875269-10-6P,
 6-((E)-2-(4-Fluorophenyl)vinyl)-3-[(1-isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one monotrifluoroacetate 875269-14-0P,
 6-(3-Methoxyphenyl)-2-(2-methylphenyl)-3-[(morpholin-2-yl)methyl]quinazolin-4(3H)-one 875269-15-1P,
 3-[(4-Isopropylmorpholin-2-yl)methyl]-6-(3-methoxyphenyl)-2-(2-methylphenyl)quinazolin-4(3H)-one 875269-16-2P,
 6-(4-Chlorophenyl)-3-[[4-(cyclobutylmethyl)morpholin-2-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875269-17-3P,
 3-[(1-Ethyl-1,2,5,6-tetrahydropyridin-3-yl)methyl]-6-(3-methoxyphenyl)-2-(2-methylphenyl)quinazolin-4(3H)-one 875269-18-4P,
 6-(4-Chlorophenyl)-3-[(1-(cyclobutylmethyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl]-2-(2-methylphenyl)quinazolin-4(3H)-one 875269-19-5P
 , 3-[[3-(3R)-1-Azabicyclo[2.2.2]oct-3-yl)methyl]-2-(2-methoxyphenyl)-6-[3-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875269-20-8P,
 3-[[3-(3S)-1-Azabicyclo[2.2.2]oct-3-yl)methyl]-6-(4-chlorophenyl)-2-(2-methoxyphenyl)quinazolin-4(3H)-one 875269-21-9P,
 3-[[3-(3S)-1-Azabicyclo[2.2.2]oct-3-yl)methyl]-2-(2-methoxyphenyl)-6-[3-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 875269-22-0P,
 2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-23-1P,
 3-[[1-(Cyclopropylmethyl)piperidin-3-yl)methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-phenoxyquinazolin-4(3H)-one 875269-24-2P
 , 3-[[1-(Cyclopropylmethyl)piperidin-3-yl)methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)quinazolin-4(3H)-one 875269-25-3P,
 3-[[1-(Cyclopropylmethyl)piperidin-3-yl)methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-methoxyphenoxy)quinazolin-4(3H)-one 875269-26-4P,
 2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]-6-phenoxyquinazolin-4(3H)-one 875269-28-6P,
 2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]-6-(3-methoxyphenoxy)quinazolin-4(3H)-one 875269-29-7P,
 3-[[1-(Cyclobutylmethyl)piperidin-3-yl)methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)quinazolin-4(3H)-one 875269-30-0P,
 3-[[1-(Cyclobutylmethyl)piperidin-3-yl)methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-methoxyphenoxy)quinazolin-4(3H)-one 875269-31-1P,
 6-Anilino-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-32-2P,
 2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-6-[(4-fluorophenyl)amino]-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-33-3P,
 6-(2,4-Difluorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-34-4P,

2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-35-5P,
 2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-fluorophenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-36-6P,
 2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-37-7P,
 6-(3-Chlorophenyl)-3-[[1-(cyclopropylmethyl)piperidin-3-yl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]quinazolin-4(3H)-one 875269-38-8P, 6-(4-Chlorophenyl)-3-[[1-(cyclopropylmethyl)piperidin-3-yl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]quinazolin-4(3H)-one 875269-39-9P,
 3-[[1-(Cyclopropylmethyl)piperidin-3-yl]methyl]-6-(2,4-difluorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]quinazolin-4(3H)-one 875269-40-2P, 3-[[1-(Cyclopropylmethyl)piperidin-3-yl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-fluorophenyl)quinazolin-4(3H)-one 875269-41-3P, 3-[[1-(Cyclopropylmethyl)piperidin-3-yl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenyl)quinazolin-4(3H)-one 875269-42-4P, 6-(4-Chlorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-[[1-(isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-43-5P,
 6-(3-Chlorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-[[1-(isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-44-6P, 6-(2,4-Difluorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-[[1-(isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-45-7P, 2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-fluorophenyl)-3-[[1-(isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-46-8P, 2-[2-Fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenyl)-3-[[1-(isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-47-9P, 6-(4-Chlorophenyl)-3-[[1-(cyclobutylmethyl)piperidin-3-yl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]quinazolin-4(3H)-one 875269-48-0P, 3-[[1-(Cyclobutylmethyl)piperidin-3-yl]methyl]-6-(2,4-difluorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]quinazolin-4(3H)-one 875269-49-1P,
 3-[[1-(Cyclobutylmethyl)piperidin-3-yl]methyl]-6-(3-fluorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]quinazolin-4(3H)-one 875269-50-4P, 3-[[1-(Cyclobutylmethyl)piperidin-3-yl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenyl)quinazolin-4(3H)-one 875269-51-5P, 2-[2,4-Bis(2-hydroxyethoxy)phenyl]-6-(3-methoxyphenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-52-6P, 2-[2,4-Bis(2-hydroxyethoxy)phenyl]-6-(2,4-difluorophenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-53-7P, 2-[2,4-Bis(2-hydroxyethoxy)phenyl]-6-(3-fluorophenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875269-54-8P, 2-[2,4-Bis(2-hydroxyethoxy)phenyl]-6-(4-fluorophenyl)-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875270-64-7P, 6-(2,4-Difluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)piperidin-3-yl]methyl]quinazolin-4(3H)-one monotrifluoroacetate 875270-65-8P,
 3-[[1-(Cyclobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)quinazolin-4(3H)-one 875270-66-9P,
 3-[[1-(Cyclobutylpiperidin-3-yl)methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)quinazolin-4(3H)-one 875270-68-1P,
 3-[[1-(Isopropylpiperidin-3-yl)methyl]-2-(2-methylphenyl)-6-(3-methylthio)phenyl]quinazolin-4(3H)-one monotrifluoroacetate 875270-69-2P, 6-(4-Chlorophenyl)-3-[[1-(cyclopropylmethyl)piperidin-3-yl]methyl]-2-[2-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinazolinones useful for regulation of glucose homeostasis and food intake)


RN 875268-29-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[4-(4-pyridinyl)-2-thiazolyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-28-3

CMF C32 H33 N5 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-31-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[4-(3-pyridinyl)-2-thiazolyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-30-7

CMF C32 H33 N5 O S



10/ 582,823

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-33-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[4-(2-pyridinyl)-2-thiazolyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-32-9

CMF C32 H33 N5 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875268-35-2 CAPLUS


CN 4(3H)-Quinazolinone, 6-[4-(1,3-benzodioxol-5-yl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-34-1

CMF C34 H34 N4 O3 S

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-37-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-[4-(3,4-difluorophenyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-36-3

CMF C33 H32 F2 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875268-39-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-[4-(4-chlorophenyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-38-5
CMF C33 H33 Cl N4 O S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875268-41-0 CAPLUS
CN 4(3H)-Quinazolinone, 6-[4-(2-methoxyphenyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-40-9
CMF C34 H36 N4 O2 S

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-43-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[4-(4-(methylsulfonyl)phenyl)-2-thiazolyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-42-1

CMF C34 H36 N4 O3 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875268-45-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-[4-(1,1-dimethylethyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-44-3

CMF C31 H38 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875268-47-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-ethyl-2-thiazolyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-46-5

CMF C29 H34 N4 O S

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-49-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl)methyl]-2-(2-methylphenyl)-6-[4-(4-methylphenyl)-2-thiazolyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-48-7

CMF C34 H36 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875268-51-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-[4-(3-methoxyphenyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-50-1

CMF C34 H36 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875268-53-4 CAPLUS


CN 4-Thiazolecarboxylic acid, 2-[3,4-dihydro-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-4-oxo-6-quinazolinyl]-, ethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-52-3

CMF C30 H34 N4 O3 S

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-55-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-[4-(4-fluorophenyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-54-5

CMF C33 H33 F N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 875268-57-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-[4-(2-furanyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-56-7
CMF C31 H32 N4 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 875268-59-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[4-[2-(trifluoromethoxy)phenyl]-2-thiazolyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-58-9
CMF C34 H33 F3 N4 O2 S

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-61-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-[4-(2-fluorophenyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinylmethyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-60-3

CMF C33 H33 F N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875268-63-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-[4-(3,5-difluorophenyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-62-5

CMF C33 H32 F2 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875268-65-8 CAPLUS


CN 4(3H)-Quinazolinone, 6-[4-(3-chloro-4-fluorophenyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-64-7

CMF C33 H32 Cl F N4 O S

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-67-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-[2,4'-bithiazol]-2'-yl-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-66-9

CMF C30 H31 N5 O S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875268-69-2 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4,5-dimethyl-2-thiazolyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-68-1

CMF C29 H34 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-71-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(4-phenyl-2-thiazolyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-70-5

CMF C33 H34 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-73-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-(5-methyl-4-phenyl-2-thiazolyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-72-7

CMF C34 H36 N4 O S




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 875268-79-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[4-(4-nitrophenyl)-2-thiazolyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-78-3
CMF C33 H33 N5 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

10/ 582,823




RN 875268-81-8 CAPLUS

CN Benzonitrile, 4-[2-[3,4-dihydro-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-4-oxo-6-quinazolinyl]-4-thiazolyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-80-7

CMF C34 H33 N5 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-83-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-[4-(2,5-dimethoxyphenyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-82-9

CMF C35 H38 N4 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-85-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[4-(4-methyl-3-pyridinyl)-2-thiazolyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-84-1

CMF C33 H35 N5 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823




RN 875268-87-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[4-[4-(trifluoromethoxy)phenyl]-2-thiazolyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-86-3

CMF C34 H33 F3 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875268-89-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-[4-[4-(difluoromethoxy)phenyl]-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-88-5

CMF C34 H34 F2 N4 O2 S

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-91-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-[4-(2,4-dimethylphenyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-90-9

CMF C35 H38 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 875268-93-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-[5-ethyl-4-(4-methoxyphenyl)-2-thiazolyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875268-92-1

CMF C36 H40 N4 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 875268-94-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-[4-(difluoromethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875268-95-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 875268-96-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-6-(3-methoxyphenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875268-97-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-6-(4-fluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875268-98-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-6-(3-fluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875268-99-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-6-(2,4-difluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875269-00-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-acetylphenyl)-2-[4-(difluoromethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875269-01-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-6-(1H-indol-5-yl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875269-02-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-6-(3,4-difluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875269-03-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chloro-4-fluorophenyl)-2-[4-(difluoromethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875269-04-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-6-(3-furanyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875269-05-9 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-(difluoromethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-6-(3-thienyl)- (CA INDEX NAME)



RN 875269-06-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-cyclopropyl-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)

10/ 582,823



RN 875269-08-2 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-6-[(1E)-2-phenylethenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875269-07-1

CMF C32 H35 N3 O

Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 875269-10-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-[(1E)-2-(4-fluorophenyl)ethenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


10/ 582,823

CM 1

CRN 875269-09-3

CMF C32 H34 F N3 O

Double bond geometry as shown.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 875269-14-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-methoxyphenyl)-2-(2-methylphenyl)-3-(2-morpholinylmethyl)- (CA INDEX NAME)




RN 875269-15-1 CAPLUS


CN 4(3H)-Quinazolinone, 6-(3-methoxyphenyl)-3-[[4-(1-methylethyl)-2-morpholinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875269-16-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[4-(cyclobutylmethyl)-2-morpholinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875269-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[1-(ethyl-1,2,5,6-tetrahydro-3-pyridinyl)methyl]-6-(3-methoxyphenyl)-2-(2-methylphenyl)- (CA INDEX NAME)




RN 875269-18-4 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclobutylmethyl)-1,2,5,6-tetrahydro-3-pyridinyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)



RN 875269-19-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-2-(2-

methoxyphenyl)-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875269-20-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-6-(4-chlorophenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 875269-21-9 CAPLUS


CN 4(3H)-Quinazolinone, 3-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-2-(2-methoxyphenyl)-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 875269-22-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875269-23-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-phenoxy- (CA INDEX NAME)




RN 875269-24-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)- (CA INDEX NAME)




RN 875269-25-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-methoxyphenoxy)- (CA INDEX NAME)




RN 875269-26-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-6-phenoxy- (CA INDEX NAME)




RN 875269-28-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-methoxyphenoxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875269-29-7 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenoxy)- (CA INDEX NAME)




RN 875269-30-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-methoxyphenoxy)- (CA INDEX NAME)



RN 875269-31-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]-6-(phenylamino)- (CA INDEX NAME)




RN 875269-32-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-[(4-fluorophenyl)amino]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875269-33-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875269-34-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-methoxyphenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875269-35-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-fluorophenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875269-36-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875269-37-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)




RN 875269-38-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)




RN 875269-39-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-6-(2,4-difluorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)




RN 875269-40-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-fluorophenyl)- (CA INDEX NAME)




RN 875269-41-3 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenyl)- (CA INDEX NAME)




RN 875269-42-4 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)



RN 875269-43-5 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(3-chlorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875269-44-6 CAPLUS
 CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875269-45-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(3-fluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875269-46-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]-6-(4-fluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (CA INDEX NAME)




RN 875269-47-9 CAPLUS


CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)




RN 875269-48-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-6-(2,4-difluorophenyl)-2-[2-fluoro-4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)



RN 875269-49-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-(2-fluoro-4-(2-hydroxyethoxy)phenyl)-6-(3-fluorophenyl)- (CA INDEX NAME)




RN 875269-50-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[1-(cyclobutylmethyl)-3-piperidinyl]methyl]-2-(2-fluoro-4-(2-hydroxyethoxy)phenyl)-6-(4-fluorophenyl)- (CA INDEX NAME)




RN 875269-51-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2,4-bis(2-hydroxyethoxy)phenyl]-6-(3-methoxyphenoxy)-3-(3-piperidinylmethyl)- (CA INDEX NAME)



RN 875269-52-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2,4-bis(2-hydroxyethoxy)phenyl]-6-(2,4-difluorophenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)



RN 875269-53-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2,4-bis(2-hydroxyethoxy)phenyl]-6-(3-fluorophenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)

10/ 582,823



RN 875269-54-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2,4-bis(2-hydroxyethoxy)phenyl]-6-(4-fluorophenyl)-3-(3-piperidinylmethyl)- (CA INDEX NAME)




RN 875270-64-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-(2,4-difluorophenyl)-2-(2-methoxyphenyl)-3-[[1-(3,3,3-trifluoropropyl)-3-piperidinyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875270-63-6

CMF C30 H28 F5 N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 875270-65-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-(3-methoxyphenyl)- (CA INDEX NAME)



RN 875270-66-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-cyclobutyl-3-piperidinyl)methyl]-2-(2-methoxyphenyl)-6-(4-methoxyphenyl)- (CA INDEX NAME)




RN 875270-68-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(1-methylethyl)-3-piperidinyl)methyl]-2-(2-methylphenyl)-6-[3-(methylthio)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 875270-67-0

CMF C31 H35 N3 O S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 875270-69-2 CAPLUS

CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-3-[[1-(cyclopropylmethyl)-3-piperidinylmethyl]-2-[2-(trifluoromethoxy)phenyl]]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L5 ANSWER 41 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:64526 CAPLUS

DOCUMENT NUMBER: 144:205159

TITLE: Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators
 AUTHOR(S): Globisch, Christoph; Pajeva, Ilza K.; Wiese, Michael
 CORPORATE SOURCE: Institute of Pharmacy, University of Bonn, Bonn, 53121, Germany
 SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(5), 1588-1598

CODEN: BMECEP; ISSN: 0968-0896



PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Tariquidar (XR9576) analogs, modulators of cancer multidrug resistance (MDR), were subjected to QSAR and 3D-QSAR analyses. The structural features contributing to anti-MDR activity were identified by the Free-Wilson anal. and pharmacophore search using Hoechst 33342 as a template. 3D-QSAR CoMFA and CoMSIA models were derived and tested. The best models yielded an external predictivity of 0.66-0.75 squared correlation coefficient and outlined HB-acceptor, steric, and hydrophobic fields as the most important 3D properties. On the basis of the QSAR and 3D-QSAR analyses it was suggested that the strong inhibitory potency of the compds. studied is related to the presence of a bulky aromatic ring system with a 3rd positioned heteroatom toward the anthranilamide nucleus in the opposite end of the tetrahydroquinoline group. The results can help in directing the rational design of new generations of potent P-glycoprotein MDR modulators.

IT 225937-91-7
 RL: PAC (Pharmacological activity); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (structure-activity relationships of series of tariquidar analogs as
 multidrug resistance modulators)
 RN 225937-91-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-(3,4-dimethoxyphenyl)ethyl]-2-[4-
 (dimethylamino)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS
 RECORD (17 CITINGS)
 REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 42 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:1288664 CAPLUS
 DOCUMENT NUMBER: 144:36366
 TITLE: Preparation of quinazoline derivatives as histamine H3
 receptor antagonists
 INVENTOR(S): Mizutani, Takashi; Nagase, Tsuyoshi; Sato, Nagaaki;
 Kanatani, Akio; Tokita, Shigeru
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 233 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115993	A1	20051208	WO 2005-JP10291	20050530
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,			


MR, NE, SN, TD, TG

AU 2005247808	A1	20051208	AU 2005-247808	20050530
CA 2569081	A1	20051208	CA 2005-2569081	20050530
EP 1757594	A1	20070228	EP 2005-745824	20050530
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
CN 1960977	A	20070509	CN 2005-80017630	20050530
IN 2006DN06865	A	20070831	IN 2006-DN6865	20061117
US 20080275069	A1	20081106	US 2006-628087	20061127
PRIORITY APPLN. INFO.:			JP 2004-162459	A 20040531
			WO 2005-JP10291	W 20050530


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 144:36366

GI



I



II

AB Title compds. I [R1 = aryl, aralkyl, alkoxy, etc.; further details on R1 are given.; R2, R3 = H, amino, alkylamino, etc.; R4 = Q1, etc.; R5 = H, alkyl, hydroxy, etc.; R7, R8 = alkyl, arylalkyl, heteroarylalkyl, with the proviso that R7 and R8 are not alkyl simultaneously; X1 = NH, O, S; Y = N, C; Ar = optionally substituted aryl, heteroaryl with alkyl, alkoxy, halo; ring A = Ph, heteroaryl containing N, O] were prepared For example, reaction

of

2-(4-hydroxyphenyl)-3,8-dimethyl-4(3H)-quinazolinone, e.g., prepared from 3-methyl-2-aminobenzoic acid in 3 steps, with 1-chloro-3-bromopropane and K2CO3 followed by in-situ treatment with piperidine afforded compound II [R = methyl; X = piperidin-1-yl]. In histamine analog binding inhibition assays, the IC50 value of compound II [R = H; X = pyrrolidin-1-yl] was 0.68 nM. Compds. I are claimed useful for the treatment of diabetes, obesity, etc.

IT

870996-72-8P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of quinazolinone derivs. as histamine H3 antagonists for treatment of obesity, diabetes, etc.)

RN

870996-72-8 CAPLUS

CN

4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-8-methoxy- (CA INDEX NAME)




IT	870996-36-4P	870996-38-6P	870996-40-0P
	870996-42-2P	870996-44-4P	870996-46-6P
	870996-48-8P	870996-50-2P	870996-52-4P
	870996-54-6P	870996-56-8P	870996-58-0P
	870996-59-1P	870996-60-4P	870996-63-7P
	870996-65-9P	870996-67-1P	870996-80-8P
	870996-83-1P	870996-84-2P	870996-85-3P,
	2-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3,8-dimethylquinazolin-4(3H)-one	870996-88-6P	870996-89-7P
	870996-90-0P	870996-91-1P	870996-92-2P
	870997-04-9P	870997-05-0P	870997-06-1P
	870997-08-3P	870997-10-7P	870997-18-5P
	870997-19-6P	870997-20-9P	870997-21-0P
	870997-22-1P	870997-23-2P	870997-24-3P
	870997-25-4P	870997-26-5P	870997-27-6P
	870997-28-7P	870997-30-1P	870997-35-6P
	870997-37-8P	870997-38-9P	870997-40-3P
	870997-41-4P	870997-42-5P	870997-43-6P
	870997-44-7P	870997-45-8P	870997-46-9P
	870997-51-6P	870997-52-7P	870997-53-8P
	870997-54-9P	870997-55-0P	870997-56-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazoline derivs. as histamine H3 antagonists for treatment of obesity, diabetes, etc.)


RN 870996-36-4 CAPLUS

CN 4(3H)-Quinazolinone, 3,8-dimethyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-38-6 CAPLUS


CN 4(3H)-Quinazolinone, 3-methyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-40-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-42-2 CAPLUS
CN 4(3H)-Quinazolinone, 3,6-dimethyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)



RN 870996-44-4 CAPLUS
CN 4(3H)-Quinazolinone, 3,5-dimethyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-46-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[4-[3-(1-piperidinyl)propoxy]phenyl]-3-propyl- (CA INDEX NAME)




RN 870996-48-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-50-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-ethyl-2-[3-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-52-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(1-methylethyl)-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-54-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-phenyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-56-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-(1-piperidinyl)propoxy]phenyl]-3-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 870996-58-0 CAPLUS


CN 4(3H)-Quinazolinone, 3,8-dimethyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]- (CA INDEX NAME)



RN 870996-59-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-methoxy-4-[3-[(3S)-3-methyl-1-piperidinyl]propoxy]phenyl]-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.




10/ 582,823

RN 870996-60-4 CAPLUS


CN 4(3H)-Quinazolinone, 8-methoxy-2-[2-methoxy-4-[3-[(3S)-3-methyl-1-piperidinyl]propoxy]phenyl]-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 870996-63-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]- (CA INDEX NAME)



RN 870996-65-9 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-(1-cyclopentyl-4-piperidinyl)phenyl]-3-methyl- (CA INDEX NAME)



RN 870996-67-1 CAPLUS


CN 4(3H)-Quinazolinone, 3,7-dimethyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)

10/ 582,823




RN 870996-80-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-8-methyl- (CA INDEX NAME)




RN 870996-83-1 CAPLUS

CN 4(3H)-Quinazolinone, 8-chloro-2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-3-methyl- (CA INDEX NAME)



RN 870996-84-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-3-methyl-8-(trifluoromethyl)- (CA INDEX NAME)




RN 870996-85-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-3,8-


10/ 582,823

dimethyl- (CA INDEX NAME)




RN 870996-88-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-8-fluoro-3-methyl- (CA INDEX NAME)



RN 870996-89-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclopentyl-4-piperidinyl)oxy]phenyl]-8-fluoro-3-methyl- (CA INDEX NAME)



RN 870996-90-0 CAPLUS


CN 4(3H)-Quinazolinone, 8-fluoro-2-[2-methoxy-4-[3-[(3S)-3-methyl-1-piperidinyl]propoxy]phenyl]-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 870996-91-1 CAPLUS

CN 4(3H)-Quinazolinone, 5-fluoro-3-methyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870996-92-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-5-fluoro-3-methyl- (CA INDEX NAME)



RN 870997-04-9 CAPLUS

CN 4(3H)-Quinazolinone, 7-methoxy-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]- (CA INDEX NAME)




10/ 582,823

RN 870997-05-0 CAPLUS


CN 4(3H)-Quinazolinone, 7-methoxy-3-methyl-2-[4-{3-[(3S)-3-methyl-1-piperidiny]propoxy}phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 870997-06-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyloxy)phenyl]-7-methoxy-3-methyl]- (CA INDEX NAME)




RN 870997-08-3 CAPLUS

CN 4(3H)-Quinazolinone, 7-bromo-2-[2-(2-fluoroethoxy)-4-[3-(1-piperidiny)propoxy]phenyl]-3-methyl- (CA INDEX NAME)




RN 870997-10-7 CAPLUS

CN Quinazoline, 2-[4-[(1-cyclobutyl-4-piperidinyloxy)phenyl]-4-(2-fluoroethoxy)-8-methoxy]- (CA INDEX NAME)




RN 870997-18-5 CAPLUS

CN Methanesulfonamide, N-[3,4-dihydro-3-methyl-4-oxo-2-[3-[3-(1-piperidinyl)propoxy]phenyl]-6-quinazoliny]- (CA INDEX NAME)




RN 870997-19-6 CAPLUS

CN Methanesulfonamide, N-[3,4-dihydro-3-methyl-4-oxo-2-[3-[3-(1-piperidinyl)propoxy]phenyl]-7-quinazoliny]- (CA INDEX NAME)




RN 870997-20-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-methyl-7-nitro-2-[3-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870997-21-0 CAPLUS

CN Methanesulfonamide, N-[3,4-dihydro-3-methyl-4-oxo-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-7-quinazoliny]- (CA INDEX NAME)




RN 870997-22-1 CAPLUS

CN Methanesulfonamide, N-[3,4-dihydro-3-methyl-4-oxo-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-6-quinazolinyl]- (CA INDEX NAME)




RN 870997-23-2 CAPLUS

CN Acetamide, N-[3,4-dihydro-3-methyl-4-oxo-2-[4-[3-(1-piperidinyl)propoxy]phenyl]-6-quinazolinyl]- (CA INDEX NAME)




RN 870997-24-3 CAPLUS

CN Acetamide, N-[3,4-dihydro-3-methyl-4-oxo-2-[4-[3-(1-piperidinyl)propoxy]phenyl]-6-quinazolinyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 870997-25-4 CAPLUS


CN 4(3H)-Quinazolinone, 3-methyl-2-[2-methyl-4-[3-(1-pyrrolidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870997-26-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-3-methyl- (CA INDEX NAME)




RN 870997-27-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-2-[3-methoxy-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-3-methyl- (CA INDEX NAME)



RN 870997-28-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-2-[2-methoxy-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-3-methyl- (CA INDEX NAME)




RN 870997-30-1 CAPLUS
CN 4(3H)-Quinazolinone, 8-methoxy-3-methyl-2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]- (CA INDEX NAME)




RN 870997-35-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]-2-methylphenyl]-3-methyl- (CA INDEX NAME)




RN 870997-37-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclopentyl-4-piperidinyl)oxy]-2-methylphenyl]-3-methyl- (CA INDEX NAME)



RN 870997-38-9 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclohexyl-4-piperidinyl)oxy]-2-methylphenyl]-3-methyl- (CA INDEX NAME)



10/ 582,823


RN 870997-40-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-3-methyl- (CA INDEX NAME)




RN 870997-41-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclopropyl-4-piperidinyl)oxy]phenyl]-3-methyl- (CA INDEX NAME)




RN 870997-42-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-8-methoxy-3-methyl- (CA INDEX NAME)




RN 870997-43-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-6-methoxy-3-methyl- (CA INDEX NAME)




RN 870997-44-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-5-methoxy-3-methyl- (CA INDEX NAME)



RN 870997-45-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclopropyl-4-piperidinyl)oxy]phenyl]-8-methoxy-3-methyl- (CA INDEX NAME)




RN 870997-46-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclopropyl-4-piperidinyl)oxy]phenyl]-5-methoxy-3-methyl- (CA INDEX NAME)



10/ 582,823


RN 870997-51-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclopropyl-4-piperidinyl)oxy]phenyl]-3-ethyl-8-methyl- (CA INDEX NAME)




RN 870997-52-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-3-ethyl-8-methyl- (CA INDEX NAME)




RN 870997-53-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclopentyl-4-piperidinyl)oxy]phenyl]-3-ethyl-8-methyl- (CA INDEX NAME)




RN 870997-54-9 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclobutyl-4-piperidinyl)oxy]-2-fluorophenyl]-3-methyl- (CA INDEX NAME)



RN 870997-55-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-[(1-cyclopentyl-4-piperidinyl)oxy]-2-fluorophenyl]-3-methyl- (CA INDEX NAME)



RN 870997-56-1 CAPLUS
 CN 3(4H)-Quinazolinecarboxylic acid, 4-oxo-2-[4-[3-(1-piperidinyl)propoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 43 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN
 ACCESSION NUMBER: 2005:638623 CAPLUS
 DOCUMENT NUMBER: 143:146662
 TITLE: 2,3-Diarylquinazolinone mitotic kinesin inhibitors, and their therapeutic use
 INVENTOR(S): Arrington, Kenneth L.; Fraley, Mark E.; Hartman, George D.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065183	A2	20050721	WO 2004-US42070	20041215
WO 2005065183	A3	20050929		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004311737	A1	20050721	AU 2004-311737	20041215
CA 2549641	A1	20050721	CA 2004-2549641	20041215
EP 1696927	A2	20060906	EP 2004-814275	20041215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1893951	A	20070110	CN 2004-80037691	20041215
JP 2007517071	T	20070628	JP 2006-549289	20041215
IN 2006DN03003	A	20070803	IN 2006-DN3003	20060525
US 20070060601	A1	20070315	US 2006-582823	20060614
PRIORITY APPLN. INFO.:			US 2003-531372P	P 20031219
			WO 2004-US42070	W 20041215

OTHER SOURCE(S): MARPAT 143:146662


AB The present invention relates to 2,3-diarylquinazolinone compds. that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compns. which comprise these compds., and methods of using them to treat cancer in mammals. Compound preparation is included.

IT 371224-17-8P 859496-05-2P 859496-22-3P
859496-30-3P 859496-36-9P 859496-40-5P
859496-46-1P 859496-55-2P 859496-60-9P
859496-65-4P 859496-71-2P 859496-76-7P
859496-81-4P 859496-86-9P 859496-89-2P
859496-93-8P 859496-97-2P 859497-00-0P
859497-03-3P 859497-06-6P 859497-09-9P
859497-12-4P 859497-15-7P 859497-17-9P
859497-20-4P 859497-22-6P 859497-27-1P
859497-31-7P 859497-34-0P 859497-37-3P
859497-40-8P 859497-42-0P 859497-45-3P
859497-48-6P 859497-50-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(diarylquinazolinone mitotic kinesin inhibitors, and therapeutic use)

RN 371224-17-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-bromophenyl)-3-(4-methylphenyl)- (CA INDEX NAME)





RN 859496-05-2 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
 [(4-methyl-1-piperazinyl)methyl]phenyl]-, 2,2,2-trifluoroacetate (1:1)
 (CA INDEX NAME)

CM 1


CRN 859493-11-1

CMF C26 H22 Cl3 F N4 O

PAGE 1-A



PAGE 2-A



10/ 582,823

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 859496-22-3 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-[(4-methyl-1-piperazinyl)methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859492-98-1

CMF C26 H22 Cl3 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859496-30-3 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-[(methylamino)methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859493-04-2

CMF C22 H15 Cl3 F N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859496-36-9 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?)
(CA INDEX NAME)

CM 1


CRN 859493-11-1

CMF C26 H22 Cl3 F N4 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859496-40-5 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-2-[2-chloro-3-[(ethylamino)methyl]phenyl]-3-(4-chloro-3-fluorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859493-18-8

CMF C23 H17 Cl3 F N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859496-46-1 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
[[[(1-methylethyl)amino]methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA
INDEX NAME)

CM 1

CRN 859493-25-7

CMF C24 H19 Cl3 F N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859496-55-2 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-2-[2-chloro-3-[(cyclobutylamino)methyl]phenyl]-3-(4-chloro-3-fluorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 859496-54-1

CMF C25 H19 Cl3 F N3 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859496-60-9 CAPLUS



CN 4(3H)-Quinazolinone, 2-[3-(1-azetidinylmethyl)-2-chlorophenyl]-7-chloro-3-(4-chloro-3-fluorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 859493-39-3

CMF C24 H17 Cl3 F N3 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859496-65-4 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-(1-pyrrolidinylmethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 859493-46-2

CMF C25 H19 Cl3 F N3 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859496-71-2 CAPLUS


CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
 [[(3S)-3-hydroxy-1-pyrrolidinyl]methyl]phenyl]-, 2,2,2-trifluoroacetate
 (1:?) (CA INDEX NAME)

CM 1

CRN 859493-55-3

CMF C25 H19 Cl3 F N3 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859496-76-7 CAPLUS


CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
[[(3S)-3-(methoxymethyl)-1-pyrrolidinyl)methyl]phenyl]-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859493-61-1

CMF C27 H23 Cl3 F N3 O2

Absolute stereochemistry.



10/ 582,823

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859496-81-4 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-[(3-pyrrolidinylamino)methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 859493-67-7

CMF C25 H20 Cl3 F N4 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823





RN 859496-86-9 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-(4-morpholinylmethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 859493-73-5
CMF C25 H19 Cl3 F N3 O2

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2


10/ 582,823




RN 859496-89-2 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-(1-piperidinylmethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 859493-79-1
CMF C26 H21 Cl3 F N3 O



PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2





RN 859496-93-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-[(4-amino-1-piperidinyl)methyl]-2-chlorophenyl]-
 7-chloro-3-(4-chloro-3-fluorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA
 INDEX NAME)

CM 1


CRN 859493-86-0

CMF C26 H22 Cl3 F N4 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823





RN 859496-97-2 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
[(4-piperidinylamino)methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA
INDEX NAME)

CM 1


CRN 859493-93-9

CMF C26 H22 Cl3 F N4 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 859497-00-0 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
 [(4-fluoro-1-piperidinyl)methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?)
 (CA INDEX NAME)


CM 1

CRN 859494-00-1


CMF C26 H20 Cl3 F2 N3 O



PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 859497-03-3 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-(1-piperazinylmethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 859494-06-7
 CMF C25 H20 Cl3 F N4 O



PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
 CMF C2 H F3 O2

10/ 582,823




RN 859497-06-6 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
[[4-(methylsulfonyl)-1-piperazinyl]methyl]phenyl]-, 2,2,2-trifluoroacetate
(1:?) (CA INDEX NAME)


CM 1

CRN 859494-20-5


CMF C26 H22 Cl3 F N4 O3 S



PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/ 582,823



RN 859497-09-9 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
 [(2-hydroxyethyl)amino]methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA
 INDEX NAME)

CM 1

CRN 859494-27-2
 CMF C23 H17 Cl3 F N3 O2



CM 2



CRN 76-05-1
 CMF C2 H F3 O2



RN 859497-12-4 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-[2-chloro-3-[[2-(
 dimethylamino)ethyl]amino]methyl]phenyl]-3-(4-chloro-3-fluorophenyl)-,
 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859494-34-1
 CMF C25 H22 Cl3 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859497-15-7 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-[[[2-(4-morpholinyl)ethyl]amino]methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 859494-40-9

CMF C27 H24 Cl3 F N4 O2

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2





RN 859497-17-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[3-[(3-amino-1-pyrrolidinyl)methyl]-2-chlorophenyl]-
7-chloro-3-(4-chloro-3-fluorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA
INDEX NAME)


CM 1

CRN 859494-46-5
CMF C25 H20 Cl3 F N4 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859497-20-4 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
 [[[1-methyl-3-piperidinyl)methyl]amino]methyl]phenyl]-,
 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 859494-53-4

CMF C28 H26 Cl3 F N4 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859497-22-6 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
 [(phenylmethyl)amino]methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA
 INDEX NAME)

CM 1

CRN 859494-67-0

CMF C28 H19 Cl3 F N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 859497-27-1 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-
[[[(1-methylethyl)amino]methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA
INDEX NAME)

CM 1

CRN 859494-88-5

CMF C24 H19 Cl3 F N3 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 859497-31-7 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-(1-pyrrolidinylmethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859494-96-5

CMF C25 H19 Cl3 F N3 O



CM 2

10/ 582,823


CRN 76-05-1
CMF C2 H F3 O2



RN 859497-34-0 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-[(3-pyrrolidinylamino)methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859495-03-7
CMF C25 H20 Cl3 F N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 859497-37-3 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-(4-morpholinylmethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859495-09-3
CMF C25 H19 Cl3 F N3 O2

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 859497-40-8 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-(1-piperidinylmethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859495-16-2

CMF C26 H21 Cl3 F N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/ 582,823



RN 859497-42-0 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-
[(4-piperidinylamino)methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA
INDEX NAME)

CM 1

CRN 859495-22-0
CMF C26 H22 Cl3 F N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 859497-45-3 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-(1-
piperazinylmethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859495-29-7
CMF C25 H20 Cl3 F N4 O

10/ 582,823



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 859497-48-6 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[[2-chloro-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859495-34-4

CMF C26 H22 Cl3 F N4 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 582,823





RN 859497-50-0 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-[2-chloro-5-[[[2-(dimethylamino)ethyl]amino]methyl]phenyl]-3-(4-chloro-3-fluorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 859495-45-7

CMF C25 H22 Cl3 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT	374920-51-1	380160-71-4	397876-29-8
	859491-98-8	859492-06-1	859492-14-1
	859492-21-0	859492-28-7	859492-39-0
	859492-45-8	859492-51-6	859492-58-3
	859492-71-0	859492-78-7	859492-91-4
	859492-98-1	859493-04-2	859493-11-1
	859493-18-8	859493-25-7	859493-31-5

859493-39-3	859493-46-2	859493-55-3
859493-61-1	859493-67-7	859493-73-5
859493-79-1	859493-86-0	859493-93-9
859494-00-1	859494-06-7	859494-13-6
859494-20-5	859494-27-2	859494-34-1
859494-40-9	859494-46-5	859494-53-4
859494-60-3	859494-67-0	859494-80-7
859494-88-5	859494-96-5	859495-03-7
859495-09-3	859495-16-2	859495-22-0
859495-29-7	859495-34-4	859495-45-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(diarylquinazolinone mitotic kinesin inhibitors, and therapeutic use)




RN 374920-51-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-chlorophenyl)-3-(4-methylphenyl)- (CA INDEX
NAME)



RN 380160-71-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-(2,4-dichlorophenyl)-3-(4-methylphenyl)- (CA INDEX
NAME)



10/ 582,823


RN 397876-29-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methylphenyl)-3-(4-methylphenyl)- (CA INDEX NAME)




RN 859491-98-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-bromophenyl)-3-(4-chlorophenyl)- (CA INDEX NAME)




RN 859492-06-1 CAPLUS


CN 4(3H)-Quinazolinone, 2-(2-bromophenyl)-3-(3-fluoro-4-methylphenyl)- (CA INDEX NAME)




RN 859492-14-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2-bromophenyl)-3-(1H-indol-5-yl)- (CA INDEX NAME)




RN 859492-21-0 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-2-(2-chlorophenyl)-3-(3-fluoro-4-methylphenyl)- (CA INDEX NAME)




RN 859492-28-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2-chlorophenyl)-3-(3-fluoro-4-methylphenyl)- (CA INDEX NAME)




RN 859492-39-0 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-(2-chlorophenyl)-3-(3-fluoro-4-methylphenyl)- (CA INDEX NAME)




RN 859492-45-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-bromophenyl)-7-chloro-3-(3-fluoro-4-methylphenyl)- (CA INDEX NAME)





RN 859492-51-6 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-2-(2-chlorophenyl)-3-(1H-indol-5-yl)- (CA INDEX NAME)





RN 859492-58-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2-bromophenyl)-7-chloro-3-(4-chloro-3-fluorophenyl)- (CA INDEX NAME)





RN 859492-71-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(5-bromo-2-chlorophenyl)-7-chloro-3-(3-fluoro-4-methylphenyl)- (CA INDEX NAME)



RN 859492-78-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-bromo-2-chlorophenyl)-7-chloro-3-(3-fluoro-4-methylphenyl)- (CA INDEX NAME)




RN 859492-91-4 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-[2-chloro-3-[(dimethylamino)methyl]phenyl]-3-(4-chloro-3-fluorophenyl)- (CA INDEX NAME)





RN 859492-98-1 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-[(4-methyl-1-piperazinyl)methyl]phenyl]- (CA INDEX NAME)



RN 859493-04-2 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-[(methylamino)methyl]phenyl]- (CA INDEX NAME)




RN 859493-11-1 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
[(4-methyl-1-piperazinyl)methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 859493-18-8 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-2-[2-chloro-3-[(ethylamino)methyl]phenyl]-3-
(4-chloro-3-fluorophenyl)- (CA INDEX NAME)



RN 859493-25-7 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-

[[(1-methylethyl)amino]methyl]phenyl]- (CA INDEX NAME)




RN 859493-31-5 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-[2-chloro-3-
 [(cyclopropylamino)methyl]phenyl]-3-(4-chloro-3-fluorophenyl)- (CA INDEX
 NAME)

PAGE 1-A





PAGE 2-A




RN 859493-39-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-(1-azetidinylmethyl)-2-chlorophenyl]-7-chloro-3-
 (4-chloro-3-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859493-46-2 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-(1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A






RN 859493-55-3 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
[[(3S)-3-hydroxy-1-pyrrolidinyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 859493-61-1 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
[[(3S)-3-(methoxymethyl)-1-pyrrolidinyl]methyl]phenyl]- (CA INDEX NAME)



Absolute stereochemistry.




RN 859493-67-7 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
[[(3S)-3-(pyrrolidinylamino)methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859493-73-5 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859493-79-1 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-(1-piperidinylmethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859493-86-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-[(4-amino-1-piperidinyl)methyl]-2-chlorophenyl]-7-chloro-3-(4-chloro-3-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859493-93-9 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-(4-(4-piperidinylamino)methyl)phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859494-00-1 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
 [(4-fluoro-1-piperidinyl)methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859494-06-7 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-(1-
 piperazinylmethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859494-13-6 CAPLUS

4(3H)-Quinazolinone, 2-[3-[(4-acetyl-1-piperazinyl)methyl]-2-chlorophenyl]-7-chloro-3-(4-chloro-3-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859494-20-5 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-[[4-(methylsulfonyl)-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 859494-27-2 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[(2-hydroxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)





RN 859494-34-1 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-[2-chloro-3-[[[2-(dimethylamino)ethyl]amino]methyl]phenyl]-3-(4-chloro-3-fluorophenyl)-
 (CA INDEX NAME)




RN 859494-40-9 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-[[[2-(4-morpholinyl)ethyl]amino]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859494-46-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-[(3-amino-1-pyrrolidinyl)methyl]-2-chlorophenyl]-7-chloro-3-(4-chloro-3-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859494-53-4 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[[2-chloro-3-[[[1-methyl-3-piperidinyl)methyl]amino]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 859494-60-3 CAPLUS
 CN Piperidinium, 3-(aminomethyl)-1-[[[2-chloro-3-[[7-chloro-3-(4-chloro-3-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-1-methyl- (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 859494-67-0 CAPLUS



CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-3-
[[(phenylmethyl)amino]methyl]phenyl]- (CA INDEX NAME)

RN 859494-80-7 CAPLUS


CN 4(3H)-Quinazolinone, 7-chloro-2-[2-chloro-5-[(ethylamino)methyl]phenyl]-3-
(4-chloro-3-fluorophenyl)- (CA INDEX NAME)



RN 859494-88-5 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-
 [[(1-methylethyl)amino]methyl]phenyl]- (CA INDEX NAME)




RN 859494-96-5 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-(1-
 pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)




RN 859495-03-7 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-[(3-pyrrolidinylamino)methyl]phenyl]- (CA INDEX NAME)




RN 859495-09-3 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)




RN 859495-16-2 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-(1-piperidinylmethyl)phenyl]- (CA INDEX NAME)




RN 859495-22-0 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-[(4-piperidinylamino)methyl]phenyl]- (CA INDEX NAME)




RN 859495-29-7 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-(1-piperazinylmethyl)phenyl]- (CA INDEX NAME)





RN 859495-34-4 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-(4-chloro-3-fluorophenyl)-2-[2-chloro-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)



RN 859495-45-7 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-[2-chloro-5-[[2-(dimethylamino)ethyl]amino]methyl]phenyl]-3-(4-chloro-3-fluorophenyl)-
(CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 44 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:426410 CAPLUS

DOCUMENT NUMBER: 142:457058

TITLE: Treatment or prevention of neoplasia by use of an
HSP90 inhibitorINVENTOR(S): Masferrer, Jaime L.; Penning, Thomas D.; Wang, Xing;
Heuvelman, Deborah M.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 190 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044194	A2	20050519	WO 2004-US36010	20041028
WO 2005044194	A3	20050721		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-515225P P 20031028

OTHER SOURCE(S): MARPAT 142:457058

AB A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of an Hsp90 inhibitor, or of a combination comprising an Hsp90 inhibitor and a Cox-2 inhibitor.


IT 178937-98-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment or prevention of neoplasia by use of HSP90 inhibitor in combination with Cox-2 inhibitor)

RN 178937-98-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(5-amino-2-propoxyphenyl)-8-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 45 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN

ACCESSION NUMBER: 2005:312785 CAPLUS

DOCUMENT NUMBER: 143:19241

TITLE: Structure-Based Validation of the 3D-QSAR Technique MaP

AUTHOR(S): Stiefl, Nikolaus; Baumann, Knut

CORPORATE SOURCE: Department of Pharmacy and Food Chemistry, University of Wuerzburg, Wuerzburg, 97074, Germany

SOURCE: Journal of Chemical Information and Modeling (2005), 45(3), 739-749

CODEN: JCISD8; ISSN: 1549-9596

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal
 LANGUAGE: English


AB For three target proteins with different binding pocket characteristics (size and shape, hydrophobicity, hydrogen-bonding) a structure-based validation of the translationally and rotationally invariant 3D-QSAR technique MaP is performed (MaP: Mapping Property distributions of mol. surfaces). The structure-based validation procedure comprises two steps: first, QSAR models are derived without using the information of the target protein. Second, the models are back-projected into the crystal structure of the binding pockets and interpreted. It is demonstrated that MaP is able to identify characteristics important for ligand binding in the cases studied here. Moreover, it is demonstrated that MaP is a versatile 3D-QSAR technique since good, predictive models could be obtained for all three data sets showing distinct characteristics.

IT 1036-50-6 1152-07-4 18818-41-2
 82256-08-4 89860-51-5 211172-81-5
 220115-32-2 852813-60-6 852813-61-7
 852813-63-9 852813-64-0 852813-65-1
 852813-66-2 852813-67-3 852813-68-4
 852813-69-5

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (structure-based validation of 3D-QSAR technique MaP)


RN 1036-50-6 CAPLUS

CN 4(3H)-Quinazolinone, 8-methoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 1152-07-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 18818-41-2 CAPLUS


CN 4(3H)-Quinazolinone, 2-(4-methylphenyl)- (CA INDEX NAME)




RN 82256-08-4 CAPLUS
 CN 4(3H)-Quinazolinone, 8-methoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 89860-51-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-hydroxyphenyl)- (CA INDEX NAME)




RN 211172-81-5 CAPLUS
 CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-hydroxyphenyl)- (CA INDEX NAME)




RN 220115-32-2 CAPLUS
 CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 852813-60-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-methylphenyl)-8-nitro- (CA INDEX NAME)




RN 852813-61-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-8-nitro- (CA INDEX NAME)




RN 852813-63-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-8-(trifluoromethyl)- (CA INDEX NAME)




RN 852813-64-0 CAPLUS
CN 8-Quinazolinecarbonitrile, 3,4-dihydro-2-(4-methylphenyl)-4-oxo- (CA INDEX NAME)




RN 852813-65-1 CAPLUS
CN 8-Quinazolinecarbonitrile, 3,4-dihydro-2-(4-methoxyphenyl)-4-oxo- (CA INDEX NAME)




RN 852813-66-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-amino-2-(4-methylphenyl)- (CA INDEX NAME)




RN 852813-67-3 CAPLUS
CN 8-Quinazolinecarboxylic acid, 3,4-dihydro-2-(4-methylphenyl)-4-oxo-, methyl ester (CA INDEX NAME)



RN 852813-68-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-hydroxyphenyl)-8-nitro- (CA INDEX NAME)



RN 852813-69-5 CAPLUS
 CN 4(3H)-Quinazolinone, 8-amino-2-(4-hydroxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (6 CITINGS)

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 46 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN

ACCESSION NUMBER: 2005:238744 CAPLUS

DOCUMENT NUMBER: 142:316851

TITLE: Preparation of fused ring heterocycles as potassium
 channel modulators

INVENTOR(S): McNaughton-Smith, Grant Andrew; Amato, George
 Salvatore; Thomas, James Barnwell

PATENT ASSIGNEE(S): Icagen, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 39 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050059823	A1	20050317	US 2004-937958	20040910
US 7223768	B2	20070529		
AU 2004272104	A1	20050324	AU 2004-272104	20040910
CA 2536633	A1	20050324	CA 2004-2536633	20040910
WO 2005025293	A2	20050324	WO 2004-US29868	20040910
WO 2005025293	A3	20050616		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1663237 A2 20060607 EP 2004-788717 20040910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

JP 2007505143 T 20070308 JP 2006-526375 20040910

US 20080058319 A1 20080306 US 2007-740831 20070426

PRIORITY APPLN. INFO.: US 2003-502109P P 20030910


US 2004-937958 A1 20040910

WO 2004-US29868 W 20040910


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:316851; MARPAT 142:316851

GI



I



II

AB Comps. I [A = (un)substituted 5-6 membered (hetero)aryl, cycloalkyl, 5-8 membered heteroaryl; X = CO, CS, SO₂; W = N, CR₃ (wherein R₃ = H, F, (un)substituted (hetero)aryl, etc.); Z = a bond, CH₂, CHF, CH:CH, etc.; Y = (CR₅R₆)_n (n = 0-4; R₅, R₆ = H, F, (un)substituted (hetero)aryl, etc.); R₁ = (un)substituted (hetero)aryl, cycloalkyl, 5-7 membered heterocyclyl, alkyl; R₂ = CF₃, (un)substituted alkyl, (hetero)aryl, cycloalkyl, 3-7 membered heterocyclyl], compns. and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinones, compns. and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions. E.g., a multi-step synthesis of II, starting from 2-trifluoromethoxyaniline, was given. The compound II and analogs were subsequently coupled with isocyanates and carboxylic acids to provide the compds. I such as 1-(2-cyclohexyl-4-oxo-4H-quinazolin-3-yl)-3-(2-fluorobenzyl)urea. The representative compds. I were tested for the ability to open voltage-gated potassium channels in the NG-108-15 FLIPR assay (data given for selected compds. I).

IT 848027-14-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolines as potassium channel modulators)

RN 848027-14-5 CAPLUS

CN Benzeneacetamide, N-[2-(4-nitrophenyl)-4-oxo-3(4H)-quinazolinyl]- (CA

INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
 REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 47 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:199466 CAPLUS

DOCUMENT NUMBER: 142:348143

TITLE: 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis

AUTHOR(S): Shcherbakova, Irina; Balandrin, Manuel F.; Fox, John; Ghatak, Anjan; Heaton, William L.; Conklin, Rebecca L. Drug Discovery, NPS Pharmaceuticals, Inc., Salt Lake City, UT, 84108, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(6), 1557-1560

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:348143

AB Structure-activity relationship studies, focused on identification of the active pharmacophore fragments in a single high-throughput screening calcilytic hit, resulted in the discovery of potent calcium receptor antagonists, substituted 3H-quinazolin-4-ones.

IT 312277-73-9P 489416-64-0P 691378-17-3P

691378-21-9P 691378-24-2P 691378-25-3P

691378-26-4P 691378-28-6P 691378-34-4P

691378-45-7P 691378-46-8P 691378-47-9P

691378-49-1P 691378-50-4P 691378-53-7P

691378-54-8P 691378-65-1P 691378-94-6P


849233-10-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(3H-quinazolin-4-ones preparation and structure-related potential for osteoporosis treatment)

RN 312277-73-9 CAPLUS


CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 489416-64-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 691378-17-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 691378-21-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-methoxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 691378-24-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 691378-25-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2,5-dihydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 691378-26-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 691378-28-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 691378-34-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(3-chlorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-45-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA
INDEX NAME)




RN 691378-46-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA
INDEX NAME)




RN 691378-47-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-5-methyl-3-(2-phenylethyl)- (CA
INDEX NAME)




RN 691378-49-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-8-methyl-3-(2-phenylethyl)- (CA
INDEX NAME)




RN 691378-50-4 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 691378-53-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5-methyl- (CA INDEX NAME)




RN 691378-54-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 691378-65-1 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-94-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)



RN 849233-10-9 CAPLUS

CN 4(3H)-Quinazolinone, 7-fluoro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 48 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:76302 CAPLUS

DOCUMENT NUMBER: 142:170068

TITLE: Small molecule toll-like receptor (TLR) antagonists

INVENTOR(S): Lipford, Grayson B.; Forsbach, Alexandra; Zepp, Charles M.

PATENT ASSIGNEE(S): Coley Pharmaceutical G.m.b.H., Germany; Coley Pharmaceutical Group, Inc.

SOURCE: PCT Int. Appl., 193 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007672	A2	20050127	WO 2004-US19714	20040618
WO 2005007672	A3	20050915		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004257149	A1	20050127	AU 2004-257149	20040618
CA 2528774	A1	20050127	CA 2004-2528774	20040618
US 20050119273	A1	20050602	US 2004-872196	20040618
US 7410975	B2	20080812		
EP 1635846	A2	20060322	EP 2004-776820	20040618
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1809357	A	20060726	CN 2004-80017064	20040618
BR 2004011514	A	20060801	BR 2004-11514	20040618
ZA 2005010028	A	20070328	ZA 2005-10028	20040618
JP 2007524615	T	20070830	JP 2006-517471	20040618
MX 2005013922	A	20060224	MX 2005-13922	20051216
IN 2006KN00153	A	20070706	IN 2006-KN153	20060119
US 20070232622	A1	20071004	US 2006-543314	20061004
IN 2008KN03435	A	20090213	IN 2008-KN3435	20080822
PRIORITY APPLN. INFO.:			US 2003-480588P	P 20030620
			US 2004-556007P	P 20040323
			US 2004-872196	A1 20040618
			WO 2004-US19714	W 20040618
			IN 2006-KN153	A3 20060119
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 142:170068				
AB	The invention provides methods and compns. useful for modulating signaling through Toll-like receptors (TLR). The methods involve contacting a TLR-expressing cell with a small mol. having a core structure including at least two rings. Certain of the compds. are 4-primary amino quinolines. Many of the compds. and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft vs. host disease, infection, sepsis, cancer, and immunodeficiency.			
IT	831226-60-9P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (small mol. toll-like receptor antagonists such as 4-primary amino quinolines to inhibit immunostimulatory signaling in response to antigens such as nucleic acids for treatment of autoimmune disorders)			
RN	831226-60-9 CAPLUS			
CN	Ethanamine, N,N-dimethyl-2-[[2-[4-(4-methyl-1-piperazinyl)phenyl]-4-			

quinazolinyl]oxy]-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 831226-59-6

CMF C23 H29 N5 O



CM 2

CRN 7664-93-9

CMF H2 O4 S



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 49 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:817853 CAPLUS

DOCUMENT NUMBER: 141:331920

TITLE: Preparation of benzamide compounds as phosphorus transport inhibitors

INVENTOR(S): Eto, Nobuaki; Nagao, Rika; Miyazaki, Tetsuko

PATENT ASSIGNEE(S): Kirin Beer Kabushiki Kaisha, Japan

SOURCE: PCT Int. Appl., 787 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085382	A1	20041007	WO 2004-JP4427	20040329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1614676 A1 20060111 EP 2004-724132 20040329
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 US 20060217426 A1 20060928 US 2006-550857 20060410
 PRIORITY APPLN. INFO.: JP 2003-89173 A 20030327
 WO 2004-JP4427 W 20040329

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 141:331920
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted unsatd. carbocycle, heterocycle; dotted line indicates single or double bond; Z = N:CR₆R₇, etc.; R₆, R₇ = H, alkyl, etc.; R₁ and R₂ in combination represents oxo and R₃ = R₄ = H or R₁ and R₄ in combination represents a bond and R₂ and R₃ in combination represents a bond; R₅ = alkyl, etc.] were prepared. For example, condensation of N-(2-hydrazinocarbonylphenyl)-3,4-dimethoxybenzaldehyde, e.g., prepared from Me 2-aminobenzoate in 2 steps, with trans-cinnamaldehyde afforded compound II in 57% yield. In sodium-dependency inhibition assays, the IC₅₀ value of compound II was 9.11 μ M. Compds. I are claimed useful for the treatment of renal insufficiency, hyperthyroidism, etc.


IT 773067-21-3P 773067-22-4P 773067-23-5P
 773067-24-6P 773067-29-1P 773067-73-5P
 773067-74-6P 773067-75-7P 773069-56-0P
 773069-57-1P 773104-28-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzamide compds. as phosphorus transport inhibitors)


RN 773067-21-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(4-fluorophenyl)methylene]amino]-2-[3-[[[(2-hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)




RN 773067-22-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-[3-[[[(2-hydroxyethyl)thio]methyl]phenyl]-3-[[[(4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 773067-23-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3,4-dimethylphenyl)methylene]amino]-2-[3-[[2-hydroxyethyl]thio]methyl]phenyl]- (CA INDEX NAME)




RN 773067-24-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-[3-[[2-hydroxyethyl]thio]methyl]phenyl]- (CA INDEX NAME)




RN 773067-29-1 CAPLUS

CN Ethanesulfonic acid, 2-[[[3-[6-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]thio]- (CA INDEX NAME)




RN 773067-73-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-[4-[[[(1,2-diethyl-4-pyrazolidinyl)amino]methyl]phenyl]-3-[[[(3,4-dimethylphenyl)methylene]amino]- (CA INDEX NAME)




RN 773067-74-6 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-[4-[[[(1,2-diethyl-4-pyrazolidinyl)amino]methyl]phenyl]-3-[[[(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 773067-75-7 CAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-[4-[[[(1,2-diethyl-4-pyrazolidinyl)amino]methyl]phenyl]- (CA INDEX NAME)




RN 773069-56-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-2-[4-[[2-(hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)



RN 773069-57-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-[[2-(diethylamino)ethyl]methylamino]methyl]phenyl]-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-[[[4-methoxyphenyl]methylene]amino]- (CA INDEX NAME)



RN 773104-28-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[4-[[1,2-diethyl-4-pyrazolidinyl]amino]methyl]phenyl]-3-[[[4-methoxyphenyl]methylene]amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 50 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:756698 CAPLUS

DOCUMENT NUMBER: 141:277632

TITLE: Preparation of quinazolines as modulators of ion channels

INVENTOR(S): Gonzales, Jesus E., III; Wilson, Dean Mitchell; Termin, Andreas Peter; Grootenhuys, Peter Diederik Jan; Zhang, Yulian; Petzoldt, Benjamin John; Fanning, Lev Tyler Dewey; Neubert, Timothy Donald; Tung, Roger D.; Martinborough, Esther; Zimmermann, Nicole
 Vertex Pharmaceuticals Incorporated, USA

PATENT ASSIGNEE(S):

SOURCE: PCT Int. Appl., 565 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078733	A1	20040916	WO 2004-US6451	20040303
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004217891	A1	20040916	AU 2004-217891	20040303
CA 2517844	A1	20040916	CA 2004-2517844	20040303
EP 1608632	A1	20051228	EP 2004-716887	20040303
EP 1608632	B1	20091230		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
BR 2004008026	A	20060207	BR 2004-8026	20040303
CN 1784391	A	20060607	CN 2004-80011981	20040303
JP 2006522119	T	20060928	JP 2006-509028	20040303
ZA 2005007979	A	20070328	ZA 2005-7979	20040303
NZ 542664	A	20090331	NZ 2004-542664	20040303
MX 2005009347	A	20080613	MX 2005-9347	20050902
NO 2005004546	A	20051125	NO 2005-4546	20051003
IN 2005KN01955	A	20061124	IN 2005-KN1955	20051003
PRIORITY APPLN. INFO.:			US 2003-451458P	P 20030303

US 2003-463797P
WO 2004-US6451P 20030418
A 20040303OTHER SOURCE(S):
GI

MARPAT 141:277632



AB The title compds. [I; NR₁R₂ = (un)substituted 3-12 membered monocyclic or bicyclic (un)saturated ring having 0-3 heteroatoms selected from N, S or O; ring A = (un)substituted 5-7 membered aryl or 8-10 membered bicyclic aryl having 0-3 heteroatoms selected from N, S or O; x = 0-4; R₃ = QR (wherein Q = a bond, alkylidene wherein up to two non-adjacent methylene units are optionally replaced by S, O, CS, etc.; R = halo, NO₂, CN, etc.)], useful as inhibitors of voltage-gated sodium channels and calcium channels, were prepared. Thus, reacting 2-(4-chloro-7-methylquinazolin-2-yl)phenol with 4-aminopiperidine in the presence of Et₃N in CH₂Cl₂ afforded 89% II. Representative compds. I were found to possess desired N-type calcium channel modulation activity and selectivity (no specific data given). Also, representative compds. I were found to possess desired voltage gated sodium channel activity and selectivity (no specific data given). The invention also provides pharmaceutically acceptable compns. comprising the compds. I and methods of using the compns. in the treatment of various disorders.


IT 378766-55-3P 421581-48-8P 757985-37-8P
757985-42-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolines as modulators of ion channels)


RN 378766-55-3 CAPLUS

CN Phenol, 2-[4-(1-methylethoxy)-2-quinazolinyl]- (CA INDEX NAME)




RN 421581-48-8 CAPLUS


CN Phenol, 2-[4-(1-methylethoxy)-2-quinazolinyl]- (CA INDEX NAME)



RN 757985-37-8 CAPLUS
CN Quinazoline, 7-chloro-2-(2-fluorophenyl)-4-(phenylmethoxy)- (CA INDEX NAME)



RN 757985-42-5 CAPLUS
CN Phenol, 2-(4-propoxy-2-quinazolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 51 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:649064 CAPLUS
DOCUMENT NUMBER: 142:68677
TITLE: Selective induction of G2/M arrest and apoptosis in HL-60 by a potent anticancer agent, HMJ-38
AUTHOR(S): Yang, Jai-Sing; Hour, Mann-Jen; Kuo, Sheng-Chu; Huang, Li-Jiau; Lee, Miau-Rong
CORPORATE SOURCE: Graduate Institute of Pharmaceutical Chemistry, School of Medicine, China Medical University, Taichung, 404, Taiwan
SOURCE: Anticancer Research (2004), 24(3A), 1769-1778
CODEN: ANTRD4; ISSN: 0250-7005
PUBLISHER: International Institute of Anticancer Research
DOCUMENT TYPE: Journal

LANGUAGE: English

AB We previously reported that HMJ-38 was the most potent 2-phenyl-4-quinazolinone derivative in inhibiting tubulin polymerization and showed


significant cytotoxicity against several human tumor cell lines. In this work, we studied its cytotoxic effect on HL-60 leukemia cells and the underlying mechanisms. We first investigated the effects of HMJ-38 on viability, cell cycle and induction of apoptosis in HL-60 and normal human peripheral blood mononuclear cells (PBMC). After 24-h treatment with HMJ-38, a dose- and time-dependent decrease in the viability of HL-60 cells was observed and the approx. IC50 was 4.48 μ M. The cytotoxic effect of HMJ-38 on PBMC was less significant than that on HL-60 cells, either with 24 or 48 h of treatment. Cell cycle anal. showed that HMJ-38 induced significant G2/M arrest and apoptosis in HL-60 cells. The HMJ-38-induced G2/M arrest occurred before the onset of apoptosis. Within 24 h of treatment, HMJ-38 influenced the CDK/cyclin B activity by increasing Chk1, Wee1 and p21 and decreasing Cdc25C protein levels. The HMJ-38-induced apoptosis was further confirmed by morphol. assessment and DNA fragmentation assay. Induction of apoptosis in HMJ-38-treated HL-60 cells was accompanied by an apparent increase of cytosolic cytochrome c, down-regulation of Bcl-2, up-regulation of Bax and cleavage of pro-caspase-9, -3 and poly(ADP)ribosylpolymerase (PARP). The results of the significant reduction of caspase activities and apoptosis by caspase inhibitors indicated that the HMJ-38-induced apoptosis was mainly mediated by activation of caspases-9 and -3. HMJ-38 also activated ERK in HL-60 cells. Pre-incubating cells with ERK inhibitors (U0126 and PD98059) attenuated the HMJ-38-induced ERK activation and apoptosis. Nevertheless, cells remained arrested in G2/M. These results suggest that HMJ-38 is a potent anticancer drug and it shows a remarkable action on cell cycle before commitment for apoptosis is reached.

IT 299897-92-0, HMJ 38

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMJ-38 induced cell cycle arrest, ERK-dependent apoptosis, reduced cell viability, inhibited cell proliferation in human HL-60 leukemia cells and was less toxic normal human peripheral blood mononuclear cells)

RN 299897-92-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-methoxyphenyl)-6-(1-pyrrolidinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 52 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN

ACCESSION NUMBER: 2004:412903 CAPLUS



DOCUMENT NUMBER: 140:423688

TITLE: Preparation of quinazolinone derivatives as

calciolytics
 INVENTOR(S): Shcherbakova, Irina; Balandrin, Manuel; Fox, John;
 Heaton, William; Conklin, Rebecca; Papac, Damon
 PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041755	A2	20040521	WO 2003-US35162	20031104
WO 2004041755	A3	20040708		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2502302	A1	20040521	CA 2003-2502302	20031104
AU 2003291761	A1	20040607	AU 2003-291761	20031104
EP 1558260	A2	20050803	EP 2003-768655	20031104
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1708306	A	20051214	CN 2003-80102626	20031104
JP 2006512315	T	20060413	JP 2004-550482	20031104
US 20060052345	A1	20060309	US 2005-531161	20050412
MX 2005004328	A	20050802	MX 2005-4328	20050422
PRIORITY APPLN. INFO.:			US 2002-423663P	P 20021104
			WO 2003-US35162	W 20031104

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 140:423688
 GI




AB The title compds. I [R1, R2, R3 = H, halo, CN, CF3, OCF3, alkyl, alkoxy, etc.; R4 (optional) = H, halo, CN, CF3, OCF3, alkyl, alkoxy, etc.; X = C or N; R5 = H, alkyl, furyl, thienyl, styryl, pyridyl, (substituted)phenyl; R6 = H, alkyl, or -(CH2)n-X1-R7; n= 0-2; X1 = O, CO, CHOH, alkyl, or a single bond; R7 = an aromatic group optionally substituted with 1-3 substituents selected from H, halo, CN, CF3, OCF3, alkyl, alkoxy, etc.] were prepared as calcium receptor antagonists for the treatment of bone diseases. Thus, reaction of 2-phenyl-benzo[d][1,3]oxazin-4-one (preparation given) with phenethylamine gave compound II. Methods to determine the biol. activity of the compound of this invention were demonstrated.

IT 691378-50-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazolinone derivs. as calcilytics)

RN 691378-50-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-fluoro-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)



IT	312277-73-9P	397876-48-1P	450401-51-1P
	488843-93-2P	489397-58-2P	489416-64-0P
	691378-17-3P	691378-18-4P	691378-19-5P
	691378-21-9P	691378-24-2P	691378-25-3P
	691378-26-4P	691378-28-6P	691378-29-7P


691378-30-0P	691378-31-1P	691378-32-2P
691378-33-3P	691378-34-4P	691378-35-5P
691378-36-6P	691378-37-7P	691378-38-8P
691378-39-9P	691378-40-2P	691378-41-3P
691378-42-4P	691378-43-5P	691378-44-6P
691378-45-7P	691378-46-8P	691378-47-9P
691378-48-0P	691378-49-1P	691378-51-5P
691378-52-6P	691378-53-7P	691378-54-8P
691378-55-9P	691378-56-0P	691378-57-1P
691378-58-2P	691378-59-3P	691378-60-6P
691378-61-7P	691378-62-8P	691378-63-9P
691378-64-0P	691378-65-1P	691378-66-2P
691378-67-3P	691378-68-4P	691378-71-9P
691378-74-2P	691378-76-4P	691378-78-6P
691378-79-7P	691378-80-0P	691378-81-1P
691378-82-2P	691378-83-3P	691378-86-6P
691378-87-7P	691378-88-8P	691378-94-6P
691378-95-7P	691378-96-8P	691378-97-9P
691378-98-0P	691378-99-1P	691379-00-7P
691379-01-8P	691379-03-0P	691379-04-1P
691379-06-3P	691379-07-4P	691380-15-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolinone derivs. as calcilytics)


RN 312277-73-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 397876-48-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methylphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 450401-51-1 CAPLUS


CN 4(3H)-Quinazolinone, 2-(4-chlorophenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 488843-93-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-chlorophenyl)-3-(2-phenylethyl)- (CA INDEX
 NAME)




RN 489397-58-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-methylphenyl)-3-(2-phenylethyl)- (CA INDEX
 NAME)




RN 489416-64-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-3-(2-phenylethyl)- (CA INDEX
 NAME)




RN 691378-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-(2-phenylethyl)- (CA INDEX
 NAME)




RN 691378-18-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-methylphenyl)-3-(2-phenylethyl)- (CA INDEX
NAME)




RN 691378-19-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-chlorophenyl)-3-(2-phenylethyl)- (CA INDEX
NAME)




RN 691378-21-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-methoxyphenyl)-3-(2-phenylethyl)- (CA INDEX
NAME)




RN 691378-24-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX
NAME)




RN 691378-25-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2,5-dihydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX
 NAME)




RN 691378-26-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(3-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX
 NAME)




RN 691378-28-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX
 NAME)




RN 691378-29-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-3-(2-phenoxyethyl)- (CA INDEX
 NAME)




RN 691378-30-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA
INDEX NAME)




RN 691378-31-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA
INDEX NAME)



RN 691378-32-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA
INDEX NAME)




RN 691378-33-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-chlorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA
INDEX NAME)




RN 691378-34-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-chlorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-35-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(2-chlorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 691378-36-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-3-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)



10/ 582,823


RN 691378-37-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-3-[2-(3-methoxyphenyl)ethyl]-
(CA INDEX NAME)




RN 691378-38-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-3-[2-(2-methoxyphenyl)ethyl]-
(CA INDEX NAME)




RN 691378-39-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-3-[(4-methylphenyl)methyl]- (CA
INDEX NAME)




RN 691378-40-2 CAPLUS


CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-3-[2-(4-methylphenyl)ethyl]- (CA
INDEX NAME)




RN 691378-41-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(3,4-dichlorophenyl)ethyl]-2-(2-hydroxyphenyl)-
(CA INDEX NAME)




RN 691378-42-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(2,4-dichlorophenyl)ethyl]-2-(2-hydroxyphenyl)-
(CA INDEX NAME)




RN 691378-43-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(3,4-dimethoxyphenyl)ethyl]-2-(2-hydroxyphenyl)-
(CA INDEX NAME)




RN 691378-44-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-6-methyl-3-(2-phenylethyl)- (CA
 INDEX NAME)




RN 691378-45-7 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA
 INDEX NAME)



RN 691378-46-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA
 INDEX NAME)




RN 691378-47-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-5-methyl-3-(2-phenylethyl)- (CA
 INDEX NAME)



10/ 582,823


RN 691378-48-0 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 691378-49-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-8-methyl-3-(2-phenylethyl)- (CA INDEX NAME)




RN 691378-51-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-fluoro-3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-52-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5-methyl- (CA INDEX NAME)




RN 691378-53-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-5-methyl- (CA INDEX NAME)




RN 691378-54-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 691378-55-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




RN 691378-56-0 CAPLUS


CN 4(3H)-Quinazolinone, 6-chloro-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-57-1 CAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 691378-58-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methoxy- (CA INDEX NAME)




RN 691378-59-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-6-hydroxy-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-60-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-8-methoxy- (CA INDEX NAME)




RN 691378-61-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-8-(trifluoromethyl)- (CA INDEX NAME)




RN 691378-62-8 CAPLUS

CN Acetamide, N-[3-[2-(3-fluorophenyl)ethyl]-3,4-dihydro-2-(2-hydroxyphenyl)-4-oxo-6-quinazolinyl]- (CA INDEX NAME)




RN 691378-63-9 CAPLUS


CN 4(3H)-Quinazolinone, 8-chloro-2-(2-hydroxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 691378-64-0 CAPLUS
 CN 4(3H)-Quinazolinone, 8-chloro-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 691378-65-1 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-66-2 CAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-67-3 CAPLUS
 CN 4(3H)-Quinazolinone, 8-chloro-3-[2-(2-fluorophenyl)ethyl]-2-(2-

hydroxyphenyl)- (CA INDEX NAME)




RN 691378-68-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-3-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)




RN 691378-71-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-fluoro-2-(2-hydroxyphenyl)-3-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 691378-74-2 CAPLUS


CN 4(3H)-Quinazolinone, 6-fluoro-2-(2-hydroxyphenyl)-3-(3-phenylpropyl)- (CA INDEX NAME)



RN 691378-76-4 CAPLUS


CN 4(3H)-Quinazolinone, 6-fluoro-2-(2-hydroxyphenyl)-3-(1-methyl-1-

phenylethyl)- (CA INDEX NAME)




RN 691378-78-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(1,1-dimethyl-2-phenylethyl)-6-fluoro-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-79-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-(1,1-dimethyl-3-phenylpropyl)-6-fluoro-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-80-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-fluoro-2-(2-hydroxyphenyl)-3-(2-phenylpropyl)- (CA INDEX NAME)




RN 691378-81-1 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-2-(2-hydroxyphenyl)-3-[(2R)-2-phenylpropyl]-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 691378-82-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-2-(2-hydroxyphenyl)-3-[(2S)-2-phenylpropyl]-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 691378-83-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,2-diphenylethyl)-6-fluoro-2-(2-hydroxyphenyl)-
 (CA INDEX NAME)




RN 691378-86-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-3-(2-phenylethyl)-5-[(2-phenylethyl)amino]-
 (CA INDEX NAME)




RN 691378-87-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3-fluorophenyl)ethyl]-7-[[2-(3-fluorophenyl)ethyl]amino]-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-88-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-phenylethyl)-2-[2-[(2-phenylethyl)amino]phenyl]- (CA INDEX NAME)




RN 691378-94-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)-3-(2-phenylethyl)- (CA INDEX NAME)




RN 691378-95-7 CAPLUS


CN 4(3H)-Quinazolinone, 3-butyl-6-fluoro-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 691378-96-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-2-(2-hydroxyphenyl)-3-propyl- (CA INDEX NAME)



RN 691378-97-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-2-(2-hydroxyphenyl)-3-(3-methylbutyl)- (CA INDEX NAME)




RN 691378-98-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(acetyloxy)phenyl]-6-fluoro-3-[2-(3-fluorophenyl)ethyl]- (CA INDEX NAME)




RN 691378-99-1 CAPLUS
CN Propanoic acid, 2-methyl-, 2-[6-fluoro-3-[2-(3-fluorophenyl)ethyl]-3,4-

dihydro-4-oxo-2-quinazolinyl]phenyl ester (CA INDEX NAME)




RN 691379-00-7 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 2-[6-fluoro-3-[2-(3-fluorophenyl)ethyl]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl ester (CA INDEX NAME)




RN 691379-01-8 CAPLUS

CN Carbamic acid, dimethyl-, 2-[6-fluoro-3-[2-(3-fluorophenyl)ethyl]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 691379-03-0 CAPLUS


CN Glycine, N-methyl-, 2-[6-fluoro-3-[2-(3-fluorophenyl)ethyl]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 691379-04-1 CAPLUS


CN 4(3H)-Quinazolinone, 6-fluoro-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 691379-06-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-fluoro-3-[2-(3-fluorophenyl)ethyl]-2-[2-(phosphonooxy)phenyl]- (CA INDEX NAME)




RN 691379-07-4 CAPLUS

CN 4(3H)-Quinazolinone, 7-fluoro-3-[2-(3-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 691380-15-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-hydroxyphenyl)-3-[2-(4-hydroxyphenyl)ethyl]-
(CA INDEX NAME)OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 53 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN

ACCESSION NUMBER: 2004:368869 CAPLUS

DOCUMENT NUMBER: 140:391291

TITLE: Preparation of quinazolinones and analogs as Factor Xa
inhibitors

INVENTOR(S): Han, Wei; Hu, Zilun

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037176	A2	20040506	WO 2003-US32816	20031016
WO 2004037176	A3	20041014		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003301662 A1 20040513 AU 2003-301662 20031016
 US 20040132732 A1 20040708 US 2003-687421 20031016
 EP 1553947 A2 20050720 EP 2003-809567 20031016
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 PRIORITY APPLN. INFO.: US 2002-420098P P 20021021
 WO 2003-US32816 W 20031016
 OTHER SOURCE(S): MARPAT 140:391291
 GI



AB Title compds. [I; M = atoms to form a (substituted) 5-6 membered aromatic or dihydroarom. (heterocyclic) ring; 1 of P4, M4 = ZAB, the other = GlG; D = (substituted) (Ph-, pyridyl-, pyrimidyl-, pyrazinyl- pyridazinyl-fused) 5-6 membered (heterocyclic) ring, etc.; Gl = null, (substituted) alkylene, alkenylene, alkynylene, etc.; Z = bond, (substituted) alkylene, alkyleneaminoalkylene, etc.; A, Y = (substituted) carbocyclyl, heterocyclyl; B = Y, XY, (alkylene)carbonylamino, etc.; X = (substituted) alkylene, imino, CO, etc.; with provisos], were prepared as antithrombotics (no data). Thus, biphenyl-4-carboxylic acid was stirred 2 h with (COCl)₂ and cat. DMF in CH₂Cl₂; the residue was added to a mixture of 2-amino-5-chloro-N-(5-chloropyridin-2-yl)benzamide (preparation given), Et₃N and DMAP in CH₂Cl₂ at 0° followed by stirring overnight at room temperature to give the desired biphenylcarboxamide. This was refluxed with HCl in dioxane/THF to give 2-biphenyl-4-yl-6-chloro-3-(5-chloropyridine-2-yl)-3H-quinazolin-4-one.

IT 687639-18-5P 687639-19-6P 687639-20-9P
 687639-21-0P 687639-22-1P 687639-23-2P
 687639-24-3P 687639-25-4P 687639-26-5P
 687639-27-6P 687639-28-7P 687639-29-8P
 687639-30-1P 687639-31-2P 687639-32-3P
 687639-33-4P 687639-34-5P 687639-35-6P
 687639-36-7P 687639-37-8P 687639-38-9P
 687639-39-0P 687639-40-3P 687639-41-4P
 687639-42-5P 687639-43-6P 687639-44-7P
 687639-45-8P 687639-46-9P 687639-47-0P
 687639-48-1P 687639-49-2P 687639-50-5P
 687639-51-6P 687639-52-7P 687639-53-8P
 687639-54-9P 687639-55-0P 687639-56-1P
 687639-57-2P 687639-58-3P 687639-59-4P
 687639-60-7P 687639-61-8P 687639-62-9P
 687639-63-0P 687639-64-1P 687639-65-2P
 687639-66-3P 687639-67-4P 687639-68-5P
 687639-69-6P 687639-70-9P 687639-71-0P
 687639-72-1P 687639-73-2P 687639-74-3P
 687639-75-4P 687639-76-5P 687639-77-6P


687639-78-7P	687639-79-8P	687639-80-1P
687639-81-2P	687639-82-3P	687639-83-4P
687639-84-5P	687639-85-6P	687639-86-7P
687639-87-8P	687639-88-9P	687639-89-0P
687639-90-3P	687639-91-4P	687639-92-5P
687639-93-6P	687639-94-7P	687639-95-8P
687639-96-9P	687639-97-0P	687639-98-1P
687639-99-2P	687640-00-2P	687640-01-3P
687640-02-4P	687640-03-5P	687640-04-6P
687640-05-7P	687640-06-8P	687640-07-9P
687640-08-0P	687640-09-1P	687640-10-4P
687640-11-5P	687640-12-6P	687640-13-7P
687640-14-8P	687640-15-9P	687640-16-0P
687640-17-1P	687640-18-2P	687640-19-3P
687640-20-6P	687640-21-7P	687640-22-8P
687640-23-9P	687640-24-0P	687640-25-1P
687640-26-2P	687640-27-3P	687640-28-4P
687640-29-5P	687640-30-8P	687640-31-9P
687640-32-0P	687640-33-1P	687640-34-2P
687640-35-3P	687640-36-4P	687640-37-5P
687640-38-6P	687640-39-7P	687640-40-0P
687640-41-1P	687640-42-2P	687640-43-3P
687640-44-4P	687640-45-5P	687640-46-6P
687640-47-7P	687640-48-8P	687640-49-9P
687640-50-2P	687640-51-3P	687640-52-4P
687640-53-5P	687640-54-6P	687640-55-7P
687640-56-8P	687640-57-9P	687640-58-0P
687640-59-1P	687640-60-4P	687640-61-5P
687640-62-6P	687640-63-7P	687640-64-8P
687640-65-9P	687640-66-0P	687640-67-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of quinazolinones and analogs as Factor Xa inhibitors)


RN 687639-18-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1H-pyrrol-2-yl)phenyl]-
(CA INDEX NAME)




RN 687639-19-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-methyl-1H-pyrrol-2-yl)phenyl]-
(CA INDEX NAME)




RN 687639-20-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-ethyl-1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)




RN 687639-21-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-aminoethyl)-1H-pyrrol-2-yl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-22-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-(methylamino)ethyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-23-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-(ethylamino)ethyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-24-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-(phenylmethylamino)ethyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-25-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-pyridinyl)-2-[4-[1-(2-[(2-pyridinylmethyl)amino]ethyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-26-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-pyridinyl)-2-[4-[1-[2-[(3-pyridinylmethyl)amino]ethyl]-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-27-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-pyridinyl)-2-[4-[1-[2-[(4-pyridinylmethyl)amino]ethyl]-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-28-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(phenylmethyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-29-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-pyridinylmethyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-30-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(3-pyridinylmethyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-31-2 CAPLUS


CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(4-pyridinylmethyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)



RN 687639-32-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-cyclohexyl-1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)




RN 687639-33-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(tetrahydro-2H-pyran-4-yl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-34-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(4-piperidinyl)-1H-

pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-35-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(1-methyl-4-piperidinyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-36-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[1-(1-acetyl-4-piperidinyl)-1H-pyrrol-2-yl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-37-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-(1-methylethyl)-1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)




RN 687639-38-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-(1-methylethyl)-1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)




RN 687639-39-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-(1-methylethyl)-1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)




RN 687639-40-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-cyclopentyl-1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)



RN 687639-41-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(tetrahydro-3-furanyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-42-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(3-pyrrolidinyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-43-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(1-methyl-3-pyrrolidinyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)



RN 687639-44-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[1-(1-acetyl-3-pyrrolidinyl)-1H-pyrrol-2-yl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)



RN 687639-45-8 CAPLUS


CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-[1-(methylsulfonyl)-3-pyrrolidinyl]-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)

3-pyrrolidinyl]-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-46-9 CAPLUS

CN Acetamide, N-[2-[2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-1H-pyrrol-1-yl]ethyl]- (CA INDEX NAME)




RN 687639-47-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-hydroxyethyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-48-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-methoxyethyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-49-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-methoxy-1-methylethyl)-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-50-5 CAPLUS

CN 1H-Pyrrole-1-acetamide, 2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 687639-51-6 CAPLUS

CN 1H-Pyrrole-1-acetamide, 2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-N-methyl- (CA INDEX NAME)




RN 687639-52-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 687639-53-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 687639-54-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-ethyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 687639-55-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[1-(2-aminoethyl)-1H-imidazol-2-yl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-56-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-[2-(methylamino)ethyl]-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-57-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[1-[2-(ethylamino)ethyl]-1H-imidazol-2-yl]phenyl]-3-(2-pyridinyl)- (CA INDEX NAME)




RN 687639-58-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[1-[2-[(phenylmethyl)amino]ethyl]-1H-imidazol-2-yl]phenyl]-3-(2-pyridinyl)- (CA INDEX NAME)




RN 687639-59-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-pyridinyl)-2-[4-[1-[2-[(2-pyridinylmethyl)amino]ethyl]-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-60-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-pyridinyl)-2-[4-[1-[2-[(2-pyridinylmethyl)amino]ethyl]-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-61-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-pyridinylmethyl)-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-62-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(3-pyridinylmethyl)-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-63-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-(4-pyridinylmethyl)-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 687639-64-1 CAPLUS


CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-cyclohexyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



10/ 582,823


RN 687639-65-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-66-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(4-piperidinyl)-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-67-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(1-methyl-4-piperidinyl)-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-68-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[1-(1-acetyl-4-piperidinyl)-1H-imidazol-2-yl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-69-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(1-methylethyl)-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-70-9 CAPLUS


CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-cyclopropyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 687639-71-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-cyclobutyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 687639-72-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-cyclopentyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 687639-73-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1-(tetrahydro-3-furanyl)-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 687639-74-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(3-pyrrolidinyl)-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-75-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(1-methyl-3-pyrrolidinyl)-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-76-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[1-(1-acetyl-3-pyrrolidinyl)-1H-imidazol-2-yl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-77-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-[1-(methylsulfonyl)-3-pyrrolidinyl]-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-78-7 CAPLUS

CN Acetamide, N-[2-[2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-1H-imidazol-1-yl]ethyl]- (CA INDEX NAME)




RN 687639-79-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-hydroxyethyl)-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-80-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-methoxyethyl)-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-81-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-methoxy-1-methylethyl)-1H-imidazol-2-yl]phenyl]- (CA INDEX NAME)




RN 687639-82-3 CAPLUS

CN 1H-imidazole-1-acetamide, 2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 687639-83-4 CAPLUS

CN 1H-Imidazole-1-acetamide, 2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-N-methyl- (CA INDEX NAME)




RN 687639-84-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(5-amino-2-furanyl)phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-85-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[5-(aminomethyl)-2-furanyl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-86-7 CAPLUS
 CN 2-Furancarboxamide, 5-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]- (CA INDEX NAME)



RN 687639-87-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-[5-(1-amino-1-methylethyl)-2-furanyl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-88-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-(3-amino-2-furanyl)phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-89-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[3-(dimethylamino)methyl]-2-furanyl]phenyl]- (CA INDEX NAME)




RN 687639-90-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[3-[1-(dimethylamino)-1-methylethyl]-2-furanyl]phenyl]- (CA INDEX NAME)




RN 687639-91-4 CAPLUS


CN 3-Furancarboxamide, 2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 687639-92-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(2-oxazolyl)phenyl]-
 (CA INDEX NAME)



RN 687639-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-[5-(aminomethyl)-2-oxazolyl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-94-7 CAPLUS
 CN 5-Oxazolecarboxamide, 2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]- (CA INDEX NAME)



10/ 582,823


RN 687639-95-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[4-(aminomethyl)-2-oxazolyl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-96-9 CAPLUS

CN 4-Oxazolecarboxamide, 2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 687639-97-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(2-thiazolyl)phenyl]- (CA INDEX NAME)




RN 687639-98-1 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[5-(aminomethyl)-2-thiazolyl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687639-99-2 CAPLUS
 CN 5-Thiazolocarboxamide, 2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 687640-00-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-(4-amino-2-thiazolyl)phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687640-01-3 CAPLUS
 CN Acetamide, N-[2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-4-thiazolyl]- (CA INDEX NAME)




RN 687640-02-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-(5-amino-2-thiazolyl)phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687640-03-5 CAPLUS
 CN Acetamide, N-[2-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-5-thiazolyl]- (CA INDEX NAME)



RN 687640-04-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 687640-05-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(2-oxo-1-imidazolidinyl)phenyl]- (CA INDEX NAME)



10/ 582,823


RN 687640-06-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(hexahydro-2-oxo-1H-1,3-diazepin-1-yl)phenyl]- (CA INDEX NAME)




RN 687640-07-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(3-amino-2-oxo-1-piperidiny)phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687640-08-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[3-(dimethylamino)-2-oxo-1-piperidiny]phenyl]- (CA INDEX NAME)




RN 687640-09-1 CAPLUS


CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[2-oxo-3-(1-pyrrolidinyl)-1-piperidiny]phenyl]- (CA INDEX NAME)




RN 687640-10-4 CAPLUS
 CN Acetamide, N-[1-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-2-oxo-3-piperidinyl]- (CA INDEX NAME)



RN 687640-11-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-(3-amino-2-oxo-1-pyrrolidinyl)phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687640-12-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]phenyl]- (CA INDEX NAME)




RN 687640-13-7 CAPLUS

CN 1H-imidazole-2-carboxamide, 1-[4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 687640-14-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(5-isoxazolyl)phenyl]- (CA INDEX NAME)




RN 687640-15-9 CAPLUS


CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(5-oxazolyl)phenyl]- (CA INDEX NAME)




RN 687640-16-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(5-thiazolyl)phenyl]-
 (CA INDEX NAME)



RN 687640-17-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(1H-1,2,3-triazol-5-yl)phenyl]-
 (CA INDEX NAME)




RN 687640-18-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(3-methyl-1H-1,2,4-triazol-5-yl)phenyl]-
 (CA INDEX NAME)




RN 687640-19-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(5-methyl-1,3,4-

thiadiazol-2-yl)phenyl]- (CA INDEX NAME)




RN 687640-20-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1,1'-biphenyl]-4-yl-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687640-21-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2'-amino[1,1'-biphenyl]-4-yl)-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687640-22-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[2'-(dimethylamino)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 687640-23-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2'-(aminomethyl)[1,1'-biphenyl]-4-yl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687640-24-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[2'-(dimethylaminomethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 687640-25-1 CAPLUS


CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(2-pyridinyl)phenyl]- (CA INDEX NAME)




RN 687640-26-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(3-pyridinyl)phenyl]-
 (CA INDEX NAME)



RN 687640-27-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(4-pyridinyl)phenyl]-
 (CA INDEX NAME)




RN 687640-28-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-(2-amino-3-pyridinyl)phenyl]-3-(5-chloro-2-pyridinyl)-
 (CA INDEX NAME)




RN 687640-29-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[2-(aminomethyl)-3-pyridinyl]phenyl]-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)




RN 687640-30-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[2-(dimethylamino)methyl]-3-pyridinyl]phenyl)- (CA INDEX NAME)




RN 687640-31-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 687640-32-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 687640-33-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(5-chloro-2-pyridinyl)-2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 687640-34-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-6-fluoro-2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 687640-35-3 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-(5-chloro-2-pyridinyl)-2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 687640-36-4 CAPLUS

CN 6-Quinazolinecarbonitrile, 3-(5-chloro-2-pyridinyl)-2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 687640-37-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-6-methoxy- (CA INDEX NAME)




RN 687640-38-6 CAPLUS

CN 6-Quinazolinecarboxamide, 3-(5-chloro-2-pyridinyl)-2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 687640-39-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(5-chloro-2-pyridinyl)-2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 687640-40-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-6-methoxy- (CA INDEX NAME)




RN 687640-41-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-6-fluoro-2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 687640-42-2 CAPLUS

CN 6-Quinazolinecarbonitrile, 3-(5-chloro-2-pyridinyl)-2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 687640-43-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 687640-44-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-(4-methoxyphenyl)- (CA INDEX NAME)




RN 687640-45-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 687640-46-6 CAPLUS
 CN Benzonitrile, 2-fluoro-5-[2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-oxo-3(4H)-quinazolinyl]- (CA INDEX NAME)




RN 687640-47-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[5-chloro-2-pyridinyl]-2-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (CA INDEX NAME)




RN 687640-48-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[4-(1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)



RN 687640-49-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[4-(1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)




RN 687640-50-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-2-[4-(1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)



10/ 582,823


RN 687640-51-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-2-[4-(1-methyl-1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)




RN 687640-52-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[4-(1-methyl-1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)




RN 687640-53-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-6-methoxy-2-[4-(1-methyl-1H-pyrrol-2-yl)phenyl]- (CA INDEX NAME)




RN 687640-54-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(2-(dimethylamino)ethyl)-1H-pyrrol-2-yl]phenyl]-6-methoxy- (CA INDEX NAME)




RN 687640-55-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(5-chloro-2-pyridinyl)-2-[4-[1-[2-(dimethylamino)ethyl]-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687640-56-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(4-chlorophenyl)-2-[4-[1-[2-(dimethylamino)ethyl]-1H-pyrrol-2-yl]phenyl]- (CA INDEX NAME)




RN 687640-57-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-6-methoxy-2-[4-(2-oxo-1-imidazolidinyl)phenyl]- (CA INDEX NAME)




RN 687640-58-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(5-chloro-2-pyridinyl)-2-[4-(2-oxo-1-imidazolidinyl)phenyl]- (CA INDEX NAME)




RN 687640-59-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(4-chlorophenyl)-2-[4-(2-oxo-1-imidazolidinyl)phenyl]- (CA INDEX NAME)




RN 687640-60-4 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(4-methoxyphenyl)-2-[4-(2-oxo-1-imidazolidinyl)phenyl]- (CA INDEX NAME)




RN 687640-61-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(5-chloro-2-pyridinyl)-2-[4-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 687640-62-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-6-methoxy-2-[4-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 687640-63-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[2-[(dimethylamino)methyl]-4,5-dihydro-1H-imidazol-1-yl]phenyl]-6-methoxy- (CA INDEX NAME)




RN 687640-64-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[4-[2-[(dimethylamino)methyl]-4,5-dihydro-1H-imidazol-1-yl]phenyl]-6-methoxy- (CA INDEX NAME)




RN 687640-65-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(4-chlorophenyl)-2-[4-[2-[(dimethylamino)methyl]-4,5-dihydro-1H-imidazol-1-yl]phenyl]- (CA INDEX NAME)




RN 687640-66-0 CAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-3-(4-chlorophenyl)-2-[4-[2-[(dimethylamino)methyl]-4,5-dihydro-1H-imidazol-1-yl]phenyl]- (CA INDEX NAME)




RN 687640-67-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[4-[2-[(dimethylamino)methyl]-4,5-dihydro-1H-imidazol-1-yl]phenyl]-3-(4-methoxyphenyl)-6-methyl- (CA INDEX NAME)



IT 687639-16-3P 687640-93-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolinones and analogs as Factor Xa inhibitors)
RN 687639-16-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1,1'-biphenyl]-4-yl-6-chloro-3-(5-chloro-2-pyridinyl)- (CA INDEX NAME)



RN 687640-93-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-3-(5-chloro-2-pyridinyl)-2-(4-methoxyphenyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 54 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:308434 CAPLUS
DOCUMENT NUMBER: 140:339338
TITLE: Preparation of quinazolin-4-one derivatives as PGD2
synthetase inhibitors
INVENTOR(S): Itai, Akiko; Muto, Susumu; Inoue, Tsuyoshi; Urade,
Yoshihiro
PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design, Inc., Japan
SOURCE: PCI Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031180	A1	20040415	WO 2003-JP12648	20031002
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2503674	A1	20040415	CA 2003-2503674	20031002
AU 2003268735	A1	20040423	AU 2003-268735	20031002
GB 2410025	A	20050720	GB 2005-7682	20031002
GB 2410025	B	20070328		
JP 4395073	B2	20100106	JP 2004-541270	20031002
US 20060229324	A1	20061012	US 2005-529946	20051004
PRIORITY APPLN. INFO.:			JP 2002-291114	A 20021003
			WO 2003-JP12648	W 20031002

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 140:339338
GI



I



II

AB The title compds. I [wherein X = (un)substituted N=CH or NHCH₂; R₁-R₄ = independently H, halo, (un)substituted alkyl, or OH; R = (un)substituted NH₂] or pharmaceutically acceptable salts, hydrates, or solvates thereof are prepared as prostaglandin D₂ synthase (PGD₂) inhibitors. For example, the compound II was prepared in a four-step synthesis. Compds. I showed strong inhibitory effect against human PGD₂.


IT 679843-55-1P 679843-56-2P 679843-57-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinazolinone derivs. as PGD₂ synthetase inhibitors)


RN 679843-55-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 679843-56-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(3-methoxyphenyl)- (CA INDEX NAME)



RN 679843-57-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(2-methoxyphenyl)- (CA INDEX NAME)





OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 55 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:308396 CAPLUS
DOCUMENT NUMBER: 140:339072
TITLE: Preparation of benzamide derivatives as LPA receptor
antagonists
INVENTOR(S): Terakado, Masahiko; Nakade, Shinji; Seko, Takuya;
Takaoka, Yoshikazu
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 304 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031118	A1	20040415	WO 2003-JP6680	20030528
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003241836	A1	20040423	AU 2003-241836	20030528
EP 1553075	A1	20050713	EP 2003-733131	20030528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK US 20060148830 A1 20060706 US 2005-530249 20050404 US 20080293764 A1 20081127 US 2008-112563 20080430 JP 2002-291137 A 20021003 WO 2003-JP6680 W 20030528 US 2005-530249 A1 20050404				

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 140:339072
GI




AB The title compds. I [wherein R = (un)substituted aliphatic hydrocarbyl or cyclyl; G = a bond or a spacer; T = CH₂ or a spacer; J = N or CH; B = (un)substituted aliphatic hydrocarbyl or cyclyl; K = a bond or a spacer; Q = a bond or a spacer; ring D = (un)substituted cyclic ring; L = a bond or a spacer; ring E = (un)substituted cyclic ring; n = 0 or 1; M = a bond or a spacer; Z = a acid group] or prodrugs, or salts thereof are prepared as lysophosphatidic acids (LPA) receptor antagonists. For example, the compound II was prepared in a multi-step synthesis. II showed inhibitory activity with IC₅₀ of 0.095 μ M against human EDG-2. I are useful for the treatment of urinary diseases, cancer-related diseases, proliferative diseases, inflammatory immune diseases, diseases caused by secretion failures, brain-related diseases, etc. (no data). Formulations containing I as an active ingredient were also described.

IT 679793-51-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of benzamide derivs. as LPA receptor antagonists)

RN 679793-51-2 CAPLUS

CN Benzoic acid, 2-[4-[3,4-dihydro-6,7,8-trimethoxy-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]phenoxy]-4-methyl-, methyl ester (CA INDEX NAME)




IT 679793-52-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzamide derivs. as LPA receptor antagonists)

RN 679793-52-3 CAPLUS

CN Benzoic acid, 2-[4-[3,4-dihydro-6,7,8-trimethoxy-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]phenoxy]-4-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 56 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:182873 CAPLUS

DOCUMENT NUMBER: 140:235499

TITLE: Preparation of aminoarylbenzoic acid derivatives as antibacterial agents for use as disinfectants and therapeutic agents

INVENTOR(S): Thorarensen, Atli; Ruble, Craig J.; Romero, Donna L.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 167 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018461	A2	20040304	WO 2003-US24791	20030820
WO 2004018461	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003265382	A1	20040311	AU 2003-265382	20030820
US 20040142981	A1	20040722	US 2003-645799	20030820
PRIORITY APPLN. INFO.:			US 2002-405614P	P 20020823
			US 2002-413596P	P 20020925
			US 2002-430351P	P 20021202
			WO 2003-US24791	W 20030820
OTHER SOURCE(S): MARPAT 140:235499				
GI				





- AB The title compds. I [X = NH; Y = CO, CS, C=NCN, or X and Y together form an alkene, or cycloalkyl; R¹ = (un)substituted-heterocycle, -heterocyclylcarbonyl, NHSO₂R³; R² = electron withdrawing group; R³ = H, (un)substituted alkyl or aryl; R⁴ = (un)substituted aryl with provisions] and their pharmaceutically acceptable salts are prepared and disclosed as antibacterial agents. Thus, e.g., II was prepared by amidation of 3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl chloride (preparation given) with 3-(2-amino-5-bromophenyl)-1,2,4-oxadiazol-5(4H)-one. In assays, the min. inhibitory concentration values (µg/mL) ranged from 0.125 - >128. As antibacterial agents I are useful for sterilization, sanitation, antiseptics, and disinfection.
- IT 666858-94-2P 666858-96-4P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of aminoarylbenzoic acid derivs. as antibacterial agents)


RN 666858-94-2 CAPLUS

CN Benzamide, N-[4-bromo-2-(3,4-dihydro-4-oxo-2-quinazolinyl)phenyl]-3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]- (CA INDEX NAME)



RN 666858-96-4 CAPLUS

CN Benzamide, N-[4-bromo-2-(3,4-dihydro-4-oxo-2-quinazolinyl)phenyl]-3-(4-morpholinylsulfonyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 57 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:120836 CAPLUS

DOCUMENT NUMBER: 140:181460

TITLE: Preparation of (piperidinylethyl)benzoheterocyclic

compounds for use as sodium channel blockers
Sun, Qun; Kyle, Donald J.; Victory, Samuel F.

PATENT ASSIGNEE(S): Euro-Celtique S.A., Luxembourg

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013111	A1	20040212	WO 2003-US23791	20030730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040152696	A1	20040805	US 2003-628487	20030729
CA 2493737	A1	20040212	CA 2003-2493737	20030730
AU 2003257015	A1	20040223	AU 2003-257015	20030730
EP 1534690	A1	20050601	EP 2003-766980	20030730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013369	A	20050621	BR 2003-13369	20030730
CN 1678592	A	20051005	CN 2003-820742	20030730
JP 2006500343	T	20060105	JP 2004-526225	20030730
MX 2005001288	A	20050908	MX 2005-1288	20050201
IN 2005KN00293	A	20051125	IN 2005-KN293	20050228
PRIORITY APPLN. INFO.:			US 2002-399702P	P 20020801
			WO 2003-US23791	W 20030730

OTHER SOURCE(S): MARPAT 140:181460
GI



AB Title compds. I [wherein R1 = independently halogen, (halo)alkyl, alkoxy, hydroxyalkyl, amino, nitro, cyano; R2, R3 = independently H, (cyclo)alkyl, haloalkyl, hydroxyalkyl, or R2 and R3 together with the nitrogen atom to which they are attached form an (un)substituted heterocyclic ring; R4 = (un)substituted phenoxyphenyl, phenylthiophenyl, phenylaminophenyl, benzylphenyl, etc.; n = 0-3; p = 2-4; X = N, NH, S; Y = O, S; and pharmaceutically acceptable salts or solvates thereof] were prepared as sodium channel blockers. For example, reaction of 2-(piperidin-1-yl)ethylamine with 2-nitrobenzoyl chloride, followed by 10%

Pd/C-catalyzed reduction and condensation with 3,3-diphenylpropenal, gave II. I were formulated as tablets and i.v. solns. Selected compds. of the invention inhibited sodium channel activity with K_i values ranging from 1 nM to 3960 nM. Thus, I and their pharmaceutical compns. are useful as sodium channel blockers for the treatment of neuronal damage following global or focal ischemia, neurodegenerative conditions, such as amyotrophic lateral sclerosis (ALS), acute or chronic pain, neuropathic pain, surgical pain, tinnitus, convulsions, manic depression, arrhythmia and diabetic neuropathy (no data).


IT 658044-71-4P 658044-72-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidineylethyl quinazolinone and benzothiazinone derivs. for use as sodium channel blockers)



RN 658044-71-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(4-fluorophenoxy)phenyl]-3-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 658044-72-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(1-piperidinyl)ethyl]-2-[3-[3-(trifluoromethyl)phenoxy]phenyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:17804 CAPLUS
 DOCUMENT NUMBER: 140:94056
 TITLE: Preparation of [(quinazolinonyl)benzyl]phosphonate diesters and their use as acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) inhibitors
 INVENTOR(S): Sakai, Yasuhiro; Miyata, Kazuyoshi; Tomoyasu, Takahiro; Kuroda, Terunori; Inoue, Yasuhide; Hagi, Akifumi; Miki, Shinya; Yoshinaga, Yoshihiro; Doi, Masako; Tsuda, Yoshihiko
 PATENT ASSIGNEE(S): Ohtsuka Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 49 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004002214	A	20040108	JP 2002-131479	20020507
JP 4110371	B2	20080702		
PRIORITY APPLN. INFO.:			JP 2002-106534	A 20020409
OTHER SOURCE(S):	MARPAT	140:94056		

GI



AB The title comps. I [R1-R4 = H, halo, lower alkyl, lower alkoxy; R5 = (un)substituted Ph, benzodioxolanyl, naphthyl, etc.], useful as antiarteriosclerotic and anticholesteremic agents, are prepared Thus, condensation of di-Et [4-(3-amino-7-chloro-4(3H)-quinazolinon-2-yl)benzyl]phosphonate with p-tolualdehyde gave I (R1 = R2 = R4 = H, R3 = Cl, R5 = 4-C6H4Me), which inhibited 75% ACAT-1 activity.

IT 642463-77-2P	642463-78-3P	642463-79-4P
642463-80-7P	642463-81-8P	642463-82-9P
642463-83-0P	642463-84-1P	642463-85-2P
642463-86-3P	642463-87-4P	642463-88-5P
642463-89-6P	642463-90-9P	642463-91-0P
642463-92-1P	642463-93-2P	642463-94-3P
642463-95-4P	642463-96-5P	642463-97-6P
642463-98-7P	642464-00-4P	642464-02-6P
642464-04-8P	642464-06-0P	642464-08-2P
642464-10-6P	642464-12-8P	642464-13-9P
642464-15-1P	642464-17-3P	642464-18-4P
642464-19-5P	642464-20-8P	642464-21-9P
642464-22-0P	642464-23-1P	642464-24-2P
642464-25-3P	642464-26-4P	642464-27-5P
642464-28-6P	642464-29-7P	642464-30-0P
642464-31-1P	642464-32-2P	642464-33-3P


642464-34-4P	642464-35-5P	642464-36-6P
642464-37-7P	642464-38-8P	642464-39-9P
642464-40-2P	642464-41-3P	642464-42-4P
642464-43-5P	642464-44-6P	642464-45-7P
642464-46-8P	642464-47-9P	642464-48-0P
642464-49-1P	642464-50-4P	642464-51-5P
642464-52-6P	642464-53-7P	642464-54-8P
642464-55-9P	642464-56-0P	642464-57-1P
642464-58-2P	642464-59-3P	642464-60-6P
642464-61-7P	642464-62-8P	642464-63-9P
642464-64-0P	642464-65-1P	642464-66-2P
642464-67-3P	642464-68-4P	642464-69-5P
642464-70-8P	642464-71-9P	642464-72-0P
642464-73-1P	642464-74-2P	642464-75-3P
642464-76-4P	642464-77-5P	642464-78-6P
642464-79-7P	642464-80-0P	642464-82-2P
642464-84-4P	642464-86-6P	642464-88-8P
642464-89-9P	642464-91-3P	642464-93-5P
642464-95-7P	642464-97-9P	642464-99-1P
642465-01-8P	642465-03-0P	642465-05-2P
642465-07-4P	642465-09-6P	642465-10-9P
642465-12-1P	642465-13-2P	642465-15-4P
642465-17-6P	642465-20-1P	642465-22-3P
642465-25-6P	642465-27-8P	642465-28-9P
642465-29-0P	642465-30-3P	642465-31-4P
642465-32-5P	642465-33-6P	642465-35-8P
642465-37-0P	642465-38-1P	642465-39-2P
642465-41-6P	642465-43-8P	642465-44-9P
642465-45-0P	642465-46-1P	642465-47-2P
642465-48-3P	642465-49-4P	642465-50-7P
642465-51-8P	642465-52-9P	642465-53-0P
642465-54-1P	642465-55-2P	642465-56-3P
642465-57-4P	642465-58-5P	642465-59-6P
642465-60-9P	642465-61-0P	642465-62-1P
642465-63-2P	642465-64-3P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [(quinazolinonyl)benzyl]phosphonate diesters as acyl-CoA:cholesterol acyltransferase-1 inhibitors for antiarteriosclerotic and anticholesteremic agents)


RN 642463-77-2 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-methylphenyl)methyl]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-78-3 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[3-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-79-4 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[2-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-80-7 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[4-ethylphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-81-8 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[[4-(1-methylethyl)phenyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-82-9 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[[4-(1,1-dimethylethyl)phenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-83-0 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[[4-(trifluoromethyl)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-84-1 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[[3-(trifluoromethyl)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-85-2 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[[2-(trifluoromethyl)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-86-3 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[[4-(trifluoromethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-87-4 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[3-(trifluoromethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-88-5 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[2-(trifluoromethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 642463-89-6 CAPLUS


CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[4-(phenoxyphenyl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 642463-90-9 CAPLUS


CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[3-(phenoxyphenyl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl

ester (9CI) (CA INDEX NAME)




RN 642463-91-0 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[4-(phenylmethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-92-1 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[3-(phenylmethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-93-2 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[2-(phenylmethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-94-3 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-(4-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-95-4 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[3-(3-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-96-5 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[2-(2-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-97-6 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[4-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-98-7 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[3-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-00-4 CAPLUS


CN Phosphonic acid, [[4-[7-chloro-3-[[2-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-02-6 CAPLUS
 CN Phosphonic acid, [[4-[7-chloro-3-[[4-(4-fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 642464-04-8 CAPLUS
 CN Phosphonic acid, [[4-[7-chloro-3-[[4-(3-fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-06-0 CAPLUS
 CN Phosphonic acid, [[4-[7-chloro-3-[[4-(2-fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-08-2 CAPLUS

CN Phosphonic acid, [[4-[3-[(2-bromophenyl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-10-6 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(4-nitrophenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-12-8 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(3-nitrophenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-13-9 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[2-nitrophenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-15-1 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-(methylthio)phenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-17-3 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[[4-(dimethylamino)phenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-18-4 CAPLUS

CN Phosphonic acid, [[4-[3-[[[4-(acetylamino)phenyl]methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-19-5 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[[4-(1-pyrrolidinyl)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-20-8 CAPLUS

CN Phosphonic acid, [[4-[3-[[[1,1'-biphenyl]-4-ylmethylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-21-9 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[3,4-dimethoxyphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-22-0 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[2,4-dimethoxyphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-23-1 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[2,5-dimethoxyphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-24-2 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[2,3-dichlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-25-3 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[2,4-dichlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-26-4 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[3,4-dichlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-27-5 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(2-hydroxy-3-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-28-6 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(2-hydroxy-4-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-29-7 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(2-hydroxy-5-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-30-0 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[2-hydroxy-6-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-31-1 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-methoxy-3-(phenylmethoxy)phenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-32-2 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-yl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-33-3 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(1-naphthalenylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 642464-34-4 CAPLUS


CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(2-naphthalenylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 642464-35-5 CAPLUS


CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(2-hydroxy-1-naphthalenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-,

diethyl ester (9CI) (CA INDEX NAME)




RN 642464-36-6 CAPLUS

CN Phosphonic acid, [[4-[[7-chloro-3,4-dihydro-4-oxo-3-[[2,3,4-trimethoxyphenyl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-37-7 CAPLUS

CN Phosphonic acid, [[4-[[7-chloro-3,4-dihydro-4-oxo-3-[[3,4,5-trimethoxyphenyl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-38-8 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(1-oxido-4-pyridinyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-39-9 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(6-methyl-2-pyridinyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-40-2 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(2-thienyl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-41-3 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(3-thienylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-42-4 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(5-methyl-2-thienyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-43-5 CAPLUS


CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(3-methyl-2-thienyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-44-6 CAPLUS
 CN Phosphonic acid, [[4-[7-chloro-3-[[5-chloro-2-thienyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 642464-45-7 CAPLUS
 CN Phosphonic acid, [[4-[3-[[5-bromo-2-thienyl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-46-8 CAPLUS
 CN Phosphonic acid, [[4-[3-[[4-bromo-2-thienyl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-47-9 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(5-bromo-2-thienyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-48-0 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(5-nitro-2-thienyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-49-1 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[(2-furanylmethylene)amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-50-4 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[(3-furanylmethylene)amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-51-5 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[5-methyl-2-furanyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-52-6 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[4,5-dimethyl-2-furanyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-53-7 CAPLUS

CN Phosphonic acid, [[4-[3-[[5-bromo-2-furanyl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-54-8 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[5-nitro-2-furanyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-55-9 CAPLUS

CN Phosphonic acid, [[4-[3-[(2-benzofuranyl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-56-0 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-57-1 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(1H-pyrrol-2-yl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-58-2 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(1-methyl-1H-pyrrol-2-yl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-59-3 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(1H-imidazol-4-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-60-6 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-61-7 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(5-methyl-1H-imidazol-4-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-62-8 CAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[[4-(3-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-63-9 CAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[[3-(4-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-64-0 CAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[[2-(4-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-65-1 CAPLUS

CN Phosphonic acid, [[4-[6-chloro-3-[[4-(4-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-66-2 CAPLUS

CN Phosphonic acid, [[4-[6-chloro-3-[[3-(3-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-67-3 CAPLUS

CN Phosphonic acid, [[4-[6-chloro-3-[[4-(4-fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-68-4 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-6-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-69-5 CAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-70-8 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-3-[[4-(methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-71-9 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-3-[[3-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-72-0 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-3-[[4-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-73-1 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-3-[[2-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-74-2 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3-[[4-(4-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-75-3 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3-[[3-(4-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-76-4 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3-[[4-(4-fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-77-5 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-3-[[4-nitrophenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-78-6 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-3-[[4-(4-methylthiophenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-79-7 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3-[[[4-(dimethylamino)phenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-80-0 CAPLUS

CN Phosphonic acid, [[4-[3-[[[4-(acetylamino)phenyl]methylene]amino]-5-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-82-2 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3-[[[3,4-dimethoxyphenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-84-4 CAPLUS

CN Phosphonic acid, [[4-[3-[[[1,3-benzodioxol-5-yl]methylene]amino]-5-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-86-6 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-4-oxo-3-[(2-thienylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-88-8 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-4-oxo-3-[(3-thienylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-89-9 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3-[(2-furanylmethylene)amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-91-3 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3-[(3-furanylmethylene)amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-93-5 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-95-7 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[[(4-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-97-9 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[[3-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-99-1 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[[[4-(trifluoromethyl)phenyl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-01-8 CAPLUS


CN Phosphonic acid, [[4-[3,4-dihydro-3-[[[4-(4-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-03-0 CAPLUS
 CN Phosphonic acid, [[4-[3,4-dihydro-3-[[2-(4-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 642465-05-2 CAPLUS
 CN Phosphonic acid, [[4-[3-[[4-(4-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-07-4 CAPLUS
 CN Phosphonic acid, [[4-[3-[[3-(4-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-09-6 CAPLUS

CN Phosphonic acid, [[4-[3-[[[4-fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-10-9 CAPLUS

CN Phosphonic acid, [[4-[3-[[[3-fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-12-1 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[[4-nitrophenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-13-2 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[[4-(methylthio)phenyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-15-4 CAPLUS

CN Phosphonic acid, [[4-[3-[[[4-(dimethylamino)phenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-17-6 CAPLUS

CN Phosphonic acid, [[4-[3-[[[4-(acetylamino)phenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-20-1 CAPLUS

CN Phosphonic acid, [[4-[3-[[[(3,4-dimethoxyphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-22-3 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-25-6 CAPLUS

CN Phosphonic acid, [[4-[3-[(6-methyl-2-pyridinyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-27-8 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[(2-thienylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-28-9 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-29-0 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-6-methyl-4-oxo-3-[[[3-(trifluoromethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-30-3 CAPLUS

CN Phosphonic acid, [[4-[3-[[3-(3-chlorophenyl)methylene]amino]-3,4-dihydro-6-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-31-4 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-3,4-dihydro-6-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-32-5 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-6-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-33-6 CAPLUS

CN Phosphonic acid, [[4-[3-[[3-(3-chlorophenyl)methylene]amino]-3,4-dihydro-5-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-35-8 CAPLUS

CN Phosphonic acid, [[4-[3-[[3,4-dimethoxyphenyl)methylene]amino]-3,4-dihydro-5-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-37-0 CAPLUS

CN Phosphonic acid, [[4-[3-[[1,3-benzodioxol-5-ylmethylene]amino]-3,4-dihydro-5-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-38-1 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-5-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-39-2 CAPLUS

CN Phosphonic acid, [[4-[3-[(3-chlorophenyl)methylene]amino]-7-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-41-6 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-7-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-43-8 CAPLUS

CN Phosphonic acid, [[4-[7-fluoro-3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-44-9 CAPLUS

CN Phosphonic acid, [[4-[3-[[3-(3-chlorophenyl)methylene]amino]-3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-45-0 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-46-1 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-8-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-47-2 CAPLUS

CN Phosphonic acid, [[4-[8-chloro-3-[(3-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-48-3 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-8-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-49-4 CAPLUS

CN Phosphonic acid, [[4-[8-chloro-3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-50-7 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-3,4-dihydro-8-methoxy-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-51-8 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-3,4-dihydro-6-methoxy-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-52-9 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-6-methoxy-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-53-0 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-6,8-dichloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-54-1 CAPLUS

CN Phosphonic acid, [[4-[6,8-dichloro-3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-55-2 CAPLUS

CN Phosphonic acid, [[4-[3-[[[(3,4-dimethoxyphenyl)methylene]amino]-3,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-56-3 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-3,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-57-4 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-6,7-dimethoxy-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-58-5 CAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-3,4-dihydro-6,8-dimethyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-59-6 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-6,8-dimethyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-60-9 CAPLUS

CN Phosphonic acid, [[4-[3-[(4-bromophenyl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-61-0 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(1H-indol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-62-1 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[[[3-(trifluoromethyl)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-63-2 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[[1-oxido-4-pyridinyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 642465-64-3 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-8-methoxy-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 59 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:17803 CAPLUS

DOCUMENT NUMBER: 140:87712

TITLE: Acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) inhibitors containing [(quinazolinonyl)benzyl]phosphonate diester derivatives

INVENTOR(S): Sakai, Yasuhiro; Miyata, Kazuyoshi; Tomoyasu, Takahiro; Kuroda, Terunori; Inoue, Yasuhide; Shu, Akifumi; Miki, Shinya; Yoshinaga, Yoshihiro; Doi, Masako; Tsuda, Yoshihiko

PATENT ASSIGNEE(S): Ohtsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004002213	A	20040108	JP 2002-131208	20020507
PRIORITY APPLN. INFO.:			JP 2002-106526	A 20020409
OTHER SOURCE(S):	MARPAT	140:87712		

GI



AB The title inhibitors, useful as antiarteriosclerotic and anticholesteremic agents, contain [(quinazolinonyl)benzyl]phosphonate diesters I [R1-R4 = H, halo, lower alkyl; R5 = (lower alkoxy-substituted) Ph, pyridyl; R6 = lower alkyl] as active ingredients are prepared. Thus, I (R1 = R2 = R4 = H, R3 = Cl, R5 = 3-C6H4OMe) inhibited 82% ACAT-1 activity.


IT	173019-00-6P	173019-01-7P	173019-02-8P
	642097-88-9P	642097-89-0P	642097-90-3P
	642097-91-4P	642097-92-5P	642097-93-6P
	642097-94-7P	642097-95-8P	642097-96-9P
	642097-97-0P	642097-98-1P	642097-99-2P
	642098-00-8P	642098-01-9P	642098-02-0P
	642098-03-1P	642098-04-2P	642098-05-3P
	642098-06-4P	642098-07-5P	642098-08-6P
	642098-09-7P	642098-10-0P	642098-11-1P
	642098-12-2P	642098-13-3P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation [(quinazolinonyl)benzyl]phosphonate diesters as acyl-CoA:cholesterol acyltransferase-1 inhibitors)


RN 173019-00-6 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(phenylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173019-01-7 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173019-02-8 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(2-pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-88-9 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[3-methoxyphenyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-89-0 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[2-methoxyphenyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-90-3 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[4-ethoxyphenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-91-4 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[2-ethoxyphenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-92-5 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[[4-(1-methylethoxy)phenyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-93-6 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[4-(1,1-dimethylethoxy)phenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-94-7 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(4-pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-95-8 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(3-pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-96-9 CAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-4-oxo-3-[(phenylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-97-0 CAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[[4-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-98-1 CAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[[3-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-99-2 CAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-4-oxo-3-[(2-pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-00-8 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-4-oxo-3-[(phenylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-01-9 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-3-[[4-methoxyphenyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-02-0 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-3-[[3-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-03-1 CAPLUS

CN Phosphonic acid, [[4-[5-chloro-3,4-dihydro-4-oxo-3-[(2-pyridinylmethylene)amino]-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-04-2 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[(phenylmethylene)amino]-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-05-3 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[4-(methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-06-4 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[3-(methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-07-5 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[[4-(pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-08-6 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[(2-pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-09-7 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[3-methoxyphenyl)methylene]amino]-6-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-10-0 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[3-methoxyphenyl)methylene]amino]-5-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-11-1 CAPLUS

CN Phosphonic acid, [[4-[7-fluoro-3,4-dihydro-3-[[3-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-12-2 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[3-methoxyphenyl)methylene]amino]-8-methyl-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 642098-13-3 CAPLUS

CN Phosphonic acid, [[4-[8-chloro-3,4-dihydro-3-[[3-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 60 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:950836 CAPLUS

DOCUMENT NUMBER: 140:16722

TITLE: Preparation of 1,1-disubstituted cycloalkyl derivatives as factor Xa inhibitors for treating a thromboembolic disorder

INVENTOR(S): Qiao, Jennifer X.; Pinto, Donald J.; Orwat, Michael J.; Han, Wei; Friedrich, Sarah R.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 686 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099276	A1	20031204	WO 2003-US13893	20030505
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003273179	A1	20031212	AU 2003-273179	20030505
US 20040254158	A1	20041216	US 2003-430024	20030505
US 7312214	B2	20071225		
EP 1505966	A1	20050216	EP 2003-755341	20030505
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, TR, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-379357P	P 20020510
			US 2002-415367P	P 20021002
			WO 2003-US13893	W 20030505

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:16722

GI




AB The present application describes 1,1-disubstituted cycloalkyl compds. and derivs. thereof (P4-P-M-M4; variables defined below; most of the examples contain 1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, e.g. the trifluoroacetate of I), or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa for treatment of a thromboembolic disorder. Although the methods of preparation are not claimed, .apprx.240 example preps. are included. A number of I exhibit Ki's of <10 μ M towards factor Xa; also some I are direct acting inhibitors (Ki < 10 μ M) of the serine protease thrombin as indicated by their ability to inhibit the cleavage of small mol. substrates by thrombin in a purified system; the specific compds. are not stated. For I: M is a 3-10 membered carbocycle or a 4-10 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, N, and N22; ring M is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds; P is fused onto ring M and is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, and N; ring P is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds; alternatively, ring P is absent and P4 is directly attached to ring M, provided that when ring P is absent, P4 and M4 are attached to the 1,2, 1,3, or 1,4 positions of ring M. One of P4 and M4 is -Z-A-B and the other -G1-G, provided that P4 and M4 are attached to different rings when ring P is present; G consists of 2 fused rings D and E (ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p; E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl; alternatively, ring D is absent and ring E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl); G1 is absent or = (CR3R3a)1-5, etc. A = (un)substituted C3-10 carbocycle and 5-12 membered heterocycle consisting of: C atoms and 1-4 heteroatoms N, O, and S(O)p; B is Y-R4a or X-Y-R4a, provided that Z and B are attached to different atoms on A and A and R4a or X and R4a are attached to the same atom on Y; Z = a bond, -(CR3R3e)1-4-, etc. Addnl. details including provisos are given in the claims.

IT 630385-70-5P 630385-71-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 1,1-disubstituted cycloalkyl derivs. as factor Xa inhibitors for treating thromboembolic disorder)


RN 630385-70-5 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(5-chloro-2-pyridinyl)-2-[4-[1,1-dimethyl-2-(4-morpholinyl)ethyl]phenyl]- (CA INDEX NAME)



RN 630385-71-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-[1-(1-methylpyrrolidinylmethyl)cyclopropyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 61 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:638282 CAPLUS

DOCUMENT NUMBER: 140:122699

TITLE: Effect of active synthetic 2-substituted quinazolinones on anti-platelet aggregation and the inhibition of superoxide anion generation by neutrophils

AUTHOR(S): Chang, Fang-Rong; Wu, Chin-Chung; Hwang, Tsong-Long; Patnam, Ramesh; Kuo, Reen-Yen; Wang, Wei-Ya; Lan, Yu-Hsuan; Wu, Yang-Chang

CORPORATE SOURCE: Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, 807, Taiwan

SOURCE: Archives of Pharmacal Research (2003), 26(7), 511-515

CODEN: APHRDQ; ISSN: 0253-6269

PUBLISHER: Pharmaceutical Society of Korea

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Quinazolinones, 2-substituted and 3-substituted, mainly synthesized by microwave irradiation, were subjected to anti-platelet aggregation and inhibition of superoxide anion generation assays. Interestingly,

2-phenyl-4-quinazolinone exhibited significant inhibitory activities toward platelet aggregation and neutrophil activation, and it might therefore serve as a prototype lead compound


IT 1152-07-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolinones as antiplatelet agents and inhibition of superoxide anion generation by neutrophils)

RN 1152-07-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 62 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:454323 CAPLUS

DOCUMENT NUMBER: 139:22501

TITLE: Preparation of glycinamide heterocyclic derivatives as factor Xa inhibitors

INVENTOR(S): Pinto, Donald J. P.; Han, Wei; Hu, Zilun

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; Qiao, Jennifer

SOURCE: PCT Int. Appl., 451 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 54

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048158	A1	20030612	WO 2002-US38239	20021127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20030232804	A1	20031218	US 2002-304070	20021125
US 7115627	B2	20061003		
WO 2003048158	A1	20030612	WO 2002-XA38239	20021127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

RW:	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	
	TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	XM,	ZW							
	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SG,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,	
CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG					
WO	2003048158	A1	200306112	WO	2002-XB38239								20021127				
W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	
	TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	XM,	ZW							
RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SG,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,	
	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG				
	WO	2003048158	A1	200306112	WO	2002-XC38239							20021127				
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
CO,		CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
GM,		HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
LS,		LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
PL,		PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	
TZ,		UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	XM,	ZW							
RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SG,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,	
	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG				
	WO	2003048158	A1	200306112	WO	2002-XD38239							20021127				
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
CO,		CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
GM,		HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
LS,		LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
PL,		PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	
TZ,		UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	XM,	ZW							
RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SG,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,	
	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG				
	WO	2003048158	A1	200													

		GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003048158	A1	20030612	WO 2002-XM38239 20021127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2003048158	A1	20030612	WO 2002-XN38239 20021127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2003048158	A1	20030612	WO 2002-XO38239 20021127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2003048158	A1	20030612	WO 2002-XP38239 20021127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2003048158	A1	20030612	WO 2002-XQ38239 20021127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003048158 A1 20030612 WO 2002-XR38239 20021127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003048158 A1 20030612 WO 2002-XS38239 20021127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003048158 A1 20030612 WO 2002-XT38239 20021127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003048158 A1 20030612 WO 2002-XV38239 20021127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003048158 A1 20030612 WO 2002-XW38239 20021127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003048158 A1 20030612 WO 2002-XW38239 20021127


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2003048158 A1 20030612 WO 2002-XX38239 20021127
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2003048158 A1 20030612 WO 2002-XX38239 20021127
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2003048158 A1 20030612 WO 2002-XX38239 20021127
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002351179 A1 20030617 AU 2002-351179 20021127
 EP 1465892 A1 20041013 EP 2002-786826 20021127
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 PRIORITY APPLN. INFO.: US 2001-336994P P 20011204
 WO 2002-US38239 20021127

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:22501

GI



AB Compds. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative I.TFA was prepared by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride, and dimethylamine. [This abstract record is one of 47 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]


IT 536759-26-9P 536759-27-0P 536759-30-5P
536759-31-6P 536759-66-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycineamide heterocyclic derivs. as factor Xa inhibitors)


RN 536759-26-9 CAPLUS

CN Acetamide, N-[4-[6-chloro-3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-2-(dimethylamino)-N-methyl- (CA INDEX NAME)




RN 536759-27-0 CAPLUS

CN Acetamide, 2-(butylmethylamino)-N-[4-[6-chloro-3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-N-methyl- (CA INDEX NAME)




RN 536759-30-5 CAPLUS

CN Acetamide, N-[4-[6-chloro-3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-N-methyl-2-(methyamino)- (CA INDEX NAME)




RN 536759-31-6 CAPLUS

CN Acetamide, N-[4-[6-chloro-3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-2-(cyclobutylamino)-N-methyl- (CA INDEX NAME)



RN 536759-66-7 CAPLUS

CN 4-Morpholineacetamide, N-[4-[6-chloro-3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 63 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:454257 CAPLUS

DOCUMENT NUMBER: 139:7167

TITLE: Preparation of glycineamide heterocyclic derivatives as
factor Xa inhibitors

INVENTOR(S): Pinto, Donald J. P.; Han, Wei; Hu, Zilun

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; Qiao, Jennifer

SOURCE: PCT Int. Appl., 448 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 54

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048081	A2	20030612	WO 2002-US37212	20021118
WO 2003048081	A3	20030912		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003048081	A2	20030612	WO 2002-XA37212	20021118
WO 2003048081	A3	20030912		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003048081	A2	20030612	WO 2002-XB37212	20021118
WO 2003048081	A3	20030912		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,
		TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
WO	2003048081				A2												
						20030612											
WO	2003048081				A3												
						20030912											
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,
		TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
WO	2003048081				A2												
						20030612											
WO	2003048081				A3												
						20030912											
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,
		TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
WO	2003048081				A2												
						20030612											
WO	2003048081				A3												
						2003091											

		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	PH,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NC,	NZ,	OM,	PR,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,
		TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
WO	2003048081			A2				20030612				WO	2002-XH37212				20021118
WO	2003048081			A3				20030912									
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NC,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,
		TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
WO	2003048081			A2				20030612				WO	2002-XI37212				20021118
WO	2003048081			A3				20030912									
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NC,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,
		TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
WO	2003048081			A2				20030612				WO	2002-XJ37212				20021118
WO	2003048081			A3				20030912									
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,

		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,
		TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
WO	2003048081				A2												
WO	2003048081				A3												
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,
		TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
WO	2003048081				A2												
WO	2003048081				A3												
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,
		TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	BJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
WO	2003048081				A2												
WO	2003048081				A3												
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,</															

	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003048081	A2 20030612	WO 2002-XW37212 20021118
WO 2003048081	A3 20030912	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003048081	A2 20030612	WO 2002-XX37212 20021118
WO 2003048081	A3 20030912	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003048081	A2 20030612	WO 2002-XY37212 20021118
WO 2003048081	A3 20030912	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003048081	A2 20030612	WO 2002-XZ37212 20021118
WO 2003048081	A3 20030912	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003048081	A2 20030612	WO 2002-XZ37212 20021118
WO 2003048081	A3 20030912	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2002350217	A1 20030617	AU 2002-350217 20021118
US 20030232804	A1 20031218	US 2002-304070 20021125
US 7115627	B2 20061003	

PRIORITY APPLN. INFO.:

US 2001-336994P

P 20011204


WO 2002-US37212

20021118

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:7167

GI



I

AB Compds. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclcyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclcyl or 5-12 membered heterocyclcyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative I.TFA was prepared by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride, and dimethylamine. [This abstract record is one of 47 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 536759-26-9P 536759-27-0P 536759-30-5P


536759-31-6P 536759-66-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycineamide heterocyclic derivs. as factor Xa inhibitors)

RN 536759-26-9 CAPLUS


CN Acetamide, N-[4-[6-chloro-3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-2-(dimethylamino)-N-methyl- (CA INDEX NAME)



RN 536759-27-0 CAPLUS


CN Acetamide, 2-(butylmethylamino)-N-[4-[6-chloro-3-(5-chloro-2-pyridinyl)-

3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-N-methyl- (CA INDEX NAME)




RN 536759-30-5 CAPLUS

CN Acetamide, N-[4-[6-chloro-3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-N-methyl-2-(methylamino)- (CA INDEX NAME)




RN 536759-31-6 CAPLUS

CN Acetamide, N-[4-[6-chloro-3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-2-(cyclobutylamino)-N-methyl- (CA INDEX NAME)



RN 536759-66-7 CAPLUS

CN 4-Morpholineacetamide, N-[4-[6-chloro-3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]-N-methyl- (CA INDEX NAME)





OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 64 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:368606 CAPLUS
DOCUMENT NUMBER: 138:368909
TITLE: Preparation of phenyl quinazolinone derivatives for
treating a patient having precancerous lesions
INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.
PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6562830	B1	20030513	US 1999-436806	19991109
PRIORITY APPLN. INFO.:			US 1999-436806	19991109
OTHER SOURCE(S):	MARPAT	138:368909		

GI




AB Title compds. I [R1-2 = H, alkyl, alkoxy; R4 = H, alkanoyl, hydroxyalkyl, etc.; R5 = alkoxy, alkenoxy, cycloalkylalkoxy, etc.] are prepared For instance, 2-(2-Ethoxyphenyl)-8-methoxyquinazolin-4(3H)-one (preparation given) is treated with chlorosulfonic acid and subsequently with piperazine to give II. I inhibit growth of neoplastic cells and are useful for the treatment of patients having precancerous lesions.

IT 130239-63-3P, 7-Nitro-2-(2-Propoxyphenyl)-4(3H)-quinazolinone
 130239-64-4P, 7-Amino-2-(2-Propoxyphenyl)-4(3H)-quinazolinone
 150479-43-9P 150479-44-0P 150479-49-5P,
 2-(2-Ethoxy-5-(morpholino)acetyl)phenyl)-8-methylquinazolin-4(3H)-one
 150479-51-9P, 8-Carbamoyl-2-(2-ethoxyphenyl)quinazolin-4(3H)-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (method of treating a patient having precancerous lesions with Ph quinazolinone derivs.)

RN 130239-63-3 CAPLUS


CN 4(3H)-Quinazolinone, 7-nitro-2-(2-propoxyphenyl)- (CA INDEX NAME)



RN 130239-64-4 CAPLUS


CN 4(3H)-Quinazolinone, 7-amino-2-(2-propoxyphenyl)- (CA INDEX NAME)

10/ 582,823




RN 150479-43-9 CAPLUS

CN 2-Propenoic acid, 3-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-propoxyphenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 150479-44-0 CAPLUS

CN 2-Propenoic acid, 3-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-propoxyphenyl]- (CA INDEX NAME)



RN 150479-49-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[2-(4-morpholinyl)acetyl]phenyl]-8-methyl- (CA INDEX NAME)




RN 150479-51-9 CAPLUS

CN 8-Quinazolinecarboxamide, 2-(2-ethoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)


(NAME)




IT 130239-61-1P, 2-(2-Propoxyphenyl)quinazolin-4(3H)-one
 130239-62-2P, 7-Methylthio-2-(2-propoxyphenyl)quinazolin-4(3H)-one
 130239-65-5P, 7-Methylamino-2-(2-Propoxyphenyl)-4(3H)-quinazolinone 150479-34-8P,
 2-[2-Ethoxy-5-(1-piperazinylsulfonyl)phenyl]-8-methoxyquinazolin-4(3H)-one
 150479-35-9P, 2-[2-Ethoxy-5-[(4-(2-hydroxyethyl)piperazinyl)sulfonyl]phenyl]-8-methoxyquinazolin-4(3H)-one
 150479-36-0P, 2-[2-Ethoxy-5-(1-piperazinylsulfonyl)phenyl]-5-methylquinazolin-4(3H)-one 150479-37-1P,
 2-[2-Ethoxy-5-[(4-(2-hydroxyethyl)piperazinyl)sulfonyl]phenyl]-5-methylquinazolin-4(3H)-one 150479-38-2P,
 2-[2-Ethoxy-5-[(4-(2-hydroxyethyl)piperazinyl)sulfonyl]phenyl]-8-methylquinazolin-4(3H)-one 150479-39-3P,
 2-[5-[(4-(2-Hydroxyethyl)piperazinyl)sulfonyl]-2-(propoxy)phenyl]-8-methylquinazolin-4(3H)-one 150479-40-6P,
 8-Methyl-2-[5-(3-(piperidinyl)propyl)sulfamoyl]-2-(propoxy)phenylquinazolin-4(3H)-one 150479-41-7P,
 2-(5-Imidazolyl-2-(propoxy)phenyl)-8-methylquinazolin-4(3H)-one 150479-42-8P, 8-Methyl-2-[5-[2-(4-methyl-1-piperazinylcarbonyl)ethenyl]-2-(propoxy)phenyl]quinazolin-4(3H)-one 150479-45-1P 150479-46-2P,
 2-[2-Ethoxy-5-[(4-(2-hydroxyethyl)piperazinyl)sulfonyl]phenyl]quinazolin-4(3H)-one 150479-47-3P,
 2-[2-Ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]quinazolin-4(3H)-one 150479-48-4P, 2-[2-Ethoxy-5-(4-carbamoylpiperidinylsulfonyl)phenyl]quinazolin-4(3H)-one 150479-50-8P, 2-[2-Ethoxy-5-(1-hydroxy-2-morpholinoethyl)phenyl]-8-methylquinazolin-4(3H)-one 150479-52-0P,
 8-Carbamoyl-2-[2-ethoxy-5-[(4-(2-hydroxyethyl)piperazinyl)sulfonyl]phenyl]quinazolin-4(3H)-one 150479-53-1P, 8-Carbamoyl-2-(2-(propoxy)phenyl)quinazolin-4(3H)-one 150479-54-2P, 8-Ethylcarbamoyl-2-(2-(propoxy)phenyl)quinazolin-4(3H)-one 150479-55-3P,
 2-(5-Acetyl-2-(propoxy)phenyl)-8-methylquinazolin-4(3H)-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (method of treating a patient having precancerous lesions with Ph quinazolinone derivs.)
 RN 130239-61-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 130239-62-2 CAPLUS
CN 4(3H)-Quinazolinone, 7-(methylthio)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 130239-65-5 CAPLUS
CN 4(3H)-Quinazolinone, 7-(methylamino)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 150479-34-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-(1-piperazinylsulfonyl)phenyl]-8-methoxy- (CA INDEX NAME)



RN 150479-35-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-8-methoxy- (CA INDEX NAME)




RN 150479-36-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-(1-piperazinylsulfonyl)phenyl]-5-methyl-
(CA INDEX NAME)


RN 150479-37-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-5-methyl- (CA INDEX NAME)




RN 150479-38-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-8-methyl- (CA INDEX NAME)




RN 150479-39-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]-2-propoxyphenyl]-8-methyl- (CA INDEX NAME)




RN 150479-40-6 CAPLUS

CN Benzenesulfonamide, 3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-N-[3-(1-piperidiny)propyl]-4-propoxy- (CA INDEX NAME)




RN 150479-41-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[5-(1H-imidazol-1-yl)-2-propoxyphenyl]-8-methyl- (CA INDEX NAME)




RN 150479-42-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-methyl-2-[5-[3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]-2-propoxyphenyl]- (CA INDEX NAME)




RN 150479-45-1 CAPLUS

CN Benzenepropanoic acid, 3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-propoxy- (CA INDEX NAME)




RN 150479-46-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)




RN 150479-47-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[[4-methyl-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)




RN 150479-48-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[3-(3,4-dihydro-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]sulfonyl]- (CA INDEX NAME)




RN 150479-50-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[1-hydroxy-2-(4-morpholinyl)ethyl]phenyl]-8-methyl- (CA INDEX NAME)




RN 150479-52-0 CAPLUS

CN 8-Quinazolinecarboxamide, 2-[[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 150479-53-1 CAPLUS

CN 8-Quinazolinecarboxamide, 3,4-dihydro-4-oxo-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 150479-54-2 CAPLUS

CN 8-Quinazolinecarboxamide, N-ethyl-3,4-dihydro-4-oxo-2-(2-propoxyphenyl)- (CA INDEX NAME)



RN 150479-55-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-(5-acetyl-2-propoxyphenyl)-8-methyl- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 65 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:261670 CAPLUS

DOCUMENT NUMBER: 138:287666

TITLE: Preparation of heteroaryllactams as Factor Xa inhibitors

INVENTOR(S): Pinto, Donald; Quan, Mimi; Orwat, Michael; Li, Yun-Long; Han, Wei; Qiao, Jennifer; Lam, Patrick; Koch, Stephanie

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 441 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 20

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026652	A1	20030403	WO 2002-US29491	20020917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,				

	CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CA 2461202	A1 20030403	CA 2002-2461202 20020917
WO 2002026652	A1 20030403	WO 2002-XA29491 20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003026652	A1 20030403	WO 2002-XB29491 20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003026652	A1 20030403	WO 2002-XC29491 20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003026652	A1 20030403	WO 2002-XD29491 20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003026652	A1 20030403	WO 2002-XE29491 20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003026652	A1 20030403	WO 2002-XF29491 20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	

		GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003026652	A1	20030403	WO 2002-XG29491 20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2003026652	A1	20030403	WO 2002-XH29491 20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2003026652	A1	20030403	WO 2002-XI29491 20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2003026652	A1	20030403	WO 2002-XJ29491 20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2003026652	A1	20030403	WO 2002-XK29491 20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003026652 A1 20030403 WO 2002-XL29491 20020917

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003026652 A1 20030403 WO 2002-XM29491 20020917

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003026652 A1 20030403 WO 2002-XN29491 20020917

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003026652 A1 20030403 WO 2002-XO29491 20020917

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003026652 A1 20030403 WO 2002-XQ29491 20020917

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

WO 2003026652 A1 20030403 WO 2002-XQ29491 20020917

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2003026652	A1 20030403	WO 2002-XR29491	20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
WO 2003026652	A1 20030403	WO 2002-XS29491	20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
AU 2002341693	A1 20030407	AU 2002-341693	20020917
AU 2002341693	B2 20080529		
US 20030191115	A1 20031009	US 2002-245122	20020917
US 6967208	B2 20051122		
EP 1427415	A1 20040616	EP 2002-775843	20020917
EP 1427415	B1 20090812		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK		
BR 2002012726	A 20040803	BR 2002-12726	20020917
CN 1578660	A 20050209	CN 2002-821537	20020917
JP 2005507889	T 20050324	JP 2003-530289	20020917
JP 4249621	B2 20090402		
HU 2004002463	A2 20050428	HU 2004-2463	20020917
NZ 531616	A 20061222	NZ 2002-531616	20020917
CN 101357914	A 20090204	CN 2008-10210432	20020917
RU 2345993	C2 20090210	RU 2004-112191	20020917
AT 439360	T 20090815	AT 2002-775843	20020917
EP 2105436	A1 20090930	EP 2009-75313	20020917
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR		
ES 2329881	T3 20091202	ES 2002-775843	20020917
IN 2004DN00590	A 20050401	IN 2004-DN590	20040309
MX 2004002526	A 20040531	MX 2004-2526	20040317
ZA 2004002184	A 20050503	ZA 2004-2184	20040318
NO 2004001163	A 20040503	NO 2004-1163	20040319
KR 908176	B1 20090716	KR 2004-704025	20040319
US 20040220174	A1 20041104	US 2004-850587	20040520
US 6989391	B2 20060124		
US 20050124602	A1 20050609	US 2004-970781	20041021

US 7005435	B2	20060228		
US 20050171085	A1	20050804	US 2004-970807	20041021
US 6995172	B2	20060207		
US 20050261287	A1	20051124	US 2005-154972	20050616
US 20050267097	A1	20051201	US 2005-198801	20050805
US 7338963	B2	20080304		
US 20070135426	A1	20070614	US 2007-623367	20070116
US 7371761	B2	20080513		
US 20080090807	A1	20080417	US 2007-955678	20071213
US 7531535	B2	20090512		
KR 2008075927	A	20080819	KR 2008-718676	20080729
KR 909141	B1	20090723		
IN 2008DN06904	A	20080926	IN 2008-DN6904	20080812
AU 2008207537	A1	20080918	AU 2008-207537	20080826
NO 2008003684	A	20040503	NO 2008-3684	20080827
JP 2009079059	A	20090416	JP 2008-265280	20081014
US 20090176758	A1	20090709	US 2009-401401	20090310

PRIORITY APPLN. INFO.:

US 2001-324165P	P	20010921
US 2002-402317P	P	20020809
AU 2002-341693	A3	20020917
CN 2002-821537	A3	20020917
EP 2002-775843	A3	20020917
JP 2003-530289	A3	20020917
US 2002-245122	A3	20020917
WO 2002-US29491	W	20020917
IN 2004-DN590	A3	20040309
KR 2004-704025	A3	20040319
US 2004-850587	A3	20040520
US 2004-970807	A1	20041021
US 2005-154972	A1	20050616
US 2005-198801	A3	20050805
US 2007-955678	A3	20071213

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S):

MARPAT 138:287666

AB P4PM4 [M = 3-10 membered (substituted) (unsatd.) carbocyclyl, 4-10 membered heterocyclyl; P = null, 5-7 membered (substituted) (unsatd.) carbocyclyl, heterocyclyl fused to ring M; 1 of P4, M4 = ZAB, the other = G1G; G = (benzo-, pyrido-, pyrimido-, pyrazino-, or pyridazino-fused) (substituted) (unsatd.) 5-6 membered (hetero)cyclyl; G1 = null, (CR3R3a)-1-5, etc.; R3, R3a = H, Me, Et, Pr, Ph, PhCH2, etc.; Z = bond, (CR3R3e)-1-4, etc.; R3e = H, SO2NHR3, SO2N(R3)2, COR3, (substituted) alkyl, alkenyl, alkynyl, etc.; A = (substituted) 3-10 membered carbocyclyl, 5-12 membered heterocyclyl; Z = XNQ; X = null, CO, SO, SO2, etc.; NQ = 4-8 membered mono- or bicyclic (substituted) (unsatd.) ring containing a CO or SO2 group adjacent to the N atom; with provisos], were prepared Thus, 6-(4-iodophenyl)-3-methoxy-1-(4-methoxyphenyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one (preparation given), δ -valerolactam, K2CO3, and CuI were refluxed in Me2SO to give 15% 3-methoxy-1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one. Several title compds. inhibited Factor Xa with IC50s 10 μ M. [This abstract record is one of 20 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 503615-29-0P, 3-(5-Chloropyridin-2-yl)-6-methoxy-2-[4-(2-oxopiperidin-1-yl)phenyl]-3H-quinazolin-4-one 503615-30-3P, 3-(5-Chloropyridin-2-yl)-6-methoxy-2-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-3H-quinazolin-4-one


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of heteroaryllactams as Factor Xa inhibitors)


RN 503615-29-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-6-methoxy-2-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 503615-30-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-6-methoxy-2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 66 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:864387 CAPLUS

DOCUMENT NUMBER: 137:353059

TITLE: Preparation of 2-phenyl-4-quinazolinones and 2-phenyl-4-alkoxy-quinazolines as anticancer and antiplatelet drugs.

INVENTOR(S): Kuo, Sheng-chu; Hour, Mann-jen; Huang, Li-jiau; Lee, Kuo-hsiung

PATENT ASSIGNEE(S): National Science Council, Taiwan

SOURCE: U.S., 23 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6479499	B1	20021112	US 2000-605618	20000628


PRIORITY APPLN. INFO.:
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 137:353059
 GI

US 2000-605618


20000628



I



II



III

AB Title compds. [I, II, III; R2-R5 = H, (CH2)nMe, OH, O(CH2)nMe, X, amino; n = 0-4; X = F, Cl, Br; R = (CH2)nMe, (CH2)nCO2(CH2)nMe; R6, R7 = H, (CH2)nMe, O(CH2)nMe, X, amino, pyrrolidinyl, piperidinyl, morpholinyl; R6R7 = OCH2O], were prepared. Thus, 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone (preparation given) inhibited 1A9 human ovarian cancer cell number

with ED50 = 0.09 µg/mL. Title compds. were evaluated for cytotoxicity against a panel of human tumor cell lines, such as epidermoid carcinoma of the nasopharynx (KB), lung carcinoma (A-549), ileocecal carcinoma (HCT-8), breast cancer (MCF-7), melanoma (SKMEL-2), ovarian cancer (1A9), glioblastoma (U-87-MG), bone (HOS), P-gp-expressing epidermoid carcinoma of the nasopharynx (KB-VIN), and prostate cancer (PC3) cell lines. Some of the compds. exhibit antiplatelet activity.


IT 1028-96-2P 1152-07-4P 56071-04-6P
 59524-96-8P, 4-Ethoxy-2-(4'-methoxyphenyl)quinazoline
 74375-40-9P, 3-Ethyl-2-(4'-methoxyphenyl)-4-quinazolinone
 132982-02-6P 132982-03-7P 299897-92-0P
 314768-99-5P 314769-00-1P 314769-01-2P
 314769-02-3P 314769-03-4P 314769-04-5P
 314769-05-6P 314769-07-8P 314769-08-9P
 314769-09-0P 314769-10-3P 329024-93-3P,
 4-Ethoxy-2-(2'-methoxyphenyl)quinazoline 329024-94-4P,
 4-Ethoxy-2-(3'-methoxyphenyl)quinazoline 329024-99-9P,
 3-Ethyl-2-(3'-methoxyphenyl)-4-quinazolinone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-Ph-4-quinazolinones and 2-Ph-4-alkoxy-quinazolines as anticancer and antiplatelet drugs)


RN 1028-96-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 1152-07-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 56071-04-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 59524-96-8 CAPLUS

CN Quinazoline, 4-ethoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 74375-40-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-ethyl-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 132982-02-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 132982-03-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 299897-92-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-methoxyphenyl)-6-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 314768-99-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-(2,3-dimethoxyphenyl)- (CA INDEX NAME)




RN 314769-00-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 314769-01-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 314769-02-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 314769-03-4 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 314769-04-5 CAPLUS
CN 4(3H)-Quinazolinone, 6-methoxy-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 314769-05-6 CAPLUS
CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 314769-07-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-(dimethylamino)-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 314769-08-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-methoxyphenyl)-6-(1-piperidinyl)- (CA INDEX NAME)




RN 314769-09-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-methoxyphenyl)-6-(4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 314769-10-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-methoxyphenyl)-6-(4-morpholinyl)- (CA INDEX NAME)



RN 329024-93-3 CAPLUS
CN Quinazoline, 4-ethoxy-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 329024-94-4 CAPLUS
CN Quinazoline, 4-ethoxy-2-(3-methoxyphenyl)- (CA INDEX NAME)



RN 329024-99-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-ethyl-2-(3-methoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 67 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:314395 CAPLUS

DOCUMENT NUMBER: 136:335540

TITLE: Use of PDE V inhibitors for improved fecundity in mammals

INVENTOR(S): Westbrook, Simon Lempriere; Zanzinger, Johannes Friedrich

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1199070	A2	20020424	EP 2001-308684	20011011
EP 1199070	A3	20040317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2359383	A1	20020420	CA 2001-2359383	20011018
US 20030018036	A1	20030123	US 2001-982445	20011018
US 6548508	B2	20030415		
AU 2001081523	A	20020502	AU 2001-81523	20011019
HU 2001004406	A2	20020729	HU 2001-4406	20011019
HU 2001004406	A3	20050728		
JP 2002220346	A	20020809	JP 2001-322195	20011019
JP 3842104	B2	20061108		
ZA 2001008617	A	20030422	ZA 2001-8617	20011019
NZ 514947	A	20050324	NZ 2001-514947	20011019
US 20030018037	A1	20030123	US 2002-229534	20020827

US 6743799	B2	20040601		
US 20040167095	A1	20040826	US 2004-778866	20040212
AU 2004233509	A1	20041223	AU 2004-233509	20041126
PRIORITY APPLN. INFO.:			GB 2000-25782	A 20001020
			US 2000-253338P	P 20001128
			US 2001-982445	A1 20011018
			AU 2001-81523	A3 20011019
			US 2002-229534	A1 20020827

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The invention relates to the use of a cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or fetus, (b) increasing the rate or probability of survival of an embryo and/or fetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity. I.v. and tablet formulations are exemplified. Formulations and packs containing the PDE V inhibitors for pharmaceutical or veterinary use are claimed.

IT	150479-34-8	150479-35-9	150479-36-0
	150479-37-1	150479-38-2	150479-39-3
	150479-40-6	150479-41-7	150479-42-8
	150479-43-9	150479-44-0	150479-45-1
	150479-46-2	150479-47-3	150479-48-4
	150479-49-5	150479-50-8	150479-51-9
	150479-52-0	150479-53-1	150479-54-2
	150479-55-3		

RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of PDE V inhibitors for improved fecundity in mammals)


RN 150479-34-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-(1-piperazinylsulfonyl)phenyl]-8-methoxy- (CA INDEX NAME)



RN 150479-35-9 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-8-methoxy- (CA INDEX NAME)



RN 150479-36-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-(1-piperazinylsulfonyl)phenyl]-5-methyl-

(CA INDEX NAME)




RN 150479-37-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-5-methyl- (CA INDEX NAME)




RN 150479-38-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-8-methyl- (CA INDEX NAME)




RN 150479-39-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]-2-propoxyphenyl]-8-methyl- (CA INDEX NAME)




RN 150479-40-6 CAPLUS


CN Benzenesulfonamide, 3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-N-[3-(1-piperidinyl)propyl]-4-propoxy- (CA INDEX NAME)




RN 150479-41-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[5-(1H-imidazol-1-yl)-2-propoxyphenyl]-8-methyl-
(CA INDEX NAME)



RN 150479-42-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-methyl-2-[5-[3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]-2-propoxyphenyl]- (CA INDEX NAME)




RN 150479-43-9 CAPLUS
CN 2-Propenoic acid, 3-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-propoxyphenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 150479-44-0 CAPLUS

CN 2-Propenoic acid, 3-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-propoxyphenyl]- (CA INDEX NAME)




RN 150479-45-1 CAPLUS

CN Benzenepropanoic acid, 3-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-propoxy- (CA INDEX NAME)




RN 150479-46-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)




RN 150479-47-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 150479-48-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[3-(3,4-dihydro-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]sulfonyl]- (CA INDEX NAME)




RN 150479-49-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[2-(4-morpholinyl)acetyl]phenyl]-8-methyl- (CA INDEX NAME)




RN 150479-50-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[1-hydroxy-2-(4-morpholinyl)ethyl]phenyl]-8-methyl- (CA INDEX NAME)




RN 150479-51-9 CAPLUS

CN 8-Quinazolinecarboxamide, 2-(2-ethoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 150479-52-0 CAPLUS

CN 8-Quinazolinecarboxamide, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 150479-53-1 CAPLUS

CN 8-Quinazolinecarboxamide, 3,4-dihydro-4-oxo-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 150479-54-2 CAPLUS

CN 8-Quinazolinecarboxamide, N-ethyl-3,4-dihydro-4-oxo-2-(2-propoxyphenyl)- (CA INDEX NAME)



RN 150479-55-3 CAPLUS


CN 4(3H)-Quinazolinone, 2-(5-acetyl-2-propoxyphenyl)-8-methyl- (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 68 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:256241 CAPLUS
DOCUMENT NUMBER: 136:294843
TITLE: Preparation of bicyclic pyrimidin-4-one based
inhibitors of factor Xa
INVENTOR(S): Zhang, Penglie; Li, Wenhao; Huang, Wenrong; Wang,
Lingyan; Jia, Zhaozhong Jon; Scarborough, Robert M.;
Zhu, Bing-Yan
PATENT ASSIGNEE(S): Cor Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026718	A2	20020404	WO 2001-US30335	20011001
WO 2002026718	A3	20020829		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002014546	A	20020408	AU 2002-14546	20011001
PRIORITY APPLN. INFO.:			US 2000-236331P	P 20000929
			WO 2001-US30335	W 20011001
OTHER SOURCE(S):	MARPAT 136:294843			
GI				



I



II



III

AB The title compds. [I or II; A = C(:NH)NMe₂, C(:NH)NH₂, 1-methylimidazol-2-yl; Q = (un)substituted phenylene, thienylene, pyridylene; R₂ = H, halo, alkoxy, etc.; R₃-R₇ = H, F, Cl, alkoxy, etc.; Y = CH, N; X = O, S; R = H, halo, alkyl, etc.; n = 1-5] having activity against mammalian factor Xa, and therefore useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis, were prepared E.g., a 4-step synthesis of III, starting with 2-amino-5-chloropyridine and 5-chloroisatoic anhydride, was given.


IT 406937-11-9P 406937-12-0P 406937-13-1P
 406937-14-2P 406937-15-3P 406937-16-4P
 406937-17-5P 406937-18-6P 406937-19-7P
 406937-20-0P 406937-21-1P 406937-22-2P
 406937-36-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic pyrimidin-4-one based inhibitors of factor Xa)


RN 406937-11-9 CAPLUS

CN Benzenecarboximidamide, 4-[6-chloro-3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N,N-dimethyl- (CA INDEX NAME)




RN 406937-12-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(5-chloro-2-pyridinyl)-2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 406937-13-1 CAPLUS

CN Benzenecarboximidamide, 4-[3-(5-chloro-2-pyridinyl)-3,4-dihydro-6-methoxy-4-oxo-2-quinazolinyl]-N,N-dimethyl- (CA INDEX NAME)




RN 406937-14-2 CAPLUS


CN 4(3H)-Quinazolinone, 3-(5-chloro-2-pyridinyl)-2-[4-(imino-1-piperidinylmethyl)phenyl]- (CA INDEX NAME)




RN 406937-15-3 CAPLUS
 CN Benzenecarboximidamide, 4-[6,8-dichloro-3-(5-chloro-2-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 406937-16-4 CAPLUS
 CN 4(3H)-Quinazolinone, 6,8-dichloro-3-(5-chloro-2-pyridinyl)-2-[4-(imino-1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)





RN 406937-17-5 CAPLUS
 CN 4(3H)-Quinazolinone, 6,8-dichloro-3-(5-chloro-2-pyridinyl)-2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 406937-18-6 CAPLUS

CN Benzenecarboximidamide, 4-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]- (CA INDEX NAME)





RN 406937-19-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[4-(imino-1-piperidinylmethyl)phenyl]- (CA INDEX NAME)




RN 406937-20-0 CAPLUS

CN Benzenecarboximidamide, 4-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N,N-dimethyl- (CA INDEX NAME)





RN 406937-21-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[4-(imino-1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)




RN 406937-22-2 CAPLUS

CN Benzenecarboximidamide, 4-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 406937-36-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-(5-chloro-2-pyridinyl)-2-[4-[(methylamino)methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 69 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:149217 CAPLUS

DOCUMENT NUMBER: 136:321360

TITLE: Synthesis and Biologic Evaluation of a Radioiodinated Quinazolinone Derivative for Enzyme-Mediated Insolubilization Therapy

AUTHOR(S): Ho, Nanhui; Harapanhalli, Ravi S.; Dahman, Bassam A.; Chen, Kai; Wang, Ketai; Adelstein, S. James; Kassiss, Amin I.

CORPORATE SOURCE: Department of Radiology, Harvard Medical School, Boston, MA, 02115, USA

SOURCE: Bioconjugate Chemistry (2002), 13(2), 357-364

CODEN: BCCHES; ISSN: 1043-1802

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have developed a new strategy that aims to concentrate therapeutic radionuclides within solid tumors. This approach, which we have named EMIT (enzyme-mediated insolubilization therapy), is a method for enzyme-dependent, site-specific, in vivo precipitation of a radioactive mol.

(from

a water-soluble precursor) within the extracellular space of solid tumors. The prodrug, ammonium 2-(2'-phosphoryloxyphenyl)-6-iodo-4-(3H)-quinazolinone, labeled with iodine-125 (125IPD) and its authentic compound labeled with iodine-127 (IPD) have been synthesized, purified, and characterized. The alkaline phosphatase (ALP)-mediated conversion of these water-soluble nonfluorescent prodrugs to the water-insol. fluorescent species, iodine-125-labeled 2-(2'-hydroxyphenyl)-6-iodo-4-(3H)-quinazolinone (125ID) and its iodine-127-labeled derivative (ID), has been demonstrated in vitro. Biodistribution studies in mice indicate that both 125IPD and 125ID are minimally retained by most tissues and organs. In addition, following its i.v. injection in mice, 125IPD is localized in ALP-rich regions and converted to 125ID, which remains indefinitely within the tissues where it is produced. We believe that EMIT is a strategy that will lead to the active and specific concentration and entrapment of therapeutic radionuclides within solid tumors, the consequent protracted irradiation of tumor cells within the range of the emitted particles, and the effective therapy of solid tumors.

IT 414902-12-8P


RL: PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and biol. evaluation of radioiodinated quinazolinone derivative

for enzyme-mediated insolubilization therapy)

RN 414902-12-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-(iodo-125I)-2-[2-(phosphonoxy)phenyl]-, ammonium salt (1:2) (CA INDEX NAME)

●2 NH₃

OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 70 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:116950 CAPLUS

DOCUMENT NUMBER: 137:163309

TITLE: Studies on Quinazolinones as Dual Inhibitors of Pgp and MRP1 in Multidrug Resistance

AUTHOR(S): Wang, Shouming; Ryder, Hamish; Pretswell, Ian; Depledge, Paul; Milton, John; Hancox, Timothy C.; Dale, Ian; Dangerfield, Wendy; Charlton, Peter; Faint, Richard; Dodd, Rory; Hassan, Stephanie

CORPORATE SOURCE: Department of Medicinal Chemistry, Xenova Ltd., Slough, Berkshire, SL1 4NL, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 571-574

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:163309

GI



AB We have identified a series of quinazolinone analogs with potent dual inhibitory activities against both P glycoprotein (Pgp) and MRP1. Compound I exhibits equal potentiation activity in both assays and appears to be slightly more active than VX-710 in reversal of Pgp and MRP1 mediated drug resistance.


IT	81144-93-6P	446293-64-7P	446293-65-8P
	446293-66-9P	446293-67-0P	446293-68-1P
	446293-69-2P	446293-70-5P	446293-71-6P
	446293-72-7P	446293-73-8P	446293-75-0P
	446293-76-1P	446293-77-2P	446293-78-3P
	446293-80-7P	446293-81-8P	446293-83-0P
	446293-84-1P	446293-85-2P	446293-86-3P
	446293-87-4P	446293-88-5P	446293-89-6P
	446293-90-9P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(quinazolinone analogs with dual inhibitory activities against P glycoprotein and MRP1)


RN 81144-93-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(dimethylamino)phenyl]-3-(phenylmethyl)- (CA INDEX NAME)




RN 446293-64-7 CAPLUS

CN 4(3H)-Quinazolinone, 6-amino-3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 446293-65-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]-6-nitro- (CA INDEX NAME)




RN 446293-66-9 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-(dimethylamino)phenyl]-3-hexyl- (CA INDEX NAME)



RN 446293-67-0 CAPLUS


CN 4(3H)-Quinazolinone, 3-(cyclohexylmethyl)-2-[4-(dimethylamino)phenyl]-
(CA INDEX NAME)

RN 446293-68-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(dimethylamino)phenyl]-3-[2-(4-pyridinyl)ethyl]-
(CA INDEX NAME)


RN 446293-69-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-
isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 446293-70-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-(dimethylamino)phenyl]-3-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)





RN 446293-71-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-[2-(3,4-dimethoxyphenyl)ethyl]methylamino]ethyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)





RN 446293-72-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-(dimethylamino)phenyl]-3-[2-[4-(3,4,5-trimethoxybenzoyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 446293-73-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-(dimethylamino)phenyl]-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 446293-75-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-[3-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 446293-76-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 446293-77-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[4-(diethylamino)phenyl]-3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]- (CA INDEX NAME)



RN 446293-78-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-(3-propylphenyl)- (CA INDEX NAME)




RN 446293-80-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 446293-81-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1,1'-biphenyl]-4-yl-3-[2-(3,4-dihydro-6,7-

dimethoxy-2(1H)-isoquinolinyl)ethyl]- (CA INDEX NAME)




RN 446293-83-0 CAPLUS

CN 4(3H)-Quinazolinone, 5-chloro-3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 446293-84-1 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 446293-85-2 CAPLUS


CN 4(3H)-Quinazolinone, 7-chloro-3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 446293-86-3 CAPLUS


CN 4(3H)-Quinazolinone, 8-chloro-3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-

isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 446293-87-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]-8-methyl- (CA INDEX NAME)




RN 446293-88-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]-8-methoxy- (CA INDEX NAME)




RN 446293-89-6 CAPLUS


CN 4(3H)-Quinazolinone, 3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]-7-nitro- (CA INDEX NAME)



RN 446293-90-9 CAPLUS
 CN 4(3H)-Quinazolinone, 7-amino-3-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



IT 446293-63-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (quinazolinone analogs with dual inhibitory activities against P glycoprotein and MRP1)
 RN 446293-63-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
 REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 71 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:780734 CAPLUS
 DOCUMENT NUMBER: 135:327353
 TITLE: Methods using a nitric oxide signaling pathway modulator for prevention and treatment of gastrointestinal disorders
 INVENTOR(S): Watkins, Crystal C.; Snyder, Solomon M.; Ferris, Christopher D.
 PATENT ASSIGNEE(S): Johns Hopkins University, USA
 SOURCE: PCT Int. Appl., 124 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078781	A2	20011025	WO 2001-US12946	20010419
WO 2001078781	A9	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2406947 A1 20011025 CA 2001-2406947 20010419

US 20020128171 A1 20020912 US 2001-840014 20010419

US 6774128 B2 20040810

EP 1365806 A2 20031203 EP 2001-930630 20010419

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR

JP 2004525857 T 20040826 JP 2001-576080 20010419

CN 1630532 A 20050622 CN 2001-810428 20010419

AU 2001257146 B2 20061130 AU 2001-257146 20010419

MX 2002010322 A 20040910 MX 2002-10322 20021018

US 20050004222 A1 20050106 US 2004-855576 20040528

AU 2006236034 A1 20061207 AU 2006-236034 20061116

PRIORITY APPLN. INFO.: US 2000-198545P P 20000419

US 2001-840014 A3 20010419

WO 2001-US12946 W 20010419

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods are disclosed for preventing or treating a gastrointestinal (GI) disorder in a mammal, e.g. a human patient. In one embodiment, the methods include administering to the mammal a therapeutically effective amount of a compound that modulates a nitric oxide (NO) signaling pathway, particularly in GI neurons. Methods of the invention are particularly useful for the treatment (including prophylactic treatment) of diabetic gastropathies and other GI disorders.

IT 150479-38-2 150479-39-3 150479-42-8


150479-52-0 150479-54-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nitric oxide signaling pathway modulator for treatment of gastrointestinal disorders)


RN 150479-38-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-8-methyl- (CA INDEX NAME)




RN 150479-39-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]-2-propoxyphenyl]-8-methyl- (CA INDEX NAME)




RN 150479-42-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-methyl-2-[5-[3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]-2-propoxyphenyl]- (CA INDEX NAME)




RN 150479-52-0 CAPLUS

CN 8-Quinazolinecarboxamide, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)



RN 150479-54-2 CAPLUS

CN 8-Quinazolinecarboxamide, N-ethyl-3,4-dihydro-4-oxo-2-(2-propoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L5 ANSWER 72 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:247321 CAPLUS

DOCUMENT NUMBER: 134:280852

TITLE: Quinazolinones useful as glycoprotein I β IX antagonists, and their preparation and use for control of thrombotic disorders

INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard

PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany; et al.

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023365	A1	20010405	WO 2000-EP8940	20000913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385921	A1	20010405	CA 2000-2385921	20000913
BR 2000014294	A	20020521	BR 2000-14294	20000913
EP 1216235	A1	20020626	EP 2000-965991	20000913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6890930	B1	20050510	US 2002-89166	20000913
NO 2002001502	A	20020326	NO 2002-1502	20020326
PRIORITY APPLN. INFO.:			US 1999-407958	A 19990928
			US 1999-287586P	P 19990928
			WO 2000-EP8940	W 20000913

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 134:280852

GI



II

AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R1 = H, A, OH, OA, OCH2Ar, Hal, NH2, NHA, NA2, NO2, cyano, COR2, CONH2, CONHA, CONA2, CO2H, CO2A, SO2A; R2, R3 = H, A, C(:NH)NH2, solid phase; R4 = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C2-4 alkylene; Z = bond, phenylene; A = (un)branched C1-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)saturated mono- or bicyclic NOS heterocyclyl; Hal = F, Cl, Br, or iodo; n = 1-3; m = 0-3; with a variety of provisos]. The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, 3-(aminomethyl)benzylamine, was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R4YCHO, oxidation of the resultant dihydroquinazolinone ring system, and cleavage from the resin with CF3CO2H, gave a variety of compds. I, e.g., the preferred compound II.


IT 332361-31-6P, 3-(3-Aminopropyl)-6-chloro-2-(2-methylphenyl)-3H-quinazolin-4-one 332361-32-7P, 3-(3-Aminopropyl)-6-methyl-2-(2-methylphenyl)-3H-quinazolin-4-one 332361-33-8P, 3-(3-Aminopropyl)-7-chloro-2-(2-methylphenyl)-3H-quinazolin-4-one 332361-34-9P, 3-(3-Aminopropyl)-6-methoxy-2-(2-methylphenyl)-3H-quinazolin-4-one 332361-35-0P, 3-(3-Aminopropyl)-2-(2-methylphenyl)-3H-quinazolin-4-one 332361-36-1P, 3-(3-Aminopropyl)-6-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one 332361-37-2P, 3-(3-Aminopropyl)-6-methyl-2-(3-methylphenyl)-3H-quinazolin-4-one 332361-38-3P, 3-(3-Aminopropyl)-7-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one 332361-39-4P, 3-(3-Aminopropyl)-6-methoxy-2-(3-methylphenyl)-3H-quinazolin-4-one 332361-40-7P, 3-(3-Aminopropyl)-2-(3-methylphenyl)-3H-quinazolin-4-one 332361-41-8P, 3-(3-Aminopropyl)-6-chloro-2-(4-methylphenyl)-3H-quinazolin-4-one 332361-42-9P, 3-(3-Aminopropyl)-6-methyl-2-(4-methylphenyl)-3H-quinazolin-4-one 332361-43-0P, 3-(3-Aminopropyl)-7-chloro-2-(4-methylphenyl)-3H-

quinazolin-4-one 332361-44-1P,
 3-(3-Aminopropyl)-6-methoxy-2-(4-methylphenyl)-3H-quinazolin-4-one
 332361-45-2P, 3-(3-Aminopropyl)-2-(4-methylphenyl)-3H-quinazolin-4-
 one 332361-46-3P, 3-(3-Aminopropyl)-6-chloro-2-(4-tert-
 butylphenyl)-3H-quinazolin-4-one 332361-47-4P,
 3-(3-Aminopropyl)-6-methyl-2-(4-tert-butylphenyl)-3H-quinazolin-4-one
 332361-48-5P, 3-(3-Aminopropyl)-7-chloro-2-(4-tert-butylphenyl)-3H-
 quinazolin-4-one 332361-49-6P,
 3-(3-Aminopropyl)-6-methoxy-2-(4-tert-butylphenyl)-3H-quinazolin-4-one
 332361-50-9P, 3-(3-Aminopropyl)-2-(4-tert-butylphenyl)-3H-
 quinazolin-4-one 332361-51-0P,
 3-(3-Aminopropyl)-6-chloro-2-(3-chlorophenyl)-3H-quinazolin-4-one
 332361-52-1P, 3-(3-Aminopropyl)-6-methyl-2-(3-chlorophenyl)-3H-
 quinazolin-4-one 332361-53-2P,
 3-(3-Aminopropyl)-7-chloro-2-(3-chlorophenyl)-3H-quinazolin-4-one
 332361-55-4P, 3-(3-Aminopropyl)-6-methoxy-2-(3-chlorophenyl)-3H-
 quinazolin-4-one 332361-56-5P,
 3-(3-Aminopropyl)-2-(3-chlorophenyl)-3H-quinazolin-4-one
 332361-57-6P, 3-(3-Aminopropyl)-6-chloro-2-(4-methoxyphenyl)-3H-
 quinazolin-4-one 332361-58-7P,
 3-(3-Aminopropyl)-6-methyl-2-(4-methoxyphenyl)-3H-quinazolin-4-one
 332361-59-8P, 3-(3-Aminopropyl)-7-chloro-2-(4-methoxyphenyl)-3H-
 quinazolin-4-one 332361-60-1P,
 3-(3-Aminopropyl)-6-methoxy-2-(4-methoxyphenyl)-3H-quinazolin-4-one
 332361-61-2P, 3-(3-Aminopropyl)-2-(4-methoxyphenyl)-3H-quinazolin-
 4-one 332361-62-3P, 3-(3-Aminopropyl)-6-chloro-2-(3-
 methoxyphenyl)-3H-quinazolin-4-one 332361-63-4P,
 3-(3-Aminopropyl)-6-methyl-2-(3-methoxyphenyl)-3H-quinazolin-4-one
 332361-64-5P, 3-(3-Aminopropyl)-7-chloro-2-(3-methoxyphenyl)-3H-
 quinazolin-4-one 332361-65-6P,
 3-(3-Aminopropyl)-6-methoxy-2-(3-methoxyphenyl)-3H-quinazolin-4-one
 332361-66-7P, 3-(3-Aminopropyl)-2-(3-methoxyphenyl)-3H-quinazolin-
 4-one 332361-87-2P, 3-(3-Aminopropyl)-2-biphenyl-4-yl-6-chloro-
 3H-quinazolin-4-one 332361-88-3P,
 3-(3-Aminopropyl)-2-biphenyl-4-yl-6-methyl-3H-quinazolin-4-one
 332361-89-4P, 3-(3-Aminopropyl)-2-biphenyl-4-yl-7-chloro-3H-
 quinazolin-4-one 332361-90-7P,
 3-(3-Aminopropyl)-2-biphenyl-4-yl-6-methoxy-3H-quinazolin-4-one
 332361-91-8P, 3-(3-Aminopropyl)-2-biphenyl-4-yl-3H-quinazolin-4-
 one 332362-26-2P, 3-(3-Aminomethylbenzyl)-6-chloro-2-(2-
 methylphenyl)-3H-quinazolin-4-one 332362-27-3P,
 3-(3-Aminomethylbenzyl)-6-methyl-2-(2-methylphenyl)-3H-quinazolin-4-one
 332362-28-4P, 3-(3-Aminomethylbenzyl)-7-chloro-2-(2-methylphenyl)-
 3H-quinazolin-4-one 332362-29-5P,
 3-(3-Aminomethylbenzyl)-6-methoxy-2-(2-methylphenyl)-3H-quinazolin-4-one
 332362-30-8P, 3-(3-Aminomethylbenzyl)-2-(2-methylphenyl)-3H-
 quinazolin-4-one 332362-31-9P,
 3-(3-Aminomethylbenzyl)-6-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one
 332362-32-0P, 3-(3-Aminomethylbenzyl)-6-methyl-2-(3-methylphenyl)-
 3H-quinazolin-4-one 332362-33-1P,
 3-(3-Aminomethylbenzyl)-7-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one
 332362-34-2P, 3-(3-Aminomethylbenzyl)-6-methoxy-2-(3-methylphenyl)-
 3H-quinazolin-4-one 332362-35-3P,
 3-(3-Aminomethylbenzyl)-2-(3-methylphenyl)-3H-quinazolin-4-one
 332362-36-4P, 3-(3-Aminomethylbenzyl)-6-chloro-2-(4-methylphenyl)-
 3H-quinazolin-4-one 332362-37-5P,
 3-(3-Aminomethylbenzyl)-6-methyl-2-(4-methylphenyl)-3H-quinazolin-4-one
 332362-38-6P, 3-(3-Aminomethylbenzyl)-7-chloro-2-(4-methylphenyl)-
 3H-quinazolin-4-one 332362-39-7P,
 3-(3-Aminomethylbenzyl)-6-methoxy-2-(4-methylphenyl)-3H-quinazolin-4-one


332362-40-0P, 3-(3-Aminomethylbenzyl)-2-(4-methylphenyl)-3H-quinazolin-4-one 332362-41-1P, 3-(3-Aminomethylbenzyl)-6-chloro-2-(4-tert-butylphenyl)-3H-quinazolin-4-one 332362-42-2P, 3-(3-Aminomethylbenzyl)-6-methyl-2-(4-tert-butylphenyl)-3H-quinazolin-4-one 332362-43-3P, 3-(3-Aminomethylbenzyl)-7-chloro-2-(4-tert-butylphenyl)-3H-quinazolin-4-one 332362-44-4P, 3-(3-Aminomethylbenzyl)-6-methoxy-2-(4-tert-butylphenyl)-3H-quinazolin-4-one 332362-45-5P, 3-(3-Aminomethylbenzyl)-2-(4-tert-butylphenyl)-3H-quinazolin-4-one 332362-46-6P, 3-(3-Aminomethylbenzyl)-6-chloro-2-(3-chlorophenyl)-3H-quinazolin-4-one 332362-47-7P, 3-(3-Aminomethylbenzyl)-6-methyl-2-(3-chlorophenyl)-3H-quinazolin-4-one 332362-48-8P, 3-(3-Aminomethylbenzyl)-7-chloro-2-(3-chlorophenyl)-3H-quinazolin-4-one 332362-49-9P, 3-(3-Aminomethylbenzyl)-6-methoxy-2-(3-chlorophenyl)-3H-quinazolin-4-one 332362-50-2P, 3-(3-Aminomethylbenzyl)-2-(3-chlorophenyl)-3H-quinazolin-4-one 332362-51-3P, 3-(3-Aminomethylbenzyl)-6-chloro-2-(4-methoxyphenyl)-3H-quinazolin-4-one 332362-52-4P, 3-(3-Aminomethylbenzyl)-6-methyl-2-(4-methoxyphenyl)-3H-quinazolin-4-one 332362-53-5P, 3-(3-Aminomethylbenzyl)-7-chloro-2-(4-methoxyphenyl)-3H-quinazolin-4-one 332362-54-6P, 3-(3-Aminomethylbenzyl)-6-methoxy-2-(4-methoxyphenyl)-3H-quinazolin-4-one 332362-55-7P, 3-(3-Aminomethylbenzyl)-2-(4-methoxyphenyl)-3H-quinazolin-4-one 332362-76-2P, 3-(3-Aminomethylbenzyl)-2-biphenyl-4-yl-6-chloro-3H-quinazolin-4-one 332362-77-3P, 3-(3-Aminomethylbenzyl)-2-biphenyl-4-yl-6-methyl-3H-quinazolin-4-one 332362-78-4P, 3-(3-Aminomethylbenzyl)-2-biphenyl-4-yl-7-chloro-3H-quinazolin-4-one 332362-80-8P, 3-(3-Aminomethylbenzyl)-2-biphenyl-4-yl-6-methoxy-3H-quinazolin-4-one 332362-81-9P, 3-(3-Aminomethylbenzyl)-2-biphenyl-4-yl-3H-quinazolin-4-one

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate)


RN 332361-31-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-chloro-2-(2-methylphenyl)- (CA INDEX NAME)




RN 332361-32-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-methyl-2-(2-methylphenyl)- (CA INDEX NAME)




RN 332361-33-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-7-chloro-2-(2-methylphenyl)- (CA INDEX NAME)




RN 332361-34-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-methoxy-2-(2-methylphenyl)- (CA INDEX NAME)




RN 332361-35-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-(2-methylphenyl)- (CA INDEX NAME)




RN 332361-36-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-chloro-2-(3-methylphenyl)- (CA INDEX NAME)




RN 332361-37-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-methyl-2-(3-methylphenyl)- (CA INDEX NAME)




RN 332361-38-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-7-chloro-2-(3-methylphenyl)- (CA INDEX NAME)




RN 332361-39-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-methoxy-2-(3-methylphenyl)- (CA INDEX NAME)




RN 332361-40-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-(3-methylphenyl)- (CA INDEX NAME)




RN 332361-41-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-chloro-2-(4-methylphenyl)- (CA
INDEX NAME)




RN 332361-42-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-methyl-2-(4-methylphenyl)- (CA
INDEX NAME)



RN 332361-43-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-7-chloro-2-(4-methylphenyl)- (CA
INDEX NAME)




RN 332361-44-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-methoxy-2-(4-methylphenyl)- (CA
INDEX NAME)




RN 332361-45-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 332361-46-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-chloro-2-[4-(1,1-dimethylethyl)phenyl]- (CA INDEX NAME)




RN 332361-47-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-[4-(1,1-dimethylethyl)phenyl]-6-methyl- (CA INDEX NAME)




RN 332361-48-5 CAPLUS


CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-7-chloro-2-[4-(1,1-dimethylethyl)phenyl]- (CA INDEX NAME)




RN 332361-49-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-[4-(1,1-dimethylethyl)phenyl]-6-methoxy- (CA INDEX NAME)




RN 332361-50-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-[4-(1,1-dimethylethyl)phenyl]- (CA INDEX NAME)




RN 332361-51-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-chloro-2-(3-chlorophenyl)- (CA INDEX NAME)




RN 332361-52-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-(3-chlorophenyl)-6-methyl- (CA INDEX NAME)




RN 332361-53-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-7-chloro-2-(3-chlorophenyl)- (CA INDEX NAME)




RN 332361-55-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-(3-chlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 332361-56-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-(3-chlorophenyl)- (CA INDEX NAME)




RN 332361-57-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-chloro-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 332361-58-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-(4-methoxyphenyl)-6-methyl- (CA INDEX NAME)




RN 332361-59-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-7-chloro-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 332361-60-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-methoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 332361-61-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 332361-62-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-chloro-2-(3-methoxyphenyl)- (CA
INDEX NAME)




RN 332361-63-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-(3-methoxyphenyl)-6-methyl- (CA
INDEX NAME)




RN 332361-64-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-7-chloro-2-(3-methoxyphenyl)- (CA
INDEX NAME)




RN 332361-65-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-methoxy-2-(3-methoxyphenyl)- (CA
INDEX NAME)




RN 332361-66-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 332361-87-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-[1,1'-biphenyl]-4-yl-6-chloro- (CA INDEX NAME)




RN 332361-88-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-[1,1'-biphenyl]-4-yl-6-methyl- (CA INDEX NAME)




RN 332361-89-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-[1,1'-biphenyl]-4-yl-7-chloro- (CA INDEX NAME)




RN 332361-90-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-[1,1'-biphenyl]-4-yl-6-methoxy-
(CA INDEX NAME)

RN 332361-91-8 CAPLUS


CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-[1,1'-biphenyl]-4-yl- (CA INDEX
NAME)

RN 332362-26-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-chloro-2-(2-
methylphenyl)- (CA INDEX NAME)


RN 332362-27-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-methyl-2-(2-
methylphenyl)- (CA INDEX NAME)




RN 332362-28-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-7-chloro-2-(2-methylphenyl)- (CA INDEX NAME)




RN 332362-29-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-methoxy-2-(2-methylphenyl)- (CA INDEX NAME)





RN 332362-30-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-(2-methylphenyl)- (CA INDEX NAME)





RN 332362-31-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-chloro-2-(3-methylphenyl)- (CA INDEX NAME)





RN 332362-32-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-methyl-2-(3-methylphenyl)- (CA INDEX NAME)





RN 332362-33-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-7-chloro-2-(3-methylphenyl)- (CA INDEX NAME)





RN 332362-34-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-methoxy-2-(3-methylphenyl)- (CA INDEX NAME)





RN 332362-35-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-(3-methylphenyl)- (CA INDEX NAME)





RN 332362-36-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-chloro-2-(4-methylphenyl)- (CA INDEX NAME)





RN 332362-37-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)





RN 332362-38-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-7-chloro-2-(4-methylphenyl)- (CA INDEX NAME)



RN 332362-39-7 CAPLUS



CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-methoxy-2-(4-methylphenyl)- (CA INDEX NAME)



RN 332362-40-0 CAPLUS



CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-(4-methylphenyl)-

(CA INDEX NAME)





RN 332362-41-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-chloro-2-[4-(1,1-dimethylethyl)phenyl]- (CA INDEX NAME)




RN 332362-42-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-[4-(1,1-dimethylethyl)phenyl]-6-methyl- (CA INDEX NAME)




RN 332362-43-3 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-7-chloro-2-[4-(1,1-dimethylethyl)phenyl]- (CA INDEX NAME)





RN 332362-44-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-[4-(1,1-dimethylethyl)phenyl]-6-methoxy- (CA INDEX NAME)





RN 332362-45-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-[4-(1,1-dimethylethyl)phenyl]- (CA INDEX NAME)





RN 332362-46-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-chloro-2-(3-chlorophenyl)- (CA INDEX NAME)





RN 332362-47-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-(3-chlorophenyl)-6-methyl- (CA INDEX NAME)





RN 332362-48-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-7-chloro-2-(3-chlorophenyl)-6-methoxy- (CA INDEX NAME)



RN 332362-49-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-(3-chlorophenyl)-6-methoxy- (CA INDEX NAME)





RN 332362-50-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-(3-chlorophenyl)-
(CA INDEX NAME)

RN 332362-51-3 CAPLUS



CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-chloro-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 332362-52-4 CAPLUS



CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-(4-methoxyphenyl)-
6-methyl- (CA INDEX NAME)

10/ 582,823





RN 332362-53-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-7-chloro-2-(4-methoxyphenyl)- (CA INDEX NAME)





RN 332362-54-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-methoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)





RN 332362-55-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)





RN 332362-76-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-[1,1'-biphenyl]-4-yl-6-chloro- (CA INDEX NAME)





RN 332362-77-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-[1,1'-biphenyl]-4-yl-6-methyl- (CA INDEX NAME)





RN 332362-78-4 CAPLUS



CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-[1,1'-biphenyl]-4-yl-7-chloro- (CA INDEX NAME)



RN 332362-80-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-[1,1'-biphenyl]-4-yl-6-methoxy- (CA INDEX NAME)





RN 332362-81-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-[1,1'-biphenyl]-4-yl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:247320 CAPLUS
 DOCUMENT NUMBER: 134:280851
 TITLE: Quinazolinones useful as glycoprotein IbIX antagonists, and their preparation and use for control of thrombotic disorders
 INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard
 PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany; et al.
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023364	A1	20010405	WO 2000-EP8939	20000913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385918	A1	20010405	CA 2000-2385918	20000913
BR 2000014311	A	20020521	BR 2000-14311	20000913
EP 1216233	A1	20020626	EP 2000-962482	20000913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2002001503	A	20020326	NO 2002-1503	20020326
US 7060706	B1	20060613	US 2002-89167	20020829
PRIORITY APPLN. INFO.:			US 1999-407939	A 19990928
			US 1999-325777P	P 19990928
			WO 2000-EP8939	W 20000913
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):	MARPAT 134:280851			
GI				



II


- AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R1 = H, A, OH, OA, OCH2Ar, Hal, NH2, NHA, NA2, NO2, cyano, COR2, CONH2, CONHA, CONA2, CO2H, CO2A, SO2A; R2, R3 = H, A, C(:NH)NH2, solid phase; R4 = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C2-4 alkylene; A = (un)branched C1-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)saturated mono- or bicyclic NOS heterocyclyl; Hal = F, Cl, Br, or iodo; n, m = 0-3]. The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, [[3-(aminomethyl)cyclohexyl]methyl]amine, was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R4YCHO, oxidation of the resultant dihydroquinazolinone ring system, and cleavage from the resin with CF3CO2H, gave a variety of compds. I, e.g., the preferred compound II.
- IT 332120-85-1P, 3-[[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-(2-methylphenyl)-3H-quinazolin-4-one 332120-86-2P, 3-[[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(2-methylphenyl)-3H-quinazolin-4-one 332120-87-3P, 3-[[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(2-methylphenyl)-3H-quinazolin-4-one 332120-88-4P, 3-[[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(2-methylphenyl)-3H-quinazolin-4-one 332120-89-5P, 3-[[[3-(Aminomethyl)cyclohexyl]methyl]-2-(2-methylphenyl)-3H-quinazolin-4-one 332120-90-8P, 3-[[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one 332120-91-9P, 3-[[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(3-methylphenyl)-3H-quinazolin-4-one 332120-92-0P, 3-[[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one 332120-93-1P, 3-[[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(3-methylphenyl)-3H-quinazolin-4-one 332120-94-2P, 3-[[[3-(Aminomethyl)cyclohexyl]methyl]-2-(3-methylphenyl)-3H-quinazolin-4-one 332120-95-3P, 3-[[[3-(Aminomethyl)cyclohexyl]methyl]-6-

chloro-2-(4-methylphenyl)-3H-quinazolin-4-one 332120-96-4P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(4-methylphenyl)-3H-
 quinazolin-4-one 332120-97-5P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(4-methylphenyl)-3H-
 quinazolin-4-one 332120-98-6P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(4-methylphenyl)-3H-
 quinazolin-4-one 332120-99-7P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(4-methylphenyl)-3H-quinazolin-4-
 one 332121-00-3P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-
 chloro-2-(4-tert-butylphenyl)-3H-quinazolin-4-one 332121-02-5P
 , 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(4-tert-butylphenyl)-3H-
 quinazolin-4-one 332121-03-6P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(4-tert-butylphenyl)-3H-
 quinazolin-4-one 332121-04-7P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(4-tert-butylphenyl)-3H-
 quinazolin-4-one 332121-05-8P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(4-tert-butylphenyl)-3H-quinazolin-
 4-one 332121-06-9P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-
 chloro-2-(3-chlorophenyl)-3H-quinazolin-4-one 332121-07-0P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(3-chlorophenyl)-3H-
 quinazolin-4-one 332121-08-1P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(3-chlorophenyl)-3H-
 quinazolin-4-one 332121-09-2P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(3-chlorophenyl)-3H-
 quinazolin-4-one 332121-10-5P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(3-chlorophenyl)-3H-quinazolin-4-
 one 332121-11-6P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-
 chloro-2-(4-methoxyphenyl)-3H-quinazolin-4-one 332121-12-7P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(4-methoxyphenyl)-3H-
 quinazolin-4-one 332121-13-8P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(4-methoxyphenyl)-3H-
 quinazolin-4-one 332121-14-9P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(4-methoxyphenyl)-3H-
 quinazolin-4-one 332121-15-0P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(4-methoxyphenyl)-3H-quinazolin-4-
 one 332121-16-1P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-
 chloro-2-(3-methoxyphenyl)-3H-quinazolin-4-one 332121-17-2P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(3-methoxyphenyl)-3H-
 quinazolin-4-one 332121-18-3P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(3-methoxyphenyl)-3H-
 quinazolin-4-one 332121-19-4P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(3-methoxyphenyl)-3H-
 quinazolin-4-one 332121-20-7P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(3-methoxyphenyl)-3H-quinazolin-4-
 one 332121-41-2P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-
 biphenyl-4-yl-6-chloro-3H-quinazolin-4-one 332121-42-3P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-biphenyl-4-yl-6-methyl-3H-
 quinazolin-4-one 332121-43-4P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-biphenyl-4-yl-7-chloro-3H-
 quinazolin-4-one 332121-44-5P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-biphenyl-4-yl-6-methoxy-3H-
 quinazolin-4-one 332121-45-6P,
 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-biphenyl-4-yl-3H-quinazolin-4-one
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of quinazolinone derivs. as glycoprotein IbIX
 antagonists)

RN 332120-85-1 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-chloro-2-(2-

methylphenyl)- (CA INDEX NAME)




RN 332120-86-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-methyl-2-(2-methylphenyl)- (CA INDEX NAME)




RN 332120-87-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-7-chloro-2-(2-methylphenyl)- (CA INDEX NAME)




RN 332120-88-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(2-methylphenyl)- (CA INDEX NAME)





RN 332120-89-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl)methyl]-2-(2-methylphenyl)- (CA INDEX NAME)





RN 332120-90-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl)methyl]-6-chloro-2-(3-methylphenyl)- (CA INDEX NAME)





RN 332120-91-9 CAPLUS



CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl)methyl]-6-methyl-2-(3-methylphenyl)- (CA INDEX NAME)





RN 332120-92-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-7-chloro-2-(3-methylphenyl)- (CA INDEX NAME)



RN 332120-93-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(3-methylphenyl)- (CA INDEX NAME)





RN 332120-94-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-(3-methylphenyl)- (CA INDEX NAME)





RN 332120-95-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-chloro-2-(4-methylphenyl)- (CA INDEX NAME)





RN 332120-96-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)





RN 332120-97-5 CAPLUS



CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-7-chloro-2-(4-methylphenyl)- (CA INDEX NAME)





RN 332120-98-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(4-methylphenyl)- (CA INDEX NAME)



RN 332120-99-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-(4-methylphenyl)- (CA INDEX NAME)





RN 332121-00-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-chloro-2-(4-(1,1-dimethylethyl)phenyl)- (CA INDEX NAME)





RN 332121-02-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[4-(1,1-dimethylethyl)phenyl]-6-methyl- (CA INDEX NAME)





RN 332121-03-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-7-chloro-2-[4-(1,1-dimethylethyl)phenyl]- (CA INDEX NAME)





RN 332121-04-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[4-(1,1-dimethylethyl)phenyl]-6-methoxy- (CA INDEX NAME)





RN 332121-05-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[4-(1,1-dimethylethyl)phenyl]- (CA INDEX NAME)





RN 332121-06-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-chloro-2-(3-chlorophenyl)- (CA INDEX NAME)





RN 332121-07-0 CAPLUS



CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-(3-chlorophenyl)-6-methyl- (CA INDEX NAME)





RN 332121-08-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-7-chloro-2-(3-chlorophenyl)- (CA INDEX NAME)





RN 332121-09-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-(3-chlorophenyl)-6-methoxy- (CA INDEX NAME)





RN 332121-10-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-(3-chlorophenyl)- (CA INDEX NAME)





RN 332121-11-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-chloro-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 332121-12-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-(4-methoxyphenyl)-6-methyl- (CA INDEX NAME)





RN 332121-13-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-7-chloro-2-(4-methoxyphenyl)- (CA INDEX NAME)





RN 332121-14-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 332121-15-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 332121-16-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-chloro-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 332121-17-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-(3-methoxyphenyl)-6-methyl- (CA INDEX NAME)




RN 332121-18-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-7-chloro-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 332121-19-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(3-methoxyphenyl)- (CA INDEX NAME)





RN 332121-20-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 332121-41-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[1,1'-biphenyl]-4-yl-6-chloro- (CA INDEX NAME)




RN 332121-42-3 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[1,1'-biphenyl]-4-yl-6-methyl- (CA INDEX NAME)





RN 332121-43-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[1,1'-biphenyl]-4-yl-7-chloro- (CA INDEX NAME)



RN 332121-44-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[1,1'-biphenyl]-4-yl-6-methoxy- (CA INDEX NAME)



RN 332121-45-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[1,1'-biphenyl]-4-yl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 74 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:111509 CAPLUS
 DOCUMENT NUMBER: 134:163052
 TITLE: Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
 INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
 SOURCE: U.S., 19 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6187779	B1	20010213	US 1998-197311	19981120
			US 1998-197311	19981120

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 134:163052

AB A method for inhibiting neoplastic cells and related conditions by exposing them to 2,8-disubstituted quinazolinone compds.


IT 180161-27-7P	180161-28-8P	180161-29-9P
180161-31-3P	180161-35-7P	180161-36-8P
180161-37-9P	180161-38-0P	180161-42-6P
180161-43-7P	180161-49-3P	180161-50-6P
180161-52-8P	180161-58-4P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of 2,8-disubstituted quinazolinones as antitumor agents)

RN 180161-27-7 CAPLUS


CN 4(3H)-Quinazolinone, 8-(3-phenyl-1-propen-1-yl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-28-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-(4-phenyl-1-buten-1-yl)-2-(2-propoxyphenyl)- (CA INDEX NAME)



RN 180161-29-9 CAPLUS
CN 4(3H)-Quinazolinone, 8-(1-methyl-4-phenyl-1-buten-1-yl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-31-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-heptyl-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-35-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-(1-ethyl-3-phenylpropyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)

INDEX NAME)




RN 180161-36-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-(3-pentyl-2-oxiranyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-37-9 CAPLUS

CN 4(3H)-Quinazolinone, 8-[3-(phenylmethyl)-2-oxiranyl]-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-38-0 CAPLUS


CN 4(3H)-Quinazolinone, 8-[3-(2-phenylethyl)-2-oxiranyl]-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-42-6 CAPLUS
CN 4(3H)-Quinazolinone, 8-(2-hydroxy-1-methylheptyl)-2-(2-propoxyphenyl)-
(CA INDEX NAME)



RN 180161-43-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-(2-hydroxy-1-methyl-3-phenylpropyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-49-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-(1-hepten-1-yl)-2-[5-(4-morpholinyisulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)




RN 180161-50-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]-8-(3-pentyl-2-oxiranyl)- (CA INDEX NAME)




RN 180161-52-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-methyl-4-phenyl-1-buten-1-yl)-2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)



RN 180161-58-4 CAPLUS

CN 4(3H)-Quinazolinone, 8-iodo-2-(2-propoxyphenyl)- (CA INDEX NAME)




IT	180161-26-6P	180161-30-2P	180161-32-4P
	180161-33-5P	180161-34-6P	180161-39-1P
	180161-40-4P	180161-41-5P	180161-45-9P
	180161-46-0P	180161-47-1P	180161-48-2P
	180161-51-7P	180161-54-0P	180161-55-1P
	180161-59-5P	325135-46-4P	325135-59-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,8-disubstituted quinazolinones as antitumor agents)


RN 180161-26-6 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-hepten-1-yl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-30-2 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-ethyl-3-phenyl-1-propen-1-yl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-32-4 CAPLUS

CN 4(3H)-Quinazolinone, 8-(3-phenylpropyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-33-5 CAPLUS

CN 4(3H)-Quinazolinone, 8-(4-phenylbutyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-34-6 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-methyl-4-phenylbutyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-39-1 CAPLUS


CN 4(3H)-Quinazolinone, 8-(2-hydroxy-1-methoxyheptyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-40-4 CAPLUS
 CN 4(3H)-Quinazolinone, 8-(2-hydroxy-1-methoxy-3-phenylpropyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)



RN 180161-41-5 CAPLUS
 CN 4(3H)-Quinazolinone, 8-(2-hydroxy-1-methoxy-4-phenylbutyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-45-9 CAPLUS
 CN 4(3H)-Quinazolinone, 8-(1-ethyl-2-hydroxyheptyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-46-0 CAPLUS

CN 4(3H)-Quinazolinone, 8-[1-methyl-2-[(methoxycarbonyl)oxy]heptyl]-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-47-1 CAPLUS

CN 4(3H)-Quinazolinone, 8-(2-azido-1-methylheptyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-48-2 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-methoxy-2-oxoheptyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-51-7 CAPLUS

CN 4(3H)-Quinazolinone, 8-(2-hydroxy-1-methoxyheptyl)-2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)




RN 180161-54-0 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-methyl-4-phenylbutyl)-2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)




RN 180161-55-1 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-ethyl-3-phenylpropyl)-2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)




RN 180161-59-5 CAPLUS

CN 4(3H)-Quinazolinone, 8-bromo-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 325135-46-4 CAPLUS

CN 4(3H)-Quinazolinone, 8-(2-hydroxy-1-methyl-4-phenylbutyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)



RN 325135-59-9 CAPLUS


CN 4(3H)-Quinazolinone, 8-(1-ethyl-3-phenyl-1-propen-1-yl)-2-[5-(4-morpholynylsulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 172 THERE ARE 172 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 75 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:392967 CAPLUS
DOCUMENT NUMBER: 133:22405
TITLE: Preventives containing
1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
derivatives and related compounds for nitric
acid-induced tolerance
INVENTOR(S): Ellis, Peter
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000159672	A	20000613	JP 1999-337606	19991129
US 6225315	B1	20010501	US 1999-442821	19991118
IL 133078	A	20061031	IL 1999-133078	19991122
EP 1022026	A2	20000726	EP 1999-309406	19991125
EP 1022026	A3	20020410		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2290766	C	20030204	CA 1999-2290766	19991126
HU 9904434	A2	20000828	HU 1999-4434	19991129
HU 9904434	A3	20030630		
ZA 9907371	A	20010529	ZA 1999-7371	19991129
NZ 515501	A	20030829	NZ 1999-515501	19991129
AU 9961788	A	20000601	AU 1999-61788	19991130
AU 767452	B2	20031113		
KR 2000035774	A	20000626	KR 1999-53785	19991130
AU 2004200573	A1	20040311	AU 2004-200573	20040213
AU 2004200573	B2	20070208		
PRIORITY APPLN. INFO.:			US 1998-110335P	P 19981130
OTHER SOURCE(S):	MARPAT 133:22405			
GI				



- AB The title compds. [I; R1 = H, C1-3 alkyl, C3-5 cycloalkyl, C1-3 perfluoroalkyl; R2 = H, C1-3 perfluoroalkyl, C1-6 alkyl substituted by OH, C1-3 alkoxy, or C3-6 cycloalkyl; R3 = C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-7 cycloalkyl, C1-6 perfluoroalkyl, C3-6 cycloalkyl-C1-6 alkyl; R4 together with the R4-bonded N completes 4-N-R6-piperazinyl; R5 = H, C1-4 alkyl, C1-3 alkoxy, NR7R8, CONR7R8; wherein R6 = H, C1-6 alkyl, hydroxy-C2-6 alkyl, R7R8N-C2-6 alkyl, R7R8NCO-C1-6 alkyl, CONR7R8, CSNR7R8, C(=NH)NR7R8; wherein R7, R8 = H, C1-4 alkyl, C1-3 alkoxy-C2-4 alkyl, hydroxy-C2-4 alkyl], pharmacol. acceptable salts, prodrugs, polymorphs, hydrates, solvates, active metabolites, or stereoisomers thereof, which are cGMP phosphodiesterase inhibitors and useful for the prevention of nitrate tolerance (no data), are prepared The title compds. also include pyrazolo[3,4-d]pyrimidin-4-one, quinazolin-4-one, purin-6-one, pyrido[3,2-d]pyrimidin-4-one, and pyrazino[1',2':1,6]pyrido[3,4-b]indole derivs.
- IT 150479-38-2P 150479-39-3P 150479-42-8P
150479-52-0P 150479-54-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preventives containing 1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one derivs. and related compds. as cGMP phosphodiesterase inhibitors for nitric acid-induced tolerance)
- RN 150479-38-2 CAPLUS
- CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-8-methyl- (CA INDEX NAME)




- RN 150479-39-3 CAPLUS
- CN 4(3H)-Quinazolinone, 2-[5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]-2-propoxyphenyl]-8-methyl- (CA INDEX NAME)




RN 150479-42-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-methyl-2-[5-[3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]-2-propoxyphenyl]- (CA INDEX NAME)




RN 150479-52-0 CAPLUS

CN 8-Quinazolinecarboxamide, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)



RN 150479-54-2 CAPLUS

CN 8-Quinazolinecarboxamide, N-ethyl-3,4-dihydro-4-oxo-2-(2-propoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L5 ANSWER 76 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:699078 CAPLUS

DOCUMENT NUMBER: 131:317778

TITLE: Phosphate derivatives for treatment of nephritis

INVENTOR(S): Miyata, Kazuyoshi; Tsuda, Yoshihiko; Koji, Yasuo;
Kuroki, Morihisa; Sakai, Yasuhiro; Mukai, Kiyoshi;
Hashimoto, Kinji; Kori, Hideaki

PATENT ASSIGNEE(S): Ohtsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11302177	A	19991102	JP 1998-116645	19980427
PRIORITY APPLN. INFO.:			JP 1998-116645	19980427

OTHER SOURCE(S): MARPAT 131:317778

AB Phosphate derivs. (Markush's structures given) are claimed for treatment of nephritis. The derivs. inhibited mesangium cell proliferation in vitro. Examples of tablets, capsules, and granules were formulated.


IT 166394-37-2 173018-47-8 173018-56-9
173018-60-5 173018-70-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phosphate derivs. for treatment of nephritis)

RN 166394-37-2 CAPLUS


CN Phosphonic acid, [[4-(4,6,7-trimethoxy-2-quinazolinyl)phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 173018-47-8 CAPLUS


CN Phosphonic acid, [[4-(5-fluoro-3,4-dihydro-3-methyl-4-oxo-2-

quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-56-9 CAPLUS

CN 3(4H)-Quinazolineacetic acid, 6-bromo-2-[4-[(diethoxyphosphinyl)methyl]phenyl]-4-oxo-, ethyl ester (CA INDEX NAME)




RN 173018-60-5 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 173018-70-7 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L5 ANSWER 77 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:571811 CAPLUS

DOCUMENT NUMBER: 131:214292

TITLE: 2- or 3-(Substituted
aminoalkoxyphenyl)quinazolin-4-ones useful as partial
estrogen agonists

INVENTOR(S): Koko, Marci Catherine; Santilli, Arthur Attilio

PATENT ASSIGNEE(S): American Home Products Corporation, USA

SOURCE: U.S., 9 pp.

CODEN: USXXAM




DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 5948775	A	19990907	US 1998-41184	19980312
PRIORITY APPLN. INFO.:			US 1997-41088P	P 19970319
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE			IN LSUS DISPLAY FORMAT	
OTHER SOURCE(S):		MARPAT 131:214292		
GI				





AB The invention relates to 2- or 3-(substituted aminoalkoxyphenyl)quinazolin-4-ones I [R1, R2 = H, (CH2)*n*NR3R4; *n* = 2-3; NR3R4 = pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl; provided that one but not both of R1 and R2 is H], which are partial estrogen agonists, and which are useful in treating osteoporosis, prostatic hypertrophy, breast cancer and endometrial cancer. Three examples and a variety of intermediates were prepared. For instance, 4-bromo-3-nitroanisole underwent a sequence of cyanation, SnCl₂ reduction, hydrolysis, and cyclization with triphosgene, to give 7-methoxyisatoic anhydride (II). This underwent amidation with 4-(2-chloroethoxy)aniline, cyclocondensation with *p*-anisaldehyde, dehydrogenation with DDQ, demethylation with BBr₃, and condensation with piperidine, to give title compound III, isolated as the HCl salt. In an estrogen receptor binding assay, III displaced 17β-estradiol with a binding potency slightly less than tamoxifen and significantly less than raloxifene.

IT 242478-03-1P, 7-Hydroxy-2-(4-hydroxyphenyl)-3-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-3H-quinazolin-4-one 242478-07-5P,
8-Hydroxy-3-(4-hydroxyphenyl)-2-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-3H-quinazolin-4-one 242478-12-2P,
8-Hydroxy-2-(4-hydroxyphenyl)-3-[4-[2-(piperidin-1-ylethoxy)phenyl]-3H-quinazolin-4-one 242478-13-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of (aminoalkoxyphenyl)quinazolinones partial estrogen agonists)


RN 242478-03-1 CAPLUS

CN 4(3H)-Quinazolinone, 7-hydroxy-2-(4-hydroxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)





RN 242478-07-5 CAPLUS

CN 4(3H)-Quinazolinone, 8-hydroxy-3-(4-(2-(1-piperidinylethoxy)phenyl)-2-(4-hydroxyphenyl))- (CA INDEX NAME)





RN 242478-12-2 CAPLUS

CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-(2-(1-piperidinylethoxy)phenyl)-3-(4-hydroxyphenyl))- (CA INDEX NAME)



RN 242478-13-3 CAPLUS

CN 4(3H)-Quinazolinone, 7-hydroxy-2-(4-(2-(1-piperidinylethoxy)phenyl)-3-(4-hydroxyphenyl))-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 78 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:511131 CAPLUS

DOCUMENT NUMBER: 131:157643

TITLE: Preparation of hydrazones derivatives for treatment or prevention of diseases related to glucose metabolic pathways

INVENTOR(S): Jacobsen, Palle; Madsen, Peter; Westergaard, Niels

PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940062	A1	19990812	WO 1999-DK53	19990203
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9926102	A	19990823	AU 1999-26102	19990203
PRIORITY APPLN. INFO.:				
			DK 1998-159	A 19980205
			US 1998-74001P	P 19980209
			WO 1999-DK53	W 19990203

OTHER SOURCE(S): MARPAT 131:157643

AB Hydrazone derivs. of formula R1R2C=NNR3R4 (I) or R1R2C=NN=CR3R4 (II)
 [R1-R4 = H, C1-8 alkyl, C3-8 cycloalkyl, OH, acyl, C1-6 alkoxy, NO2, cyano, (un)substituted carbonyl, (un)substituted amino, (un)substituted

sulfonamide, (un)substituted (hetero)aryl, etc.; R1 and R2 or R3 and R4 may together form an (un)substituted hetero- or carbocycle], were prep'd for use as medicaments in therapy especially in the treatment of diseases related to glucose metabolic pathways. Specifically, claimed compds. I and II were prepared for use in the treatment or prevention of diseases of the endocrinol. system, preferably hyperglycemia, NIDDM, or diabetes, and for treatment of glycogen storage disease or hypoglycemia. Compns. of the invention are claimed to exhibit glucose-6-phosphatase inhibitory activity with IC50 values of less than 100 μ M (no data). Thus, 4-chlorobenzaldehyde was added to N,N-dibenzylhydrazine in DMF followed by addition of tri-Et orthoformate to form N,N-dibenzyl-N'-(4-chlorobenzylidene)hydrazine, i.e., I (where R1 = H, R2 = C6H4-p-Cl, and R3 = R4 = CH2Ph), in 94% yield.

IT 237403-41-7P, 2-(4-Bromophenyl)-3-[[3,4-dihydroxybenzylidene)amino]-3H-quinazolin-4-one
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of hydrazone derivs. for treatment or prevention of diseases of the endocrinol. system, preferably hyperglycemia, NIDDM, or diabetes, and for treatment of glycogen storage disease or hypoglycemia)
 RN 237403-41-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-bromophenyl)-3-[[3,4-dihydroxyphenyl)methylene]amino]- (CA INDEX NAME)





OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 79 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN
 ACCESSION NUMBER: 1999:188605 CAPLUS
 DOCUMENT NUMBER: 131:340
 TITLE: Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives
 AUTHOR(S): Roe, Michael; Folkes, Adrian; Ashworth, Philip; Brumwell, Julie; Chima, Lal; Hunjan, Sukhjit; Pretswell, Ian; Dangerfield, Wendy; Ryder, Hamish; Charlton, Peter
 CORPORATE SOURCE: Xenova Ltd., Slough, SL1 4EF, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(4), 595-600
 CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have synthesized and evaluated a series of anthranilamide based modulators of P-glycoprotein. These studies have identified XR9576, a potent inhibitor of P-glycoprotein in vitro and in vivo. The general synthesis and the SAR of these compds. are described.
IT 225937-91-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel anthranilamide derivs. for reversal of P-glycoprotein mediated multidrug resistance)
RN 225937-91-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(3,4-dimethoxyphenyl)ethyl]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 77 THERE ARE 77 CAPLUS RECORDS THAT CITE THIS RECORD (77 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 80 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN

ACCESSION NUMBER: 1999:39702 CAPLUS

DOCUMENT NUMBER: 130:264103

TITLE: Preliminary evaluation of 2-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-3-methyl-6-methoxy-4(3H)-quinazolinone ([±]HX-CH 44) as a selective β1-adrenoceptor ligand for PET

AUTHOR(S): Valette, Heric; Dolle, Frederic; Guenther, Ilonka; Demphel, Stephane; Rasetti, Christine; Hinnen, Francoise; Fuseau, Chantal; Crouzel, Christian

CORPORATE SOURCE: Departement de Recherche Medicale, Service Hospitalier Frederic Joliot, Orsay, Fr.

SOURCE: Nuclear Medicine and Biology (1998), Volume Date 1999, 26(1), 105-109

CODEN: NMBIEO; ISSN: 0969-8051

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB (±)-3-[11C]Methyl-2-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-6-methoxy-4(3H)-quinazolinone ([±]-[11C]HX-CH 44) was labeled with carbon-11 using [11C]iodomethane with the


corresponding N-demethylated precursor. Then, 30-90 mCi (1.10-3.33 GBq) of pure $[11C]HX-CH$ 44 were obtained 30 min after end of bombardment with specific radioactivities of 500-1,400 mCi/ μ mol (18.5-51.8 GBq/ μ mol). Myocardial uptake in dogs was 0.340 ± 0.043 pmol/mL tissue per nmol injected, 10-15 min postinjection. Heart-to-lung ratio was 3 from the 5th to the 30th minute. Only 35% of the myocardial radioactivity could be displaced. Tissue uptake could not be blocked with appropriate compounds. Therefore, $(\pm)-[11C]HX-CH$ 44 does not appear to be a suitable ligand for the study of myocardial $\beta 1$ -adrenoceptors in positron emission tomography.

IT 222027-74-9P

RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(evaluation of $(\pm)-[11C]HX-CH$ 44 as a selective $\beta 1$ -adrenoceptor ligand for PET)

RN 222027-74-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-6-methoxy-3-(methyl- ^{11}C)- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 81 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:756610 CAPLUS

DOCUMENT NUMBER: 130:133636

TITLE: Resistance-Modifying Agents. 5. Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP)

AUTHOR(S): Griffin, Roger J.; Srinivasan, Sheila; Bowman, Karen; Calvert, A. Hilary; Curtin, Nicola J.; Newell, David R.; Pemberton, Louise C.; Golding, Bernard T.

CORPORATE SOURCE: Department of Chemistry, The University of Newcastle upon Tyne, Newcastle upon Tyne, NE1 7RU, UK
SOURCE: Journal of Medicinal Chemistry (1998), 41(26), 5247-5256

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Clin. studies concerning the role of poly(ADP-ribose) polymerase (PARP) in the repair of drug- and radiation-induced DNA damage have been impeded by the poor solubility, lack of potency, and limited specificity of currently available inhibitors. A series of 2-alkyl- and 2-aryl-substituted


8-hydroxy-, 8-methoxy-, and 8-methylquinazolin-4(3H)-ones has been synthesized and evaluated for PARP inhibitory activity in permeabilized L1210 murine leukemia cells. 8-Methoxy- and 8-methylquinazolinones (14-34) were readily prepared by acylation of 3-substituted anthranilamides with the appropriate acid chloride, followed by base-catalyzed cyclization. The requisite 8-hydroxyquinazolinones (6, 35-39) were synthesized by demethylation of the corresponding 8-methoxyquinazolinones with BBr₃. N-Methylation of 8-methoxy-2-methylquinazolinone (15) with MeI, followed by O-demethylation by BBr₃, afforded the control N3-methylquinazolinones 42 and 43, resp. In general, an 8-hydroxy or 8-Me substituent enhanced inhibitory activity in comparison with an 8-methoxy group. 2-Phenylquinazolinones were marginally less potent than the corresponding 2-methylquinazolinones, but the introduction of an electron-withdrawing or electron-donating 4'-substituent on the 2-aryl ring invariably increased potency. This was particularly evident in the 8-methylquinazolinone series (IC₅₀ values 0.13-0.27 μ M), which are among the most potent PARP inhibitors reported to date. N3-Methylquinazolinones 42 and 43 were essentially devoid of activity (IC₅₀ values > 100 μ M). In studies with L1210 cells in vitro, a concentration of 200 μ M 8-hydroxy-2-methylquinazolinone (6, NU1025) (IC₅₀ value 0.40 μ M) potentiated the cytotoxicity of the monomethylating agent 5-(3-methyltriazene-1-yl)imidazole-4-carboxamide and γ -radiation 3.5- and 1.4-fold, resp., at the 10% survival level.

IT	211172-79-1P	211172-81-5P	211172-82-6P
	211172-84-8P	211172-86-0P	220115-21-9P
	220115-23-1P	220115-24-2P	220115-25-3P
	220115-26-4P	220115-29-7P	220115-30-0P
	220115-31-1P	220115-32-2P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and cytotoxicity-potentiating activity of quinazolinone inhibitors of DNA repair involving poly(ADP-ribose) polymerase)


RN 211172-79-1 CAPLUS

CN Benzonitrile, 4-(3,4-dihydro-8-hydroxy-4-oxo-2-quinazolinyl)- (CA INDEX NAME)




RN 211172-81-5 CAPLUS


CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-hydroxyphenyl)- (CA INDEX NAME)




RN 211172-82-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-aminophenyl)-8-hydroxy- (CA INDEX NAME)




RN 211172-84-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 211172-86-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-hydroxyphenyl)-8-methyl- (CA INDEX NAME)




RN 220115-21-9 CAPLUS
CN 4(3H)-Quinazolinone, 8-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 220115-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-azidophenyl)-8-methyl- (CA INDEX NAME)




RN 220115-24-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-azidophenyl)-8-methoxy- (CA INDEX NAME)




RN 220115-25-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-aminophenyl)-8-methyl- (CA INDEX NAME)




RN 220115-26-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-aminophenyl)-8-methoxy- (CA INDEX NAME)




RN 220115-29-7 CAPLUS
CN Benzamide, 4-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)- (CA INDEX NAME)




RN 220115-30-0 CAPLUS
CN Benzamide, 4-(3,4-dihydro-8-methoxy-4-oxo-2-quinazolinyl)- (CA INDEX NAME)



RN 220115-31-1 CAPLUS
CN Benzoic acid, 4-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-, methyl ester (CA INDEX NAME)



RN 220115-32-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-methylphenyl)- (CA INDEX NAME)




IT 1036-50-6P 82256-08-4P 172462-88-3P
 181135-49-9P 181135-50-2P 211172-78-0P
 211172-83-7P 211172-85-9P 220115-22-0P
 220115-27-5P 220115-28-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and reaction of; preparation and cytotoxicity-potentiating activity of quinazolinone inhibitors of DNA repair involving poly(ADP-ribose) polymerase)


RN 1036-50-6 CAPLUS

CN 4(3H)-Quinazolinone, 8-methoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 82256-08-4 CAPLUS

CN 4(3H)-Quinazolinone, 8-methoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 172462-88-3 CAPLUS


CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-nitrophenyl)- (CA INDEX NAME)




RN 181135-49-9 CAPLUS
CN 4(3H)-Quinazolinone, 8-methoxy-2-(4-nitrophenyl)- (CA INDEX NAME)




RN 181135-50-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-methyl-2-(4-nitrophenyl)- (CA INDEX NAME)




RN 211172-78-0 CAPLUS
CN Benzonitrile, 4-(3,4-dihydro-8-methoxy-4-oxo-2-quinazolinyl)- (CA INDEX NAME)




RN 211172-83-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-methoxy-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 211172-85-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-8-methyl- (CA INDEX NAME)




RN 220115-22-0 CAPLUS
 CN Benzonitrile, 4-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)- (CA INDEX NAME)



RN 220115-27-5 CAPLUS
 CN Benzoic acid, 4-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)- (CA INDEX NAME)



RN 220115-28-6 CAPLUS
 CN Benzoic acid, 4-(3,4-dihydro-8-methoxy-4-oxo-2-quinazolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 63 THERE ARE 63 CAPLUS RECORDS THAT CITE THIS
RECORD (64 CITINGS)
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 82 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1998:388524 CAPLUS
DOCUMENT NUMBER: 129:54381
ORIGINAL REFERENCE NO.: 129:11337a,11340a
TITLE: Preparation of heterocycliccatechols as
phosphodiesterase inhibitors.
INVENTOR(S): Lee, Jung Geun; Jang, Myung Shik; Shu, Byoung Chul;
Lee, Kwang Hyuk; Lee, Yun Ha; Kim, Young Ji
PATENT ASSIGNEE(S): Cheil Jedang Corporation, S. Korea
SOURCE: PCI Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9823620	A1	19980604	WO 1997-KR150	19970804
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9737098	A	19980622	AU 1997-37098	19970804
US 6103729	A	20000815	US 1997-931303	19970916
PRIORITY APPLN. INFO.:			KR 1996-58701	A 19961128
			KR 1997-15476	A 19970425
			KR 1997-27909	A 19970627
			WO 1997-KR150	W 19970804

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 129:54381

GI




AB Title compds. [I; R1 = alkyl, cycloalkyl, (substituted) Ph, pyrimidyl, pyridyl; X, Y Z = O, N, S optionally substituted with alkyl, cycloalkane, Ph; W = O, S], were prepared Thus, 4-amino-1H-5-pyrazolecarboxamide in pyridine was treated with 3-cyclopentyloxy-4-methoxybenzoyl chloride (preparation given) to give 3-(3-cyclopentyloxy-4-methoxybenzoylamino)-1H-pyrazole-4-carboxamide. The latter gave 90% inhibition of phosphodiesterase IV.

IT 132982-03-7P 208597-70-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocyclycatechols as phosphodiesterase inhibitors)


RN 132982-03-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



RN 208597-70-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[3-(cyclopentyloxy)-4-methoxyphenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 83 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN

ACCESSION NUMBER: 1996:509779 CAPLUS


DOCUMENT NUMBER: 125:168013

ORIGINAL REFERENCE NO.: 125:31489a,31492a


TITLE: Preparation of 2,8-disubstituted quinazolinones as antiinflammatories and cardiovascular agents.
 INVENTOR(S): Heiker, Fred R.; Niewoehner, Ulrich; Hartwig, Wolfgang; Schuetz, Helmuth; Bischoff, Erwin; Perzborn, Elisabeth; Schramm, Matthias
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Eur. Pat. Appl., 33 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 722937	A1	19960724	EP 1996-100154	19960108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 19501481	A1	19960725	DE 1995-19501481	19950119
IN 184956	A1	20001007	IN 1995-DE2408	19951226
US 5721238	A	19980224	US 1996-584865	19960111
AU 9640980	A	19960725	AU 1996-40980	19960115
AU 704102	B2	19990415		
CA 2167345	A1	19960720	CA 1996-2167345	19960116
IL 116770	A	20000831	IL 1996-116770	19960116
RO 117451	B1	20020329	RO 1996-77	19960116
FI 9600227	A	19960720	FI 1996-227	19960117
JP 08253457	A	19961001	JP 1996-22973	19960117
NO 9600222	A	19960722	NO 1996-222	19960118
NO 307513	B1	20000417		
ZA 9600397	A	19960828	ZA 1996-397	19960118
BR 9600148	A	19980106	BR 1996-148	19960118
RU 2158733	C2	20001110	RU 1996-100854	19960118
CN 1134417	A	19961030	CN 1996-101906	19960119
HU 9600114	A2	19961230	HU 1996-114	19960119
HU 9600114	A3	20000328		

PRIORITY APPLN. INFO.: DE 1995-19501481 A 19950119
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 125:168013; MARPAT 125:168013
 GI



I



II

AB Title compds. [I; A = (alkyl-substituted) oxiranyl, CR1(:CHR2), CHR3LR4, CH2R5; R1 = H, alkyl; R2, R4 = alkyl, phenylalkyl; R3 = alkyl, OH, alkoxy, etc.; R5 = alkyl, phenylalkyl, PhCH2, PhCH2CH2; L = CO, CH(OH), CH2, CHN3, CH(OSO2R7); R7 = alkyl, Ph; D = H, aminosulfonyl; E = alkyl], were prepared


Thus, title compound (II), prepared via coupling of 2-(2-propoxy-5-morpholinosulfonylphenyl)-8-bromoquinazolin-4(3H)-one with 5-phenyl-2-pentene followed by hydrogenation, inhibited phosphodiesterase II and phosphodiesterase V with IC₅₀ = 0.5 nM and 1 nM, resp.

IT	180161-26-6P	180161-27-7P	180161-28-8P
	180161-29-9P	180161-30-2P	180161-31-3P
	180161-32-4P	180161-33-5P	180161-34-6P
	180161-35-7P	180161-36-8P	180161-37-9P
	180161-38-0P	180161-39-1P	180161-40-4P
	180161-41-5P	180161-42-6P	180161-43-7P
	180161-44-8P	180161-45-9P	180161-46-0P
	180161-47-1P	180161-48-2P	180161-49-3P
	180161-50-6P	180161-51-7P	180161-52-8P
	180161-53-9P	180161-54-0P	180161-55-1P
	180322-34-3P		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,8-disubstituted quinazolinones as antiinflammatories and cardiovascular agents)


RN 180161-26-6 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-hepten-1-yl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-27-7 CAPLUS

CN 4(3H)-Quinazolinone, 8-(3-phenyl-1-propen-1-yl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-28-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-(4-phenyl-1-buten-1-yl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-29-9 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-methyl-4-phenyl-1-buten-1-yl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-30-2 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-ethyl-3-phenyl-1-propen-1-yl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-31-3 CAPLUS

CN 4(3H)-Quinazolinone, 8-heptyl-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-32-4 CAPLUS

CN 4(3H)-Quinazolinone, 8-(3-phenylpropyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-33-5 CAPLUS

CN 4(3H)-Quinazolinone, 8-(4-phenylbutyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-34-6 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-methyl-4-phenylbutyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-35-7 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-ethyl-3-phenylpropyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-36-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-(3-pentyl-2-oxiranyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-37-9 CAPLUS

CN 4(3H)-Quinazolinone, 8-[3-(phenylmethyl)-2-oxiranyl]-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-38-0 CAPLUS

CN 4(3H)-Quinazolinone, 8-[3-(2-phenylethyl)-2-oxiranyl]-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-42-6 CAPLUS

CN 4(3H)-Quinazolinone, 8-(2-hydroxy-1-methylheptyl)-2-(2-propoxyphenyl)-
(CA INDEX NAME)



RN 180161-43-7 CAPLUS


CN 4(3H)-Quinazolinone, 8-(2-hydroxy-1-methyl-3-phenylpropyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-44-8 CAPLUS

CN 4(1H)-Quinazolinone, 8-(2-hydroxy-1-methoxy-4-phenylbutyl)-2-(2-propoxyphenyl)-, (R*,R*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 180161-45-9 CAPLUS
CN 4(3H)-Quinazolinone, 8-(1-ethyl-2-hydroxyheptyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)



RN 180161-46-0 CAPLUS
CN 4(3H)-Quinazolinone, 8-[1-methyl-2-[(methylsulfonyl)oxy]heptyl]-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-47-1 CAPLUS
CN 4(3H)-Quinazolinone, 8-(2-azido-1-methylheptyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-48-2 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-methoxy-2-oxoheptyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 180161-49-3 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-hepten-1-yl)-2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)




RN 180161-50-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]-8-(3-pentyl-2-oxiranyl)- (CA INDEX NAME)




RN 180161-51-7 CAPLUS

CN 4(3H)-Quinazolinone, 8-(2-hydroxy-1-methoxyheptyl)-2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)




RN 180161-52-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-methyl-4-phenyl-1-buten-1-yl)-2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)




RN 180161-53-9 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-methyl-3-phenyl-1-propen-1-yl)-2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)




RN 180161-54-0 CAPLUS

CN 4(3H)-Quinazolinone, 8-(1-methyl-4-phenylbutyl)-2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)



RN 180161-55-1 CAPLUS


CN 4(3H)-Quinazolinone, 8-(1-ethyl-3-phenylpropyl)-2-[5-(4-morpholinylsulfonyl)-2-propoxyphenyl]- (CA INDEX NAME)



RN 180322-34-3 CAPLUS

CN 4(1H)-Quinazolinone, 8-(2-hydroxy-1-methoxy-4-phenylbutyl)-2-(2-propoxyphenyl)-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)

L5 ANSWER 84 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:458027 CAPLUS

DOCUMENT NUMBER: 125:105133

ORIGINAL REFERENCE NO.: 125:19435a,19438a

TITLE: Bicyclic heterocyclic compounds for the treatment of impotence

INVENTOR(S): Campbell, Simon Fraser

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Research and Development Company, N.V./s.A.; Pfizer Inc.; Campbell, Simon, Fraser

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616657	A1	19960606	WO 1995-EP4065	19951016
W: CA, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2203389	A1	19960606	CA 1995-2203389	19951016
CA 2203389	C	20021217		
EP 793498	A1	19970910	EP 1995-935453	19951016
EP 793498	B1	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09512835	T	19971222	JP 1995-518108	19951016
JP 2001048787	A	20010220	JP 2000-133197	19951016
AT 229335	T	20021215	AT 1995-935453	19951016
PT 793498	E	20030331	PT 1995-935453	19951016
ES 2187578	T3	20030616	ES 1995-935453	19951016
US 6100270	A	20000808	US 1997-836671	19970522
US 6534511	B1	20030318	US 2000-542489	20000403
PRIORITY APPLN. INFO.:			GB 1994-23911	A 19941126
			JP 1996-518108	A3 19951016
			WO 1995-EP4065	W 19951016
			US 1997-836671	A3 19970522

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 125:105133

AB 5-Arylpyrazolo[4,3-d]pyrimidin-7-ones,

6-arylpyrazolo[3,4-d]pyrimidin-4-ones, 2-arylquinazolin-4-ones,

2-arylpyridin-6-ones and 2-arylpyrido[3,2-d]pyrimidin-4-ones, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, are used for the curative or prophylactic treatment of erectile dysfunction in males.


IT 150479-38-2 150479-39-3 150479-42-8

150479-52-0 150479-54-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bicyclic heterocyclic compds. for the treatment of impotence)


RN 150479-38-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-8-methyl- (CA INDEX NAME)




RN 150479-39-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]-2-propoxyphenyl]-8-methyl- (CA INDEX NAME)




RN 150479-42-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-methyl-2-[5-[3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]-2-propoxyphenyl]- (CA INDEX NAME)




RN 150479-52-0 CAPLUS

CN 8-Quinazolinecarboxamide, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)



RN 150479-54-2 CAPLUS

CN 8-Quinazolinecarboxamide, N-ethyl-3,4-dihydro-4-oxo-2-(2-propoxyphenyl)-
(CA INDEX NAME)

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS
RECORD (11 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 85 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN

ACCESSION NUMBER: 1996:446568 CAPLUS

DOCUMENT NUMBER: 125:114672

ORIGINAL REFERENCE NO.: 125:21527a, 21530a

TITLE: Preparation of quinazoline derivatives as cyclic GMP
phosphodiesterase inhibitors
Oota, Tomoki; Taguchi, Minoru; Kawashima, Yutaka;
Hatayama, Katsuo

INVENTOR(S): Taisho Pharmaceutical Co., Ltd., Japan
PATENT ASSIGNEE(S): Jpn. Kokai Tokkyo Koho, 13 pp.

SOURCE: CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08104679	A	19960423	JP 1995-175879	19950712
JP 3702493	B2	20051005		
PRIORITY APPLN. INFO.:			JP 1995-175879	A 19950712

OTHER SOURCE(S):
GI

MARPAT 125:114672




AB The title compds. I [R1 = H, Me, etc.; R2 = alkyl; n = 0 or 1; X = halo, etc.] are prepared. The title compound II (NMR data given) in vitro showed IC50 of 2.9 nM against cyclic GMP phosphodiesterase.

IT	178937-75-2P	178937-76-3P	178937-77-4P
	178937-78-5P	178937-79-6P	178937-80-9P
	178937-81-0P	178937-82-1P	178937-83-2P
	178937-84-3P	178937-85-4P	178937-86-5P
	178937-87-6P	178937-88-7P	178937-89-8P
	178937-90-1P	178937-91-2P	178937-92-3P
	178937-93-4P	178937-94-5P	178937-95-6P
	178937-96-7P	178937-97-8P	178937-98-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as cyclic GMP phosphodiesterase inhibitors)


RN 178937-75-2 CAPLUS

CN Acetamide, 2-chloro-N-[3-(3,4-dihydro-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]- (CA INDEX NAME)




RN 178937-76-3 CAPLUS

CN 4-Morpholinecarboxamide, N-[3-(3,4-dihydro-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]- (CA INDEX NAME)




RN 178937-77-4 CAPLUS

CN 4-Morpholineacetamide, N-[3-(3,4-dihydro-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]- (CA INDEX NAME)




RN 178937-78-5 CAPLUS

CN 1-Pyrrolidineacetamide, N-[3-(3,4-dihydro-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]-3-hydroxy- (CA INDEX NAME)




RN 178937-79-6 CAPLUS

CN 1-Piperidineacetamide, N-[3-(3,4-dihydro-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]-4-hydroxy- (CA INDEX NAME)




RN 178937-80-9 CAPLUS

CN 1-Piperidineacetamide, N-[3-(3,4-dihydro-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]- (CA INDEX NAME)




RN 178937-81-0 CAPLUS

CN Acetamide, 2-[bis(2-hydroxyethyl)amino]-N-[3-(3,4-dihydro-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]- (CA INDEX NAME)




RN 178937-82-1 CAPLUS

CN Carbamic acid, [3-(1,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 178937-83-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 178937-84-3 CAPLUS

CN 4-Thiomorpholinecarboxamide, N-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]- (CA INDEX NAME)




RN 178937-85-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]- (CA INDEX NAME)




RN 178937-86-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]-4-hydroxy- (CA INDEX NAME)




RN 178937-87-6 CAPLUS

CN 1H-Azepine-1-carboxamide, N-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]hexahydro- (CA INDEX NAME)




RN 178937-88-7 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]- (CA INDEX NAME)




RN 178937-89-8 CAPLUS

CN Carbamic acid, [3-(1,4-dihydro-8-methoxy-4-oxo-2-quinazolinyl)-4-propoxyphenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 178937-90-1 CAPLUS

CN 4-Morpholinecarboxamide, N-[3-(3,4-dihydro-8-methoxy-4-oxo-2-quinazolinyl)-4-propoxyphenyl]- (CA INDEX NAME)




RN 178937-91-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[3-(3,4-dihydro-8-methoxy-4-oxo-2-quinazolinyl)-4-propoxyphenyl]- (CA INDEX NAME)




RN 178937-92-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[3-(3,4-dihydro-8-methoxy-4-oxo-2-quinazolinyl)-4-propoxyphenyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 178937-93-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-ethoxy-5-nitrophenyl)- (CA INDEX NAME)




RN 178937-94-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-ethoxy-5-nitrophenyl)-8-methyl- (CA INDEX NAME)




RN 178937-95-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(5-amino-2-ethoxyphenyl)- (CA INDEX NAME)




RN 178937-96-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(5-amino-2-propoxyphenyl)-8-methyl- (CA INDEX NAME)




RN 178937-97-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-methoxy-2-(5-nitro-2-propoxyphenyl)- (CA INDEX NAME)



RN 178937-98-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(5-amino-2-propoxyphenyl)-8-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L5 ANSWER 86 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1996:273045 CAPLUS
 DOCUMENT NUMBER: 124:331723
 ORIGINAL REFERENCE NO.: 124:61205a,61208a
 TITLE: Quinazolythiazoles as CNS acting agents
 AUTHOR(S): Pandey, Vinod Kumar; Gupta, Manjusha
 CORPORATE SOURCE: Dep. Chem., Univ. Lucknow, Lucknow, 226 007, India
 SOURCE: Acta Pharmaceutica (Zagreb) (1996), 46(1), 51-9
 CODEN: ACPHEE; ISSN: 1330-0075
 PUBLISHER: Croatian Pharmaceutical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Treatment of anthranilic acid with an aryl acid chloride in the presence of pyridine yielded 2-aryl-4-oxo-3,1-benzoxazine which on treatment with p-aminoacetophenone in the presence of anhydrous pyridine afforded 2-aryl-3-(p-acetylphenyl)-3,4-dihydro-4-oxo-quinazolines (I) in excellent yields. Reaction of I with thiosemicarbazide in the presence of ethanol resulted in 2-aryl-4-oxo-3,4-dihydro-quinazolyl-3-[p-(acetophenone thiosemicarbazones)] (II) in the yields ranging from 60-65%. Reaction of II with acetophenone and iodine in glacial acetic acid yielded 2-aryl-4-oxo-3,4-dihydroquinazolyl-3-[p-(5'-phenyl-3'-thiazolyl)acetophenoneazines] in moderate yields; these compds. showed psychotropic activity without any toxicity (ALD50 values were > 1000 mg kg-1). Most of the compds. were also found to possess writhing effect while only one compound exhibited hyperthermic activity. Four of such compds. showed promising CNS stimulant activity and two compds. were found to exert CNS depressant activity.

IT 176772-14-8P 176772-16-0P 176772-18-2P
 176772-19-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and structure activity of quinazolythiazoles as central nervous system agents)


RN 176772-14-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-acetylphenyl)-2-(2-chlorophenyl)- (CA INDEX NAME)




RN 176772-16-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-acetylphenyl)-2-(2-nitrophenyl)- (CA INDEX NAME)




RN 176772-18-2 CAPLUS


CN 4(3H)-Quinazolinone, 3-(4-acetylphenyl)-2-(4-bromophenyl)- (CA INDEX NAME)



RN 176772-19-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-acetylphenyl)-2-(4-chlorophenyl)- (CA INDEX NAME)




L5 ANSWER 87 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1996:148287 CAPLUS
DOCUMENT NUMBER: 124:219969
ORIGINAL REFERENCE NO.: 124:40381a, 40384a
TITLE: Synthesis and Hypolipidemic Activities of Novel
2-[4-[(Diethoxyphosphoryl)methyl]phenyl]quinazolines
and 4(3H)-Quinazolinones
AUTHOR(S): Kurogi, Yasuhisa; Inoue, Yasuhide; Tsutsumi, Kazuhiko;
Nakamura, Shizuo; Nagao, Kazushi; Yoshitsugu, Hiroki;
Tsuda, Yoshihiko
CORPORATE SOURCE: Nutrition Research Institute, Otsuka Pharmaceutical
Factory Inc., Naruto, 772, Japan
SOURCE: Journal of Medicinal Chemistry (1996), 39(7), 1433-7
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB The novel compound NO-1886, 4-[(diethoxyphosphoryl)methyl]-N-(4-bromo-2-cyanophenyl)benzamide (I), a hypolipidemic agent which appears to increase lipoprotein lipase activity in rats. Various analogs of NO-1886 were

synthesized to study the structure-activity relation of this hypolipidemic drug. A novel series of quinazolines and 4(3H)-quinazolinones were prepared by cyclization of NO-1886 derivs. Derivs. bearing a 4-[(diethoxyphosphoryl)methyl]phenyl group at the 2-position were found to lower triglyceride and total cholesterol levels. In accord with the decrease in log P*, quinazolines and 4(3H)-quinazolinones showed good absorption and hypolipidemic activity. When the quinazolinone ring system is substituted at positions 6 and 7 with methoxy groups, increased hypolipidemic activity was observed. The highest hypolipidemic activity was observed when the 3-position was substituted by a Me or benzyl group.

- IT 166394-81-6P, 2-[4-[(Diethoxyphosphoryl)methyl]phenyl]-4-hydroxyquinazoline
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (synthesis and hypolipidemic activities of novel 2-[4-[(diethoxyphosphoryl)methyl]phenyl]quinazolines and 4(3H)-quinazolinones)
- RN 166394-81-6 CAPLUS
- CN Phosphonic acid, [[4-(1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




- IT 166394-19-0P, 2-[4-[(Diethoxyphosphoryl)methyl]phenyl]-4-methoxyquinazoline 166394-21-4P 166394-22-5P
 166394-26-9P, 2-[4-[(Diethoxyphosphoryl)methyl]phenyl]-6-bromo-4-phenoxyquinazoline 166394-31-6P 166394-32-7P
 166394-37-2P 166394-38-3P 166394-72-5P
 166394-73-6P 166394-74-7P 166394-75-8P
 166394-76-9P 166394-77-0P 166394-88-3P
 166394-89-4P 166394-90-7P 166394-91-8P
 173018-46-7P, 2-[4-[(Diethoxyphosphoryl)methyl]phenyl]-3-methyl-4(3H)-quinazolinone 173018-47-8P 173018-50-3P
 173018-51-4P 173018-52-5P 173018-53-6P
 173018-54-7P 173018-55-8P 173018-57-0P
 173018-59-2P 173018-60-5P,
 2-[4-[(Diethoxyphosphoryl)methyl]phenyl]-6,7-dimethoxy-3-methyl-4(3H)-quinazolinone 173018-61-6P,
 2-[4-[(Diethoxyphosphoryl)methyl]phenyl]-3-benzyl-6,7-dimethoxy-4(3H)-quinazolinone 173018-65-0P,
 2-[4-[(Diisopropoxyphosphoryl)methyl]phenyl]-6,7-dimethoxy-3-methyl-4(3H)-quinazoline 174877-91-9P 174877-92-0P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and hypolipidemic activities of novel 2-[4-[(diethoxyphosphoryl)methyl]phenyl]quinazolines and 4(3H)-quinazolinones)
- RN 166394-19-0 CAPLUS
- CN Phosphonic acid, [[4-(4-methoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-21-4 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-4-methoxy-2-quinazolinyl)phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 166394-22-5 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-4-ethoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-26-9 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-4-phenoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-31-6 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-4-methoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-32-7 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-37-2 CAPLUS

CN Phosphonic acid, [[4-(4,6,7-trimethoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-38-3 CAPLUS

CN Phosphonic acid, [[4-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-72-5 CAPLUS

CN Phosphonic acid, [[4-(5-fluoro-4-methoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-73-6 CAPLUS


CN Phosphonic acid, [[4-(5-fluoro-1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-74-7 CAPLUS
 CN Phosphonic acid, [[4-(4,6,7-trimethoxy-2-quinazolinyl)phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 166394-75-8 CAPLUS
 CN Phosphonic acid, [[4-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 166394-76-9 CAPLUS
 CN Phosphonic acid, [[4-(4,6,7-trimethoxy-2-quinazolinyl)phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 166394-77-0 CAPLUS
 CN Phosphonic acid, [[4-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 166394-88-3 CAPLUS

CN Phosphonic acid, [[4-[6,7-dimethoxy-4-(phenylmethoxy)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-89-4 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-[(4-bromo-2-fluorophenyl)methoxy]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 166394-90-7 CAPLUS


CN Acetic acid, 2-[[6-bromo-2-[4-[(diethoxyphosphinyl)methyl]phenyl]-4-quinazolinyl]oxy]- (CA INDEX NAME)



RN 166394-91-8 CAPLUS


CN Phosphonic acid, [[4-[6,7-dimethoxy-4-(2-propenyloxy)-2-

quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-46-7 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-47-8 CAPLUS

CN Phosphonic acid, [[4-(5-fluoro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-50-3 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-51-4 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-52-5 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-3,4-dihydro-4-oxo-3-(2-propenyl)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-53-6 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-54-7 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-55-8 CAPLUS

CN 3(4H)-Quinazolineacetic acid, 6-bromo-2-[4-(diethoxyphosphinyl)methyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 173018-57-0 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 173018-59-2 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 173018-60-5 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-61-6 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-6,7-dimethoxy-4-oxo-3-(phenylmethyl)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-65-0 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 174877-91-9 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(2-propenyloxy)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 174877-92-0 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-6,7-dimethoxy-4-oxo-3-(2-propenyl)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)

L5 ANSWER 88 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:71553 CAPLUS

DOCUMENT NUMBER: 124:261073

ORIGINAL REFERENCE NO.: 124:48374h, 48375a


TITLE: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
 INVENTOR(S): Spada, Alfred P.; Myers, Michael R.; Maguire, Martin P.; Persons, Paul E.

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA


SOURCE: U.S., 33 pp. Cont.-in-part of U.S. Ser. No. 988,515,
abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5480883	A	19960102	US 1993-166199	19931210
US 5710158	A	19980120	US 1994-229886	19940419
WO 9515758	A1	19950615	WO 1994-US14180	19941208
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9513050	A	19950627	AU 1995-13050	19941208
EP 871448	A1	19981021	EP 1995-904308	19941208
EP 871448	B1	20050302		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
EP 1488792	A2	20041222	EP 2004-19772	19941208
EP 1488792	A3	20050105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 289814	T	20050315	AT 1995-904308	19941208
PT 871448	E	20050531	PT 1995-904308	19941208
ES 2236701	T3	20050716	ES 1995-904308	19941208
MX 9409601	A	20050224	MX 1994-9601	19941212
US 5656643	A	19970812	US 1995-385258	19950208
US 5795889	A	19980818	US 1995-386271	19950209
US 5646153	A	19970708	US 1995-439027	19950511
US 6645969	B1	20031111	US 1995-521852	19950518
US 5721237	A	19980224	US 1995-469147	19950606
US 5714493	A	19980203	US 1996-652444	19960604
US 6057320	A	20000502	US 1997-881991	19970625
US 36256	E	19990720	US 1997-988005	19971210
AU 9965543	A	20000323	AU 1999-65543	19991230
AU 739382	B2	20011011		
US 37650	E1	20020409	US 2000-496399	20000202
US 20040014774	A1	20040122	US 2003-617342	20030710
PRIORITY APPLN. INFO.:				
			US 1991-698420	B2 19910510
			US 1992-988515	B2 19921210
			WO 1992-US3736	A2 19920506
			US 1993-146072	A3 19931108
			US 1993-166199	A2 19931210
			US 1994-229886	A 19940419
			EP 1995-904308	A3 19941208
			WO 1994-US14180	W 19941208
			US 1995-439027	A3 19950511
			US 1995-521852	A3 19950518
			US 1996-652444	A5 19960604

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 124:261073; MARPAT 124:261073
 GI



II



III

AB The invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compds. Ar1XAr2 [I; Ar1, Ar2 = (un)substituted mono- or bicyclic rings with 0-3 substituents; X = (CHR1)0-4 or (CHR1)mZ(CHR1)n; Z = O, NR2, S, SO, SO2; m, n = 0-3; R1, R2 = H, alkyl] exhibiting protein tyrosine kinase inhibition activity. I inhibit abnormal cell proliferation in proliferative disorders by selectively inhibiting EGF and/or PDGF receptor. Approx. 300 compds. I are listed with characterizing data, and biol. data for selected compds. are given. For example, m-ClC6H4OH was treated with NaH in THF, followed by 4-chloro-6,7-dimethoxyquinazoline, to give title compound II. The claimed quinazolinone derivative III inhibited

PDGF-R


cell-free autophosphorylation with an IC50 of 0.02-0.05 μ M.

IT 1152-07-4P 74375-16-9P 146535-77-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of bis mono- and bicyclic aryl and heteroaryl compds. as protein tyrosine kinase inhibitors)


RN 1152-07-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 74375-16-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-methyl-2-(4-methylphenyl)- (CA INDEX NAME)



RN 146535-77-5 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 51 THERE ARE 51 CAPLUS RECORDS THAT CITE THIS
RECORD (62 CITINGS)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 89 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1995:994887 CAPLUS
DOCUMENT NUMBER: 124:86997
ORIGINAL REFERENCE NO.: 124:16351a,16354a
TITLE: Preparation of benzamide analogs as poly(ADP-ribose)
polymerase inhibitors
INVENTOR(S): Griffin, Roger John; Calvert, Alan Hilary; Curtin,
Nicola Jane; Newell, David Richard; Golding, Bernard
Thomas
PATENT ASSIGNEE(S): Cancer Research Campaign Technology Ltd., UK
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9524379	A1	19950914	WO 1995-GB513	19950309
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2184747	A1	19950914	CA 1995-2184747	19950309
CA 2184747	C	20031014		
CA 2350941	A1	19950914	CA 1995-2350941	19950309
CA 2352592	A1	19950914	CA 1995-2352592	19950309
CA 2352592	C	20060606		
AU 9518565	A	19950925	AU 1995-18565	19950309
AU 693167	B2	19980625		
EP 749415	A1	19961227	EP 1995-910653	19950309
EP 749415	B1	19990908		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1143358	A	19970219	CN 1995-192011	19950309
CN 1081624	C	20020327		
JP 09510704	T	19971028	JP 1995-523316	19950309
EP 879820	A1	19981125	EP 1998-202102	19950309
EP 879820	B1	20011212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 897915	A1	19990224	EP 1998-202103	19950309
EP 897915	B1	20030122		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE

AT 184271	T	19990915	AT 1995-910653	19950309
ES 2135707	T3	19991101	ES 1995-910653	19950309
AT 210651	T	20011215	AT 1998-202102	19950309
PT 879820	E	20020628	PT 1998-202102	19950309
ES 2169472	T3	20020701	ES 1998-202102	19950309
AT 231494	T	20030215	AT 1998-202103	19950309
US 5756510	A	19980526	US 1996-706326	19960830
US 6015827	A	20000118	US 1998-56928	19980408
GR 3031886	T3	20000229	GR 1999-402976	19991118
US 6316455	B1	20011113	US 1999-448485	19991124
PRIORITY APPLN. INFO.:			GB 1994-4485	A 19940309
			CA 1995-2184747	A3 19950309
			EP 1995-910653	A3 19950309
			WO 1995-GB513	W 19950309
			US 1996-706326	A3 19960830
			US 1998-56928	A3 19980408

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 124:86997

GI




AB Title compds. [I; R = R₁ = H and R₂ = (ar)alkoxy, alkenyloxy, OPh, etc.; R₁R = N:CR₃ and R₂ = OH, alkyl, alkoxy, aryl, etc., and R₃ = H, alkyl, (un)substituted aryl(alkyl); R = H and R₂R₁ = OCR₅:N and R₅ = H, alkyl, (un)substituted aryl(alkyl)] were prepared. Thus, 4,3-(HO)(H₂N)C₆H₃CO₂Me (preparation given) was amidated by 4-(MeO)C₆H₄COCl and the product cyclized to give, after NH₃ treatment, title compound II which had IC₅₀ of 1.1μM against poly(ADP-ribose) polymerase in vitro.

IT 172462-88-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzamide analogs as poly(ADP-ribose) polymerase inhibitors)

RN 172462-88-3 CAPLUS

CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-nitrophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 35 THERE ARE 35 CAPLUS RECORDS THAT CITE THIS RECORD (49 CITINGS)
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 90 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:994818 CAPLUS

DOCUMENT NUMBER: 124:117591

ORIGINAL REFERENCE NO.: 124:21913a, 21916a

TITLE: Preparation and formulation of quinazolinonylbenzylphosphonic acid diester derivatives as hypolipemics, antihypertensives, and antidiabetics

INVENTOR(S): Kuroki, Yasuhisa; Miyata, Kazuyoshi; Tsuda, Yoshihiko; Inoue, Yasuhide; Kanaya, Jun; Sato, Keigo
 PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan
 SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9524410	A1	19950914	WO 1995-JP303	19950227
W: AU, CA, CN, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 08143586	A	19960604	JP 1995-35261	19950223
JP 3533542	B2	20040531		
CA 2184891	A1	19950914	CA 1995-2184891	19950227
CA 2184891	C	20000926		
AU 9518244	A	19950925	AU 1995-18244	19950227
AU 679344	B2	19970626		
EP 749974	A1	19961227	EP 1995-909996	19950227
EP 749974	B1	20010627		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1147257	A	19970409	CN 1995-192824	19950227
CN 1066739	C	20010606		
AT 202567	T	20010715	AT 1995-909996	19950227
TW 379225	B	20000111	TW 1995-84102161	19950307
US 5798344	A	19980825	US 1996-704740	19960905
PRIORITY APPLN. INFO.:				
			JP 1994-37361	A 19940308
			JP 1994-126526	A 19940608
			JP 1994-251484	A 19940919
			WO 1995-JP303	W 19950227

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 124:117591

GI




AB The title compds. I [R1, R2, R3 and R6 represent each independently hydrogen, lower alkyl, halogen, nitro, etc.; R4 represents Ph, lower alkyl, phenylalkyl, etc.; R5 represents lower alkyl; R7 represents lower alkoxy, hydroxy, Ph, or phenylated lower alkoxy or lower alkylamino wherein the Ph group may be halogenated; X1 and X2 represent each oxygen or sulfur; A represents oxygen or a single bond; and Z represents lower alkylene] are prepared. The title compound II [R1 = F; R2 = H] at 100 mg/Kg orally decreased blood glucose in rats by 50%. The title compound II [R1 = H; R2 = Br] at 100 mg/Kg orally decreased plasma triglycerides in rats by 35%.

IT	173018-45-6P	173018-46-7P	173018-47-8P
	173018-48-9P	173018-49-0P	173018-50-3P
	173018-51-4P	173018-52-5P	173018-53-6P
	173018-54-7P	173018-55-8P	173018-56-9P
	173018-57-0P	173018-58-1P	173018-59-2P
	173018-60-5P	173018-61-6P	173018-62-7P
	173018-63-8P	173018-64-9P	173018-65-0P
	173018-66-1P	173018-67-2P	173018-68-3P
	173018-70-7P	173018-71-8P	173018-72-9P
	173018-73-0P	173018-74-1P	173018-75-2P
	173018-76-3P	173018-77-4P	173018-78-5P
	173018-79-6P	173018-80-9P	173018-81-0P
	173018-82-1P	173018-83-2P	173018-84-3P
	173018-85-4P	173018-86-5P	173018-87-6P
	173018-88-7P	173018-89-8P	173018-90-1P
	173018-91-2P	173018-92-3P	173018-93-4P
	173018-94-5P	173018-95-6P	173018-96-7P
	173018-97-8P	173018-98-9P	173018-99-0P
	173019-00-6P	173019-01-7P	173019-02-8P
	173019-03-9P	173019-04-0P	173019-05-1P
	173019-06-2P	173019-07-3P	173019-08-4P
	173019-09-5P	173019-10-8P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolinonylbenzylphosphonic acid diester derivs. as hypolipemics, antihypertensives, and antidiabetics)


RN 173018-45-6 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-46-7 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-47-8 CAPLUS

CN Phosphonic acid, [[4-(5-fluoro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-48-9 CAPLUS

CN Phosphonic acid, [[4-[5-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-49-0 CAPLUS

CN Phosphonic acid, [[4-(5-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-50-3 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-51-4 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-52-5 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-3,4-dihydro-4-oxo-3-(2-propenyl)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-53-6 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-54-7 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-55-8 CAPLUS

CN 3(4H)-Quinazolineacetic acid, 6-bromo-2-[4-[(diethoxyphosphinyl)methyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 173018-56-9 CAPLUS

CN 3(4H)-Quinazolineacetic acid, 6-bromo-2-[4-[(diethoxyphosphinyl)methyl]phenyl]-4-oxo-, ethyl ester (CA INDEX NAME)




RN 173018-57-0 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 173018-58-1 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-3-methyl-6-nitro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-59-2 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 173018-60-5 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-61-6 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-6,7-dimethoxy-4-oxo-3-(phenylmethyl)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-62-7 CAPLUS

CN Phosphonic acid, [[4-[3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-63-8 CAPLUS

CN Phosphonic acid, [[4-[3-[(4-bromophenyl)methyl]-3,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-64-9 CAPLUS

CN 3(4H)-Quinazolineacetic acid, 2-[4-[(diethoxyphosphinyl)methyl]phenyl]-6,7-dimethoxy-4-oxo- (CA INDEX NAME)




RN 173018-65-0 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 173018-66-1 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-6,7-dimethoxy-4-oxo-3-(phenylmethyl)-2-quinazolinyl]phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 173018-67-2 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-6,7-dimethoxy-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 173018-68-3 CAPLUS

CN Phosphonothioic acid, [[4-(5-fluoro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, O,O-diethyl ester (9CI) (CA INDEX NAME)




RN 173018-70-7 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-71-8 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-3-methyl-7-nitro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-72-9 CAPLUS

CN Phosphonic acid, [[4-(7-bromo-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-73-0 CAPLUS

CN Phosphonic acid, [[4-(8-bromo-3,4-dihydro-7-methoxy-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-74-1 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-methyl-4-oxo-7-(trifluoromethyl)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-75-2 CAPLUS

CN Phosphonic acid, [[4-(7-fluoro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-76-3 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-8-methoxy-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-77-4 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-78-5 CAPLUS

CN 3(4H)-Quinazolineacetic acid, 7-chloro-2-[4-[(diethoxyphosphinyl)methyl]phenyl]-4-oxo- (CA INDEX NAME)




RN 173018-79-6 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-6,7,8-trimethoxy-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-80-9 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-6-iodo-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-81-0 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-82-1 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3-cyclohexyl-3,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-83-2 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3,4-dihydro-3-(methoxymethyl)-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-84-3 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3,4-dihydro-4-oxo-3-(2-propynyl)-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-85-4 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-(2-phenylethyl)-2-quinazolininyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-86-5 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-(2-oxo-2-phenylethyl)-2-quinazolininyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-87-6 CAPLUS

CN Phosphonic acid, [[4-(5-bromo-3,4-dihydro-3-methyl-4-oxo-2-quinazolininyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-88-7 CAPLUS

CN Phosphonic acid, [[4-(7-bromo-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 173018-89-8 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-90-1 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-7-nitro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-91-2 CAPLUS

CN Phosphonic acid, [[4-(7-cyano-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-92-3 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 173018-93-4 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 173018-94-5 CAPLUS

CN Phosphonic acid, [[4-(3,4-dihydro-3,6-dimethyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-95-6 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 173018-96-7 CAPLUS

CN Phosphonic acid, [[3-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-97-8 CAPLUS

CN Phosphonic acid, [[2-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-98-9 CAPLUS

CN Phosphonic acid, [2-[4-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenoxy]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173018-99-0 CAPLUS

CN Phosphonic acid, [[4-(3-amino-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173019-00-6 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(phenylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173019-01-7 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173019-02-8 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(2-pyridinyl)methylene]amino]-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173019-03-9 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl)methyl]-, monoethyl ester (9CI) (CA INDEX NAME)




RN 173019-04-0 CAPLUS

CN Phosphonamidic acid, P-[[4-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-N-(phenylmethyl)-, ethyl ester (CA INDEX NAME)




RN 173019-05-1 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, (4-chlorophenyl)methyl ethyl ester (9CI) (CA INDEX NAME)




RN 173019-06-2 CAPLUS

CN Phosphonic acid, [[4-(7-chloro-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, ethyl phenylmethyl ester (9CI) (CA INDEX NAME)




RN 173019-07-3 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-(diacetylamino)-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, ethyl phenylmethyl ester (9CI) (CA INDEX NAME)




RN 173019-08-4 CAPLUS

CN Phosphonic acid, [[4-(7-amino-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173019-09-5 CAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-methyl-4-oxo-7-[(phenylsulfonyl)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 173019-10-8 CAPLUS

CN Phosphonic acid, [[4-[7-(benzoylamino)-3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 91 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:737316 CAPLUS

DOCUMENT NUMBER: 123:144272

ORIGINAL REFERENCE NO.: 123:25717a, 25720a

TITLE: Preparation of quinazolinylbenzyl phosphonates derivatives as hyperlipidemia, hypertension, and diabetes agents

INVENTOR(S): Kurogi, Yasuhisa; Miyata, Kazuyoshi; Nakamura, Shizuo; Kondo, Mitsuyoshi; Iwamoto, Takeshi; Naba, Chieko; Tsuda, Yoshihiko; Inoue, Yasuhide; Kanaya, Jun; Sato, Keigo

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9500524	A1	19950105	WO 1994-JP883	19940531
W: AU, CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2142597	A1	19950105	CA 1994-2142597	19940531


CA 2142597	C	20040113		
AU 9468558	A	19950117	AU 1994-68558	19940531
AU 664337	B2	19951109		
EP 655456	A1	19950531	EP 1994-917137	19940531
EP 655456	B1	20000906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1112365	A	19951122	CN 1994-190513	19940531
CN 1048018	C	20000105		
JP 2926274	B2	19990728	JP 1994-502639	19940531
AT 196145	T	20000915	AT 1994-917137	19940531
US 5624918	A	19970429	US 1995-387907	19950205

PRIORITY APPLN. INFO.:

	JP 1993-146528	A	19930617
	WO 1994-JP883	W	19940531

OTHER SOURCE(S): MARPAT 123:144272

GI



AB The preparation of title compds. I (A = O, S; R1, R2, R9, R10 = each independently H, lower alkoxy, nitro, lower alkyl, halogenated lower alkyl, halo; R3 = Ph, -B-R6 [B = O, S; R6 = H, lower alkyl, cycloalkyl, Ph, phenylated lower alkyl wherein Ph may be halogenated, phenoxyated lower alkyl, lower-alkoxy carbonyl-substituted lower alkyl, carboxylated lower alkyl or lower alkenyl, -NR7R8, R7, R8 = each independently H, lower alkyl, amino or cycloalkyl, R7R8 = combined together to form lower alkylene]; R4, R5 = each independently H, lower alkyl), useful as remedies for hyperlipidemia, hypertension, diabetes, and so forth, is described. Thus, reaction of o-aminobenzonitrile with 4-(EtO)2P(O)CH2C6H4COCl gave di-Et 4-[N-(2-cyanophenyl)carbamoyl]benzylphosphonate which on cyclization in the presence of MeOH gave p-substituted title compound I (R1, R2, R9, R10 = H, R3 = OMe, A = O, R4, R5 = Et). I lowered the triglycerides by 37-86% at 100 mg/kg P.O. in rats with Triton-induced hyperlipemia. Tablet, capsule, and granular formulation was also given.


IT	166394-19-0P	166394-20-3P	166394-21-4P
	166394-22-5P	166394-23-6P	166394-24-7P
	166394-25-8P	166394-26-9P	166394-27-0P
	166394-28-1P	166394-29-2P	166394-30-5P
	166394-31-6P	166394-32-7P	166394-33-8P
	166394-34-9P	166394-35-0P	166394-36-1P
	166394-37-2P	166394-38-3P	166394-61-2P
	166394-62-3P	166394-72-5P	166394-73-6P
	166394-74-7P	166394-75-8P	166394-76-9P
	166394-77-0P	166394-78-1P	166394-79-2P
	166394-80-5P	166394-81-6P	166394-82-7P
	166394-83-8P	166394-84-9P	166394-85-0P
	166394-86-1P	166394-87-2P	166394-88-3P
	166394-89-4P	166394-90-7P	166394-91-8P
	166394-92-9P	166394-93-0P	166394-94-1P

166394-95-2P 166394-96-3P 166394-97-4P
 166394-98-5P 166394-99-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazolinylbenzyl phosphonates derivs. as hyperlipidemia, hypertension, and diabetes agents)


RN 166394-19-0 CAPLUS

CN Phosphonic acid, [[4-(4-methoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-20-3 CAPLUS

CN Phosphonic acid, [[4-(4-ethoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-21-4 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-4-methoxy-2-quinazolinyl)phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 166394-22-5 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-4-ethoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-23-6 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(1-methylethoxy)-2-quinazoliny]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-24-7 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(hexyloxy)-2-quinazoliny]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-25-8 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(cyclohexyloxy)-2-quinazoliny]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-26-9 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-phenoxy-2-quinazoliny]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-27-0 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(phenylmethoxy)-2-quinazoliny]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-28-1 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(2-phenoxyethoxy)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-29-2 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-4-methoxy-2-quinazolinyl)phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 166394-30-5 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 166394-31-6 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-4-methoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-32-7 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-33-8 CAPLUS

CN Phosphonic acid, [[4-(6-chloro-4-methoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-34-9 CAPLUS

CN Phosphonic acid, [[4-(6-chloro-1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-35-0 CAPLUS

CN Phosphonic acid, [[4-(4-methoxy-6-nitro-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-36-1 CAPLUS

CN Phosphonic acid, [[4-(1,4-dihydro-6-nitro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-37-2 CAPLUS

CN Phosphonic acid, [[4-(4,6,7-trimethoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-38-3 CAPLUS

CN Phosphonic acid, [[4-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-61-2 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-4-methoxy-2-quinazolinyl)phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)




RN 166394-62-3 CAPLUS

CN Phosphonic acid, [[4-(6-bromo-4-ethoxy-2-quinazolinyl)phenyl]methyl]-, monoethyl ester (9CI) (CA INDEX NAME)




RN 166394-72-5 CAPLUS

CN Phosphonic acid, [[4-(5-fluoro-4-methoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-73-6 CAPLUS

CN Phosphonic acid, [[4-(5-fluoro-1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-74-7 CAPLUS

CN Phosphonic acid, [[4-(4,6,7-trimethoxy-2-quinazolinyl)phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 166394-75-8 CAPLUS

CN Phosphonic acid, [[4-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 166394-76-9 CAPLUS

CN Phosphonic acid, [[4-(4,6,7-trimethoxy-2-quinazolinyl)phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 166394-77-0 CAPLUS

CN Phosphonic acid, [[4-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 166394-78-1 CAPLUS


CN Phosphonic acid, [[4-(7-chloro-4-methoxy-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-79-2 CAPLUS
 CN Phosphonic acid, [[4-(7-chloro-1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-80-5 CAPLUS
 CN Phosphonic acid, [[4-(7-fluoro-1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-81-6 CAPLUS
 CN Phosphonic acid, [[4-(1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-82-7 CAPLUS
 CN Phosphonic acid, [[4-(1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 166394-83-8 CAPLUS
 CN Phosphonic acid, [[4-(5-chloro-1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-84-9 CAPLUS
 CN Phosphonic acid, [[4-[1,4-dihydro-4-oxo-7-(trifluoromethyl)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 166394-85-0 CAPLUS
 CN Phosphonic acid, [[4-(1,4-dihydro-6-methyl-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-86-1 CAPLUS
 CN Phosphonic acid, [[4-(1,4-dihydro-7-nitro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-87-2 CAPLUS

CN Phosphonic acid, [[4-(5,7-dichloro-1,4-dihydro-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-88-3 CAPLUS

CN Phosphonic acid, [[4-[6,7-dimethoxy-4-(phenylmethoxy)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-89-4 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-[(4-bromo-2-fluorophenyl)methoxy]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-90-7 CAPLUS

CN Acetic acid, 2-[[6-bromo-2-[4-[(diethoxyphosphinyl)methyl]phenyl]phenyl]-4-quinazolinyl]oxy]- (CA INDEX NAME)




RN 166394-91-8 CAPLUS

CN Phosphonic acid, [[4-[6,7-dimethoxy-4-(2-propenyloxy)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-92-9 CAPLUS

CN Phosphonic acid, [[4-[6,7-dimethoxy-4-(phenylmethoxy)-2-quinazolinyl]phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 166394-93-0 CAPLUS

CN Phosphonic acid, [[4-[6,7-dimethoxy-4-(2-phenylethoxy)-2-quinazolinyl]phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 166394-94-1 CAPLUS

CN Acetic acid, 2-[[2-[4-[(diethoxyphosphinyl)methyl]phenyl]-6,7-dimethoxy-4-quinazolinyl]oxy]-, methyl ester (CA INDEX NAME)




RN 166394-95-2 CAPLUS

CN Phosphonic acid, [[4-[[4-(4-bromo-2-fluorophenyl)methoxy]-6,7-dimethoxy-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-96-3 CAPLUS

CN Phosphonic acid, [[4-[5-fluoro-4-(phenylmethoxy)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-97-4 CAPLUS

CN Phosphonic acid, [[4-[7-chloro-4-(phenylmethoxy)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-98-5 CAPLUS

CN Acetic acid, 2-[[7-chloro-2-[4-[(diethoxyphosphinyl)methyl]phenyl]-4-quinazolinyl]oxy]-, methyl ester (CA INDEX NAME)



RN 166394-99-6 CAPLUS

CN Phosphonic acid, [[4-(1,4-dihydro-6,7,8-trimethoxy-4-oxo-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 92 OF 102 CAPLUS COPYRIGHT 2010 ACS on SIN

ACCESSION NUMBER: 1993:517246 CAPLUS

DOCUMENT NUMBER: 119:117246

ORIGINAL REFERENCE NO.: 119:21091a, 21094a

TITLE: Preparation and formulation of fused heterocyclic compounds as angiotensin II antagonists
 Naka, Takehiko; Inada, Yoshiyuki
 Takeda Chemical Industries, Ltd., Japan
 Can. Pat. Appl., 160 pp.

SOURCE: CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2066094	A1	19921017	CA 1992-2066094	19920415
CA 2066094	C	20030624		
JP 05163267	A	19930629	JP 1992-137485	19920415
JP 3260415	B2	20020225		
JP 2001328988	A	20011127	JP 2001-159745	19920415
EP 518033	A1	19921216	EP 1992-106621	19920416
EP 518033	B1	20030702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
KR 217164	B1	19990901	KR 1992-6383	19920416
AT 244240	T	20030715	AT 1992-106621	19920416
EP 1327631	A2	20030716	EP 2003-6453	19920416
EP 1327631	A3	20040211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT				

US 5389641
PRIORITY APPLN. INFO.:

A 19950214

US 1993-127356

19930928

JP 1991-173473

A 19910416

JP 1991-263341

A 19910705

JP 1991-315629

A 19910925

JP 1992-137485

A3 19920415

EP 1992-106621


A3 19920416

US 1992-868841

B1 19920416

OTHER SOURCE(S):
GI

MARPAT 119:11/246



AB Title compds. (I R1 = an optionally substituted hydrocarbon residue which may be attached through a hetero atom; R2 = a group capable of forming an anion or a group convertible thereinto; R3 = an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hetero atom; X = a direct bond or a spacer having an atomic length of two or less between the R3 group and the ring W group; W = an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hetero atom; a, c and d are independently selected from the group consisting of one or two optionally substituted carbon atoms and one or two optionally substituted hetero atoms; b and e are independently selected from the group consisting of one optionally substituted carbon atom and one optionally substituted nitrogen atom; the dotted line is a bond to form one double bond; n is an integer of 1 or 2 and when a, which is an optionally substituted carbon atom, is taken together with R1, R1c:a may form a ring) were prepared. Thus, 3-methyl-4,5-diaminopyridine was cyclocondensed with BuCO₂H and the product converted in 3 steps to imidazopyridinecarboxylate II (R = H, R4 = Me) which was condensed with R5Br (R5 = biphenylmethyl group Q, R6 = CPh3) to give, after deprotection and saponification, II (R = Q, R4 = R6 = H) which gave 63% inhibition of angiotensin II binding at 10⁻⁷M in vitro.


IT 149323-82-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as angiotensin II antagonist)

RN 149323-82-0 CAPLUS

CN 1H-Benzimidazole-7-carboxylic acid,

2-butyl-1-[[3,4-dihydro-3-methyl-4-oxo-2-[2-(2H-tetrazol-5-yl)phenyl]-6-quinazolinyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

L5 ANSWER 93 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1988:406539 CAPLUS

DOCUMENT NUMBER: 109:6539

ORIGINAL REFERENCE NO.: 109:1241a,1244a

TITLE: Quinazolin-4-one derivatives as drugs, agrochemicals, or fluorescent substances and a process for their preparation

INVENTOR(S): Terakawa, Masaaki

PATENT ASSIGNEE(S): Agency of Industrial Sciences and Technology, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 62258368	A	19871110	JP 1986-52071	19860310
JP 05039950	B	19930616		
PRIORITY APPLN. INFO.:			JP 1986-52071	19860310
OTHER SOURCE(S):	CASREACT	109:6539		
GI				



I



II

AB The title compds. I [R1 = (un)substituted alkyl, aryl, aralkyl or heterocycllyl; R2 = R1, H, halo, NO2, HOCH2], useful as drugs, agrochems., or fluorescent substances (no data), were prepared from II (R3 = OH, alkoxy, NH2). A 1:2:5.9 (mol) mixture of o-H2NC6H4CO2Me, Me3CCN, and MeOH in a teflon capsule placed in an high pressure reactor was pressurized to 7000 atm and heated to 140°, the pressure was raised to 8000 atm and the


mixture was kept 20 h to give 86% I (R1 = Me3C, R2 = H).

IT 18818-39-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug, agrochem. or fluorescent substance)

RN 18818-39-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-methylphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L5 ANSWER 94 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1988:124084 CAPLUS

DOCUMENT NUMBER: 108:124084

ORIGINAL REFERENCE NO.: 108:20149a, 20152a

TITLE: Synthesis of quinazolinyl triazines as potential anthelmintics

AUTHOR(S): Pandey, V. K.; Garg, Punita

CORPORATE SOURCE: Dep. Chem., Univ. Lucknow, Lucknow, 226 007, India


SOURCE: Indian Journal of Pharmaceutical Sciences (1987),
49(5), 172-4

CODEN: IJSDIW; ISSN: 0250-474X

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I


AB Six quinazolinyl triazines (I, R = Ph, benzyl, o-hydroxyphenyl, styryl, 2-phthalimidomethyl, or p-hydroxyphenyl) were prepared. The highest activity was given by I (R = benzyl) against infestation by *Ancylostoma ceylanicum* (in hamsters) and *Nippostrongylus brasiliensis* (in rats).

IT 113368-04-0P 113368-07-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and anthelmintic activity of)


RN 113368-04-0 CAPLUS

CN 4(3H)-Quinazolinone, 3,3',3''-(1,3,5-triazine-1,3,5(2H,4H,6H)-triyl)tris[2-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 113368-07-3 CAPLUS

CN 4(3H)-Quinazolinone, 3,3',3''-(1,3,5-triazine-1,3,5(2H,4H,6H)-triyl)tris[2-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L5 ANSWER 95 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1988:112476 CAPLUS

DOCUMENT NUMBER: 108:112476


ORIGINAL REFERENCE NO.: 108:18429a,18432a

TITLE: Preparation of phenylquinazoline derivatives as
anticonvulsants and antiepileptics

INVENTOR(S): Hino, Katsuhiko; Uno, Jun; Kai, Naoyoshi; Furukawa,
Kiyoshi

PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62145073	A	19870629	JP 1985-286748	19851219
PRIORITY APPLN. INFO.: GI			JP 1985-286748	19851219



AB The title compds. [I; X = O, S; Ar = (un)substituted aryl, Ph, pyridyl; R1 = H, halo, alkyl, CF3, alkoxy, OH, NH2, or two R1 form alkylenedioxy; R2 = ANR3R4 or Q (A = alkylene; R3, R4 = alkyl, cycloalkyl, substituted aralkyl, etc.; R5 = H, alkyl, cycloalkyl, etc.); n, l = 1-3; m = 0-2], useful as anticonvulsants and antiepileptics (no data) were prepared. A mixture of 0.57 g HO(CH2)2NMe2 and 0.18 g 60% NaH in DMF was stirred at room temperature for 30 min. Following addition of 1 g

2-chloro-4-phenylquinazoline, the reaction mixture was stirred at room temperature for 1 h and at 50° for 1 h to give 2-[2-(dimethylamino)ethoxy]quinazoline derivative II as maleic acid salt.

IT 113242-15-2P 113242-17-4P 113242-19-6P
 113242-21-0P 113242-23-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as anticonvulsant)

RN 113242-15-2 CAPLUS


CN 2-Propanamine, 1-[[2-(4-fluorophenyl)-4-quinazolinyl]oxy]-N,N,2-trimethyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 113242-14-1

CMF C20 H22 F N3 O

10/ 582,823




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 113242-17-4 CAPLUS

CN Ethanamine, 2-([2-(4-fluorophenyl)-4-quinazolinyl]oxy)-N,N-dimethyl-,
(2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 113242-16-3

CMF C18 H18 F N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 113242-19-6 CAPLUS


CN 1-Propanamine, 3-([2-(4-fluorophenyl)-4-quinazolinyl]oxy)-N,N-dimethyl-,
(2Z)-2-butenedioate (1:1) (CA INDEX NAME)

10/ 582,823

CM 1

CRN 113242-18-5

CMF C19 H20 F N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 113242-21-0 CAPLUS

CN Ethanamine, 2-[[2-(4-methoxyphenyl)-4-quinazolinyl]oxy]-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 113242-20-9

CMF C19 H21 N3 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 113242-23-2 CAPLUS
 CN 1-Propanamine, 3-[[2-(4-methoxyphenyl)-4-quinazolinyl]oxy]-N,N-dimethyl-,
 (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 113242-22-1
 CMF C20 H23 N3 O2



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L5 ANSWER 96 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1984:103384 CAPLUS
 DOCUMENT NUMBER: 100:103384
 ORIGINAL REFERENCE NO.: 100:15717a,15720a
 TITLE: Pyrimidinones and their acid addition salts
 INVENTOR(S): Heider, Joachim
 PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 18 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3220898	A1	19831208	DE 1982-3220898	19820603
FI 8301914	A	19831204	FI 1983-1914	19830530
DD 210904	A5	19840627	DD 1983-251638	19830601
DK 8302508	A	19831204	DK 1983-2508	19830602
NO 8301994	A	19831205	NO 1983-1994	19830602
HU 31146	A2	19840428	HU 1983-1976	19830602
HU 190846	B	19861128		
CA 1217768	A1	19870207	CA 1983-429507	19830602

PRIORITY APPLN. INFO.:



DE 1982-3220898

A 19820603

OTHER SOURCE(S):

CASREACT 100:103384; MARPAT 100:103384

GI




AB Condensed title compds. (I) [RR1 = (un)substituted pyrido or benzo; Z- = C3-4 (hydroxy)alkylene; R2, R4 = H or C1-3 alkyl; R3 = H or C1-3 alkoxy; R5 = C1-6 alkyl, aralkyl, (aryloxy)alkyl, etc.] were prepared as antiarrhythmics, antihypertensives, and sympatholytics (no data). Thus, 3,4-dihydro-2-(4-hydroxyphenyl)-6-methoxy-3-methyl-4-quinazolinone was refluxed 10 h with Me3CNHCH2CH(OH)CH2Cl in EtOH to give 27.6% propoxyquinazolinone derivative II.

IT	83722-14-9P	83722-15-0P	83722-17-2P
	83722-20-7P	83722-22-9P	83722-23-0P
	83722-24-1P	83722-25-2P	83722-26-3P
	83722-28-5P	83722-29-6P	83722-30-9P
	83722-34-3P	83722-35-4P	83722-36-5P
	83722-37-6P	83722-40-1P	83722-42-3P
	83722-44-5P	83722-45-6P	83722-47-8P
	83722-48-9P	83722-56-9P	83722-58-1P
	83722-60-5P	83722-63-8P	83722-64-9P
	88933-00-0P	88933-01-1P	88933-02-2P
	88933-03-3P	88933-04-4P	88933-05-5P
	88933-06-6P	88933-07-7P	88933-08-8P
	88933-15-7P	88947-74-4P	88947-75-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as pharmaceutical)


RN 83722-14-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-6-methoxy-3-methyl- (CA INDEX NAME)



RN 83722-15-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-2-hydroxypropoxy]phenyl]-6-methoxy-3-methyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 83722-17-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-[[2-hydroxy-3-(4-methoxyphenoxy)propyl]amino]propoxy]phenyl]-6-methoxy-3-methyl- (CA INDEX NAME)




RN 83722-20-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-6-methoxy- (CA INDEX NAME)



RN 83722-22-9 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[3-[(1,1-dimethylethyl)amino]propoxy]phenyl]-8-methoxy-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 83722-23-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[[2-(2-methoxyphenyl)ethyl]amino]propoxy]phenyl]-6-methoxy-3-methyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 83722-24-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-(diethylamino)-2-hydroxypropoxy]phenyl]-6-methoxy-3-methyl- (CA INDEX NAME)




RN 83722-25-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-6-methoxy-3-methyl- (CA INDEX NAME)




RN 83722-26-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-6-methoxy- (CA INDEX NAME)



RN 83722-28-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[(2-methoxyphenyl)ethyl]amino]propoxy]phenyl]-8-methoxy-3-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 83722-29-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[3-(diethylamino)-2-hydroxypropoxy]phenyl]-8-methoxy-3-methyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 83722-30-9 CAPLUS


CN 4 (3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[[2-(2-methylphenoxy)ethyl]amino]propoxy]phenyl]-8-methoxy-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 83722-34-3 CAPLUS

CN 4 (3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[[2-(2-methoxyphenyl)ethyl]amino]propoxy]phenyl]-6,7-dimethoxy-3-methyl-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 83722-35-4 CAPLUS


CN 4 (3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[[2-(2-methylphenoxy)ethyl]amino]propoxy]phenyl]-6,7-dimethoxy-3-methyl-, hydrochloride (1:3) (CA INDEX NAME)

10/ 582,823



RN 83722-36-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[3-[(1,1-dimethylethyl)amino]propoxy]phenyl]-6,7-dimethoxy-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 83722-37-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[3-[[2-hydroxy-3-(3-methylphenoxy)propyl]amino]propoxy]phenyl]-6,7-dimethoxy-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 83722-40-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3-methoxyphenyl]-6-methoxy-3-methyl- (CA INDEX NAME)




RN 83722-42-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-3-methyl-6-nitro- (CA INDEX NAME)




RN 83722-44-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-3,6-dimethyl- (CA INDEX NAME)




RN 83722-45-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-3,6-dimethyl- (CA INDEX NAME)




RN 83722-47-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-3-methyl- (CA INDEX NAME)



RN 83722-48-9 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[3-(diethylamino)propoxy]phenyl]-3-methyl-, hydriodide (1:1) (CA INDEX NAME)



● HI

RN 83722-56-9 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[4-[[2-hydroxy-3-(4-methoxyphenoxy)propyl]amino]butoxy]phenyl]-6-methoxy-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 83722-58-1 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[3-[[2-hydroxy-3-(4-methoxyphenoxy)propyl]amino]propoxy]phenyl]-8-methoxy-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 83722-60-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-6-methoxy-3-(1-methylethyl)- (CA INDEX NAME)




RN 83722-63-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-2-hydroxypropoxy]phenyl]-6-methoxy-3-methyl- (CA INDEX NAME)




RN 83722-64-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[[2-(2-methoxyphenyl)ethyl]amino]propoxy]phenyl]-6-methoxy-3-methyl- (CA INDEX NAME)




RN 88933-00-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-(diethylamino)propoxy]phenyl]-3-methyl- (CA INDEX NAME)




RN 88933-01-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-[(1,1-dimethylethyl)amino]propoxy]phenyl]-8-methoxy- (CA INDEX NAME)




RN 88933-02-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-[(1,1-dimethylethyl)amino]propoxy]phenyl]-6,7-dimethoxy-3-methyl- (CA INDEX NAME)




RN 88933-03-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[[2-(2-methoxyphenyl)ethyl]amino]propoxy]phenyl]-8-methoxy-3-methyl- (CA INDEX NAME)




RN 88933-04-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[3-(diethylamino)-2-hydroxypropoxy]phenyl]-8-methoxy-3-methyl- (CA INDEX NAME)




RN 88933-05-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[[2-(2-methylphenoxy)ethyl]amino]propoxy]phenyl]-8-methoxy-3-methyl- (CA INDEX NAME)




RN 88933-06-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[[3-(3-methylphenoxy)propyl]amino]propoxy]phenyl]-8-methoxy-3-methyl- (CA INDEX NAME)




RN 88933-07-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-[2-hydroxy-3-[[2-(2-methoxyphenyl)ethyl]amino]propoxy]phenyl]-6,7-dimethoxy-3-methyl- (CA INDEX NAME)




RN 88933-08-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-[3-[[2-hydroxy-3-(3-methylphenoxy)propyl]amino]propoxy]phenyl]-6,7-dimethoxy-3-methyl- (CA INDEX NAME)




RN 88933-15-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-[3-[[2-(3,4-dimethoxyphenyl)ethyl]propylamino]-2-hydroxypropoxy]phenyl]-6-methoxy-3-methyl- (CA INDEX NAME)



RN 88947-74-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[4-[4-[[2-hydroxy-3-(4-methoxyphenoxy)propyl]amino]butoxy]phenyl]-6-methoxy-3-methyl- (CA INDEX NAME)



RN 88947-75-5 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[4-[3-[[2-hydroxy-3-(4-methoxyphenoxy)propyl]amino]propoxy]phenyl]-8-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

L5 ANSWER 97 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1982:616206 CAPLUS
 DOCUMENT NUMBER: 97:216206
 ORIGINAL REFERENCE NO.: 97:36293a,36296a
 TITLE: Pyrimidinones and their use as medicines
 INVENTOR(S): Heider, Joachim; Austel, Volkhard; Eberlein, Wolfgang; Kadatz, Rudolf; Lillie, Christian
 PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SOURCE: Eur. Pat. Appl., 50 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 54132	A1	19820623	EP 1981-108623	19811021
EP 54132	B1	19841010		

R: AT, BE, CH, DE, FR, IT, LU, NL, SE

DE 3046871	A1	19820722	DE 1980-3046871	19801212
DE 3115447	A1	19821230	DE 1981-3115447	19810416
AT 9797	T	19841015	AT 1981-108623	19811021
SU 1056900	A3	19831123	SU 1981-3354550	19811118
DK 8105254	A	19820613	DK 1981-5254	19811126
US 4379788	A	19830412	US 1981-327348	19811204
DD 208151	A5	19840328	DD 1981-235494	19811207
FI 8103971	A	19820613	FI 1981-3971	19811210
CS 227024	B2	19840416	CS 1981-9180	19811210
IL 64504	A	19850228	IL 1981-64504	19811210
PL 135330	B1	19851031	PL 1981-234175	19811210
NO 8104239	A	19820614	NO 1981-4239	19811211
AU 8178473	A	19820617	AU 1981-78473	19811211
AU 543568	B2	19850426		
GB 2090249	A	19820707	GB 1981-37458	19811211
GB 2090249	B	19840822		
JP 57123170	A	19820731	JP 1981-199948	19811211
ZA 8108609	A	19830831	ZA 1981-8609	19811211
HU 29675	A2	19840228	HU 1981-3747	19811211
CA 1217767	A1	19870207	CA 1981-392067	19811211


PRIORITY APPLN. INFO.:

DE 1980-3046871	A	19801212
DE 1981-3115447	A	19810416
EP 1981-108623	A	19811021


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 97:216206; MARPAT 97:216206

GI



I



II


AB Pyrimidinones I [X = alkylene, hydroxyalkylene; R, R₄ = H, alkyl; R₁R₂ = atoms required to complete a benzene or pyridine ring; R₃ = H, alkoxy; R₅ = (un)substituted alkyl] were prepared. Thus 2,3-H₂N(MeO)C₆H₃CO₂H was treated with 4-AcOC₆H₄COCl and the resulting benzoxazinone was treated with MeNH₂ to give II (R₆ = H). Reaction of II (R₆ = H) with epibromohydrin and aminolysis gave II [R₆ = CH₂CH(OH)CH₂NHMe] which at 0.5 mg/kg i.v. in dogs gave a 20 mm decrease in arterial blood pressure, a 21/min decrease in heart rate, and 33% decrease in dp/dt maximum.

IT 83722-32-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. activity of)

RN 83722-32-1 CAPLUS

CN 4 (3H)-Quinazolinone, 2-[4-[3-[[2-hydroxy-3-(3-methylphenoxy)propyl]amino]propoxy]phenyl]-8-methoxy-3-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)

L5 ANSWER 98 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1980:191075 CAPLUS

DOCUMENT NUMBER: 92:191075

ORIGINAL REFERENCE NO.: 92:30821a,30824a

TITLE: Substituted quinazolones as anticonvulsants

AUTHOR(S): Srivastava, V. K.; Pandey, B. R.; Gupta, R. C.;

Barthwal, J. P.; Kishore, K.

CORPORATE SOURCE: Dep. Pharmacol. Therap., King George's Med. Coll.,

Lucknow, 226 003, India

SOURCE: Indian Journal of Physiology and Pharmacology (1979),


23(4), 347-9

CODEN: IJPPAZ; ISSN: 0019-5499

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB Anticonvulsant activities of substituted quinazolones I (R = H or halogen; R1 = H, Br, or Cl; R2 = H, Cl, or NO2) (100 mg/kg, i.p.) were tested against pentylenetetrazole-induced convulsions in albino mice. All I tested provided some protection against pentylenetetrazole convulsion; the range of protection was from 20 to 80%. Maximum protection was observed with I; R = R1 = Br, R2 = H [73492-16-7]. Structure-activity relations is discussed.

IT 73492-11-2 73492-12-3 73492-13-4


73492-14-5 73492-15-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anticonvulsant activity of)


RN 73492-11-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-benzoyl-4-chlorophenyl)-2-(2-chlorophenyl)-6-iodo- (CA INDEX NAME)




RN 73492-12-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-benzoyl-4-chlorophenyl)-6,8-dichloro-2-(2-chlorophenyl)- (CA INDEX NAME)




RN 73492-13-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-benzoyl-4-chlorophenyl)-6,8-dichloro-2-(4-nitrophenyl)- (CA INDEX NAME)




RN 73492-14-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-benzoyl-4-chlorophenyl)-6-bromo-2-(4-nitrophenyl)- (CA INDEX NAME)



RN 73492-15-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-benzoyl-4-chlorophenyl)-6,7-dibromo-2-(4-nitrophenyl)- (CA INDEX NAME)



L5 ANSWER 99 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1979:586405 CAPLUS

DOCUMENT NUMBER: 91:186405

ORIGINAL REFERENCE NO.: 91:29887a,29890a

TITLE: Antitumor activity, biomimetic oxidation and metabolism of heterocyclic triazines

AUTHOR(S): Stevens, Malcolm F. G.; Gescher, Andreas; Turnbull, Colin P.

CORPORATE SOURCE: Dep. Pharm., Univ. Aston, Birmingham, UK


SOURCE: Biochemical Pharmacology (1979), 28(6), 769-76

CODEN: BCPA6; ISSN: 0006-2952

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Triazenoquinazolines, with variations in the quinazoline nucleus or triazene side-chain, generally had no antitumor activity; e.g., I [71825-17-7] was inactive against L1210 lymphoid leukemia in mice. The aminoquinazoline series, however, were the most toxic agents against human epidermoid carcinoma of the nasopharynx in cell culture, with ED50 values of 1.2-2.3 $\mu\text{g/mL}$; e.g., I had an ED50 of 1.5 $\mu\text{g/mL}$. Substitution in the quinazoline nucleus by Br atoms or replacement of the aminoquinazoline by a 2,4-diamino-s-triazin-6-yl fragment decreased the chemotherapeutic effect. 1-(4-Chlorophenylazo)piperidine (II) [62499-15-4], when oxidized with KMnO_4 in aqueous acetone at pH 6-9, yielded 8 oxidation products, similar

to those produced by oxidation of II via the Udenfried process or by incubation with rat liver homogenates or fortified microsomes, the major product being 1-(4-chlorophenylazo)piperidin-2-one [62499-17-6] (5% yield). Oxidation of 1-(4-chlorophenylazo)pyrrolidine [62499-16-5] with KMnO_4 in aqueous


acetone or incubation with liver homogenates or microsomes yielded 3 products, e.g. 1-(4-chlorophenylazo)pyrrolidin-2-one [65568-22-1] (5% yield). KMnO_4 oxidation of III [54762-78-6] yielded a bis(chlorophenyl)triazene, 4-chloroaniline [106-47-8], and a morpholin-3-ol compound (25%); the latter was formed from III upon incubation with liver homogenates or microsomes, but was not formed in vivo.

IT 52745-18-3 62888-04-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(antitumor activity of)

RN 52745-18-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-[2-(1-piperidinyl)diazenyl]phenyl]- (CA INDEX NAME)




RN 62888-04-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-(3,3-dimethyl-1-triazen-1-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 100 OF 102 CAPLUS COPYRIGHT 2010 ACS ON STN
 ACCESSION NUMBER: 1979:568210 CAPLUS
 DOCUMENT NUMBER: 91:168210
 ORIGINAL REFERENCE NO.: 91:27001a,27004a
 TITLE: Antiallergic agents. II.
 2-Aryl-3,4-dihydro-4-oxo-6-quinazolinecarboxylic acids
 AUTHOR(S): Doria, Gianfederico; Romeo, Ciriaco; Sberze, Piero;
 Tibolla, Marcellino; Corno, Maria Luisa; Cadelli,
 Giancarlo
 CORPORATE SOURCE: Dep. Chem., Carlo Erba Res. Inst., Milan, 20159, Italy
 SOURCE: European Journal of Medicinal Chemistry (1979), 14(3),
 247-51
 CODEN: EJMCA5; ISSN: 0009-4374
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 91:168210
 GI



AB The title compds. I (R = H or Me; R1 = H, Me, alkoxy; R2 = H, Me, Et, Pr, alkoxy, allyloxy) were prepared from Na 5-methyl-2-nitrobenzoate

[71746-29-7] and tested for antiallergic activity by the passive cutaneous anaphylactic reaction in rats. Many of the compds. given parenterally were as active as di-Na cromoglycate. Some compds. were also active orally. 2-(2-Ethoxy-3-methoxyphenyl)-3,4-dihydro-4-oxo-6-quinazolinecarboxylic acid [68274-48-6] had the highest activity.


Structure-activity relations are discussed.

IT	63746-16-7P	63746-17-8P	63746-18-9P
	63746-19-0P	63746-21-4P	63746-22-5P
	63746-23-6P	63746-24-7P	63746-36-1P
	63746-37-2P	63746-38-3P	68274-48-6P
	68274-49-7P	68274-50-0P	68274-51-1P
	68274-52-2P	68274-56-6P	68274-57-7P
	68274-58-8P	68274-59-9P	68274-61-3P
	68274-64-6P	68274-65-7P	68274-66-8P
	68274-68-0P	68274-69-1P	68315-12-8P
	68315-15-1P	71746-22-0P	71746-23-1P
	71746-24-2P	71746-25-3P	71746-26-4P
	71746-28-6P		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and antiallergic activity of)


RN 63746-16-7 CAPLUS

CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-2-[2-(1-methylethoxy)phenyl]-4-oxo- (CA INDEX NAME)




RN 63746-17-8 CAPLUS

CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-2-(2-methoxyphenyl)-4-oxo- (CA INDEX NAME)




RN 63746-18-9 CAPLUS

CN 6-Quinazolinecarboxylic acid, 2-(2-ethoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 63746-19-0 CAPLUS

CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-2-[2-(2-propen-1-yloxy)phenyl]- (CA INDEX NAME)




RN 63746-21-4 CAPLUS

CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 63746-22-5 CAPLUS

CN 6-Quinazolinecarboxylic acid, 2-(2-butoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 63746-23-6 CAPLUS

CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-2-[2-(2-methylpropoxy)phenyl]-4-oxo- (CA INDEX NAME)




RN 63746-24-7 CAPLUS

CN 6-Quinazolinecarboxylic acid, 2-[2-(2-ethoxyethoxy)phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 63746-36-1 CAPLUS

CN 6-Quinazolinecarboxylic acid, 2-[2-(hexyloxy)phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 63746-37-2 CAPLUS

CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-2-(4-methoxyphenyl)-4-oxo- (CA INDEX NAME)




RN 63746-38-3 CAPLUS


CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-2-(3-methoxyphenyl)-4-oxo- (CA INDEX NAME)




RN 68274-48-6 CAPLUS
CN 6-Quinazolinecarboxylic acid, 2-(2-ethoxy-3-methoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68274-49-7 CAPLUS
CN 6-Quinazolinecarboxylic acid, 2-(2,3-dimethoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68274-50-0 CAPLUS
CN 6-Quinazolinecarboxylic acid, 2-(2-butoxy-3-methoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68274-51-1 CAPLUS
CN 6-Quinazolinecarboxylic acid, 2-(2,3-diethoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68274-52-2 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 2-(2-ethoxy-5-methoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68274-56-6 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 2-(2-ethoxy-3-methylphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68274-57-7 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-2-(2-methoxy-3-methylphenyl)-4-oxo- (CA INDEX NAME)




RN 68274-58-8 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 2-(2,5-diethoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68274-59-9 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 2-(5-ethoxy-2-methoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)



RN 68274-61-3 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 2-[2-ethoxy-5-(1-methylethoxy)phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68274-64-6 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 2-(2-ethoxy-5-propoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68274-65-7 CAPLUS

CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-2-[2-methoxy-5-(2-propen-1-yloxy)phenyl]-4-oxo- (CA INDEX NAME)




RN 68274-66-8 CAPLUS

CN 6-Quinazolinecarboxylic acid, 2-[2-ethoxy-5-(2-propen-1-yloxy)phenyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68274-68-0 CAPLUS

CN 6-Quinazolinecarboxylic acid, 2-(2-ethoxy-5-ethylphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68274-69-1 CAPLUS


CN 6-Quinazolinecarboxylic acid, 2-(2-ethoxy-5-propylphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 68315-12-8 CAPLUS
CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-2-[5-methoxy-2-(1-methylethoxy)phenyl]-4-oxo- (CA INDEX NAME)




RN 68315-15-1 CAPLUS
CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-2-[3-methoxy-2-(1-methylethoxy)phenyl]-4-oxo- (CA INDEX NAME)




RN 71746-22-0 CAPLUS
CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-2-(2-methylphenyl)-4-oxo- (CA INDEX NAME)




RN 71746-23-1 CAPLUS
CN 6-Quinazolinecarboxylic acid, 2-(2-ethoxy-4-methoxyphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)




RN 71746-24-2 CAPLUS
CN 6-Quinazolinecarboxylic acid, 2-(2-ethoxy-4-methylphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)



RN 71746-25-3 CAPLUS
CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-2-(2-methoxy-5-methylphenyl)-4-oxo- (CA INDEX NAME)




RN 71746-26-4 CAPLUS
CN 6-Quinazolinecarboxylic acid, 2-(2-ethoxy-5-methylphenyl)-3,4-dihydro-4-oxo- (CA INDEX NAME)



RN 71746-28-6 CAPLUS
CN 6-Quinazolinecarboxylic acid, 3,4-dihydro-3-methyl-2-[2-(1-

methylethoxy)phenyl]-4-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L5 ANSWER 101 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1974:486076 CAPLUS

DOCUMENT NUMBER: 81:86076

ORIGINAL REFERENCE NO.: 81:13623a,13626a

TITLE: Antimalarials. 2.
 α -Di-n-butylaminomethyl-2-(p-chlorophenyl)-5-quinazolinemethanol

AUTHOR(S): Cruickshank, Philip A.; Hymans, William E.

CORPORATE SOURCE: Chem. Res. Dev. Cent., FMC Corp., Princeton, NJ, USA

SOURCE: Journal of Medicinal Chemistry (1974), 17(4), 468-9

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The title compound (I) [52171-80-9] was prepared and tested against Plasmodium berghei in mice and P. gallinaceum in chicks. I cured P. berghei in mice at 480 mg/kg, but caused severe photosensitivity.

IT 52171-72-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antimalarial activity of)

RN 52171-72-9 CAPLUS

CN 5-Quinazolinecarboxylic acid, 2-(4-chlorophenyl)-3,4-dihydro-4-oxo-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L5 ANSWER 102 OF 102 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1970:466536 CAPLUS

DOCUMENT NUMBER: 73:66536

ORIGINAL REFERENCE NO.: 73:10899a,10902a

TITLE: Medicinal chemistry of oxoquinazolines. VII.
 Synthesis and pharmacology of some 4-oxoquinazolines and related 4-propargyloxyquinazolines and open amides

AUTHOR(S): Kronberg, Leif; Bogentoft, Conny; Westerlund, Douglas; Danielsson, Bengt; Ljungberg, Stellan; Paalzow, Lennart

CORPORATE SOURCE: Dep. Org. Chem., Farmaceut. Fak., Stockholm, Swed.

SOURCE: Acta Pharmaceutica Suecica (1970), 7(1), 37-46
 CODEN: APSXAS; ISSN: 0001-6675

DOCUMENT TYPE: Journal

LANGUAGE: English


GI For diagram(s), see printed CA Issue.

AB The chemistry and pharmacol. of 26 4-oxoquinazolines and related compds. were studied. I (R = p-ClC₆H₄, R₁ = R₂ = H) showed a small anticonvulsant activity. I (R = CH₂CHPh or 2-furyl; R₁ = R₂ = H; or R = Ph, R₁ = R₂ = Cl) and II had significant antidiuretic activity, while I (R = CH₂Ph or CH₂CH₂Ph; R₁ = R₂ = H; or R = Ph, R₁ = Cl, R₂ = H) had significant diuretic activity. No correlation was found between the antidiuretic and analgesic activities of the 4 antidiuretics. I (R = Ph, R₁ = R₂ = H) possessed sedative and spasmolytic activities.

IT 26059-90-5 26059-91-6 26059-97-2
 26197-89-7 26207-28-3
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmacology of)


RN 26059-90-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(3-methylphenyl)-3-(2-propyn-1-yl)- (CA INDEX NAME)



RN 26059-91-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-(4-methylphenyl)-3-(2-propyn-1-yl)- (CA INDEX NAME)




RN 26059-97-2 CAPLUS

CN Quinazoline, 2-(4-nitrophenyl)-4-(2-propyn-1-yloxy)- (CA INDEX NAME)


10/ 582,823



RN 26197-89-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-3-(2-propyn-1-yl)- (CA INDEX
NAME)



RN 26207-28-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-chlorophenyl)-3-(2-propyn-1-yl)- (CA INDEX
NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 14:00:25 ON 11 JAN 2010)

FILE 'REGISTRY' ENTERED AT 14:00:50 ON 11 JAN 2010

L1 STRUCTURE UPLOADED

L2 10463 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:01:37 ON 11 JAN 2010

L3 733 S L2

L4 462 S L3 NOT PY>2003

L5 102 S L2/THU

=> log y

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

XXXXXXXXXXXXXXXXXXXX

10/ 582,823

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-86.70	-86.70

STN INTERNATIONAL LOGOFF AT 14:07:48 ON 11 JAN 2010